id	sid	tid	token	lemma	pos
ajst-32571	1	1	177	177	NUM
ajst-32571	1	2	cldn6	cldn6	NOUN
ajst-32571	1	3	-	-	PUNCT
ajst-32571	1	4	car	car	NOUN
ajst-32571	1	5	-	-	PUNCT
ajst-32571	1	6	t	t	NOUN
ajst-32571	1	7	cell	cell	NOUN
ajst-32571	1	8	therapy	therapy	NOUN
ajst-32571	1	9	in	in	ADP
ajst-32571	1	10	ovarian	ovarian	ADJ
ajst-32571	1	11	cancer	cancer	NOUN
ajst-32571	1	12	:	:	PUNCT
ajst-32571	1	13	overcoming	overcome	VERB
ajst-32571	1	14	the	the	DET
ajst-32571	1	15	challenges	challenge	NOUN
ajst-32571	1	16	of	of	ADP
ajst-32571	1	17	tumour	tumour	NOUN
ajst-32571	1	18	heterogeneity	heterogeneity	NOUN
ajst-32571	1	19	yinglan	yinglan	PROPN
ajst-32571	1	20	wang	wang	PROPN
ajst-32571	1	21	1	1	NUM
ajst-32571	1	22	,	,	PUNCT
ajst-32571	1	23	a	a	DET
ajst-32571	1	24	,	,	PUNCT
ajst-32571	1	25	zhiqian	zhiqian	NOUN
ajst-32571	1	26	liu	liu	PROPN
ajst-32571	1	27	2	2	NUM
ajst-32571	1	28	,	,	PUNCT
ajst-32571	1	29	b	b	PROPN
ajst-32571	1	30	1	1	NUM
ajst-32571	1	31	shenzhen	shenzhen	PROPN
ajst-32571	1	32	college	college	PROPN
ajst-32571	1	33	of	of	ADP
ajst-32571	1	34	international	international	ADJ
ajst-32571	1	35	education	education	NOUN
ajst-32571	1	36	,	,	PUNCT
ajst-32571	1	37	shenzhen	shenzhen	PROPN
ajst-32571	1	38	,	,	PUNCT
ajst-32571	1	39	guangdong	guangdong	PROPN
ajst-32571	1	40	,	,	PUNCT
ajst-32571	1	41	china	china	PROPN
ajst-32571	1	42	2	2	NUM
ajst-32571	1	43	shanghai	shanghai	PROPN
ajst-32571	1	44	united	united	PROPN
ajst-32571	1	45	international	international	PROPN
ajst-32571	1	46	school	school	NOUN
ajst-32571	1	47	gubei	gubei	NOUN
ajst-32571	1	48	,	,	PUNCT
ajst-32571	1	49	shanghai	shanghai	PROPN
ajst-32571	1	50	,	,	PUNCT
ajst-32571	1	51	china	china	PROPN
ajst-32571	1	52	a	a	DET
ajst-32571	1	53	s23256.wang@stu.scie.com.cn	s23256.wang@stu.scie.com.cn	PROPN
ajst-32571	1	54	,	,	PUNCT
ajst-32571	1	55	b	b	NOUN
ajst-32571	1	56	aarenliu919@gmail.com	aarenliu919@gmail.com	X
ajst-32571	1	57	abstract	abstract	ADJ
ajst-32571	1	58	.	.	PUNCT
ajst-32571	2	1	chimeric	chimeric	ADJ
ajst-32571	2	2	antigen	antigen	ADJ
ajst-32571	2	3	receptor	receptor	NOUN
ajst-32571	2	4	t	t	NOUN
ajst-32571	2	5	cells	cell	NOUN
ajst-32571	2	6	(	(	PUNCT
ajst-32571	2	7	car	car	NOUN
ajst-32571	2	8	-	-	PUNCT
ajst-32571	2	9	t	t	NOUN
ajst-32571	2	10	cells	cell	NOUN
ajst-32571	2	11	)	)	PUNCT
ajst-32571	2	12	are	be	AUX
ajst-32571	2	13	synthetically	synthetically	ADV
ajst-32571	2	14	modified	modify	VERB
ajst-32571	2	15	versions	version	NOUN
ajst-32571	2	16	of	of	ADP
ajst-32571	2	17	t	t	NOUN
ajst-32571	2	18	lymphocytes	lymphocyte	VERB
ajst-32571	2	19	with	with	ADP
ajst-32571	2	20	an	an	DET
ajst-32571	2	21	additional	additional	ADJ
ajst-32571	2	22	car	car	NOUN
ajst-32571	2	23	that	that	PRON
ajst-32571	2	24	allows	allow	VERB
ajst-32571	2	25	specific	specific	ADJ
ajst-32571	2	26	,	,	PUNCT
ajst-32571	2	27	customised	customise	VERB
ajst-32571	2	28	antigen	antigen	ADJ
ajst-32571	2	29	binding	bind	VERB
ajst-32571	2	30	and	and	CCONJ
ajst-32571	2	31	subsequent	subsequent	ADJ
ajst-32571	2	32	cell	cell	NOUN
ajst-32571	2	33	elimination	elimination	NOUN
ajst-32571	2	34	by	by	ADP
ajst-32571	2	35	apoptosis	apoptosis	NOUN
ajst-32571	2	36	.	.	PUNCT
ajst-32571	3	1	for	for	ADP
ajst-32571	3	2	ovarian	ovarian	ADJ
ajst-32571	3	3	cancer	cancer	NOUN
ajst-32571	3	4	,	,	PUNCT
ajst-32571	3	5	claudin-6	claudin-6	NUM
ajst-32571	3	6	(	(	PUNCT
ajst-32571	3	7	cldn6	cldn6	PROPN
ajst-32571	3	8	)	)	PUNCT
ajst-32571	3	9	is	be	AUX
ajst-32571	3	10	an	an	DET
ajst-32571	3	11	excellent	excellent	ADJ
ajst-32571	3	12	target	target	NOUN
ajst-32571	3	13	antigen	antigen	NOUN
ajst-32571	3	14	for	for	ADP
ajst-32571	3	15	car	car	NOUN
ajst-32571	3	16	-	-	PUNCT
ajst-32571	3	17	t	t	NOUN
ajst-32571	3	18	therapy	therapy	NOUN
ajst-32571	3	19	,	,	PUNCT
ajst-32571	3	20	due	due	ADP
ajst-32571	3	21	to	to	ADP
ajst-32571	3	22	its	its	PRON
ajst-32571	3	23	high	high	ADJ
ajst-32571	3	24	expression	expression	NOUN
ajst-32571	3	25	within	within	ADP
ajst-32571	3	26	ovarian	ovarian	ADJ
ajst-32571	3	27	cancer	cancer	NOUN
ajst-32571	3	28	tissue	tissue	NOUN
ajst-32571	3	29	and	and	CCONJ
ajst-32571	3	30	low	low	ADJ
ajst-32571	3	31	expression	expression	NOUN
ajst-32571	3	32	in	in	ADP
ajst-32571	3	33	healthy	healthy	ADJ
ajst-32571	3	34	adult	adult	NOUN
ajst-32571	3	35	cells	cell	NOUN
ajst-32571	3	36	.	.	PUNCT
ajst-32571	4	1	scientists	scientist	NOUN
ajst-32571	4	2	have	have	AUX
ajst-32571	4	3	therefore	therefore	ADV
ajst-32571	4	4	developed	develop	VERB
ajst-32571	4	5	cldn6	cldn6	NOUN
ajst-32571	4	6	-	-	PUNCT
ajst-32571	4	7	specific	specific	ADJ
ajst-32571	4	8	car	car	NOUN
ajst-32571	4	9	-	-	PUNCT
ajst-32571	4	10	t	t	NOUN
ajst-32571	4	11	cell	cell	NOUN
ajst-32571	4	12	therapy	therapy	NOUN
ajst-32571	4	13	(	(	PUNCT
ajst-32571	4	14	cldn6car	cldn6car	NOUN
ajst-32571	4	15	-	-	PUNCT
ajst-32571	4	16	t	t	NOUN
ajst-32571	4	17	)	)	PUNCT
ajst-32571	4	18	.	.	PUNCT
ajst-32571	5	1	cldn6	cldn6	NOUN
ajst-32571	5	2	-	-	PUNCT
ajst-32571	5	3	car	car	NOUN
ajst-32571	5	4	-	-	PUNCT
ajst-32571	5	5	t	t	NOUN
ajst-32571	5	6	offers	offer	VERB
ajst-32571	5	7	benefits	benefit	NOUN
ajst-32571	5	8	compared	compare	VERB
ajst-32571	5	9	to	to	ADP
ajst-32571	5	10	traditional	traditional	ADJ
ajst-32571	5	11	surgery	surgery	NOUN
ajst-32571	5	12	and	and	CCONJ
ajst-32571	5	13	chemotherapy	chemotherapy	NOUN
ajst-32571	5	14	,	,	PUNCT
ajst-32571	5	15	but	but	CCONJ
ajst-32571	5	16	faces	face	VERB
ajst-32571	5	17	immature	immature	ADJ
ajst-32571	5	18	clinical	clinical	ADJ
ajst-32571	5	19	outcomes	outcome	NOUN
ajst-32571	5	20	and	and	CCONJ
ajst-32571	5	21	heterogeneity	heterogeneity	NOUN
ajst-32571	5	22	-	-	PUNCT
ajst-32571	5	23	related	relate	VERB
ajst-32571	5	24	limitations	limitation	NOUN
ajst-32571	5	25	,	,	PUNCT
ajst-32571	5	26	including	include	VERB
ajst-32571	5	27	antigen	antigen	ADJ
ajst-32571	5	28	escape	escape	NOUN
ajst-32571	5	29	,	,	PUNCT
ajst-32571	5	30	tme	tme	NOUN
ajst-32571	5	31	immunosuppression	immunosuppression	NOUN
ajst-32571	5	32	,	,	PUNCT
ajst-32571	5	33	and	and	CCONJ
ajst-32571	5	34	cancer	cancer	NOUN
ajst-32571	5	35	-	-	PUNCT
ajst-32571	5	36	associated	associate	VERB
ajst-32571	5	37	fibroblasts	fibroblast	NOUN
ajst-32571	5	38	.	.	PUNCT
ajst-32571	6	1	in	in	ADP
ajst-32571	6	2	the	the	DET
ajst-32571	6	3	face	face	NOUN
ajst-32571	6	4	of	of	ADP
ajst-32571	6	5	these	these	DET
ajst-32571	6	6	challenges	challenge	NOUN
ajst-32571	6	7	,	,	PUNCT
ajst-32571	6	8	possible	possible	ADJ
ajst-32571	6	9	solutions	solution	NOUN
ajst-32571	6	10	currently	currently	ADV
ajst-32571	6	11	being	be	AUX
ajst-32571	6	12	examined	examine	VERB
ajst-32571	6	13	and	and	CCONJ
ajst-32571	6	14	developed	develop	VERB
ajst-32571	6	15	include	include	VERB
ajst-32571	6	16	multi	multi	ADJ
ajst-32571	6	17	-	-	ADJ
ajst-32571	6	18	target	target	ADJ
ajst-32571	6	19	therapy	therapy	NOUN
ajst-32571	6	20	,	,	PUNCT
ajst-32571	6	21	cxcr2	cxcr2	NOUN
ajst-32571	6	22	-	-	PUNCT
ajst-32571	6	23	targeting	target	VERB
ajst-32571	6	24	,	,	PUNCT
ajst-32571	6	25	bionic	bionic	ADJ
ajst-32571	6	26	physical	physical	ADJ
ajst-32571	6	27	barriers	barrier	NOUN
ajst-32571	6	28	,	,	PUNCT
ajst-32571	6	29	and	and	CCONJ
ajst-32571	6	30	the	the	DET
ajst-32571	6	31	use	use	NOUN
ajst-32571	6	32	of	of	ADP
ajst-32571	6	33	heparanase	heparanase	NOUN
ajst-32571	6	34	.	.	PUNCT
ajst-32571	7	1	keywords	keyword	NOUN
ajst-32571	7	2	:	:	PUNCT
ajst-32571	7	3	cldn6	cldn6	NOUN
ajst-32571	7	4	-	-	PUNCT
ajst-32571	7	5	car	car	NOUN
ajst-32571	7	6	-	-	PUNCT
ajst-32571	7	7	t	t	NOUN
ajst-32571	7	8	;	;	PUNCT
ajst-32571	7	9	immunotherapy	immunotherapy	NOUN
ajst-32571	7	10	;	;	PUNCT
ajst-32571	7	11	ovarian	ovarian	ADJ
ajst-32571	7	12	cancer	cancer	NOUN
ajst-32571	7	13	;	;	PUNCT
ajst-32571	7	14	heterogeneity	heterogeneity	NOUN
ajst-32571	7	15	.	.	PUNCT
ajst-32571	8	1	1	1	X
ajst-32571	8	2	.	.	X
ajst-32571	8	3	introduction	introduction	NOUN
ajst-32571	8	4	ovarian	ovarian	ADJ
ajst-32571	8	5	tumours	tumour	NOUN
ajst-32571	8	6	exist	exist	VERB
ajst-32571	8	7	in	in	ADP
ajst-32571	8	8	a	a	DET
ajst-32571	8	9	complex	complex	ADJ
ajst-32571	8	10	assortment	assortment	NOUN
ajst-32571	8	11	of	of	ADP
ajst-32571	8	12	subtypes	subtype	NOUN
ajst-32571	8	13	[	[	X
ajst-32571	8	14	1	1	NUM
ajst-32571	8	15	]	]	PUNCT
ajst-32571	8	16	.	.	PUNCT
ajst-32571	9	1	depending	depend	VERB
ajst-32571	9	2	on	on	ADP
ajst-32571	9	3	their	their	PRON
ajst-32571	9	4	specific	specific	ADJ
ajst-32571	9	5	tissue	tissue	NOUN
ajst-32571	9	6	of	of	ADP
ajst-32571	9	7	origin	origin	NOUN
ajst-32571	9	8	and	and	CCONJ
ajst-32571	9	9	stage	stage	NOUN
ajst-32571	9	10	of	of	ADP
ajst-32571	9	11	development	development	NOUN
ajst-32571	9	12	,	,	PUNCT
ajst-32571	9	13	ovarian	ovarian	ADJ
ajst-32571	9	14	tumors	tumor	NOUN
ajst-32571	9	15	are	be	AUX
ajst-32571	9	16	categorized	categorize	VERB
ajst-32571	9	17	into	into	ADP
ajst-32571	9	18	epithelial	epithelial	ADJ
ajst-32571	9	19	ovarian	ovarian	ADJ
ajst-32571	9	20	cancers	cancer	NOUN
ajst-32571	9	21	(	(	PUNCT
ajst-32571	9	22	90	90	NUM
ajst-32571	9	23	%	%	NOUN
ajst-32571	9	24	of	of	ADP
ajst-32571	9	25	cases	case	NOUN
ajst-32571	9	26	)	)	PUNCT
ajst-32571	9	27	,	,	PUNCT
ajst-32571	9	28	germ	germ	NOUN
ajst-32571	9	29	cell	cell	NOUN
ajst-32571	9	30	ovarian	ovarian	ADJ
ajst-32571	9	31	cancers	cancer	NOUN
ajst-32571	9	32	,	,	PUNCT
ajst-32571	9	33	and	and	CCONJ
ajst-32571	9	34	sex	sex	NOUN
ajst-32571	9	35	-	-	PUNCT
ajst-32571	9	36	cord	cord	NOUN
ajst-32571	9	37	stromal	stromal	ADJ
ajst-32571	9	38	tumors	tumor	NOUN
ajst-32571	9	39	,	,	PUNCT
ajst-32571	9	40	with	with	ADP
ajst-32571	9	41	subsequent	subsequent	ADJ
ajst-32571	9	42	subcategories	subcategorie	NOUN
ajst-32571	9	43	,	,	PUNCT
ajst-32571	9	44	each	each	PRON
ajst-32571	9	45	primarily	primarily	ADV
ajst-32571	9	46	corresponding	correspond	VERB
ajst-32571	9	47	to	to	ADP
ajst-32571	9	48	a	a	DET
ajst-32571	9	49	traditional	traditional	ADJ
ajst-32571	9	50	surgical	surgical	ADJ
ajst-32571	9	51	approach	approach	NOUN
ajst-32571	9	52	and/or	and/or	CCONJ
ajst-32571	9	53	chemotherapy	chemotherapy	NOUN
ajst-32571	10	1	[	[	X
ajst-32571	10	2	2	2	NUM
ajst-32571	10	3	]	]	PUNCT
ajst-32571	10	4	.	.	PUNCT
ajst-32571	11	1	a	a	DET
ajst-32571	11	2	relatively	relatively	ADV
ajst-32571	11	3	new	new	ADJ
ajst-32571	11	4	and	and	CCONJ
ajst-32571	11	5	promising	promising	ADJ
ajst-32571	11	6	form	form	NOUN
ajst-32571	11	7	of	of	ADP
ajst-32571	11	8	immunotherapy	immunotherapy	NOUN
ajst-32571	11	9	developed	develop	VERB
ajst-32571	11	10	in	in	ADP
ajst-32571	11	11	recent	recent	ADJ
ajst-32571	11	12	years	year	NOUN
ajst-32571	11	13	,	,	PUNCT
ajst-32571	11	14	car	car	NOUN
ajst-32571	11	15	-	-	PUNCT
ajst-32571	11	16	t	t	NOUN
ajst-32571	11	17	cell	cell	NOUN
ajst-32571	11	18	therapy	therapy	NOUN
ajst-32571	11	19	utilizes	utilize	VERB
ajst-32571	11	20	the	the	DET
ajst-32571	11	21	addition	addition	NOUN
ajst-32571	11	22	of	of	ADP
ajst-32571	11	23	artificially	artificially	ADV
ajst-32571	11	24	engineered	engineer	VERB
ajst-32571	11	25	cars	car	NOUN
ajst-32571	11	26	(	(	PUNCT
ajst-32571	11	27	chimeric	chimeric	ADJ
ajst-32571	11	28	antigen	antigen	ADJ
ajst-32571	11	29	receptors	receptor	NOUN
ajst-32571	11	30	)	)	PUNCT
ajst-32571	11	31	to	to	ADP
ajst-32571	11	32	t	t	PROPN
ajst-32571	11	33	lymphocytes	lymphocyte	NOUN
ajst-32571	11	34	,	,	PUNCT
ajst-32571	11	35	enabling	enable	VERB
ajst-32571	11	36	them	they	PRON
ajst-32571	11	37	to	to	PART
ajst-32571	11	38	bind	bind	VERB
ajst-32571	11	39	to	to	ADP
ajst-32571	11	40	a	a	DET
ajst-32571	11	41	designated	designate	VERB
ajst-32571	11	42	target	target	NOUN
ajst-32571	11	43	antigen	antigen	NOUN
ajst-32571	12	1	[	[	X
ajst-32571	12	2	3	3	NUM
ajst-32571	12	3	]	]	PUNCT
ajst-32571	12	4	.	.	PUNCT
ajst-32571	13	1	following	follow	VERB
ajst-32571	13	2	the	the	DET
ajst-32571	13	3	success	success	NOUN
ajst-32571	13	4	and	and	CCONJ
ajst-32571	13	5	fda	fda	PROPN
ajst-32571	13	6	approval	approval	NOUN
ajst-32571	13	7	of	of	ADP
ajst-32571	13	8	car	car	NOUN
ajst-32571	13	9	-	-	PUNCT
ajst-32571	13	10	t	t	NOUN
ajst-32571	13	11	use	use	NOUN
ajst-32571	13	12	to	to	PART
ajst-32571	13	13	treat	treat	VERB
ajst-32571	13	14	b	b	NUM
ajst-32571	13	15	-	-	PUNCT
ajst-32571	13	16	cell	cell	NOUN
ajst-32571	13	17	leukemia	leukemia	NOUN
ajst-32571	13	18	in	in	ADP
ajst-32571	13	19	2017	2017	NUM
ajst-32571	13	20	[	[	X
ajst-32571	13	21	4	4	NUM
ajst-32571	13	22	]	]	PUNCT
ajst-32571	13	23	,	,	PUNCT
ajst-32571	13	24	scientists	scientist	NOUN
ajst-32571	13	25	have	have	AUX
ajst-32571	13	26	turned	turn	VERB
ajst-32571	13	27	to	to	ADP
ajst-32571	13	28	car	car	NOUN
ajst-32571	13	29	-	-	PUNCT
ajst-32571	13	30	t	t	NOUN
ajst-32571	13	31	as	as	ADP
ajst-32571	13	32	a	a	DET
ajst-32571	13	33	potential	potential	ADJ
ajst-32571	13	34	solution	solution	NOUN
ajst-32571	13	35	for	for	ADP
ajst-32571	13	36	other	other	ADJ
ajst-32571	13	37	cancers	cancer	NOUN
ajst-32571	13	38	,	,	PUNCT
ajst-32571	13	39	including	include	VERB
ajst-32571	13	40	ovarian	ovarian	ADJ
ajst-32571	13	41	cancer	cancer	NOUN
ajst-32571	13	42	.	.	PUNCT
ajst-32571	14	1	among	among	ADP
ajst-32571	14	2	the	the	DET
ajst-32571	14	3	various	various	ADJ
ajst-32571	14	4	candidates	candidate	NOUN
ajst-32571	14	5	,	,	PUNCT
ajst-32571	14	6	cldn6	cldn6	NOUN
ajst-32571	14	7	(	(	PUNCT
ajst-32571	14	8	claudin-6	claudin-6	NUM
ajst-32571	14	9	)	)	PUNCT
ajst-32571	14	10	,	,	PUNCT
ajst-32571	14	11	a	a	DET
ajst-32571	14	12	membrane	membrane	NOUN
ajst-32571	14	13	protein	protein	NOUN
ajst-32571	14	14	that	that	PRON
ajst-32571	14	15	is	be	AUX
ajst-32571	14	16	abundantly	abundantly	ADV
ajst-32571	14	17	expressed	express	VERB
ajst-32571	14	18	on	on	ADP
ajst-32571	14	19	ovarian	ovarian	ADJ
ajst-32571	14	20	cancer	cancer	NOUN
ajst-32571	14	21	cells	cell	NOUN
ajst-32571	14	22	but	but	CCONJ
ajst-32571	14	23	not	not	PART
ajst-32571	14	24	in	in	ADP
ajst-32571	14	25	adult	adult	NOUN
ajst-32571	14	26	tissue	tissue	NOUN
ajst-32571	14	27	,	,	PUNCT
ajst-32571	14	28	is	be	AUX
ajst-32571	14	29	gradually	gradually	ADV
ajst-32571	14	30	showing	show	VERB
ajst-32571	14	31	promise	promise	NOUN
ajst-32571	14	32	through	through	ADP
ajst-32571	14	33	preclinical	preclinical	ADJ
ajst-32571	14	34	investigations	investigation	NOUN
ajst-32571	14	35	[	[	X
ajst-32571	14	36	5	5	NUM
ajst-32571	14	37	]	]	PUNCT
ajst-32571	14	38	.	.	PUNCT
ajst-32571	15	1	however	however	ADV
ajst-32571	15	2	,	,	PUNCT
ajst-32571	15	3	it	it	PRON
ajst-32571	15	4	remains	remain	VERB
ajst-32571	15	5	evident	evident	ADJ
ajst-32571	15	6	that	that	SCONJ
ajst-32571	15	7	the	the	DET
ajst-32571	15	8	therapeutic	therapeutic	ADJ
ajst-32571	15	9	effect	effect	NOUN
ajst-32571	15	10	of	of	ADP
ajst-32571	15	11	car	car	NOUN
ajst-32571	15	12	-	-	PUNCT
ajst-32571	15	13	t	t	PROPN
ajst-32571	15	14	is	be	AUX
ajst-32571	15	15	lower	low	ADJ
ajst-32571	15	16	in	in	ADP
ajst-32571	15	17	solid	solid	ADJ
ajst-32571	15	18	tumour	tumour	ADJ
ajst-32571	15	19	cancers	cancer	NOUN
ajst-32571	15	20	than	than	ADP
ajst-32571	15	21	haematologic	haematologic	ADJ
ajst-32571	15	22	cancers	cancer	NOUN
ajst-32571	15	23	,	,	PUNCT
ajst-32571	15	24	owing	owe	VERB
ajst-32571	15	25	to	to	ADP
ajst-32571	15	26	the	the	DET
ajst-32571	15	27	intercellular	intercellular	ADJ
ajst-32571	15	28	,	,	PUNCT
ajst-32571	15	29	intracellular	intracellular	ADJ
ajst-32571	15	30	immunosuppressive	immunosuppressive	ADJ
ajst-32571	15	31	environments	environment	NOUN
ajst-32571	15	32	and	and	CCONJ
ajst-32571	15	33	especially	especially	ADV
ajst-32571	15	34	the	the	DET
ajst-32571	15	35	heterogeneous	heterogeneous	ADJ
ajst-32571	15	36	nature	nature	NOUN
ajst-32571	15	37	of	of	ADP
ajst-32571	15	38	solid	solid	ADJ
ajst-32571	15	39	tumours	tumour	NOUN
ajst-32571	16	1	[	[	X
ajst-32571	16	2	6	6	NUM
ajst-32571	16	3	]	]	PUNCT
ajst-32571	16	4	—	—	PUNCT
ajst-32571	16	5	the	the	DET
ajst-32571	16	6	wide	wide	ADJ
ajst-32571	16	7	range	range	NOUN
ajst-32571	16	8	of	of	ADP
ajst-32571	16	9	ovarian	ovarian	ADJ
ajst-32571	16	10	cancers	cancer	NOUN
ajst-32571	16	11	,	,	PUNCT
ajst-32571	16	12	in	in	ADP
ajst-32571	16	13	particular	particular	ADJ
ajst-32571	16	14	epithelial	epithelial	ADJ
ajst-32571	16	15	ovarian	ovarian	ADJ
ajst-32571	16	16	cancer	cancer	NOUN
ajst-32571	16	17	with	with	ADP
ajst-32571	16	18	its	its	PRON
ajst-32571	16	19	at	at	ADV
ajst-32571	16	20	least	least	ADV
ajst-32571	16	21	five	five	NUM
ajst-32571	16	22	subtypes	subtype	NOUN
ajst-32571	16	23	[	[	X
ajst-32571	16	24	7	7	NUM
ajst-32571	16	25	]	]	PUNCT
ajst-32571	16	26	,	,	PUNCT
ajst-32571	16	27	reflects	reflect	VERB
ajst-32571	16	28	this	this	DET
ajst-32571	16	29	histological	histological	ADJ
ajst-32571	16	30	heterogeneity	heterogeneity	NOUN
ajst-32571	16	31	.	.	PUNCT
ajst-32571	17	1	these	these	DET
ajst-32571	17	2	limitations	limitation	NOUN
ajst-32571	17	3	must	must	AUX
ajst-32571	17	4	be	be	AUX
ajst-32571	17	5	addressed	address	VERB
ajst-32571	17	6	to	to	PART
ajst-32571	17	7	avoid	avoid	VERB
ajst-32571	17	8	hindering	hinder	VERB
ajst-32571	17	9	future	future	ADJ
ajst-32571	17	10	development	development	NOUN
ajst-32571	17	11	and	and	CCONJ
ajst-32571	17	12	clinical	clinical	ADJ
ajst-32571	17	13	applications	application	NOUN
ajst-32571	17	14	.	.	PUNCT
ajst-32571	18	1	in	in	ADP
ajst-32571	18	2	this	this	DET
ajst-32571	18	3	review	review	NOUN
ajst-32571	18	4	,	,	PUNCT
ajst-32571	18	5	we	we	PRON
ajst-32571	18	6	evaluate	evaluate	VERB
ajst-32571	18	7	potential	potential	ADJ
ajst-32571	18	8	solutions	solution	NOUN
ajst-32571	18	9	,	,	PUNCT
ajst-32571	18	10	including	include	VERB
ajst-32571	18	11	multi	multi	ADJ
ajst-32571	18	12	-	-	ADJ
ajst-32571	18	13	target	target	NOUN
ajst-32571	18	14	therapy	therapy	NOUN
ajst-32571	18	15	,	,	PUNCT
ajst-32571	18	16	cxcr2	cxcr2	NOUN
ajst-32571	18	17	-	-	PUNCT
ajst-32571	18	18	targeting	target	VERB
ajst-32571	18	19	,	,	PUNCT
ajst-32571	18	20	bionic	bionic	ADJ
ajst-32571	18	21	physical	physical	ADJ
ajst-32571	18	22	barriers	barrier	NOUN
ajst-32571	18	23	,	,	PUNCT
ajst-32571	18	24	and	and	CCONJ
ajst-32571	18	25	heparanase	heparanase	NOUN
ajst-32571	18	26	release	release	NOUN
ajst-32571	18	27	,	,	PUNCT
ajst-32571	18	28	that	that	PRON
ajst-32571	18	29	have	have	AUX
ajst-32571	18	30	been	be	AUX
ajst-32571	18	31	explored	explore	VERB
ajst-32571	18	32	to	to	PART
ajst-32571	18	33	address	address	VERB
ajst-32571	18	34	the	the	DET
ajst-32571	18	35	issues	issue	NOUN
ajst-32571	18	36	of	of	ADP
ajst-32571	18	37	ovarian	ovarian	ADJ
ajst-32571	18	38	cancer	cancer	NOUN
ajst-32571	18	39	heterogeneity	heterogeneity	NOUN
ajst-32571	18	40	.	.	PUNCT
ajst-32571	19	1	2	2	X
ajst-32571	19	2	.	.	X
ajst-32571	19	3	cldn6	cldn6	NOUN
ajst-32571	19	4	-	-	PUNCT
ajst-32571	19	5	car	car	NOUN
ajst-32571	19	6	-	-	PUNCT
ajst-32571	19	7	t	t	NOUN
ajst-32571	19	8	cell	cell	NOUN
ajst-32571	19	9	therapy	therapy	NOUN
ajst-32571	19	10	overview	overview	NOUN
ajst-32571	19	11	and	and	CCONJ
ajst-32571	19	12	mechanisms	mechanism	NOUN
ajst-32571	19	13	2.1	2.1	NUM
ajst-32571	19	14	ovarian	ovarian	ADJ
ajst-32571	19	15	cancer	cancer	NOUN
ajst-32571	19	16	traditional	traditional	ADJ
ajst-32571	19	17	treatment	treatment	NOUN
ajst-32571	19	18	commonly	commonly	ADV
ajst-32571	19	19	,	,	PUNCT
ajst-32571	19	20	benign	benign	ADJ
ajst-32571	19	21	ovarian	ovarian	ADJ
ajst-32571	19	22	tumours	tumour	NOUN
ajst-32571	19	23	are	be	AUX
ajst-32571	19	24	treated	treat	VERB
ajst-32571	19	25	with	with	ADP
ajst-32571	19	26	surgery	surgery	NOUN
ajst-32571	19	27	,	,	PUNCT
ajst-32571	19	28	and	and	CCONJ
ajst-32571	19	29	malignant	malignant	ADJ
ajst-32571	19	30	ovarian	ovarian	ADJ
ajst-32571	19	31	cancers	cancer	NOUN
ajst-32571	19	32	are	be	AUX
ajst-32571	19	33	treated	treat	VERB
ajst-32571	19	34	using	use	VERB
ajst-32571	19	35	a	a	DET
ajst-32571	19	36	combined	combine	VERB
ajst-32571	19	37	course	course	NOUN
ajst-32571	19	38	of	of	ADP
ajst-32571	19	39	surgery	surgery	NOUN
ajst-32571	19	40	and	and	CCONJ
ajst-32571	19	41	chemotherapy	chemotherapy	NOUN
ajst-32571	20	1	[	[	X
ajst-32571	20	2	2	2	NUM
ajst-32571	20	3	]	]	PUNCT
ajst-32571	20	4	.	.	PUNCT
ajst-32571	21	1	the	the	DET
ajst-32571	21	2	limitations	limitation	NOUN
ajst-32571	21	3	of	of	ADP
ajst-32571	21	4	surgery	surgery	NOUN
ajst-32571	21	5	and	and	CCONJ
ajst-32571	21	6	chemotherapy	chemotherapy	NOUN
ajst-32571	21	7	in	in	ADP
ajst-32571	21	8	cancer	cancer	NOUN
ajst-32571	21	9	treatment	treatment	NOUN
ajst-32571	21	10	are	be	AUX
ajst-32571	21	11	well	well	ADV
ajst-32571	21	12	-	-	PUNCT
ajst-32571	21	13	recognised	recognise	VERB
ajst-32571	21	14	:	:	PUNCT
ajst-32571	21	15	surgery	surgery	NOUN
ajst-32571	21	16	generates	generate	VERB
ajst-32571	21	17	trauma	trauma	NOUN
ajst-32571	21	18	in	in	ADP
ajst-32571	21	19	surrounding	surround	VERB
ajst-32571	21	20	178	178	NUM
ajst-32571	21	21	tissues	tissue	NOUN
ajst-32571	21	22	and	and	CCONJ
ajst-32571	21	23	cells	cell	NOUN
ajst-32571	21	24	[	[	X
ajst-32571	21	25	8	8	NUM
ajst-32571	21	26	]	]	PUNCT
ajst-32571	21	27	;	;	PUNCT
ajst-32571	21	28	minimal	minimal	ADJ
ajst-32571	21	29	residual	residual	ADJ
ajst-32571	21	30	disease	disease	NOUN
ajst-32571	21	31	from	from	ADP
ajst-32571	21	32	unremoved	unremoved	ADJ
ajst-32571	21	33	deposits	deposit	NOUN
ajst-32571	21	34	can	can	AUX
ajst-32571	21	35	also	also	ADV
ajst-32571	21	36	lead	lead	VERB
ajst-32571	21	37	to	to	ADP
ajst-32571	21	38	subsequent	subsequent	ADJ
ajst-32571	21	39	re	re	NOUN
ajst-32571	21	40	-	-	NOUN
ajst-32571	21	41	progression	progression	NOUN
ajst-32571	21	42	and	and	CCONJ
ajst-32571	21	43	re	re	NOUN
ajst-32571	21	44	-	-	NOUN
ajst-32571	21	45	proliferation	proliferation	NOUN
ajst-32571	21	46	of	of	ADP
ajst-32571	21	47	cancer	cancer	NOUN
ajst-32571	21	48	[	[	X
ajst-32571	21	49	9	9	NUM
ajst-32571	21	50	]	]	PUNCT
ajst-32571	21	51	.	.	PUNCT
ajst-32571	22	1	therefore	therefore	ADV
ajst-32571	22	2	,	,	PUNCT
ajst-32571	22	3	surgery	surgery	NOUN
ajst-32571	22	4	is	be	AUX
ajst-32571	22	5	frequently	frequently	ADV
ajst-32571	22	6	used	use	VERB
ajst-32571	22	7	in	in	ADP
ajst-32571	22	8	conjunction	conjunction	NOUN
ajst-32571	22	9	with	with	ADP
ajst-32571	22	10	other	other	ADJ
ajst-32571	22	11	therapeutic	therapeutic	ADJ
ajst-32571	22	12	approaches	approach	NOUN
ajst-32571	22	13	.	.	PUNCT
ajst-32571	23	1	chemotherapy	chemotherapy	NOUN
ajst-32571	23	2	,	,	PUNCT
ajst-32571	23	3	which	which	PRON
ajst-32571	23	4	involves	involve	VERB
ajst-32571	23	5	the	the	DET
ajst-32571	23	6	administration	administration	NOUN
ajst-32571	23	7	of	of	ADP
ajst-32571	23	8	chemicals	chemical	NOUN
ajst-32571	23	9	by	by	ADP
ajst-32571	23	10	injection	injection	NOUN
ajst-32571	23	11	or	or	CCONJ
ajst-32571	23	12	orally	orally	ADV
ajst-32571	23	13	,	,	PUNCT
ajst-32571	23	14	faces	face	VERB
ajst-32571	23	15	several	several	ADJ
ajst-32571	23	16	disadvantages	disadvantage	NOUN
ajst-32571	23	17	,	,	PUNCT
ajst-32571	23	18	including	include	VERB
ajst-32571	23	19	low	low	ADJ
ajst-32571	23	20	solubility	solubility	NOUN
ajst-32571	23	21	in	in	ADP
ajst-32571	23	22	water	water	NOUN
ajst-32571	23	23	,	,	PUNCT
ajst-32571	23	24	the	the	DET
ajst-32571	23	25	development	development	NOUN
ajst-32571	23	26	of	of	ADP
ajst-32571	23	27	drug	drug	NOUN
ajst-32571	23	28	resistance	resistance	NOUN
ajst-32571	23	29	(	(	PUNCT
ajst-32571	23	30	notably	notably	ADV
ajst-32571	23	31	through	through	ADP
ajst-32571	23	32	efflux	efflux	NOUN
ajst-32571	23	33	pumps	pump	NOUN
ajst-32571	23	34	)	)	PUNCT
ajst-32571	23	35	,	,	PUNCT
ajst-32571	23	36	a	a	DET
ajst-32571	23	37	lack	lack	NOUN
ajst-32571	23	38	of	of	ADP
ajst-32571	23	39	chemical	chemical	ADJ
ajst-32571	23	40	specificity	specificity	NOUN
ajst-32571	23	41	towards	towards	ADP
ajst-32571	23	42	target	target	NOUN
ajst-32571	23	43	cells	cell	NOUN
ajst-32571	23	44	[	[	X
ajst-32571	23	45	10	10	NUM
ajst-32571	23	46	]	]	PUNCT
ajst-32571	23	47	,	,	PUNCT
ajst-32571	23	48	and	and	CCONJ
ajst-32571	23	49	cytotoxicity	cytotoxicity	NOUN
ajst-32571	23	50	towards	towards	ADP
ajst-32571	23	51	healthy	healthy	ADJ
ajst-32571	23	52	body	body	NOUN
ajst-32571	23	53	cells	cell	NOUN
ajst-32571	23	54	[	[	X
ajst-32571	23	55	9	9	NUM
ajst-32571	23	56	]	]	PUNCT
ajst-32571	23	57	.	.	PUNCT
ajst-32571	24	1	2.2	2.2	NUM
ajst-32571	24	2	car	car	NOUN
ajst-32571	24	3	-	-	PUNCT
ajst-32571	24	4	t	t	NOUN
ajst-32571	24	5	cell	cell	NOUN
ajst-32571	24	6	therapy	therapy	NOUN
ajst-32571	24	7	overview	overview	VERB
ajst-32571	24	8	chimeric	chimeric	ADJ
ajst-32571	24	9	antigen	antigen	ADJ
ajst-32571	24	10	receptor	receptor	NOUN
ajst-32571	24	11	t	t	NOUN
ajst-32571	24	12	cell	cell	NOUN
ajst-32571	24	13	(	(	PUNCT
ajst-32571	24	14	car	car	NOUN
ajst-32571	24	15	-	-	PUNCT
ajst-32571	24	16	t	t	NOUN
ajst-32571	24	17	cell	cell	NOUN
ajst-32571	24	18	)	)	PUNCT
ajst-32571	24	19	therapy	therapy	NOUN
ajst-32571	24	20	,	,	PUNCT
ajst-32571	24	21	a	a	DET
ajst-32571	24	22	relatively	relatively	ADV
ajst-32571	24	23	new	new	ADJ
ajst-32571	24	24	immunotherapy	immunotherapy	NOUN
ajst-32571	24	25	and	and	CCONJ
ajst-32571	24	26	adoptive	adoptive	ADJ
ajst-32571	24	27	cell	cell	NOUN
ajst-32571	24	28	therapy	therapy	NOUN
ajst-32571	24	29	that	that	PRON
ajst-32571	24	30	just	just	ADV
ajst-32571	24	31	gained	gain	VERB
ajst-32571	24	32	official	official	ADJ
ajst-32571	24	33	approval	approval	NOUN
ajst-32571	24	34	in	in	ADP
ajst-32571	24	35	2017	2017	NUM
ajst-32571	25	1	[	[	X
ajst-32571	25	2	6	6	NUM
ajst-32571	25	3	]	]	PUNCT
ajst-32571	25	4	,	,	PUNCT
ajst-32571	25	5	involves	involve	VERB
ajst-32571	25	6	the	the	DET
ajst-32571	25	7	specific	specific	ADJ
ajst-32571	25	8	modification	modification	NOUN
ajst-32571	25	9	of	of	ADP
ajst-32571	25	10	patient	patient	ADJ
ajst-32571	25	11	t	t	NOUN
ajst-32571	25	12	cells	cell	NOUN
ajst-32571	25	13	,	,	PUNCT
ajst-32571	25	14	particularly	particularly	ADV
ajst-32571	25	15	cytotoxic	cytotoxic	ADJ
ajst-32571	25	16	cd8	cd8	PROPN
ajst-32571	25	17	+	+	PROPN
ajst-32571	25	18	t	t	PROPN
ajst-32571	25	19	cells	cell	NOUN
ajst-32571	25	20	[	[	X
ajst-32571	25	21	11	11	NUM
ajst-32571	25	22	]	]	PUNCT
ajst-32571	25	23	.	.	PUNCT
ajst-32571	26	1	specifically	specifically	ADV
ajst-32571	26	2	manufactured	manufacture	VERB
ajst-32571	26	3	artificial	artificial	ADJ
ajst-32571	26	4	chimeric	chimeric	ADJ
ajst-32571	26	5	antigen	antigen	ADJ
ajst-32571	26	6	receptor	receptor	NOUN
ajst-32571	26	7	(	(	PUNCT
ajst-32571	26	8	car	car	NOUN
ajst-32571	26	9	)	)	PUNCT
ajst-32571	26	10	proteins	protein	NOUN
ajst-32571	26	11	are	be	AUX
ajst-32571	26	12	added	add	VERB
ajst-32571	26	13	to	to	ADP
ajst-32571	26	14	the	the	DET
ajst-32571	26	15	t	t	NOUN
ajst-32571	26	16	cells	cell	NOUN
ajst-32571	26	17	through	through	ADP
ajst-32571	26	18	viral	viral	ADJ
ajst-32571	26	19	[	[	X
ajst-32571	26	20	12	12	NUM
ajst-32571	26	21	]	]	PUNCT
ajst-32571	26	22	or	or	CCONJ
ajst-32571	26	23	non	non	ADJ
ajst-32571	26	24	-	-	ADJ
ajst-32571	26	25	viral	viral	ADJ
ajst-32571	26	26	insertion	insertion	NOUN
ajst-32571	26	27	of	of	ADP
ajst-32571	26	28	genetic	genetic	ADJ
ajst-32571	26	29	sequences	sequence	NOUN
ajst-32571	26	30	(	(	PUNCT
ajst-32571	26	31	especially	especially	ADV
ajst-32571	26	32	via	via	ADP
ajst-32571	26	33	electroporation	electroporation	NOUN
ajst-32571	26	34	,	,	PUNCT
ajst-32571	26	35	liposomes	liposome	NOUN
ajst-32571	26	36	,	,	PUNCT
ajst-32571	26	37	or	or	CCONJ
ajst-32571	26	38	nanoparticles	nanoparticle	NOUN
ajst-32571	26	39	)	)	PUNCT
ajst-32571	27	1	[	[	X
ajst-32571	27	2	13	13	NUM
ajst-32571	27	3	]	]	PUNCT
ajst-32571	27	4	,	,	PUNCT
ajst-32571	27	5	which	which	PRON
ajst-32571	27	6	permit	permit	VERB
ajst-32571	27	7	the	the	DET
ajst-32571	27	8	synthesis	synthesis	NOUN
ajst-32571	27	9	and	and	CCONJ
ajst-32571	27	10	expression	expression	NOUN
ajst-32571	27	11	of	of	ADP
ajst-32571	27	12	the	the	DET
ajst-32571	27	13	receptor	receptor	NOUN
ajst-32571	27	14	protein	protein	NOUN
ajst-32571	27	15	after	after	ADP
ajst-32571	27	16	intracellular	intracellular	ADJ
ajst-32571	27	17	transcription	transcription	NOUN
ajst-32571	27	18	and	and	CCONJ
ajst-32571	27	19	translation	translation	NOUN
ajst-32571	27	20	.	.	PUNCT
ajst-32571	28	1	the	the	DET
ajst-32571	28	2	car	car	NOUN
ajst-32571	28	3	enables	enable	VERB
ajst-32571	28	4	the	the	DET
ajst-32571	28	5	t	t	NOUN
ajst-32571	28	6	cells	cell	NOUN
ajst-32571	28	7	to	to	PART
ajst-32571	28	8	detect	detect	VERB
ajst-32571	28	9	and	and	CCONJ
ajst-32571	28	10	bind	bind	VERB
ajst-32571	28	11	to	to	ADP
ajst-32571	28	12	the	the	DET
ajst-32571	28	13	complementary	complementary	ADJ
ajst-32571	28	14	antigen	antigen	NOUN
ajst-32571	28	15	on	on	ADP
ajst-32571	28	16	target	target	NOUN
ajst-32571	28	17	cells	cell	NOUN
ajst-32571	28	18	,	,	PUNCT
ajst-32571	28	19	further	far	ADV
ajst-32571	28	20	allowing	allow	VERB
ajst-32571	28	21	induced	induced	ADJ
ajst-32571	28	22	apoptosis	apoptosis	NOUN
ajst-32571	28	23	by	by	ADP
ajst-32571	28	24	the	the	DET
ajst-32571	28	25	secretion	secretion	NOUN
ajst-32571	28	26	of	of	ADP
ajst-32571	28	27	perforin	perforin	NOUN
ajst-32571	28	28	and	and	CCONJ
ajst-32571	28	29	granzymes	granzyme	VERB
ajst-32571	28	30	[	[	X
ajst-32571	28	31	12	12	NUM
ajst-32571	28	32	]	]	PUNCT
ajst-32571	28	33	.	.	PUNCT
ajst-32571	29	1	figure	figure	NOUN
ajst-32571	29	2	1	1	NUM
ajst-32571	29	3	.	.	PUNCT
ajst-32571	29	4	car	car	NOUN
ajst-32571	29	5	-	-	PUNCT
ajst-32571	29	6	t	t	NOUN
ajst-32571	29	7	cell	cell	NOUN
ajst-32571	29	8	manufacture	manufacture	NOUN
ajst-32571	29	9	and	and	CCONJ
ajst-32571	29	10	subsequent	subsequent	ADJ
ajst-32571	29	11	apoptosis	apoptosis	NOUN
ajst-32571	29	12	induction	induction	NOUN
ajst-32571	29	13	in	in	ADP
ajst-32571	29	14	antigen	antigen	NOUN
ajst-32571	29	15	-	-	PUNCT
ajst-32571	29	16	expressing	express	VERB
ajst-32571	29	17	cancer	cancer	NOUN
ajst-32571	29	18	cells	cell	NOUN
ajst-32571	29	19	.	.	PUNCT
ajst-32571	30	1	the	the	DET
ajst-32571	30	2	car	car	NOUN
ajst-32571	30	3	gene	gene	NOUN
ajst-32571	30	4	is	be	AUX
ajst-32571	30	5	inserted	insert	VERB
ajst-32571	30	6	into	into	ADP
ajst-32571	30	7	t	t	NOUN
ajst-32571	30	8	cells	cell	NOUN
ajst-32571	30	9	collected	collect	VERB
ajst-32571	30	10	by	by	ADP
ajst-32571	30	11	leukapheresis	leukapheresis	NOUN
ajst-32571	30	12	,	,	PUNCT
ajst-32571	30	13	after	after	ADP
ajst-32571	30	14	which	which	PRON
ajst-32571	30	15	the	the	DET
ajst-32571	30	16	car	car	NOUN
ajst-32571	30	17	-	-	PUNCT
ajst-32571	30	18	t	t	NOUN
ajst-32571	30	19	cells	cell	NOUN
ajst-32571	30	20	are	be	AUX
ajst-32571	30	21	multiplied	multiply	VERB
ajst-32571	30	22	and	and	CCONJ
ajst-32571	30	23	infused	infuse	VERB
ajst-32571	30	24	back	back	ADV
ajst-32571	30	25	into	into	ADP
ajst-32571	30	26	the	the	DET
ajst-32571	30	27	patient	patient	NOUN
ajst-32571	30	28	.	.	PUNCT
ajst-32571	31	1	the	the	DET
ajst-32571	31	2	car	car	NOUN
ajst-32571	31	3	structure	structure	NOUN
ajst-32571	31	4	includes	include	VERB
ajst-32571	31	5	an	an	DET
ajst-32571	31	6	antigen	antigen	ADJ
ajst-32571	31	7	recognition	recognition	NOUN
ajst-32571	31	8	domain	domain	NOUN
ajst-32571	31	9	and	and	CCONJ
ajst-32571	31	10	intracellular	intracellular	ADJ
ajst-32571	31	11	signalling	signal	VERB
ajst-32571	31	12	domain(s	domain(s	NOUN
ajst-32571	31	13	)	)	PUNCT
ajst-32571	31	14	.	.	PUNCT
ajst-32571	32	1	[	[	X
ajst-32571	32	2	14	14	NUM
ajst-32571	32	3	]	]	X
ajst-32571	32	4	a	a	DET
ajst-32571	32	5	car	car	NOUN
ajst-32571	32	6	mimics	mimic	VERB
ajst-32571	32	7	the	the	DET
ajst-32571	32	8	structure	structure	NOUN
ajst-32571	32	9	of	of	ADP
ajst-32571	32	10	a	a	DET
ajst-32571	32	11	natural	natural	ADJ
ajst-32571	32	12	antibody	antibody	NOUN
ajst-32571	32	13	and	and	CCONJ
ajst-32571	32	14	typically	typically	ADV
ajst-32571	32	15	resembles	resemble	VERB
ajst-32571	32	16	a	a	DET
ajst-32571	32	17	linkage	linkage	NOUN
ajst-32571	32	18	of	of	ADP
ajst-32571	32	19	antigen	antigen	ADJ
ajst-32571	32	20	recognition	recognition	NOUN
ajst-32571	32	21	,	,	PUNCT
ajst-32571	32	22	hinge	hinge	NOUN
ajst-32571	32	23	,	,	PUNCT
ajst-32571	32	24	transmembrane	transmembrane	NOUN
ajst-32571	32	25	,	,	PUNCT
ajst-32571	32	26	and	and	CCONJ
ajst-32571	32	27	intracellular	intracellular	ADJ
ajst-32571	32	28	signaling	signal	VERB
ajst-32571	32	29	domains	domain	NOUN
ajst-32571	32	30	[	[	X
ajst-32571	32	31	15	15	NUM
ajst-32571	32	32	]	]	PUNCT
ajst-32571	32	33	.	.	PUNCT
ajst-32571	33	1	the	the	DET
ajst-32571	33	2	antigen	antigen	ADJ
ajst-32571	33	3	recognition	recognition	NOUN
ajst-32571	33	4	domain	domain	NOUN
ajst-32571	33	5	is	be	AUX
ajst-32571	33	6	a	a	DET
ajst-32571	33	7	single	single	ADJ
ajst-32571	33	8	-	-	PUNCT
ajst-32571	33	9	chain	chain	NOUN
ajst-32571	33	10	fragment	fragment	NOUN
ajst-32571	33	11	variant	variant	NOUN
ajst-32571	33	12	(	(	PUNCT
ajst-32571	33	13	scfv	scfv	PROPN
ajst-32571	33	14	)	)	PUNCT
ajst-32571	33	15	of	of	ADP
ajst-32571	33	16	heavy	heavy	ADJ
ajst-32571	33	17	and	and	CCONJ
ajst-32571	33	18	light	light	ADJ
ajst-32571	33	19	regions	region	NOUN
ajst-32571	33	20	derived	derive	VERB
ajst-32571	33	21	from	from	ADP
ajst-32571	33	22	antibodies	antibody	NOUN
ajst-32571	33	23	,	,	PUNCT
ajst-32571	33	24	designed	design	VERB
ajst-32571	33	25	to	to	PART
ajst-32571	33	26	bind	bind	VERB
ajst-32571	33	27	with	with	ADP
ajst-32571	33	28	a	a	DET
ajst-32571	33	29	particular	particular	ADJ
ajst-32571	33	30	target	target	NOUN
ajst-32571	33	31	antigen	antigen	NOUN
ajst-32571	34	1	[	[	X
ajst-32571	34	2	12	12	NUM
ajst-32571	34	3	]	]	PUNCT
ajst-32571	34	4	;	;	PUNCT
ajst-32571	34	5	the	the	DET
ajst-32571	34	6	hinge	hinge	NOUN
ajst-32571	34	7	domain	domain	NOUN
ajst-32571	34	8	enables	enable	VERB
ajst-32571	34	9	flexibility	flexibility	NOUN
ajst-32571	34	10	of	of	ADP
ajst-32571	34	11	the	the	DET
ajst-32571	34	12	antigen	antigen	ADJ
ajst-32571	34	13	recognition	recognition	NOUN
ajst-32571	34	14	region	region	NOUN
ajst-32571	34	15	;	;	PUNCT
ajst-32571	34	16	the	the	DET
ajst-32571	34	17	transmembrane	transmembrane	NOUN
ajst-32571	34	18	domain	domain	NOUN
ajst-32571	34	19	provides	provide	VERB
ajst-32571	34	20	stability	stability	NOUN
ajst-32571	34	21	and	and	CCONJ
ajst-32571	34	22	anchorage	anchorage	NOUN
ajst-32571	34	23	to	to	ADP
ajst-32571	34	24	the	the	DET
ajst-32571	34	25	cell	cell	NOUN
ajst-32571	34	26	membrane	membrane	NOUN
ajst-32571	34	27	;	;	PUNCT
ajst-32571	34	28	and	and	CCONJ
ajst-32571	34	29	the	the	DET
ajst-32571	34	30	intracellular	intracellular	ADJ
ajst-32571	34	31	signalling	signal	VERB
ajst-32571	34	32	domain	domain	NOUN
ajst-32571	34	33	governs	govern	VERB
ajst-32571	34	34	cell	cell	NOUN
ajst-32571	34	35	activation	activation	NOUN
ajst-32571	34	36	after	after	ADP
ajst-32571	34	37	binding	bind	VERB
ajst-32571	34	38	,	,	PUNCT
ajst-32571	34	39	by	by	ADP
ajst-32571	34	40	setting	set	VERB
ajst-32571	34	41	off	off	ADP
ajst-32571	34	42	necessary	necessary	ADJ
ajst-32571	34	43	signalling	signal	VERB
ajst-32571	34	44	pathways	pathway	NOUN
ajst-32571	34	45	within	within	ADP
ajst-32571	34	46	the	the	DET
ajst-32571	34	47	lymphocyte	lymphocyte	NOUN
ajst-32571	34	48	that	that	PRON
ajst-32571	34	49	enable	enable	VERB
ajst-32571	34	50	induction	induction	NOUN
ajst-32571	34	51	of	of	ADP
ajst-32571	34	52	apoptosis	apoptosis	NOUN
ajst-32571	34	53	[	[	X
ajst-32571	34	54	15	15	NUM
ajst-32571	34	55	]	]	PUNCT
ajst-32571	34	56	.	.	PUNCT
ajst-32571	35	1	in	in	ADP
ajst-32571	35	2	contrast	contrast	NOUN
ajst-32571	35	3	to	to	ADP
ajst-32571	35	4	traditional	traditional	ADJ
ajst-32571	35	5	cancer	cancer	NOUN
ajst-32571	35	6	therapy	therapy	NOUN
ajst-32571	35	7	methods	method	NOUN
ajst-32571	35	8	,	,	PUNCT
ajst-32571	35	9	car	car	NOUN
ajst-32571	35	10	-	-	PUNCT
ajst-32571	35	11	t	t	NOUN
ajst-32571	35	12	cell	cell	NOUN
ajst-32571	35	13	therapy	therapy	NOUN
ajst-32571	35	14	offers	offer	VERB
ajst-32571	35	15	several	several	ADJ
ajst-32571	35	16	advantages	advantage	NOUN
ajst-32571	35	17	.	.	PUNCT
ajst-32571	36	1	for	for	ADP
ajst-32571	36	2	example	example	NOUN
ajst-32571	36	3	,	,	PUNCT
ajst-32571	36	4	unlike	unlike	ADP
ajst-32571	36	5	surgery	surgery	NOUN
ajst-32571	36	6	and	and	CCONJ
ajst-32571	36	7	chemotherapy	chemotherapy	NOUN
ajst-32571	36	8	,	,	PUNCT
ajst-32571	36	9	car	car	NOUN
ajst-32571	36	10	-	-	PUNCT
ajst-32571	36	11	t	t	NOUN
ajst-32571	36	12	kills	kill	VERB
ajst-32571	36	13	cancerous	cancerous	ADJ
ajst-32571	36	14	cells	cell	NOUN
ajst-32571	36	15	with	with	ADP
ajst-32571	36	16	extreme	extreme	ADJ
ajst-32571	36	17	precision	precision	NOUN
ajst-32571	36	18	,	,	PUNCT
ajst-32571	36	19	without	without	ADP
ajst-32571	36	20	causing	cause	VERB
ajst-32571	36	21	damage	damage	NOUN
ajst-32571	36	22	to	to	ADP
ajst-32571	36	23	healthy	healthy	ADJ
ajst-32571	36	24	bystander	bystander	NOUN
ajst-32571	36	25	cells	cell	NOUN
ajst-32571	36	26	.	.	PUNCT
ajst-32571	37	1	in	in	ADP
ajst-32571	37	2	doing	do	VERB
ajst-32571	37	3	so	so	ADV
ajst-32571	37	4	,	,	PUNCT
ajst-32571	37	5	as	as	ADV
ajst-32571	37	6	long	long	ADV
ajst-32571	37	7	as	as	SCONJ
ajst-32571	37	8	they	they	PRON
ajst-32571	37	9	do	do	AUX
ajst-32571	37	10	not	not	PART
ajst-32571	37	11	express	express	VERB
ajst-32571	37	12	the	the	DET
ajst-32571	37	13	same	same	ADJ
ajst-32571	37	14	targeted	target	VERB
ajst-32571	37	15	antigen	antigen	NOUN
ajst-32571	37	16	[	[	X
ajst-32571	37	17	16	16	NUM
ajst-32571	37	18	]	]	PUNCT
ajst-32571	37	19	,	,	PUNCT
ajst-32571	37	20	the	the	DET
ajst-32571	37	21	characteristic	characteristic	NOUN
ajst-32571	37	22	of	of	ADP
ajst-32571	37	23	engineered	engineer	VERB
ajst-32571	37	24	lymphocytes	lymphocyte	NOUN
ajst-32571	37	25	being	be	AUX
ajst-32571	37	26	native	native	ADJ
ajst-32571	37	27	to	to	ADP
ajst-32571	37	28	the	the	DET
ajst-32571	37	29	patient	patient	NOUN
ajst-32571	37	30	[	[	X
ajst-32571	37	31	17	17	NUM
ajst-32571	37	32	]	]	PUNCT
ajst-32571	37	33	also	also	ADV
ajst-32571	37	34	excludes	exclude	VERB
ajst-32571	37	35	the	the	DET
ajst-32571	37	36	possibility	possibility	NOUN
ajst-32571	37	37	of	of	ADP
ajst-32571	37	38	immune	immune	ADJ
ajst-32571	37	39	system	system	NOUN
ajst-32571	37	40	rejection	rejection	NOUN
ajst-32571	37	41	.	.	PUNCT
ajst-32571	38	1	the	the	DET
ajst-32571	38	2	unique	unique	ADJ
ajst-32571	38	3	customisability	customisability	NOUN
ajst-32571	38	4	and	and	CCONJ
ajst-32571	38	5	continual	continual	ADJ
ajst-32571	38	6	improvability	improvability	NOUN
ajst-32571	38	7	of	of	ADP
ajst-32571	38	8	the	the	DET
ajst-32571	38	9	car	car	NOUN
ajst-32571	38	10	structure	structure	NOUN
ajst-32571	38	11	,	,	PUNCT
ajst-32571	38	12	along	along	ADP
ajst-32571	38	13	with	with	ADP
ajst-32571	38	14	the	the	DET
ajst-32571	38	15	non	non	PROPN
ajst-32571	38	16	-	-	NOUN
ajst-32571	38	17	mhc	mhc	NOUN
ajst-32571	38	18	(	(	PUNCT
ajst-32571	38	19	major	major	ADJ
ajst-32571	38	20	histocompatibility	histocompatibility	NOUN
ajst-32571	38	21	179	179	NUM
ajst-32571	38	22	complex)-reliant	complex)-reliant	NOUN
ajst-32571	38	23	mechanism	mechanism	NOUN
ajst-32571	38	24	[	[	X
ajst-32571	38	25	11	11	NUM
ajst-32571	38	26	]	]	PUNCT
ajst-32571	38	27	,	,	PUNCT
ajst-32571	38	28	contribute	contribute	VERB
ajst-32571	38	29	to	to	ADP
ajst-32571	38	30	bolstering	bolster	VERB
ajst-32571	38	31	the	the	DET
ajst-32571	38	32	potential	potential	NOUN
ajst-32571	38	33	of	of	ADP
ajst-32571	38	34	car	car	NOUN
ajst-32571	38	35	-	-	PUNCT
ajst-32571	38	36	t	t	NOUN
ajst-32571	38	37	as	as	ADP
ajst-32571	38	38	a	a	DET
ajst-32571	38	39	cancer	cancer	NOUN
ajst-32571	38	40	-	-	PUNCT
ajst-32571	38	41	solving	solve	VERB
ajst-32571	38	42	candidate	candidate	NOUN
ajst-32571	38	43	.	.	PUNCT
ajst-32571	39	1	figure	figure	NOUN
ajst-32571	39	2	2	2	NUM
ajst-32571	39	3	.	.	PUNCT
ajst-32571	40	1	mhc	mhc	PROPN
ajst-32571	40	2	independence	independence	NOUN
ajst-32571	40	3	of	of	ADP
ajst-32571	40	4	car	car	NOUN
ajst-32571	40	5	-	-	PUNCT
ajst-32571	40	6	t	t	NOUN
ajst-32571	40	7	cells	cell	NOUN
ajst-32571	40	8	.	.	PUNCT
ajst-32571	41	1	(	(	PUNCT
ajst-32571	41	2	a	a	X
ajst-32571	41	3	)	)	PUNCT
ajst-32571	41	4	antigen	antigen	ADJ
ajst-32571	41	5	presentation	presentation	NOUN
ajst-32571	41	6	on	on	ADP
ajst-32571	41	7	mhc	mhc	PROPN
ajst-32571	41	8	-	-	PUNCT
ajst-32571	41	9	i	i	PRON
ajst-32571	41	10	permits	permit	VERB
ajst-32571	41	11	target	target	NOUN
ajst-32571	41	12	cancer	cancer	NOUN
ajst-32571	41	13	cell	cell	NOUN
ajst-32571	41	14	elimination	elimination	NOUN
ajst-32571	41	15	by	by	ADP
ajst-32571	41	16	the	the	DET
ajst-32571	41	17	t	t	NOUN
ajst-32571	41	18	cell	cell	NOUN
ajst-32571	41	19	;	;	PUNCT
ajst-32571	41	20	(	(	PUNCT
ajst-32571	41	21	b	b	X
ajst-32571	41	22	)	)	PUNCT
ajst-32571	41	23	mhc	mhc	NOUN
ajst-32571	41	24	-	-	PUNCT
ajst-32571	41	25	i	i	PRON
ajst-32571	41	26	downregulation	downregulation	NOUN
ajst-32571	41	27	inhibits	inhibit	VERB
ajst-32571	41	28	t	t	NOUN
ajst-32571	41	29	cell	cell	NOUN
ajst-32571	41	30	-	-	PUNCT
ajst-32571	41	31	binding	bind	VERB
ajst-32571	41	32	and	and	CCONJ
ajst-32571	41	33	activation	activation	NOUN
ajst-32571	41	34	,	,	PUNCT
ajst-32571	41	35	thus	thus	ADV
ajst-32571	41	36	preventing	prevent	VERB
ajst-32571	41	37	cancer	cancer	NOUN
ajst-32571	41	38	cell	cell	NOUN
ajst-32571	41	39	elimination	elimination	NOUN
ajst-32571	41	40	;	;	PUNCT
ajst-32571	41	41	(	(	PUNCT
ajst-32571	41	42	c	c	X
ajst-32571	41	43	)	)	PUNCT
ajst-32571	41	44	a	a	DET
ajst-32571	41	45	car	car	NOUN
ajst-32571	41	46	-	-	PUNCT
ajst-32571	41	47	modified	modify	VERB
ajst-32571	41	48	t	t	NOUN
ajst-32571	41	49	cell	cell	NOUN
ajst-32571	41	50	recognises	recognise	VERB
ajst-32571	41	51	a	a	DET
ajst-32571	41	52	tumour	tumour	NOUN
ajst-32571	41	53	-	-	PUNCT
ajst-32571	41	54	associated	associate	VERB
ajst-32571	41	55	antigen	antigen	NOUN
ajst-32571	41	56	and	and	CCONJ
ajst-32571	41	57	induces	induce	VERB
ajst-32571	41	58	cancer	cancer	NOUN
ajst-32571	41	59	cell	cell	NOUN
ajst-32571	41	60	elimination	elimination	NOUN
ajst-32571	41	61	despite	despite	SCONJ
ajst-32571	41	62	mhc	mhc	PROPN
ajst-32571	41	63	-	-	PUNCT
ajst-32571	41	64	i	i	PRON
ajst-32571	41	65	downregulation	downregulation	NOUN
ajst-32571	41	66	.	.	PUNCT
ajst-32571	42	1	[	[	X
ajst-32571	42	2	18	18	NUM
ajst-32571	42	3	]	]	SYM
ajst-32571	42	4	2.3	2.3	NUM
ajst-32571	42	5	cldn6	cldn6	NOUN
ajst-32571	42	6	and	and	CCONJ
ajst-32571	42	7	car	car	NOUN
ajst-32571	42	8	-	-	PUNCT
ajst-32571	42	9	t	t	NOUN
ajst-32571	42	10	cell	cell	NOUN
ajst-32571	42	11	therapy	therapy	NOUN
ajst-32571	42	12	though	though	SCONJ
ajst-32571	42	13	primarily	primarily	ADV
ajst-32571	42	14	developed	develop	VERB
ajst-32571	42	15	for	for	ADP
ajst-32571	42	16	haematologic	haematologic	ADJ
ajst-32571	42	17	cancers	cancer	NOUN
ajst-32571	42	18	,	,	PUNCT
ajst-32571	42	19	recent	recent	ADJ
ajst-32571	42	20	preclinical	preclinical	ADJ
ajst-32571	42	21	studies	study	NOUN
ajst-32571	42	22	have	have	AUX
ajst-32571	42	23	successfully	successfully	ADV
ajst-32571	42	24	begun	begin	VERB
ajst-32571	42	25	to	to	PART
ajst-32571	42	26	apply	apply	VERB
ajst-32571	42	27	car	car	NOUN
ajst-32571	42	28	-	-	PUNCT
ajst-32571	42	29	t	t	NOUN
ajst-32571	42	30	cell	cell	NOUN
ajst-32571	42	31	therapy	therapy	NOUN
ajst-32571	42	32	to	to	ADP
ajst-32571	42	33	various	various	ADJ
ajst-32571	42	34	solid	solid	ADJ
ajst-32571	42	35	tumorous	tumorous	ADJ
ajst-32571	42	36	cancers	cancer	NOUN
ajst-32571	42	37	,	,	PUNCT
ajst-32571	42	38	including	include	VERB
ajst-32571	42	39	ovarian	ovarian	ADJ
ajst-32571	42	40	cancer	cancer	NOUN
ajst-32571	42	41	.	.	PUNCT
ajst-32571	43	1	claudin-6	claudin-6	NUM
ajst-32571	43	2	(	(	PUNCT
ajst-32571	43	3	cldn6	cldn6	PROPN
ajst-32571	43	4	)	)	PUNCT
ajst-32571	43	5	is	be	AUX
ajst-32571	43	6	a	a	DET
ajst-32571	43	7	member	member	NOUN
ajst-32571	43	8	of	of	ADP
ajst-32571	43	9	the	the	DET
ajst-32571	43	10	claudin	claudin	PROPN
ajst-32571	43	11	(	(	PUNCT
ajst-32571	43	12	cldn	cldn	NOUN
ajst-32571	43	13	)	)	PUNCT
ajst-32571	43	14	family	family	NOUN
ajst-32571	43	15	,	,	PUNCT
ajst-32571	43	16	a	a	DET
ajst-32571	43	17	group	group	NOUN
ajst-32571	43	18	of	of	ADP
ajst-32571	43	19	tight	tight	ADJ
ajst-32571	43	20	junction	junction	NOUN
ajst-32571	43	21	transmembrane	transmembrane	NOUN
ajst-32571	43	22	proteins	protein	NOUN
ajst-32571	43	23	present	present	ADJ
ajst-32571	43	24	on	on	ADP
ajst-32571	43	25	epi	epi	NOUN
ajst-32571	43	26	and	and	CCONJ
ajst-32571	43	27	endothelial	endothelial	ADJ
ajst-32571	43	28	cells	cell	NOUN
ajst-32571	43	29	that	that	PRON
ajst-32571	43	30	play	play	VERB
ajst-32571	43	31	a	a	DET
ajst-32571	43	32	role	role	NOUN
ajst-32571	43	33	in	in	ADP
ajst-32571	43	34	paracellular	paracellular	ADJ
ajst-32571	43	35	barriers	barrier	NOUN
ajst-32571	43	36	and	and	CCONJ
ajst-32571	43	37	therefore	therefore	ADV
ajst-32571	43	38	regulate	regulate	VERB
ajst-32571	43	39	the	the	DET
ajst-32571	43	40	permeability	permeability	NOUN
ajst-32571	43	41	of	of	ADP
ajst-32571	43	42	epithelia	epithelia	PROPN
ajst-32571	43	43	and	and	CCONJ
ajst-32571	43	44	endothelia	endothelia	PROPN
ajst-32571	44	1	[	[	X
ajst-32571	44	2	19	19	NUM
ajst-32571	44	3	]	]	X
ajst-32571	44	4	,	,	PUNCT
ajst-32571	44	5	alongside	alongside	ADP
ajst-32571	44	6	occludin	occludin	NOUN
ajst-32571	44	7	and	and	CCONJ
ajst-32571	44	8	tricellulin	tricellulin	PRON
ajst-32571	45	1	[	[	X
ajst-32571	45	2	20	20	NUM
ajst-32571	45	3	]	]	PUNCT
ajst-32571	45	4	.	.	PUNCT
ajst-32571	46	1	figure	figure	VERB
ajst-32571	46	2	3	3	NUM
ajst-32571	46	3	.	.	PUNCT
ajst-32571	46	4	paracellular	paracellular	ADJ
ajst-32571	46	5	junction	junction	NOUN
ajst-32571	46	6	structures	structure	NOUN
ajst-32571	46	7	of	of	ADP
ajst-32571	46	8	epithelial	epithelial	ADJ
ajst-32571	46	9	cells	cell	NOUN
ajst-32571	46	10	.	.	PUNCT
ajst-32571	47	1	(	(	PUNCT
ajst-32571	47	2	a	a	X
ajst-32571	47	3	)	)	PUNCT
ajst-32571	47	4	epithelial	epithelial	ADJ
ajst-32571	47	5	cells	cell	NOUN
ajst-32571	47	6	;	;	PUNCT
ajst-32571	47	7	(	(	PUNCT
ajst-32571	47	8	b	b	X
ajst-32571	47	9	)	)	PUNCT
ajst-32571	47	10	an	an	DET
ajst-32571	47	11	enlarged	enlarge	VERB
ajst-32571	47	12	diagram	diagram	NOUN
ajst-32571	47	13	of	of	ADP
ajst-32571	47	14	the	the	DET
ajst-32571	47	15	tight	tight	ADJ
ajst-32571	47	16	junction	junction	NOUN
ajst-32571	47	17	,	,	PUNCT
ajst-32571	47	18	adherens	adheren	NOUN
ajst-32571	47	19	junction	junction	NOUN
ajst-32571	47	20	,	,	PUNCT
ajst-32571	47	21	gap	gap	NOUN
ajst-32571	47	22	junction	junction	NOUN
ajst-32571	47	23	,	,	PUNCT
ajst-32571	47	24	and	and	CCONJ
ajst-32571	47	25	desmosomes	desmosome	NOUN
ajst-32571	47	26	sections	section	NOUN
ajst-32571	47	27	between	between	ADP
ajst-32571	47	28	epithelial	epithelial	ADJ
ajst-32571	47	29	cells	cell	NOUN
ajst-32571	47	30	;	;	PUNCT
ajst-32571	47	31	(	(	PUNCT
ajst-32571	47	32	c	c	X
ajst-32571	47	33	)	)	PUNCT
ajst-32571	47	34	a	a	DET
ajst-32571	47	35	three	three	NUM
ajst-32571	47	36	-	-	PUNCT
ajst-32571	47	37	dimensional	dimensional	ADJ
ajst-32571	47	38	representation	representation	NOUN
ajst-32571	47	39	of	of	ADP
ajst-32571	47	40	the	the	DET
ajst-32571	47	41	junctions	junction	NOUN
ajst-32571	47	42	.	.	PUNCT
ajst-32571	48	1	[	[	X
ajst-32571	48	2	21	21	NUM
ajst-32571	48	3	]	]	SYM
ajst-32571	48	4	cldn6	cldn6	PROPN
ajst-32571	48	5	,	,	PUNCT
ajst-32571	48	6	which	which	PRON
ajst-32571	48	7	is	be	AUX
ajst-32571	48	8	usually	usually	ADV
ajst-32571	48	9	present	present	ADJ
ajst-32571	48	10	only	only	ADV
ajst-32571	48	11	in	in	ADP
ajst-32571	48	12	the	the	DET
ajst-32571	48	13	embryonic	embryonic	ADJ
ajst-32571	48	14	tissues	tissue	NOUN
ajst-32571	48	15	of	of	ADP
ajst-32571	48	16	specific	specific	ADJ
ajst-32571	48	17	organs	organ	NOUN
ajst-32571	48	18	[	[	X
ajst-32571	48	19	20	20	NUM
ajst-32571	48	20	]	]	PUNCT
ajst-32571	48	21	,	,	PUNCT
ajst-32571	48	22	is	be	AUX
ajst-32571	48	23	overexpressed	overexpresse	VERB
ajst-32571	48	24	in	in	ADP
ajst-32571	48	25	ovarian	ovarian	ADJ
ajst-32571	48	26	cancers	cancer	NOUN
ajst-32571	48	27	.	.	PUNCT
ajst-32571	49	1	in	in	ADP
ajst-32571	49	2	contrast	contrast	NOUN
ajst-32571	49	3	,	,	PUNCT
ajst-32571	49	4	regular	regular	ADJ
ajst-32571	49	5	adult	adult	NOUN
ajst-32571	49	6	cells	cell	NOUN
ajst-32571	49	7	generally	generally	ADV
ajst-32571	49	8	lack	lack	VERB
ajst-32571	49	9	such	such	ADJ
ajst-32571	49	10	expression	expression	NOUN
ajst-32571	49	11	[	[	X
ajst-32571	49	12	22	22	NUM
ajst-32571	49	13	]	]	SYM
ajst-32571	49	14	180	180	NUM
ajst-32571	49	15	—	—	PUNCT
ajst-32571	49	16	rendering	render	VERB
ajst-32571	49	17	cldn6	cldn6	NOUN
ajst-32571	49	18	an	an	DET
ajst-32571	49	19	ideal	ideal	ADJ
ajst-32571	49	20	oncofetal	oncofetal	ADJ
ajst-32571	49	21	target	target	NOUN
ajst-32571	49	22	for	for	ADP
ajst-32571	49	23	car	car	NOUN
ajst-32571	49	24	-	-	PUNCT
ajst-32571	49	25	t	t	NOUN
ajst-32571	49	26	therapy	therapy	NOUN
ajst-32571	49	27	[	[	X
ajst-32571	49	28	23	23	NUM
ajst-32571	49	29	]	]	PUNCT
ajst-32571	49	30	.	.	PUNCT
ajst-32571	50	1	for	for	ADP
ajst-32571	50	2	example	example	NOUN
ajst-32571	50	3	,	,	PUNCT
ajst-32571	50	4	an	an	DET
ajst-32571	50	5	investigation	investigation	NOUN
ajst-32571	50	6	demonstrated	demonstrate	VERB
ajst-32571	50	7	69.4	69.4	NUM
ajst-32571	50	8	%	%	NOUN
ajst-32571	50	9	of	of	ADP
ajst-32571	50	10	tested	test	VERB
ajst-32571	50	11	ovarian	ovarian	ADJ
ajst-32571	50	12	carcinoma	carcinoma	NOUN
ajst-32571	50	13	samples	sample	NOUN
ajst-32571	50	14	exhibited	exhibit	VERB
ajst-32571	50	15	cldn6	cldn6	NOUN
ajst-32571	50	16	expression	expression	NOUN
ajst-32571	50	17	[	[	X
ajst-32571	50	18	24	24	NUM
ajst-32571	50	19	]	]	PUNCT
ajst-32571	50	20	.	.	PUNCT
ajst-32571	51	1	it	it	PRON
ajst-32571	51	2	is	be	AUX
ajst-32571	51	3	agreed	agree	VERB
ajst-32571	51	4	that	that	SCONJ
ajst-32571	51	5	cldn6	cldn6	NOUN
ajst-32571	51	6	is	be	AUX
ajst-32571	51	7	crucial	crucial	ADJ
ajst-32571	51	8	in	in	ADP
ajst-32571	51	9	normal	normal	ADJ
ajst-32571	51	10	stem	stem	NOUN
ajst-32571	51	11	cell	cell	NOUN
ajst-32571	51	12	differentiation	differentiation	NOUN
ajst-32571	51	13	and	and	CCONJ
ajst-32571	51	14	the	the	DET
ajst-32571	51	15	formation	formation	NOUN
ajst-32571	51	16	of	of	ADP
ajst-32571	51	17	epithelial	epithelial	ADJ
ajst-32571	51	18	tissue	tissue	NOUN
ajst-32571	51	19	,	,	PUNCT
ajst-32571	51	20	and	and	CCONJ
ajst-32571	51	21	may	may	AUX
ajst-32571	51	22	be	be	AUX
ajst-32571	51	23	utilized	utilize	VERB
ajst-32571	51	24	by	by	ADP
ajst-32571	51	25	cancerous	cancerous	ADJ
ajst-32571	51	26	cells	cell	NOUN
ajst-32571	51	27	to	to	PART
ajst-32571	51	28	increase	increase	VERB
ajst-32571	51	29	tight	tight	ADJ
ajst-32571	51	30	junction	junction	NOUN
ajst-32571	51	31	leakage	leakage	NOUN
ajst-32571	51	32	for	for	ADP
ajst-32571	51	33	the	the	DET
ajst-32571	51	34	acquisition	acquisition	NOUN
ajst-32571	51	35	of	of	ADP
ajst-32571	51	36	nutrition	nutrition	NOUN
ajst-32571	51	37	and	and	CCONJ
ajst-32571	51	38	growth	growth	NOUN
ajst-32571	51	39	factors	factor	NOUN
ajst-32571	51	40	,	,	PUNCT
ajst-32571	51	41	as	as	ADV
ajst-32571	51	42	well	well	ADV
ajst-32571	51	43	as	as	ADP
ajst-32571	51	44	to	to	PART
ajst-32571	51	45	create	create	VERB
ajst-32571	51	46	space	space	NOUN
ajst-32571	51	47	for	for	ADP
ajst-32571	51	48	invasion	invasion	NOUN
ajst-32571	51	49	and	and	CCONJ
ajst-32571	51	50	development	development	NOUN
ajst-32571	52	1	[	[	X
ajst-32571	52	2	25	25	NUM
ajst-32571	52	3	]	]	PUNCT
ajst-32571	52	4	,	,	PUNCT
ajst-32571	52	5	which	which	PRON
ajst-32571	52	6	explains	explain	VERB
ajst-32571	52	7	its	its	PRON
ajst-32571	52	8	high	high	ADJ
ajst-32571	52	9	expression	expression	NOUN
ajst-32571	52	10	in	in	ADP
ajst-32571	52	11	ovarian	ovarian	ADJ
ajst-32571	52	12	cancer	cancer	NOUN
ajst-32571	52	13	.	.	PUNCT
ajst-32571	53	1	cldn6	cldn6	NOUN
ajst-32571	53	2	-	-	PUNCT
ajst-32571	53	3	car	car	NOUN
ajst-32571	53	4	,	,	PUNCT
ajst-32571	53	5	claudin	claudin	VERB
ajst-32571	53	6	6	6	NUM
ajst-32571	53	7	-	-	PUNCT
ajst-32571	53	8	specific	specific	ADJ
ajst-32571	53	9	chimeric	chimeric	ADJ
ajst-32571	53	10	antigen	antigen	ADJ
ajst-32571	53	11	receptors	receptor	NOUN
ajst-32571	53	12	,	,	PUNCT
ajst-32571	53	13	are	be	AUX
ajst-32571	53	14	designed	design	VERB
ajst-32571	53	15	by	by	ADP
ajst-32571	53	16	modifying	modify	VERB
ajst-32571	53	17	various	various	ADJ
ajst-32571	53	18	domains	domain	NOUN
ajst-32571	53	19	of	of	ADP
ajst-32571	53	20	the	the	DET
ajst-32571	53	21	car	car	NOUN
ajst-32571	53	22	structure	structure	NOUN
ajst-32571	53	23	.	.	PUNCT
ajst-32571	54	1	the	the	DET
ajst-32571	54	2	scfv	scfv	NOUN
ajst-32571	54	3	of	of	ADP
ajst-32571	54	4	the	the	DET
ajst-32571	54	5	antigen	antigen	ADJ
ajst-32571	54	6	recognition	recognition	NOUN
ajst-32571	54	7	domain	domain	NOUN
ajst-32571	54	8	that	that	PRON
ajst-32571	54	9	exhibits	exhibit	VERB
ajst-32571	54	10	specificity	specificity	NOUN
ajst-32571	54	11	to	to	ADP
ajst-32571	54	12	cldn6	cldn6	NOUN
ajst-32571	54	13	is	be	AUX
ajst-32571	54	14	derived	derive	VERB
ajst-32571	54	15	from	from	ADP
ajst-32571	54	16	the	the	DET
ajst-32571	54	17	imab206	imab206	PROPN
ajst-32571	54	18	-	-	PUNCT
ajst-32571	54	19	c46s	c46	NOUN
ajst-32571	54	20	antibody	antibody	NOUN
ajst-32571	54	21	[	[	X
ajst-32571	54	22	26	26	NUM
ajst-32571	54	23	]	]	PUNCT
ajst-32571	54	24	.	.	PUNCT
ajst-32571	55	1	the	the	DET
ajst-32571	55	2	hinge	hinge	NOUN
ajst-32571	55	3	region	region	NOUN
ajst-32571	55	4	is	be	AUX
ajst-32571	55	5	made	make	VERB
ajst-32571	55	6	of	of	ADP
ajst-32571	55	7	the	the	DET
ajst-32571	55	8	cd8α	cd8α	NOUN
ajst-32571	55	9	protein	protein	NOUN
ajst-32571	55	10	,	,	PUNCT
ajst-32571	55	11	and	and	CCONJ
ajst-32571	55	12	the	the	DET
ajst-32571	55	13	intracellular	intracellular	ADJ
ajst-32571	55	14	signalling	signal	VERB
ajst-32571	55	15	domain	domain	NOUN
ajst-32571	55	16	below	below	ADP
ajst-32571	55	17	the	the	DET
ajst-32571	55	18	transmembrane	transmembrane	NOUN
ajst-32571	55	19	domain	domain	NOUN
ajst-32571	55	20	consists	consist	VERB
ajst-32571	55	21	of	of	ADP
ajst-32571	55	22	a	a	DET
ajst-32571	55	23	costimulatory	costimulatory	NOUN
ajst-32571	55	24	4	4	NUM
ajst-32571	55	25	-	-	SYM
ajst-32571	55	26	1bb	1bb	NOUN
ajst-32571	55	27	connected	connect	VERB
ajst-32571	55	28	to	to	ADP
ajst-32571	55	29	cd3ζ	cd3ζ	NOUN
ajst-32571	56	1	[	[	X
ajst-32571	56	2	27	27	NUM
ajst-32571	56	3	]	]	PUNCT
ajst-32571	56	4	.	.	PUNCT
ajst-32571	57	1	cd3ζ	cd3ζ	NOUN
ajst-32571	57	2	contains	contain	VERB
ajst-32571	57	3	three	three	NUM
ajst-32571	57	4	portions	portion	NOUN
ajst-32571	57	5	called	call	VERB
ajst-32571	57	6	immunoreceptor	immunoreceptor	NOUN
ajst-32571	57	7	tyrosine	tyrosine	NOUN
ajst-32571	57	8	-	-	PUNCT
ajst-32571	57	9	based	base	VERB
ajst-32571	57	10	activation	activation	NOUN
ajst-32571	57	11	motifs	motif	NOUN
ajst-32571	57	12	(	(	PUNCT
ajst-32571	57	13	itams	itam	NOUN
ajst-32571	57	14	)	)	PUNCT
ajst-32571	57	15	,	,	PUNCT
ajst-32571	57	16	which	which	PRON
ajst-32571	57	17	undergo	undergo	VERB
ajst-32571	57	18	phosphorylation	phosphorylation	NOUN
ajst-32571	57	19	upon	upon	SCONJ
ajst-32571	57	20	stimulation	stimulation	NOUN
ajst-32571	57	21	and	and	CCONJ
ajst-32571	57	22	trigger	trigger	VERB
ajst-32571	57	23	intracellular	intracellular	ADJ
ajst-32571	57	24	transduction	transduction	NOUN
ajst-32571	57	25	signalling	signal	VERB
ajst-32571	57	26	pathways	pathway	NOUN
ajst-32571	57	27	activating	activate	VERB
ajst-32571	57	28	the	the	DET
ajst-32571	57	29	t	t	NOUN
ajst-32571	57	30	cell	cell	NOUN
ajst-32571	58	1	[	[	X
ajst-32571	58	2	28	28	NUM
ajst-32571	58	3	]	]	X
ajst-32571	58	4	;	;	PUNCT
ajst-32571	58	5	4	4	NUM
ajst-32571	58	6	-	-	SYM
ajst-32571	58	7	1bb	1bb	NUM
ajst-32571	58	8	,	,	PUNCT
ajst-32571	58	9	once	once	ADV
ajst-32571	58	10	activated	activate	VERB
ajst-32571	58	11	,	,	PUNCT
ajst-32571	58	12	increases	increase	VERB
ajst-32571	58	13	synthesis	synthesis	NOUN
ajst-32571	58	14	of	of	ADP
ajst-32571	58	15	the	the	DET
ajst-32571	58	16	anti	anti	ADJ
ajst-32571	58	17	-	-	ADJ
ajst-32571	58	18	apoptotic	apoptotic	ADJ
ajst-32571	58	19	proteins	protein	NOUN
ajst-32571	58	20	bcl	bcl	NOUN
ajst-32571	58	21	-	-	PUNCT
ajst-32571	58	22	x(l	x(l	PROPN
ajst-32571	58	23	)	)	PUNCT
ajst-32571	58	24	,	,	PUNCT
ajst-32571	58	25	bfl-1	bfl-1	X
ajst-32571	58	26	,	,	PUNCT
ajst-32571	58	27	c	c	X
ajst-32571	58	28	-	-	PUNCT
ajst-32571	58	29	flip	flip	ADJ
ajst-32571	58	30	,	,	PUNCT
ajst-32571	58	31	and	and	CCONJ
ajst-32571	58	32	downregulates	downregulate	VERB
ajst-32571	58	33	expression	expression	NOUN
ajst-32571	58	34	of	of	ADP
ajst-32571	58	35	the	the	DET
ajst-32571	58	36	erk	erk	PROPN
ajst-32571	58	37	-	-	PUNCT
ajst-32571	58	38	dependent	dependent	ADJ
ajst-32571	58	39	bim	bim	NOUN
ajst-32571	58	40	gene	gene	NOUN
ajst-32571	58	41	,	,	PUNCT
ajst-32571	58	42	thus	thus	ADV
ajst-32571	58	43	preventing	prevent	VERB
ajst-32571	58	44	activation	activation	NOUN
ajst-32571	58	45	-	-	PUNCT
ajst-32571	58	46	induced	induce	VERB
ajst-32571	58	47	cell	cell	NOUN
ajst-32571	58	48	death	death	NOUN
ajst-32571	59	1	[	[	X
ajst-32571	59	2	29	29	NUM
ajst-32571	59	3	]	]	PUNCT
ajst-32571	59	4	.	.	PUNCT
ajst-32571	60	1	altogether	altogether	ADV
ajst-32571	60	2	,	,	PUNCT
ajst-32571	60	3	when	when	SCONJ
ajst-32571	60	4	a	a	DET
ajst-32571	60	5	cldn6	cldn6	NOUN
ajst-32571	60	6	-	-	PUNCT
ajst-32571	60	7	specific	specific	ADJ
ajst-32571	60	8	car	car	NOUN
ajst-32571	60	9	-	-	PUNCT
ajst-32571	60	10	t	t	NOUN
ajst-32571	60	11	lymphocyte	lymphocyte	NOUN
ajst-32571	60	12	binds	bind	VERB
ajst-32571	60	13	to	to	ADP
ajst-32571	60	14	a	a	DET
ajst-32571	60	15	cldn6	cldn6	NOUN
ajst-32571	60	16	molecule	molecule	NOUN
ajst-32571	60	17	,	,	PUNCT
ajst-32571	60	18	activation	activation	NOUN
ajst-32571	60	19	and	and	CCONJ
ajst-32571	60	20	proliferation	proliferation	NOUN
ajst-32571	60	21	of	of	ADP
ajst-32571	60	22	the	the	DET
ajst-32571	60	23	t	t	PROPN
ajst-32571	60	24	cell	cell	NOUN
ajst-32571	60	25	occur	occur	VERB
ajst-32571	60	26	,	,	PUNCT
ajst-32571	60	27	and	and	CCONJ
ajst-32571	60	28	apoptosis	apoptosis	NOUN
ajst-32571	60	29	can	can	AUX
ajst-32571	60	30	be	be	AUX
ajst-32571	60	31	induced	induce	VERB
ajst-32571	60	32	in	in	ADP
ajst-32571	60	33	the	the	DET
ajst-32571	60	34	detected	detect	VERB
ajst-32571	60	35	cldn6	cldn6	NOUN
ajst-32571	60	36	-	-	PUNCT
ajst-32571	60	37	expressing	express	VERB
ajst-32571	60	38	cell	cell	NOUN
ajst-32571	60	39	.	.	PUNCT
ajst-32571	61	1	cldn6	cldn6	NOUN
ajst-32571	61	2	-	-	PUNCT
ajst-32571	61	3	car	car	NOUN
ajst-32571	61	4	-	-	PUNCT
ajst-32571	61	5	t	t	NOUN
ajst-32571	61	6	offers	offer	VERB
ajst-32571	61	7	advantages	advantage	NOUN
ajst-32571	61	8	over	over	ADP
ajst-32571	61	9	other	other	ADJ
ajst-32571	61	10	current	current	ADJ
ajst-32571	61	11	ovarian	ovarian	ADJ
ajst-32571	61	12	cancer	cancer	NOUN
ajst-32571	61	13	car	car	NOUN
ajst-32571	61	14	-	-	PUNCT
ajst-32571	61	15	t	t	NOUN
ajst-32571	61	16	cell	cell	NOUN
ajst-32571	61	17	therapies	therapy	NOUN
ajst-32571	61	18	,	,	PUNCT
ajst-32571	61	19	such	such	ADJ
ajst-32571	61	20	as	as	ADP
ajst-32571	61	21	those	those	PRON
ajst-32571	61	22	targeting	target	VERB
ajst-32571	61	23	mesothelin	mesothelin	NOUN
ajst-32571	61	24	and	and	CCONJ
ajst-32571	61	25	human	human	ADJ
ajst-32571	61	26	epidermal	epidermal	ADJ
ajst-32571	61	27	growth	growth	NOUN
ajst-32571	61	28	factor	factor	NOUN
ajst-32571	61	29	receptor	receptor	NOUN
ajst-32571	61	30	2	2	NUM
ajst-32571	61	31	(	(	PUNCT
ajst-32571	61	32	her2	her2	PROPN
ajst-32571	61	33	)	)	PUNCT
ajst-32571	62	1	[	[	X
ajst-32571	62	2	30	30	NUM
ajst-32571	62	3	]	]	PUNCT
ajst-32571	62	4	.	.	PUNCT
ajst-32571	63	1	this	this	PRON
ajst-32571	63	2	is	be	AUX
ajst-32571	63	3	especially	especially	ADV
ajst-32571	63	4	due	due	ADJ
ajst-32571	63	5	to	to	ADP
ajst-32571	63	6	the	the	DET
ajst-32571	63	7	minimal	minimal	ADJ
ajst-32571	63	8	to	to	ADP
ajst-32571	63	9	no	no	DET
ajst-32571	63	10	expression	expression	NOUN
ajst-32571	63	11	of	of	ADP
ajst-32571	63	12	cldn6	cldn6	NOUN
ajst-32571	63	13	in	in	ADP
ajst-32571	63	14	healthy	healthy	ADJ
ajst-32571	63	15	adult	adult	NOUN
ajst-32571	63	16	cells	cell	NOUN
ajst-32571	63	17	[	[	X
ajst-32571	63	18	21	21	NUM
ajst-32571	63	19	]	]	X
ajst-32571	63	20	,	,	PUNCT
ajst-32571	63	21	which	which	PRON
ajst-32571	63	22	minimizes	minimize	VERB
ajst-32571	63	23	the	the	DET
ajst-32571	63	24	risks	risk	NOUN
ajst-32571	63	25	of	of	ADP
ajst-32571	63	26	treatment	treatment	NOUN
ajst-32571	63	27	harming	harm	VERB
ajst-32571	63	28	normal	normal	ADJ
ajst-32571	63	29	tissues	tissue	NOUN
ajst-32571	63	30	.	.	PUNCT
ajst-32571	64	1	additionally	additionally	ADV
ajst-32571	64	2	,	,	PUNCT
ajst-32571	64	3	high	high	ADJ
ajst-32571	64	4	expression	expression	NOUN
ajst-32571	64	5	in	in	ADP
ajst-32571	64	6	cancerous	cancerous	ADJ
ajst-32571	64	7	cells	cell	NOUN
ajst-32571	64	8	remains	remain	VERB
ajst-32571	64	9	even	even	ADV
ajst-32571	64	10	after	after	ADP
ajst-32571	64	11	metastasis	metastasis	NOUN
ajst-32571	64	12	[	[	X
ajst-32571	64	13	31	31	NUM
ajst-32571	64	14	]	]	PUNCT
ajst-32571	64	15	,	,	PUNCT
ajst-32571	64	16	making	make	VERB
ajst-32571	64	17	cldn6	cldn6	NOUN
ajst-32571	64	18	an	an	DET
ajst-32571	64	19	ideal	ideal	ADJ
ajst-32571	64	20	target	target	NOUN
ajst-32571	64	21	.	.	PUNCT
ajst-32571	65	1	however	however	ADV
ajst-32571	65	2	,	,	PUNCT
ajst-32571	65	3	compared	compare	VERB
ajst-32571	65	4	to	to	ADP
ajst-32571	65	5	other	other	ADJ
ajst-32571	65	6	therapies	therapy	NOUN
ajst-32571	65	7	,	,	PUNCT
ajst-32571	65	8	cldn6	cldn6	NOUN
ajst-32571	65	9	-	-	PUNCT
ajst-32571	65	10	targeting	targeting	NOUN
ajst-32571	65	11	also	also	ADV
ajst-32571	65	12	implies	imply	VERB
ajst-32571	65	13	unique	unique	ADJ
ajst-32571	65	14	precautions	precaution	NOUN
ajst-32571	65	15	related	relate	VERB
ajst-32571	65	16	to	to	ADP
ajst-32571	65	17	higher	high	ADJ
ajst-32571	65	18	requirements	requirement	NOUN
ajst-32571	65	19	for	for	ADP
ajst-32571	65	20	antibody	antibody	NOUN
ajst-32571	65	21	specificity	specificity	NOUN
ajst-32571	65	22	,	,	PUNCT
ajst-32571	65	23	due	due	ADP
ajst-32571	65	24	to	to	ADP
ajst-32571	65	25	the	the	DET
ajst-32571	65	26	structural	structural	ADJ
ajst-32571	65	27	similarity	similarity	NOUN
ajst-32571	65	28	of	of	ADP
ajst-32571	65	29	cldn6	cldn6	NOUN
ajst-32571	65	30	to	to	ADP
ajst-32571	65	31	other	other	ADJ
ajst-32571	65	32	cldn	cldn	ADJ
ajst-32571	65	33	proteins	protein	NOUN
ajst-32571	65	34	present	present	ADJ
ajst-32571	65	35	in	in	ADP
ajst-32571	65	36	normal	normal	ADJ
ajst-32571	65	37	adult	adult	NOUN
ajst-32571	65	38	cells	cell	NOUN
ajst-32571	65	39	.	.	PUNCT
ajst-32571	66	1	cldn9	cldn9	NOUN
ajst-32571	66	2	especially	especially	ADV
ajst-32571	66	3	shares	share	VERB
ajst-32571	66	4	all	all	DET
ajst-32571	66	5	but	but	CCONJ
ajst-32571	66	6	three	three	NUM
ajst-32571	66	7	amino	amino	ADJ
ajst-32571	66	8	acids	acid	NOUN
ajst-32571	66	9	on	on	ADP
ajst-32571	66	10	its	its	PRON
ajst-32571	66	11	extracellular	extracellular	ADJ
ajst-32571	66	12	region	region	NOUN
ajst-32571	66	13	and	and	CCONJ
ajst-32571	66	14	is	be	AUX
ajst-32571	66	15	expressed	express	VERB
ajst-32571	66	16	in	in	ADP
ajst-32571	66	17	skeletal	skeletal	ADJ
ajst-32571	66	18	muscle	muscle	NOUN
ajst-32571	66	19	,	,	PUNCT
ajst-32571	66	20	bone	bone	NOUN
ajst-32571	66	21	,	,	PUNCT
ajst-32571	66	22	and	and	CCONJ
ajst-32571	66	23	brain	brain	NOUN
ajst-32571	66	24	cells	cell	NOUN
ajst-32571	66	25	,	,	PUNCT
ajst-32571	66	26	as	as	ADV
ajst-32571	66	27	well	well	ADV
ajst-32571	66	28	as	as	ADP
ajst-32571	66	29	those	those	PRON
ajst-32571	66	30	in	in	ADP
ajst-32571	66	31	cardiovascular	cardiovascular	ADJ
ajst-32571	66	32	system	system	NOUN
ajst-32571	66	33	tissues	tissue	NOUN
ajst-32571	66	34	[	[	X
ajst-32571	66	35	31	31	NUM
ajst-32571	66	36	]	]	PUNCT
ajst-32571	66	37	.	.	PUNCT
ajst-32571	67	1	errors	error	NOUN
ajst-32571	67	2	in	in	ADP
ajst-32571	67	3	targeting	target	VERB
ajst-32571	67	4	may	may	AUX
ajst-32571	67	5	lead	lead	VERB
ajst-32571	67	6	to	to	ADP
ajst-32571	67	7	severe	severe	ADJ
ajst-32571	67	8	side	side	NOUN
ajst-32571	67	9	effects	effect	NOUN
ajst-32571	67	10	.	.	PUNCT
ajst-32571	68	1	3	3	X
ajst-32571	68	2	.	.	X
ajst-32571	68	3	limitations	limitation	NOUN
ajst-32571	68	4	in	in	ADP
ajst-32571	68	5	cldn6	cldn6	NOUN
ajst-32571	68	6	-	-	PUNCT
ajst-32571	68	7	car	car	NOUN
ajst-32571	68	8	-	-	PUNCT
ajst-32571	68	9	t	t	NOUN
ajst-32571	68	10	cell	cell	NOUN
ajst-32571	68	11	therapy	therapy	NOUN
ajst-32571	68	12	3.1	3.1	NUM
ajst-32571	68	13	immature	immature	ADJ
ajst-32571	68	14	clinical	clinical	ADJ
ajst-32571	68	15	outcome	outcome	NOUN
ajst-32571	68	16	figure	figure	NOUN
ajst-32571	68	17	4	4	NUM
ajst-32571	68	18	.	.	PUNCT
ajst-32571	69	1	clinical	clinical	ADJ
ajst-32571	69	2	data	datum	NOUN
ajst-32571	69	3	chart	chart	NOUN
ajst-32571	69	4	and	and	CCONJ
ajst-32571	69	5	table	table	NOUN
ajst-32571	69	6	.	.	PUNCT
ajst-32571	70	1	6	6	NUM
ajst-32571	70	2	patients	patient	NOUN
ajst-32571	70	3	achieved	achieve	VERB
ajst-32571	70	4	partial	partial	ADJ
ajst-32571	70	5	response	response	NOUN
ajst-32571	70	6	(	(	PUNCT
ajst-32571	70	7	pr	pr	NOUN
ajst-32571	70	8	)	)	PUNCT
ajst-32571	70	9	,	,	PUNCT
ajst-32571	70	10	1	1	NUM
ajst-32571	70	11	achieved	achieve	VERB
ajst-32571	70	12	complete	complete	ADJ
ajst-32571	70	13	response	response	NOUN
ajst-32571	70	14	(	(	PUNCT
ajst-32571	70	15	cr	cr	NOUN
ajst-32571	70	16	)	)	PUNCT
ajst-32571	70	17	,	,	PUNCT
ajst-32571	70	18	and	and	CCONJ
ajst-32571	70	19	the	the	DET
ajst-32571	70	20	orr	orr	PROPN
ajst-32571	70	21	was	be	AUX
ajst-32571	70	22	33	33	NUM
ajst-32571	70	23	%	%	NOUN
ajst-32571	70	24	.	.	PUNCT
ajst-32571	71	1	[	[	X
ajst-32571	71	2	27	27	NUM
ajst-32571	71	3	]	]	SYM
ajst-32571	71	4	181	181	NUM
ajst-32571	71	5	in	in	ADP
ajst-32571	71	6	a	a	DET
ajst-32571	71	7	clinical	clinical	ADJ
ajst-32571	71	8	trial	trial	NOUN
ajst-32571	71	9	of	of	ADP
ajst-32571	71	10	the	the	DET
ajst-32571	71	11	car	car	NOUN
ajst-32571	71	12	-	-	PUNCT
ajst-32571	71	13	t	t	NOUN
ajst-32571	71	14	cell	cell	NOUN
ajst-32571	71	15	amplifying	amplify	VERB
ajst-32571	71	16	vaccine	vaccine	NOUN
ajst-32571	71	17	(	(	PUNCT
ajst-32571	71	18	carvac	carvac	NOUN
ajst-32571	71	19	)	)	PUNCT
ajst-32571	71	20	,	,	PUNCT
ajst-32571	71	21	it	it	PRON
ajst-32571	71	22	has	have	AUX
ajst-32571	71	23	been	be	AUX
ajst-32571	71	24	demonstrated	demonstrate	VERB
ajst-32571	71	25	that	that	SCONJ
ajst-32571	71	26	a	a	DET
ajst-32571	71	27	therapy	therapy	NOUN
ajst-32571	71	28	combining	combine	VERB
ajst-32571	71	29	the	the	DET
ajst-32571	71	30	targeting	targeting	NOUN
ajst-32571	71	31	of	of	ADP
ajst-32571	71	32	cldn6	cldn6	NOUN
ajst-32571	71	33	on	on	ADP
ajst-32571	71	34	ovarian	ovarian	ADJ
ajst-32571	71	35	cancer	cancer	NOUN
ajst-32571	71	36	cells	cell	NOUN
ajst-32571	71	37	with	with	ADP
ajst-32571	71	38	car	car	NOUN
ajst-32571	71	39	-	-	PUNCT
ajst-32571	71	40	t	t	NOUN
ajst-32571	71	41	technology	technology	NOUN
ajst-32571	71	42	has	have	VERB
ajst-32571	71	43	a	a	DET
ajst-32571	71	44	positive	positive	ADJ
ajst-32571	71	45	effect	effect	NOUN
ajst-32571	71	46	on	on	ADP
ajst-32571	71	47	cancer	cancer	NOUN
ajst-32571	71	48	treatment	treatment	NOUN
ajst-32571	71	49	.	.	PUNCT
ajst-32571	72	1	among	among	ADP
ajst-32571	72	2	the	the	DET
ajst-32571	72	3	clinical	clinical	ADJ
ajst-32571	72	4	responses	response	NOUN
ajst-32571	72	5	of	of	ADP
ajst-32571	72	6	cldn6	cldn6	NOUN
ajst-32571	72	7	-	-	PUNCT
ajst-32571	72	8	car	car	NOUN
ajst-32571	72	9	-	-	PUNCT
ajst-32571	72	10	t	t	NOUN
ajst-32571	72	11	infusion	infusion	NOUN
ajst-32571	72	12	±carvac	±carvac	NOUN
ajst-32571	72	13	,	,	PUNCT
ajst-32571	72	14	21	21	NUM
ajst-32571	72	15	out	out	ADP
ajst-32571	72	16	of	of	ADP
ajst-32571	72	17	22	22	NUM
ajst-32571	72	18	patients	patient	NOUN
ajst-32571	72	19	were	be	AUX
ajst-32571	72	20	treated	treat	VERB
ajst-32571	72	21	according	accord	VERB
ajst-32571	72	22	to	to	ADP
ajst-32571	72	23	the	the	DET
ajst-32571	72	24	protocol	protocol	NOUN
ajst-32571	72	25	,	,	PUNCT
ajst-32571	72	26	including	include	VERB
ajst-32571	72	27	6	6	NUM
ajst-32571	72	28	cases	case	NOUN
ajst-32571	72	29	of	of	ADP
ajst-32571	72	30	partial	partial	ADJ
ajst-32571	72	31	response	response	NOUN
ajst-32571	72	32	and	and	CCONJ
ajst-32571	72	33	1	1	NUM
ajst-32571	72	34	case	case	NOUN
ajst-32571	72	35	of	of	ADP
ajst-32571	72	36	complete	complete	ADJ
ajst-32571	72	37	response	response	NOUN
ajst-32571	72	38	.	.	PUNCT
ajst-32571	73	1	therefore	therefore	ADV
ajst-32571	73	2	,	,	PUNCT
ajst-32571	73	3	the	the	DET
ajst-32571	73	4	unconfirmed	unconfirmed	ADJ
ajst-32571	73	5	objective	objective	ADJ
ajst-32571	73	6	response	response	NOUN
ajst-32571	73	7	rate	rate	NOUN
ajst-32571	73	8	(	(	PUNCT
ajst-32571	73	9	orr	orr	PROPN
ajst-32571	73	10	)	)	PUNCT
ajst-32571	73	11	was	be	AUX
ajst-32571	73	12	33	33	NUM
ajst-32571	73	13	%	%	NOUN
ajst-32571	73	14	(	(	PUNCT
ajst-32571	73	15	7/21	7/21	NUM
ajst-32571	73	16	)	)	PUNCT
ajst-32571	73	17	,	,	PUNCT
ajst-32571	73	18	and	and	CCONJ
ajst-32571	73	19	the	the	DET
ajst-32571	73	20	disease	disease	NOUN
ajst-32571	73	21	control	control	NOUN
ajst-32571	73	22	rate	rate	NOUN
ajst-32571	73	23	was	be	AUX
ajst-32571	73	24	67	67	NUM
ajst-32571	73	25	%	%	NOUN
ajst-32571	73	26	(	(	PUNCT
ajst-32571	73	27	14/21	14/21	NUM
ajst-32571	73	28	)	)	PUNCT
ajst-32571	73	29	.	.	PUNCT
ajst-32571	74	1	in	in	ADP
ajst-32571	74	2	subsequent	subsequent	ADJ
ajst-32571	74	3	repeated	repeat	VERB
ajst-32571	74	4	evaluations	evaluation	NOUN
ajst-32571	74	5	,	,	PUNCT
ajst-32571	74	6	the	the	DET
ajst-32571	74	7	total	total	ADJ
ajst-32571	74	8	number	number	NOUN
ajst-32571	74	9	of	of	ADP
ajst-32571	74	10	observed	observe	VERB
ajst-32571	74	11	target	target	NOUN
ajst-32571	74	12	lesions	lesion	NOUN
ajst-32571	74	13	continued	continue	VERB
ajst-32571	74	14	to	to	PART
ajst-32571	74	15	decrease	decrease	VERB
ajst-32571	74	16	[	[	X
ajst-32571	74	17	27	27	NUM
ajst-32571	74	18	]	]	PUNCT
ajst-32571	74	19	.	.	PUNCT
ajst-32571	75	1	although	although	SCONJ
ajst-32571	75	2	the	the	DET
ajst-32571	75	3	therapy	therapy	NOUN
ajst-32571	75	4	has	have	AUX
ajst-32571	75	5	shown	show	VERB
ajst-32571	75	6	encouraging	encouraging	ADJ
ajst-32571	75	7	results	result	NOUN
ajst-32571	75	8	,	,	PUNCT
ajst-32571	75	9	its	its	PRON
ajst-32571	75	10	orr	orr	NOUN
ajst-32571	75	11	of	of	ADP
ajst-32571	75	12	less	less	ADJ
ajst-32571	75	13	than	than	ADP
ajst-32571	75	14	half	half	NOUN
ajst-32571	75	15	indicates	indicate	VERB
ajst-32571	75	16	that	that	SCONJ
ajst-32571	75	17	it	it	PRON
ajst-32571	75	18	is	be	AUX
ajst-32571	75	19	still	still	ADV
ajst-32571	75	20	far	far	ADV
ajst-32571	75	21	from	from	ADP
ajst-32571	75	22	maturity	maturity	NOUN
ajst-32571	75	23	.	.	PUNCT
ajst-32571	76	1	cldn6	cldn6	NOUN
ajst-32571	76	2	expression	expression	NOUN
ajst-32571	76	3	rates	rate	NOUN
ajst-32571	76	4	in	in	ADP
ajst-32571	76	5	ovarian	ovarian	ADJ
ajst-32571	76	6	cancer	cancer	NOUN
ajst-32571	76	7	cells	cell	NOUN
ajst-32571	76	8	vary	vary	VERB
ajst-32571	76	9	due	due	ADJ
ajst-32571	76	10	to	to	ADP
ajst-32571	76	11	heterogeneity	heterogeneity	NOUN
ajst-32571	76	12	,	,	PUNCT
ajst-32571	76	13	which	which	PRON
ajst-32571	76	14	may	may	AUX
ajst-32571	76	15	be	be	AUX
ajst-32571	76	16	considered	consider	VERB
ajst-32571	76	17	a	a	DET
ajst-32571	76	18	significant	significant	ADJ
ajst-32571	76	19	factor	factor	NOUN
ajst-32571	76	20	contributing	contribute	VERB
ajst-32571	76	21	to	to	ADP
ajst-32571	76	22	unsatisfactory	unsatisfactory	ADJ
ajst-32571	76	23	clinical	clinical	ADJ
ajst-32571	76	24	outcomes	outcome	NOUN
ajst-32571	76	25	.	.	PUNCT
ajst-32571	77	1	3.2	3.2	NUM
ajst-32571	77	2	heterogeneity	heterogeneity	NOUN
ajst-32571	77	3	affecting	affect	VERB
ajst-32571	77	4	the	the	DET
ajst-32571	77	5	efficacy	efficacy	NOUN
ajst-32571	77	6	of	of	ADP
ajst-32571	77	7	therapy	therapy	NOUN
ajst-32571	77	8	ovarian	ovarian	ADJ
ajst-32571	77	9	cancer	cancer	NOUN
ajst-32571	77	10	is	be	AUX
ajst-32571	77	11	heterogeneous	heterogeneous	ADJ
ajst-32571	77	12	(	(	PUNCT
ajst-32571	77	13	as	as	SCONJ
ajst-32571	77	14	can	can	AUX
ajst-32571	77	15	be	be	AUX
ajst-32571	77	16	seen	see	VERB
ajst-32571	77	17	from	from	ADP
ajst-32571	77	18	its	its	PRON
ajst-32571	77	19	large	large	ADJ
ajst-32571	77	20	number	number	NOUN
ajst-32571	77	21	of	of	ADP
ajst-32571	77	22	subtypes	subtype	NOUN
ajst-32571	77	23	)	)	PUNCT
ajst-32571	77	24	.	.	PUNCT
ajst-32571	78	1	its	its	PRON
ajst-32571	78	2	expression	expression	NOUN
ajst-32571	78	3	varies	vary	VERB
ajst-32571	78	4	among	among	ADP
ajst-32571	78	5	different	different	ADJ
ajst-32571	78	6	individuals	individual	NOUN
ajst-32571	78	7	or	or	CCONJ
ajst-32571	78	8	within	within	ADP
ajst-32571	78	9	different	different	ADJ
ajst-32571	78	10	cells	cell	NOUN
ajst-32571	78	11	of	of	ADP
ajst-32571	78	12	the	the	DET
ajst-32571	78	13	same	same	ADJ
ajst-32571	78	14	individual	individual	NOUN
ajst-32571	78	15	[	[	X
ajst-32571	78	16	32	32	NUM
ajst-32571	78	17	]	]	PUNCT
ajst-32571	78	18	.	.	PUNCT
ajst-32571	79	1	differences	difference	NOUN
ajst-32571	79	2	in	in	ADP
ajst-32571	79	3	tumour	tumour	ADJ
ajst-32571	79	4	microenvironments	microenvironment	NOUN
ajst-32571	79	5	(	(	PUNCT
ajst-32571	79	6	tmes	tme	NOUN
ajst-32571	79	7	)	)	PUNCT
ajst-32571	80	1	[	[	X
ajst-32571	80	2	33	33	NUM
ajst-32571	80	3	]	]	PUNCT
ajst-32571	80	4	,	,	PUNCT
ajst-32571	80	5	genetic	genetic	ADJ
ajst-32571	80	6	factors	factor	NOUN
ajst-32571	80	7	[	[	X
ajst-32571	80	8	34	34	NUM
ajst-32571	80	9	]	]	PUNCT
ajst-32571	80	10	,	,	PUNCT
ajst-32571	80	11	and	and	CCONJ
ajst-32571	80	12	temporal	temporal	ADJ
ajst-32571	80	13	conditions	condition	NOUN
ajst-32571	80	14	[	[	X
ajst-32571	80	15	35	35	NUM
ajst-32571	80	16	]	]	PUNCT
ajst-32571	80	17	are	be	AUX
ajst-32571	80	18	important	important	ADJ
ajst-32571	80	19	factors	factor	NOUN
ajst-32571	80	20	contributing	contribute	VERB
ajst-32571	80	21	to	to	ADP
ajst-32571	80	22	heterogeneity	heterogeneity	NOUN
ajst-32571	80	23	.	.	PUNCT
ajst-32571	81	1	a	a	DET
ajst-32571	81	2	common	common	ADJ
ajst-32571	81	3	cause	cause	NOUN
ajst-32571	81	4	of	of	ADP
ajst-32571	81	5	car	car	NOUN
ajst-32571	81	6	-	-	PUNCT
ajst-32571	81	7	t	t	NOUN
ajst-32571	81	8	therapy	therapy	NOUN
ajst-32571	81	9	ineffectiveness	ineffectiveness	NOUN
ajst-32571	81	10	is	be	AUX
ajst-32571	81	11	antigen	antigen	ADJ
ajst-32571	81	12	escape	escape	NOUN
ajst-32571	81	13	.	.	PUNCT
ajst-32571	82	1	due	due	ADP
ajst-32571	82	2	to	to	ADP
ajst-32571	82	3	heterogeneity	heterogeneity	NOUN
ajst-32571	82	4	,	,	PUNCT
ajst-32571	82	5	tumour	tumour	ADJ
ajst-32571	82	6	subclonal	subclonal	ADJ
ajst-32571	82	7	cells	cell	NOUN
ajst-32571	82	8	differentiate	differentiate	VERB
ajst-32571	82	9	into	into	ADP
ajst-32571	82	10	antigen	antigen	NOUN
ajst-32571	82	11	-	-	PUNCT
ajst-32571	82	12	negative	negative	ADJ
ajst-32571	82	13	and	and	CCONJ
ajst-32571	82	14	antigen	antigen	ADV
ajst-32571	82	15	-	-	PUNCT
ajst-32571	82	16	positive	positive	ADJ
ajst-32571	82	17	types	type	NOUN
ajst-32571	82	18	.	.	PUNCT
ajst-32571	83	1	under	under	ADP
ajst-32571	83	2	therapeutic	therapeutic	ADJ
ajst-32571	83	3	pressure	pressure	NOUN
ajst-32571	83	4	,	,	PUNCT
ajst-32571	83	5	antigen	antigen	NOUN
ajst-32571	83	6	-	-	PUNCT
ajst-32571	83	7	negative	negative	ADJ
ajst-32571	83	8	tumour	tumour	NOUN
ajst-32571	83	9	subclones	subclone	NOUN
ajst-32571	83	10	are	be	AUX
ajst-32571	83	11	selected	select	VERB
ajst-32571	83	12	and	and	CCONJ
ajst-32571	83	13	proliferated	proliferate	VERB
ajst-32571	83	14	,	,	PUNCT
ajst-32571	83	15	allowing	allow	VERB
ajst-32571	83	16	them	they	PRON
ajst-32571	83	17	to	to	PART
ajst-32571	83	18	evade	evade	VERB
ajst-32571	83	19	attack	attack	NOUN
ajst-32571	83	20	by	by	ADP
ajst-32571	83	21	losing	lose	VERB
ajst-32571	83	22	their	their	PRON
ajst-32571	83	23	antigens	antigen	NOUN
ajst-32571	83	24	,	,	PUNCT
ajst-32571	83	25	which	which	PRON
ajst-32571	83	26	results	result	VERB
ajst-32571	83	27	in	in	ADP
ajst-32571	83	28	tumour	tumour	NOUN
ajst-32571	83	29	recurrence	recurrence	NOUN
ajst-32571	83	30	.	.	PUNCT
ajst-32571	84	1	at	at	ADP
ajst-32571	84	2	the	the	DET
ajst-32571	84	3	same	same	ADJ
ajst-32571	84	4	time	time	NOUN
ajst-32571	84	5	,	,	PUNCT
ajst-32571	84	6	the	the	DET
ajst-32571	84	7	remaining	remain	VERB
ajst-32571	84	8	antigen	antigen	ADJ
ajst-32571	84	9	-	-	PUNCT
ajst-32571	84	10	positive	positive	ADJ
ajst-32571	84	11	cells	cell	NOUN
ajst-32571	84	12	may	may	AUX
ajst-32571	84	13	continuously	continuously	ADV
ajst-32571	84	14	stimulate	stimulate	VERB
ajst-32571	84	15	car	car	NOUN
ajst-32571	84	16	-	-	PUNCT
ajst-32571	84	17	t	t	NOUN
ajst-32571	84	18	cells	cell	NOUN
ajst-32571	84	19	at	at	ADP
ajst-32571	84	20	low	low	ADJ
ajst-32571	84	21	levels	level	NOUN
ajst-32571	84	22	,	,	PUNCT
ajst-32571	84	23	leading	lead	VERB
ajst-32571	84	24	to	to	ADP
ajst-32571	84	25	car	car	NOUN
ajst-32571	84	26	-	-	PUNCT
ajst-32571	84	27	t	t	NOUN
ajst-32571	84	28	cell	cell	NOUN
ajst-32571	84	29	exhaustion	exhaustion	NOUN
ajst-32571	84	30	[	[	X
ajst-32571	84	31	36	36	NUM
ajst-32571	84	32	]	]	PUNCT
ajst-32571	84	33	.	.	PUNCT
ajst-32571	85	1	such	such	ADJ
ajst-32571	85	2	implications	implication	NOUN
ajst-32571	85	3	of	of	ADP
ajst-32571	85	4	heterogeneous	heterogeneous	ADJ
ajst-32571	85	5	expression	expression	NOUN
ajst-32571	85	6	are	be	AUX
ajst-32571	85	7	also	also	ADV
ajst-32571	85	8	unavoidable	unavoidable	ADJ
ajst-32571	85	9	for	for	ADP
ajst-32571	85	10	the	the	DET
ajst-32571	85	11	cldn6	cldn6	NOUN
ajst-32571	85	12	protein	protein	NOUN
ajst-32571	85	13	,	,	PUNCT
ajst-32571	85	14	despite	despite	SCONJ
ajst-32571	85	15	its	its	PRON
ajst-32571	85	16	relatively	relatively	ADV
ajst-32571	85	17	high	high	ADJ
ajst-32571	85	18	presence	presence	NOUN
ajst-32571	85	19	in	in	ADP
ajst-32571	85	20	ovarian	ovarian	ADJ
ajst-32571	85	21	cancer	cancer	NOUN
ajst-32571	85	22	tumors	tumor	NOUN
ajst-32571	85	23	.	.	PUNCT
ajst-32571	86	1	furthermore	furthermore	ADV
ajst-32571	86	2	,	,	PUNCT
ajst-32571	86	3	as	as	ADP
ajst-32571	86	4	with	with	ADP
ajst-32571	86	5	other	other	ADJ
ajst-32571	86	6	solid	solid	ADJ
ajst-32571	86	7	tumor	tumor	NOUN
ajst-32571	86	8	-	-	PUNCT
ajst-32571	86	9	targeting	target	VERB
ajst-32571	86	10	car	car	NOUN
ajst-32571	86	11	-	-	PUNCT
ajst-32571	86	12	t	t	NOUN
ajst-32571	86	13	therapies	therapy	NOUN
ajst-32571	86	14	,	,	PUNCT
ajst-32571	86	15	immunosuppression	immunosuppression	NOUN
ajst-32571	86	16	in	in	ADP
ajst-32571	86	17	the	the	DET
ajst-32571	86	18	tme	tme	NOUN
ajst-32571	86	19	also	also	ADV
ajst-32571	86	20	reduces	reduce	VERB
ajst-32571	86	21	the	the	DET
ajst-32571	86	22	efficacy	efficacy	NOUN
ajst-32571	86	23	of	of	ADP
ajst-32571	86	24	cldn6	cldn6	PROPN
ajst-32571	86	25	-	-	PUNCT
ajst-32571	86	26	car	car	NOUN
ajst-32571	86	27	-	-	PUNCT
ajst-32571	86	28	t	t	NOUN
ajst-32571	86	29	[	[	X
ajst-32571	86	30	37	37	NUM
ajst-32571	86	31	]	]	PUNCT
ajst-32571	86	32	.	.	PUNCT
ajst-32571	87	1	in	in	ADP
ajst-32571	87	2	heterogeneous	heterogeneous	ADJ
ajst-32571	87	3	tumour	tumour	ADJ
ajst-32571	87	4	regions	region	NOUN
ajst-32571	87	5	,	,	PUNCT
ajst-32571	87	6	regulatory	regulatory	ADJ
ajst-32571	87	7	t	t	NOUN
ajst-32571	87	8	cells	cell	NOUN
ajst-32571	87	9	(	(	PUNCT
ajst-32571	87	10	tregs	treg	NOUN
ajst-32571	87	11	)	)	PUNCT
ajst-32571	87	12	,	,	PUNCT
ajst-32571	87	13	myeloid	myeloid	NOUN
ajst-32571	87	14	-	-	PUNCT
ajst-32571	87	15	derived	derive	VERB
ajst-32571	87	16	suppressor	suppressor	NOUN
ajst-32571	87	17	cells	cell	NOUN
ajst-32571	87	18	(	(	PUNCT
ajst-32571	87	19	mdscs	mdsc	NOUN
ajst-32571	87	20	)	)	PUNCT
ajst-32571	87	21	,	,	PUNCT
ajst-32571	87	22	m2	m2	PROPN
ajst-32571	87	23	macrophages	macrophage	NOUN
ajst-32571	87	24	,	,	PUNCT
ajst-32571	87	25	and	and	CCONJ
ajst-32571	87	26	tumour	tumour	NOUN
ajst-32571	87	27	-	-	PUNCT
ajst-32571	87	28	associated	associate	VERB
ajst-32571	87	29	macrophages	macrophage	NOUN
ajst-32571	87	30	(	(	PUNCT
ajst-32571	87	31	tams	tam	NOUN
ajst-32571	87	32	)	)	PUNCT
ajst-32571	87	33	interact	interact	VERB
ajst-32571	87	34	either	either	CCONJ
ajst-32571	87	35	by	by	ADP
ajst-32571	87	36	cell	cell	NOUN
ajst-32571	87	37	contact	contact	NOUN
ajst-32571	87	38	or	or	CCONJ
ajst-32571	87	39	secretion	secretion	NOUN
ajst-32571	87	40	of	of	ADP
ajst-32571	87	41	cytokines	cytokine	NOUN
ajst-32571	87	42	such	such	ADJ
ajst-32571	87	43	as	as	ADP
ajst-32571	87	44	transforming	transform	VERB
ajst-32571	87	45	growth	growth	NOUN
ajst-32571	87	46	factor	factor	NOUN
ajst-32571	87	47	-	-	PUNCT
ajst-32571	87	48	beta	beta	NOUN
ajst-32571	87	49	(	(	PUNCT
ajst-32571	87	50	tgf	tgf	PROPN
ajst-32571	87	51	-	-	PUNCT
ajst-32571	87	52	β	β	NOUN
ajst-32571	87	53	)	)	PUNCT
ajst-32571	87	54	and	and	CCONJ
ajst-32571	87	55	interleukin-10	interleukin-10	PROPN
ajst-32571	87	56	(	(	PUNCT
ajst-32571	87	57	il-10	il-10	NUM
ajst-32571	87	58	)	)	PUNCT
ajst-32571	87	59	,	,	PUNCT
ajst-32571	87	60	hindering	hinder	VERB
ajst-32571	87	61	car	car	NOUN
ajst-32571	87	62	-	-	PUNCT
ajst-32571	87	63	t	t	NOUN
ajst-32571	87	64	functionality	functionality	NOUN
ajst-32571	87	65	and	and	CCONJ
ajst-32571	87	66	activity	activity	NOUN
ajst-32571	87	67	[	[	X
ajst-32571	87	68	38][39	38][39	PROPN
ajst-32571	87	69	]	]	X
ajst-32571	87	70	.	.	PUNCT
ajst-32571	88	1	moreover	moreover	ADV
ajst-32571	88	2	,	,	PUNCT
ajst-32571	88	3	hypoxic	hypoxic	ADJ
ajst-32571	88	4	regions	region	NOUN
ajst-32571	88	5	in	in	ADP
ajst-32571	88	6	metabolic	metabolic	NOUN
ajst-32571	88	7	competition	competition	NOUN
ajst-32571	88	8	,	,	PUNCT
ajst-32571	88	9	such	such	ADJ
ajst-32571	88	10	as	as	ADP
ajst-32571	88	11	the	the	DET
ajst-32571	88	12	ascites	ascite	NOUN
ajst-32571	88	13	microenvironment	microenvironment	NOUN
ajst-32571	88	14	in	in	ADP
ajst-32571	88	15	ovarian	ovarian	ADJ
ajst-32571	88	16	cancer	cancer	NOUN
ajst-32571	88	17	,	,	PUNCT
ajst-32571	88	18	or	or	CCONJ
ajst-32571	88	19	conditions	condition	NOUN
ajst-32571	88	20	like	like	ADP
ajst-32571	88	21	nutrient	nutrient	NOUN
ajst-32571	88	22	deficiency	deficiency	NOUN
ajst-32571	88	23	and	and	CCONJ
ajst-32571	88	24	acidic	acidic	ADJ
ajst-32571	88	25	ph	ph	NOUN
ajst-32571	88	26	,	,	PUNCT
ajst-32571	88	27	can	can	AUX
ajst-32571	88	28	inhibit	inhibit	VERB
ajst-32571	88	29	the	the	DET
ajst-32571	88	30	proliferation	proliferation	NOUN
ajst-32571	88	31	and	and	CCONJ
ajst-32571	88	32	cytokine	cytokine	ADJ
ajst-32571	88	33	secretion	secretion	NOUN
ajst-32571	88	34	of	of	ADP
ajst-32571	88	35	car	car	NOUN
ajst-32571	88	36	-	-	PUNCT
ajst-32571	88	37	t	t	NOUN
ajst-32571	88	38	cells	cell	NOUN
ajst-32571	88	39	[	[	X
ajst-32571	88	40	40][41	40][41	X
ajst-32571	88	41	]	]	X
ajst-32571	88	42	.	.	PUNCT
ajst-32571	89	1	the	the	DET
ajst-32571	89	2	physical	physical	ADJ
ajst-32571	89	3	barrier	barrier	NOUN
ajst-32571	89	4	constructed	construct	VERB
ajst-32571	89	5	by	by	ADP
ajst-32571	89	6	cancer	cancer	NOUN
ajst-32571	89	7	-	-	PUNCT
ajst-32571	89	8	associated	associate	VERB
ajst-32571	89	9	fibroblasts	fibroblast	NOUN
ajst-32571	89	10	(	(	PUNCT
ajst-32571	89	11	cafs	cafs	NOUN
ajst-32571	89	12	)	)	PUNCT
ajst-32571	89	13	additionally	additionally	ADV
ajst-32571	89	14	reduces	reduce	VERB
ajst-32571	89	15	car	car	NOUN
ajst-32571	89	16	-	-	PUNCT
ajst-32571	89	17	t	t	NOUN
ajst-32571	89	18	efficacy	efficacy	NOUN
ajst-32571	89	19	.	.	PUNCT
ajst-32571	90	1	cafs	cafs	PROPN
ajst-32571	90	2	are	be	AUX
ajst-32571	90	3	the	the	DET
ajst-32571	90	4	main	main	ADJ
ajst-32571	90	5	stromal	stromal	ADJ
ajst-32571	90	6	cells	cell	NOUN
ajst-32571	90	7	in	in	ADP
ajst-32571	90	8	the	the	DET
ajst-32571	90	9	tme	tme	NOUN
ajst-32571	90	10	.	.	PUNCT
ajst-32571	91	1	they	they	PRON
ajst-32571	91	2	secrete	secrete	VERB
ajst-32571	91	3	a	a	DET
ajst-32571	91	4	large	large	ADJ
ajst-32571	91	5	amount	amount	NOUN
ajst-32571	91	6	of	of	ADP
ajst-32571	91	7	extracellular	extracellular	ADJ
ajst-32571	91	8	matrix	matrix	NOUN
ajst-32571	91	9	(	(	PUNCT
ajst-32571	91	10	ecm	ecm	NOUN
ajst-32571	91	11	)	)	PUNCT
ajst-32571	91	12	components	component	NOUN
ajst-32571	91	13	,	,	PUNCT
ajst-32571	91	14	such	such	ADJ
ajst-32571	91	15	as	as	ADP
ajst-32571	91	16	collagen	collagen	NOUN
ajst-32571	91	17	and	and	CCONJ
ajst-32571	91	18	fibronectin	fibronectin	NOUN
ajst-32571	91	19	,	,	PUNCT
ajst-32571	91	20	to	to	PART
ajst-32571	91	21	form	form	VERB
ajst-32571	91	22	a	a	DET
ajst-32571	91	23	tight	tight	ADJ
ajst-32571	91	24	physical	physical	ADJ
ajst-32571	91	25	barrier	barrier	NOUN
ajst-32571	91	26	[	[	X
ajst-32571	91	27	42	42	NUM
ajst-32571	91	28	]	]	PUNCT
ajst-32571	91	29	.	.	PUNCT
ajst-32571	92	1	this	this	PRON
ajst-32571	92	2	causes	cause	VERB
ajst-32571	92	3	difficulty	difficulty	NOUN
ajst-32571	92	4	in	in	ADP
ajst-32571	92	5	car	car	NOUN
ajst-32571	92	6	-	-	PUNCT
ajst-32571	92	7	t	t	NOUN
ajst-32571	92	8	movement	movement	NOUN
ajst-32571	92	9	and	and	CCONJ
ajst-32571	92	10	infiltration	infiltration	NOUN
ajst-32571	92	11	towards	towards	ADP
ajst-32571	92	12	the	the	DET
ajst-32571	92	13	tumour	tumour	NOUN
ajst-32571	92	14	cells	cell	NOUN
ajst-32571	92	15	[	[	X
ajst-32571	92	16	43	43	NUM
ajst-32571	92	17	]	]	PUNCT
ajst-32571	92	18	.	.	PUNCT
ajst-32571	93	1	4	4	X
ajst-32571	93	2	.	.	X
ajst-32571	93	3	future	future	ADJ
ajst-32571	93	4	prospects	prospect	NOUN
ajst-32571	93	5	4.1	4.1	NUM
ajst-32571	93	6	multi	multi	ADJ
ajst-32571	93	7	-	-	ADJ
ajst-32571	93	8	target	target	NOUN
ajst-32571	93	9	therapy	therapy	NOUN
ajst-32571	93	10	and	and	CCONJ
ajst-32571	93	11	cldn6	cldn6	NOUN
ajst-32571	93	12	targeting	target	VERB
ajst-32571	93	13	reinforcement	reinforcement	NOUN
ajst-32571	93	14	the	the	DET
ajst-32571	93	15	design	design	NOUN
ajst-32571	93	16	of	of	ADP
ajst-32571	93	17	multi	multi	ADJ
ajst-32571	93	18	-	-	ADJ
ajst-32571	93	19	target	target	NOUN
ajst-32571	93	20	therapy	therapy	NOUN
ajst-32571	93	21	can	can	AUX
ajst-32571	93	22	effectively	effectively	ADV
ajst-32571	93	23	alleviate	alleviate	VERB
ajst-32571	93	24	the	the	DET
ajst-32571	93	25	escape	escape	NOUN
ajst-32571	93	26	of	of	ADP
ajst-32571	93	27	single	single	ADJ
ajst-32571	93	28	-	-	PUNCT
ajst-32571	93	29	target	target	NOUN
ajst-32571	93	30	antigens	antigen	NOUN
ajst-32571	93	31	.	.	PUNCT
ajst-32571	94	1	similar	similar	ADJ
ajst-32571	94	2	to	to	ADP
ajst-32571	94	3	cldn6	cldn6	PROPN
ajst-32571	94	4	,	,	PUNCT
ajst-32571	94	5	prame	prame	NOUN
ajst-32571	94	6	,	,	PUNCT
ajst-32571	94	7	and	and	CCONJ
ajst-32571	94	8	ctcfl	ctcfl	PROPN
ajst-32571	94	9	are	be	AUX
ajst-32571	94	10	strictly	strictly	ADV
ajst-32571	94	11	tumour	tumour	ADJ
ajst-32571	94	12	-	-	PUNCT
ajst-32571	94	13	specific	specific	ADJ
ajst-32571	94	14	antigens	antigen	NOUN
ajst-32571	94	15	,	,	PUNCT
ajst-32571	94	16	and	and	CCONJ
ajst-32571	94	17	their	their	PRON
ajst-32571	94	18	expression	expression	NOUN
ajst-32571	94	19	in	in	ADP
ajst-32571	94	20	ovarian	ovarian	ADJ
ajst-32571	94	21	cancer	cancer	NOUN
ajst-32571	94	22	is	be	AUX
ajst-32571	94	23	more	more	ADJ
ajst-32571	94	24	than	than	ADP
ajst-32571	94	25	20	20	NUM
ajst-32571	94	26	times	time	NOUN
ajst-32571	94	27	greater	great	ADJ
ajst-32571	94	28	than	than	ADP
ajst-32571	94	29	in	in	ADP
ajst-32571	94	30	healthy	healthy	ADJ
ajst-32571	94	31	tissues	tissue	NOUN
ajst-32571	94	32	(	(	PUNCT
ajst-32571	94	33	excluding	exclude	VERB
ajst-32571	94	34	reproductive	reproductive	ADJ
ajst-32571	94	35	organs	organ	NOUN
ajst-32571	94	36	)	)	PUNCT
ajst-32571	94	37	.	.	PUNCT
ajst-32571	95	1	prame	prame	NOUN
ajst-32571	95	2	and	and	CCONJ
ajst-32571	95	3	ctcfl	ctcfl	PROPN
ajst-32571	95	4	are	be	AUX
ajst-32571	95	5	promising	promise	VERB
ajst-32571	95	6	dual	dual	ADJ
ajst-32571	95	7	targets	target	NOUN
ajst-32571	95	8	for	for	ADP
ajst-32571	95	9	cldn6	cldn6	NOUN
ajst-32571	95	10	-	-	PUNCT
ajst-32571	95	11	car	car	NOUN
ajst-32571	95	12	-	-	PUNCT
ajst-32571	95	13	t	t	NOUN
ajst-32571	95	14	treatment	treatment	NOUN
ajst-32571	95	15	of	of	ADP
ajst-32571	95	16	ovarian	ovarian	ADJ
ajst-32571	95	17	cancer	cancer	NOUN
ajst-32571	95	18	.	.	PUNCT
ajst-32571	96	1	in	in	ADP
ajst-32571	96	2	the	the	DET
ajst-32571	96	3	trial	trial	NOUN
ajst-32571	96	4	,	,	PUNCT
ajst-32571	96	5	prame	prame	NOUN
ajst-32571	96	6	-	-	PUNCT
ajst-32571	96	7	specific	specific	ADJ
ajst-32571	96	8	tcr	tcr	PROPN
ajst-32571	96	9	-	-	PUNCT
ajst-32571	96	10	t	t	PROPN
ajst-32571	96	11	cells	cell	NOUN
ajst-32571	96	12	demonstrated	demonstrate	VERB
ajst-32571	96	13	high	high	ADJ
ajst-32571	96	14	cytotoxicity	cytotoxicity	NOUN
ajst-32571	96	15	and	and	CCONJ
ajst-32571	96	16	exhibited	exhibit	VERB
ajst-32571	96	17	significant	significant	ADJ
ajst-32571	96	18	tumor	tumor	NOUN
ajst-32571	96	19	-	-	PUNCT
ajst-32571	96	20	suppressive	suppressive	ADJ
ajst-32571	96	21	effects	effect	NOUN
ajst-32571	96	22	against	against	ADP
ajst-32571	96	23	primary	primary	ADJ
ajst-32571	96	24	ovarian	ovarian	ADJ
ajst-32571	96	25	cancer	cancer	NOUN
ajst-32571	96	26	cells	cell	NOUN
ajst-32571	96	27	,	,	PUNCT
ajst-32571	96	28	both	both	CCONJ
ajst-32571	96	29	in	in	ADP
ajst-32571	96	30	vitro	vitro	X
ajst-32571	96	31	and	and	CCONJ
ajst-32571	96	32	in	in	ADP
ajst-32571	96	33	vivo	vivo	NOUN
ajst-32571	96	34	.	.	PUNCT
ajst-32571	97	1	ctcfldirected	ctcfldirecte	VERB
ajst-32571	97	2	tcr	tcr	PROPN
ajst-32571	97	3	-	-	PUNCT
ajst-32571	97	4	t	t	PROPN
ajst-32571	97	5	cells	cell	NOUN
ajst-32571	97	6	also	also	ADV
ajst-32571	97	7	effectively	effectively	ADV
ajst-32571	97	8	recognized	recognize	VERB
ajst-32571	97	9	primary	primary	ADJ
ajst-32571	97	10	patient	patient	NOUN
ajst-32571	97	11	-	-	PUNCT
ajst-32571	97	12	derived	derive	VERB
ajst-32571	97	13	cells	cell	NOUN
ajst-32571	97	14	,	,	PUNCT
ajst-32571	97	15	confirming	confirm	VERB
ajst-32571	97	16	their	their	PRON
ajst-32571	97	17	antigenic	antigenic	ADJ
ajst-32571	97	18	specificity	specificity	NOUN
ajst-32571	97	19	[	[	X
ajst-32571	97	20	44	44	NUM
ajst-32571	97	21	]	]	PUNCT
ajst-32571	97	22	.	.	PUNCT
ajst-32571	98	1	jointly	jointly	ADV
ajst-32571	98	2	targeting	target	VERB
ajst-32571	98	3	these	these	DET
ajst-32571	98	4	antigens	antigen	NOUN
ajst-32571	98	5	can	can	AUX
ajst-32571	98	6	expand	expand	VERB
ajst-32571	98	7	the	the	DET
ajst-32571	98	8	coverage	coverage	NOUN
ajst-32571	98	9	of	of	ADP
ajst-32571	98	10	heterogeneous	heterogeneous	ADJ
ajst-32571	98	11	ovarian	ovarian	ADJ
ajst-32571	98	12	tumours	tumour	NOUN
ajst-32571	98	13	in	in	ADP
ajst-32571	98	14	cldn6	cldn6	PROPN
ajst-32571	98	15	-	-	PUNCT
ajst-32571	98	16	car	car	NOUN
ajst-32571	98	17	-	-	PUNCT
ajst-32571	98	18	t	t	NOUN
ajst-32571	98	19	therapy	therapy	NOUN
ajst-32571	98	20	.	.	PUNCT
ajst-32571	99	1	mesothelin	mesothelin	NOUN
ajst-32571	99	2	(	(	PUNCT
ajst-32571	99	3	msln	msln	NOUN
ajst-32571	99	4	)	)	PUNCT
ajst-32571	99	5	is	be	AUX
ajst-32571	99	6	another	another	DET
ajst-32571	99	7	ideal	ideal	ADJ
ajst-32571	99	8	target	target	NOUN
ajst-32571	99	9	that	that	PRON
ajst-32571	99	10	can	can	AUX
ajst-32571	99	11	serve	serve	VERB
ajst-32571	99	12	as	as	ADP
ajst-32571	99	13	a	a	DET
ajst-32571	99	14	dual	dual	ADJ
ajst-32571	99	15	with	with	ADP
ajst-32571	99	16	cldn6	cldn6	PROPN
ajst-32571	99	17	.	.	PUNCT
ajst-32571	100	1	similar	similar	ADJ
ajst-32571	100	2	to	to	ADP
ajst-32571	100	3	prame	prame	NOUN
ajst-32571	100	4	and	and	CCONJ
ajst-32571	100	5	ctcfl	ctcfl	PROPN
ajst-32571	100	6	,	,	PUNCT
ajst-32571	100	7	msln	msln	NOUN
ajst-32571	100	8	is	be	AUX
ajst-32571	100	9	a	a	DET
ajst-32571	100	10	cell	cell	NOUN
ajst-32571	100	11	-	-	PUNCT
ajst-32571	100	12	surface	surface	NOUN
ajst-32571	100	13	protein	protein	NOUN
ajst-32571	100	14	lowly	lowly	ADJ
ajst-32571	100	15	expressed	express	VERB
ajst-32571	100	16	on	on	ADP
ajst-32571	100	17	normal	normal	ADJ
ajst-32571	100	18	skin	skin	NOUN
ajst-32571	100	19	cells	cell	NOUN
ajst-32571	100	20	[	[	X
ajst-32571	100	21	45	45	NUM
ajst-32571	100	22	]	]	PUNCT
ajst-32571	100	23	but	but	CCONJ
ajst-32571	100	24	182	182	NUM
ajst-32571	100	25	highly	highly	ADV
ajst-32571	100	26	expressed	express	VERB
ajst-32571	100	27	in	in	ADP
ajst-32571	100	28	a	a	DET
ajst-32571	100	29	variety	variety	NOUN
ajst-32571	100	30	of	of	ADP
ajst-32571	100	31	epithelial	epithelial	ADJ
ajst-32571	100	32	-	-	PUNCT
ajst-32571	100	33	derived	derive	VERB
ajst-32571	100	34	cancer	cancer	NOUN
ajst-32571	100	35	tissues	tissue	NOUN
ajst-32571	100	36	,	,	PUNCT
ajst-32571	100	37	including	include	VERB
ajst-32571	100	38	ovarian	ovarian	ADJ
ajst-32571	100	39	cancer	cancer	NOUN
ajst-32571	100	40	[	[	X
ajst-32571	100	41	46][47	46][47	NOUN
ajst-32571	100	42	]	]	PUNCT
ajst-32571	100	43	.	.	PUNCT
ajst-32571	101	1	this	this	PRON
ajst-32571	101	2	makes	make	VERB
ajst-32571	101	3	msln	msln	NOUN
ajst-32571	101	4	as	as	ADV
ajst-32571	101	5	precise	precise	ADJ
ajst-32571	101	6	in	in	ADP
ajst-32571	101	7	positioning	positioning	NOUN
ajst-32571	101	8	as	as	ADP
ajst-32571	101	9	cldn6	cldn6	PROPN
ajst-32571	101	10	.	.	PUNCT
ajst-32571	102	1	with	with	ADP
ajst-32571	102	2	multiple	multiple	ADJ
ajst-32571	102	3	target	target	NOUN
ajst-32571	102	4	sites	site	NOUN
ajst-32571	102	5	,	,	PUNCT
ajst-32571	102	6	even	even	ADV
ajst-32571	102	7	if	if	SCONJ
ajst-32571	102	8	tumour	tumour	ADJ
ajst-32571	102	9	cells	cell	NOUN
ajst-32571	102	10	downregulate	downregulate	VERB
ajst-32571	102	11	or	or	CCONJ
ajst-32571	102	12	lose	lose	VERB
ajst-32571	102	13	cldn6	cldn6	NOUN
ajst-32571	102	14	expression	expression	NOUN
ajst-32571	102	15	,	,	PUNCT
ajst-32571	102	16	the	the	DET
ajst-32571	102	17	targets	target	NOUN
ajst-32571	102	18	prame	prame	NOUN
ajst-32571	102	19	,	,	PUNCT
ajst-32571	102	20	ctcfl	ctcfl	PROPN
ajst-32571	102	21	,	,	PUNCT
ajst-32571	102	22	and	and	CCONJ
ajst-32571	102	23	msln	msln	NOUN
ajst-32571	102	24	can	can	AUX
ajst-32571	102	25	still	still	ADV
ajst-32571	102	26	be	be	AUX
ajst-32571	102	27	recognized	recognize	VERB
ajst-32571	102	28	by	by	ADP
ajst-32571	102	29	car	car	NOUN
ajst-32571	102	30	-	-	PUNCT
ajst-32571	102	31	t	t	NOUN
ajst-32571	102	32	,	,	PUNCT
ajst-32571	102	33	thereby	thereby	ADV
ajst-32571	102	34	avoiding	avoid	VERB
ajst-32571	102	35	complete	complete	ADJ
ajst-32571	102	36	evasion	evasion	NOUN
ajst-32571	102	37	.	.	PUNCT
ajst-32571	103	1	currently	currently	ADV
ajst-32571	103	2	,	,	PUNCT
ajst-32571	103	3	there	there	PRON
ajst-32571	103	4	is	be	VERB
ajst-32571	103	5	a	a	DET
ajst-32571	103	6	lack	lack	NOUN
ajst-32571	103	7	of	of	ADP
ajst-32571	103	8	mature	mature	ADJ
ajst-32571	103	9	clinical	clinical	ADJ
ajst-32571	103	10	data	datum	NOUN
ajst-32571	103	11	on	on	ADP
ajst-32571	103	12	the	the	DET
ajst-32571	103	13	dual	dual	ADJ
ajst-32571	103	14	-	-	PUNCT
ajst-32571	103	15	target	target	NOUN
ajst-32571	103	16	or	or	CCONJ
ajst-32571	103	17	multi	multi	ADJ
ajst-32571	103	18	-	-	ADJ
ajst-32571	103	19	target	target	ADJ
ajst-32571	103	20	car	car	NOUN
ajst-32571	103	21	-	-	PUNCT
ajst-32571	103	22	t	t	NOUN
ajst-32571	103	23	treatment	treatment	NOUN
ajst-32571	103	24	of	of	ADP
ajst-32571	103	25	ovarian	ovarian	ADJ
ajst-32571	103	26	cancer	cancer	NOUN
ajst-32571	103	27	targeting	target	VERB
ajst-32571	103	28	cldn6	cldn6	NOUN
ajst-32571	103	29	and	and	CCONJ
ajst-32571	103	30	another	another	DET
ajst-32571	103	31	target	target	NOUN
ajst-32571	103	32	;	;	PUNCT
ajst-32571	103	33	however	however	ADV
ajst-32571	103	34	,	,	PUNCT
ajst-32571	103	35	this	this	PRON
ajst-32571	103	36	is	be	AUX
ajst-32571	103	37	a	a	DET
ajst-32571	103	38	promising	promising	ADJ
ajst-32571	103	39	direction	direction	NOUN
ajst-32571	103	40	for	for	ADP
ajst-32571	103	41	future	future	ADJ
ajst-32571	103	42	development	development	NOUN
ajst-32571	103	43	.	.	PUNCT
ajst-32571	104	1	in	in	ADP
ajst-32571	104	2	addition	addition	NOUN
ajst-32571	104	3	to	to	ADP
ajst-32571	104	4	directing	direct	VERB
ajst-32571	104	5	focus	focus	NOUN
ajst-32571	104	6	towards	towards	ADP
ajst-32571	104	7	alternative	alternative	ADJ
ajst-32571	104	8	targets	target	NOUN
ajst-32571	104	9	,	,	PUNCT
ajst-32571	104	10	an	an	DET
ajst-32571	104	11	investigation	investigation	NOUN
ajst-32571	104	12	has	have	AUX
ajst-32571	104	13	also	also	ADV
ajst-32571	104	14	been	be	AUX
ajst-32571	104	15	conducted	conduct	VERB
ajst-32571	104	16	into	into	ADP
ajst-32571	104	17	other	other	ADJ
ajst-32571	104	18	methods	method	NOUN
ajst-32571	104	19	of	of	ADP
ajst-32571	104	20	cldn6	cldn6	NOUN
ajst-32571	104	21	-	-	PUNCT
ajst-32571	104	22	targeting	targeting	NOUN
ajst-32571	104	23	and	and	CCONJ
ajst-32571	104	24	the	the	DET
ajst-32571	104	25	consolidation	consolidation	NOUN
ajst-32571	104	26	of	of	ADP
ajst-32571	104	27	the	the	DET
ajst-32571	104	28	cldn6	cldn6	NOUN
ajst-32571	104	29	-	-	PUNCT
ajst-32571	104	30	car	car	NOUN
ajst-32571	104	31	-	-	PUNCT
ajst-32571	104	32	t	t	NOUN
ajst-32571	104	33	cell	cell	NOUN
ajst-32571	104	34	therapy	therapy	NOUN
ajst-32571	104	35	.	.	PUNCT
ajst-32571	105	1	in	in	ADP
ajst-32571	105	2	a	a	DET
ajst-32571	105	3	set	set	NOUN
ajst-32571	105	4	of	of	ADP
ajst-32571	105	5	preclinical	preclinical	ADJ
ajst-32571	105	6	investigations	investigation	NOUN
ajst-32571	105	7	,	,	PUNCT
ajst-32571	105	8	where	where	SCONJ
ajst-32571	105	9	cldn6	cldn6	NOUN
ajst-32571	105	10	-	-	PUNCT
ajst-32571	105	11	car	car	NOUN
ajst-32571	105	12	-	-	PUNCT
ajst-32571	105	13	t	t	NOUN
ajst-32571	105	14	demonstrated	demonstrate	VERB
ajst-32571	105	15	robust	robust	ADJ
ajst-32571	105	16	and	and	CCONJ
ajst-32571	105	17	specific	specific	ADJ
ajst-32571	105	18	tumor	tumor	NOUN
ajst-32571	105	19	regression	regression	NOUN
ajst-32571	105	20	in	in	ADP
ajst-32571	105	21	mouse	mouse	NOUN
ajst-32571	105	22	models	model	NOUN
ajst-32571	105	23	of	of	ADP
ajst-32571	105	24	solid	solid	ADJ
ajst-32571	105	25	tumor	tumor	NOUN
ajst-32571	105	26	cancers	cancer	NOUN
ajst-32571	105	27	,	,	PUNCT
ajst-32571	105	28	a	a	DET
ajst-32571	105	29	nanoparticulate	nanoparticulate	ADJ
ajst-32571	105	30	rna	rna	NOUN
ajst-32571	105	31	vaccine	vaccine	NOUN
ajst-32571	105	32	was	be	AUX
ajst-32571	105	33	designed	design	VERB
ajst-32571	105	34	to	to	PART
ajst-32571	105	35	augment	augment	VERB
ajst-32571	105	36	cldn6	cldn6	NOUN
ajst-32571	105	37	expression	expression	NOUN
ajst-32571	105	38	on	on	ADP
ajst-32571	105	39	cells	cell	NOUN
ajst-32571	105	40	,	,	PUNCT
ajst-32571	105	41	thereby	thereby	ADV
ajst-32571	105	42	increasing	increase	VERB
ajst-32571	105	43	the	the	DET
ajst-32571	105	44	persistence	persistence	NOUN
ajst-32571	105	45	of	of	ADP
ajst-32571	105	46	cldn6	cldn6	NOUN
ajst-32571	105	47	-	-	PUNCT
ajst-32571	105	48	car	car	NOUN
ajst-32571	105	49	-	-	PUNCT
ajst-32571	105	50	t	t	NOUN
ajst-32571	105	51	in	in	ADP
ajst-32571	105	52	vivo	vivo	NOUN
ajst-32571	105	53	and	and	CCONJ
ajst-32571	105	54	strengthening	strengthen	VERB
ajst-32571	105	55	the	the	DET
ajst-32571	105	56	cytotoxic	cytotoxic	ADJ
ajst-32571	105	57	response	response	NOUN
ajst-32571	105	58	[	[	X
ajst-32571	105	59	48	48	NUM
ajst-32571	105	60	]	]	PUNCT
ajst-32571	105	61	.	.	PUNCT
ajst-32571	106	1	in	in	ADP
ajst-32571	106	2	another	another	DET
ajst-32571	106	3	study	study	NOUN
ajst-32571	106	4	,	,	PUNCT
ajst-32571	106	5	bnt142	bnt142	PROPN
ajst-32571	106	6	,	,	PUNCT
ajst-32571	106	7	an	an	DET
ajst-32571	106	8	rna	rna	NOUN
ajst-32571	106	9	-	-	PUNCT
ajst-32571	106	10	containing	contain	VERB
ajst-32571	106	11	lipid	lipid	NOUN
ajst-32571	106	12	nanoparticle	nanoparticle	NOUN
ajst-32571	106	13	carrying	carry	VERB
ajst-32571	106	14	genes	gene	NOUN
ajst-32571	106	15	for	for	ADP
ajst-32571	106	16	a	a	DET
ajst-32571	106	17	t	t	NOUN
ajst-32571	106	18	cell	cell	NOUN
ajst-32571	106	19	-	-	PUNCT
ajst-32571	106	20	engaging	engage	VERB
ajst-32571	106	21	bispecific	bispecific	NOUN
ajst-32571	106	22	antibody	antibody	NOUN
ajst-32571	106	23	that	that	PRON
ajst-32571	106	24	binds	bind	VERB
ajst-32571	106	25	to	to	ADP
ajst-32571	106	26	cd3	cd3	PROPN
ajst-32571	106	27	markers	marker	NOUN
ajst-32571	106	28	,	,	PUNCT
ajst-32571	106	29	was	be	AUX
ajst-32571	106	30	also	also	ADV
ajst-32571	106	31	demonstrated	demonstrate	VERB
ajst-32571	106	32	in	in	ADP
ajst-32571	106	33	animal	animal	NOUN
ajst-32571	106	34	models	model	NOUN
ajst-32571	106	35	to	to	PART
ajst-32571	106	36	generate	generate	VERB
ajst-32571	106	37	potent	potent	ADJ
ajst-32571	106	38	cytotoxic	cytotoxic	ADJ
ajst-32571	106	39	activity	activity	NOUN
ajst-32571	106	40	against	against	ADP
ajst-32571	106	41	cldn6	cldn6	NOUN
ajst-32571	106	42	-	-	PUNCT
ajst-32571	106	43	positive	positive	ADJ
ajst-32571	106	44	tumor	tumor	NOUN
ajst-32571	106	45	cells	cell	NOUN
ajst-32571	106	46	[	[	X
ajst-32571	106	47	49	49	NUM
ajst-32571	106	48	]	]	PUNCT
ajst-32571	106	49	.	.	PUNCT
ajst-32571	107	1	regarding	regard	VERB
ajst-32571	107	2	an	an	DET
ajst-32571	107	3	extension	extension	NOUN
ajst-32571	107	4	of	of	ADP
ajst-32571	107	5	the	the	DET
ajst-32571	107	6	t	t	PROPN
ajst-32571	107	7	cell	cell	NOUN
ajst-32571	107	8	concept	concept	NOUN
ajst-32571	107	9	,	,	PUNCT
ajst-32571	107	10	remarkable	remarkable	ADJ
ajst-32571	107	11	tumor	tumor	NOUN
ajst-32571	107	12	reduction	reduction	NOUN
ajst-32571	107	13	was	be	AUX
ajst-32571	107	14	achieved	achieve	VERB
ajst-32571	107	15	by	by	ADP
ajst-32571	107	16	an	an	DET
ajst-32571	107	17	antibody	antibody	NOUN
ajst-32571	107	18	-	-	PUNCT
ajst-32571	107	19	drug	drug	NOUN
ajst-32571	107	20	conjugate	conjugate	NOUN
ajst-32571	107	21	designated	designate	VERB
ajst-32571	107	22	cldn6	cldn6	PROPN
ajst-32571	107	23	-	-	PUNCT
ajst-32571	107	24	23	23	NUM
ajst-32571	107	25	-	-	PUNCT
ajst-32571	107	26	adc	adc	NOUN
ajst-32571	107	27	in	in	ADP
ajst-32571	107	28	xenograft	xenograft	NOUN
ajst-32571	107	29	models	model	NOUN
ajst-32571	107	30	expressing	express	VERB
ajst-32571	107	31	cldn6	cldn6	NOUN
ajst-32571	107	32	,	,	PUNCT
ajst-32571	107	33	indicating	indicate	VERB
ajst-32571	107	34	an	an	DET
ajst-32571	107	35	effective	effective	ADJ
ajst-32571	107	36	method	method	NOUN
ajst-32571	107	37	for	for	ADP
ajst-32571	107	38	targeting	target	VERB
ajst-32571	107	39	cldn6	cldn6	NOUN
ajst-32571	107	40	via	via	ADP
ajst-32571	107	41	non	non	ADJ
ajst-32571	107	42	-	-	ADJ
ajst-32571	107	43	cellular	cellular	ADJ
ajst-32571	107	44	platforms	platform	NOUN
ajst-32571	107	45	[	[	X
ajst-32571	107	46	22	22	NUM
ajst-32571	107	47	]	]	PUNCT
ajst-32571	107	48	.	.	PUNCT
ajst-32571	108	1	the	the	DET
ajst-32571	108	2	shared	share	VERB
ajst-32571	108	3	capacity	capacity	NOUN
ajst-32571	108	4	of	of	ADP
ajst-32571	108	5	cldn6	cldn6	NOUN
ajst-32571	108	6	-	-	PUNCT
ajst-32571	108	7	car	car	NOUN
ajst-32571	108	8	-	-	PUNCT
ajst-32571	108	9	t	t	NOUN
ajst-32571	108	10	and	and	CCONJ
ajst-32571	108	11	other	other	ADJ
ajst-32571	108	12	cldn6	cldn6	NOUN
ajst-32571	108	13	-	-	PUNCT
ajst-32571	108	14	targeted	target	VERB
ajst-32571	108	15	therapies	therapy	NOUN
ajst-32571	108	16	,	,	PUNCT
ajst-32571	108	17	as	as	SCONJ
ajst-32571	108	18	illustrated	illustrate	VERB
ajst-32571	108	19	in	in	ADP
ajst-32571	108	20	these	these	DET
ajst-32571	108	21	findings	finding	NOUN
ajst-32571	108	22	,	,	PUNCT
ajst-32571	108	23	could	could	AUX
ajst-32571	108	24	potentially	potentially	ADV
ajst-32571	108	25	be	be	AUX
ajst-32571	108	26	integrated	integrate	VERB
ajst-32571	108	27	to	to	PART
ajst-32571	108	28	enhance	enhance	VERB
ajst-32571	108	29	the	the	DET
ajst-32571	108	30	efficacy	efficacy	NOUN
ajst-32571	108	31	of	of	ADP
ajst-32571	108	32	heterogeneous	heterogeneous	ADJ
ajst-32571	108	33	ovarian	ovarian	ADJ
ajst-32571	108	34	cancer	cancer	NOUN
ajst-32571	108	35	treatments	treatment	NOUN
ajst-32571	108	36	.	.	PUNCT
ajst-32571	109	1	4.2	4.2	NUM
ajst-32571	109	2	cxcr2	cxcr2	NOUN
ajst-32571	109	3	-	-	PUNCT
ajst-32571	109	4	targeting	target	VERB
ajst-32571	109	5	and	and	CCONJ
ajst-32571	109	6	bionic	bionic	ADJ
ajst-32571	109	7	physical	physical	ADJ
ajst-32571	109	8	barriers	barrier	NOUN
ajst-32571	109	9	mdscs	mdsc	NOUN
ajst-32571	109	10	play	play	VERB
ajst-32571	109	11	a	a	DET
ajst-32571	109	12	pivotal	pivotal	ADJ
ajst-32571	109	13	role	role	NOUN
ajst-32571	109	14	in	in	ADP
ajst-32571	109	15	promoting	promote	VERB
ajst-32571	109	16	immunosuppression	immunosuppression	NOUN
ajst-32571	109	17	through	through	ADP
ajst-32571	109	18	multiple	multiple	ADJ
ajst-32571	109	19	pathways	pathway	NOUN
ajst-32571	109	20	within	within	ADP
ajst-32571	109	21	the	the	DET
ajst-32571	109	22	tme	tme	NOUN
ajst-32571	110	1	[	[	X
ajst-32571	110	2	50	50	NUM
ajst-32571	110	3	]	]	PUNCT
ajst-32571	110	4	.	.	PUNCT
ajst-32571	111	1	they	they	PRON
ajst-32571	111	2	secrete	secrete	VERB
ajst-32571	111	3	immunosuppressive	immunosuppressive	ADJ
ajst-32571	111	4	mediators	mediator	NOUN
ajst-32571	111	5	,	,	PUNCT
ajst-32571	111	6	including	include	VERB
ajst-32571	111	7	inducible	inducible	ADJ
ajst-32571	111	8	nitric	nitric	ADJ
ajst-32571	111	9	oxide	oxide	NOUN
ajst-32571	111	10	synthase	synthase	NOUN
ajst-32571	111	11	(	(	PUNCT
ajst-32571	111	12	inos	ino	NOUN
ajst-32571	111	13	)	)	PUNCT
ajst-32571	111	14	,	,	PUNCT
ajst-32571	111	15	arginase-1	arginase-1	PROPN
ajst-32571	111	16	(	(	PUNCT
ajst-32571	111	17	arg1	arg1	PROPN
ajst-32571	111	18	)	)	PUNCT
ajst-32571	111	19	,	,	PUNCT
ajst-32571	111	20	and	and	CCONJ
ajst-32571	111	21	tgf	tgf	PROPN
ajst-32571	111	22	-	-	PUNCT
ajst-32571	111	23	β	β	PROPN
ajst-32571	111	24	,	,	PUNCT
ajst-32571	111	25	alongside	alongside	ADP
ajst-32571	111	26	immune	immune	NOUN
ajst-32571	111	27	-	-	PUNCT
ajst-32571	111	28	evasive	evasive	ADJ
ajst-32571	111	29	niche	niche	NOUN
ajst-32571	111	30	-	-	PUNCT
ajst-32571	111	31	reinforcing	reinforce	VERB
ajst-32571	111	32	il-10	il-10	PRON
ajst-32571	111	33	,	,	PUNCT
ajst-32571	111	34	cyclooxygenase-2	cyclooxygenase-2	NUM
ajst-32571	111	35	(	(	PUNCT
ajst-32571	111	36	cox2	cox2	PROPN
ajst-32571	111	37	)	)	PUNCT
ajst-32571	111	38	,	,	PUNCT
ajst-32571	111	39	and	and	CCONJ
ajst-32571	111	40	indoleamine	indoleamine	VERB
ajst-32571	111	41	2,3	2,3	NUM
ajst-32571	111	42	-	-	NOUN
ajst-32571	111	43	dioxygenase	dioxygenase	NOUN
ajst-32571	111	44	(	(	PUNCT
ajst-32571	111	45	ido	ido	NOUN
ajst-32571	111	46	)	)	PUNCT
ajst-32571	112	1	[	[	X
ajst-32571	112	2	51][52][53	51][52][53	NUM
ajst-32571	112	3	]	]	PUNCT
ajst-32571	112	4	.	.	PUNCT
ajst-32571	113	1	in	in	ADP
ajst-32571	113	2	cancers	cancer	NOUN
ajst-32571	113	3	,	,	PUNCT
ajst-32571	113	4	the	the	DET
ajst-32571	113	5	g	g	PROPN
ajst-32571	113	6	protein	protein	NOUN
ajst-32571	113	7	-	-	PUNCT
ajst-32571	113	8	coupled	couple	VERB
ajst-32571	113	9	c	c	NOUN
ajst-32571	113	10	-	-	PUNCT
ajst-32571	113	11	x	x	NOUN
ajst-32571	113	12	-	-	NOUN
ajst-32571	113	13	c	c	ADJ
ajst-32571	113	14	motif	motif	NOUN
ajst-32571	113	15	chemokine	chemokine	ADJ
ajst-32571	113	16	receptor	receptor	NOUN
ajst-32571	113	17	2	2	NUM
ajst-32571	113	18	(	(	PUNCT
ajst-32571	113	19	cxcr2	cxcr2	NOUN
ajst-32571	113	20	)	)	PUNCT
ajst-32571	113	21	plays	play	VERB
ajst-32571	113	22	a	a	DET
ajst-32571	113	23	significant	significant	ADJ
ajst-32571	113	24	role	role	NOUN
ajst-32571	113	25	in	in	ADP
ajst-32571	113	26	recruiting	recruiting	NOUN
ajst-32571	113	27	mdscs	mdsc	NOUN
ajst-32571	113	28	to	to	ADP
ajst-32571	113	29	the	the	DET
ajst-32571	113	30	tme	tme	NOUN
ajst-32571	114	1	[	[	X
ajst-32571	114	2	54	54	NUM
ajst-32571	114	3	]	]	PUNCT
ajst-32571	114	4	.	.	PUNCT
ajst-32571	115	1	figure	figure	NOUN
ajst-32571	115	2	5	5	NUM
ajst-32571	115	3	.	.	PUNCT
ajst-32571	116	1	immunosuppressive	immunosuppressive	ADJ
ajst-32571	116	2	cells	cell	NOUN
ajst-32571	116	3	in	in	ADP
ajst-32571	116	4	the	the	DET
ajst-32571	116	5	tme	tme	NOUN
ajst-32571	116	6	.	.	PUNCT
ajst-32571	117	1	cxcl1	cxcl1	NOUN
ajst-32571	117	2	,	,	PUNCT
ajst-32571	117	3	cxcl2	cxcl2	PROPN
ajst-32571	117	4	,	,	PUNCT
ajst-32571	117	5	cxcl5	cxcl5	PROPN
ajst-32571	117	6	,	,	PUNCT
ajst-32571	117	7	and	and	CCONJ
ajst-32571	117	8	cxcl8	cxcl8	NOUN
ajst-32571	117	9	recruit	recruit	ADJ
ajst-32571	117	10	pmn	pmn	ADJ
ajst-32571	117	11	-	-	PUNCT
ajst-32571	117	12	mdscs	mdsc	NOUN
ajst-32571	117	13	and	and	CCONJ
ajst-32571	117	14	m	m	NOUN
ajst-32571	117	15	-	-	PUNCT
ajst-32571	117	16	mdscs	mdsc	NOUN
ajst-32571	117	17	to	to	PART
ajst-32571	117	18	form	form	VERB
ajst-32571	117	19	an	an	DET
ajst-32571	117	20	immunosuppressive	immunosuppressive	ADJ
ajst-32571	117	21	physical	physical	ADJ
ajst-32571	117	22	barrier	barrier	NOUN
ajst-32571	117	23	[	[	X
ajst-32571	117	24	55	55	NUM
ajst-32571	117	25	]	]	PUNCT
ajst-32571	117	26	.	.	PUNCT
ajst-32571	118	1	pns	pns	NOUN
ajst-32571	118	2	-	-	PUNCT
ajst-32571	118	3	mdscs	mdsc	NOUN
ajst-32571	118	4	and	and	CCONJ
ajst-32571	118	5	m	m	NOUN
ajst-32571	118	6	-	-	PUNCT
ajst-32571	118	7	mdscs	mdsc	NOUN
ajst-32571	118	8	secrete	secrete	NOUN
ajst-32571	118	9	inos	ino	NOUN
ajst-32571	118	10	,	,	PUNCT
ajst-32571	118	11	arg1	arg1	PROPN
ajst-32571	118	12	,	,	PUNCT
ajst-32571	118	13	tgf	tgf	PROPN
ajst-32571	118	14	-	-	PUNCT
ajst-32571	118	15	β	β	PROPN
ajst-32571	118	16	,	,	PUNCT
ajst-32571	118	17	il-10	il-10	PRON
ajst-32571	118	18	,	,	PUNCT
ajst-32571	118	19	and	and	CCONJ
ajst-32571	118	20	cox2	cox2	NOUN
ajst-32571	118	21	,	,	PUNCT
ajst-32571	118	22	inhibiting	inhibit	VERB
ajst-32571	118	23	t	t	NOUN
ajst-32571	118	24	cell	cell	NOUN
ajst-32571	118	25	function	function	NOUN
ajst-32571	119	1	[	[	X
ajst-32571	119	2	53	53	NUM
ajst-32571	119	3	]	]	PUNCT
ajst-32571	119	4	.	.	PUNCT
ajst-32571	120	1	[	[	X
ajst-32571	120	2	56	56	NUM
ajst-32571	120	3	]	]	PUNCT
ajst-32571	120	4	to	to	PART
ajst-32571	120	5	enhance	enhance	VERB
ajst-32571	120	6	t	t	PROPN
ajst-32571	120	7	cell	cell	NOUN
ajst-32571	120	8	infiltration	infiltration	NOUN
ajst-32571	120	9	within	within	ADP
ajst-32571	120	10	tumours	tumours	PROPN
ajst-32571	120	11	,	,	PUNCT
ajst-32571	120	12	scientists	scientist	NOUN
ajst-32571	120	13	are	be	AUX
ajst-32571	120	14	developing	develop	VERB
ajst-32571	120	15	cxcr2	cxcr2	NOUN
ajst-32571	120	16	-	-	PUNCT
ajst-32571	120	17	modified	modify	VERB
ajst-32571	120	18	car	car	NOUN
ajst-32571	120	19	-	-	PUNCT
ajst-32571	120	20	t	t	NOUN
ajst-32571	120	21	cells	cell	NOUN
ajst-32571	120	22	[	[	X
ajst-32571	120	23	57][58][59	57][58][59	NUM
ajst-32571	120	24	]	]	PUNCT
ajst-32571	120	25	.	.	PUNCT
ajst-32571	121	1	cxcr2	cxcr2	NOUN
ajst-32571	121	2	antagonists	antagonist	NOUN
ajst-32571	121	3	are	be	AUX
ajst-32571	121	4	currently	currently	ADV
ajst-32571	121	5	being	be	AUX
ajst-32571	121	6	investigated	investigate	VERB
ajst-32571	121	7	as	as	ADP
ajst-32571	121	8	anti	anti	ADJ
ajst-32571	121	9	-	-	ADJ
ajst-32571	121	10	inflammatory	inflammatory	ADJ
ajst-32571	121	11	183	183	NUM
ajst-32571	121	12	treatments	treatment	NOUN
ajst-32571	121	13	for	for	ADP
ajst-32571	121	14	various	various	ADJ
ajst-32571	121	15	diseases	disease	NOUN
ajst-32571	121	16	,	,	PUNCT
ajst-32571	121	17	including	include	VERB
ajst-32571	121	18	chronic	chronic	ADJ
ajst-32571	121	19	obstructive	obstructive	ADJ
ajst-32571	121	20	pulmonary	pulmonary	ADJ
ajst-32571	121	21	disease	disease	NOUN
ajst-32571	121	22	(	(	PUNCT
ajst-32571	121	23	copd	copd	PROPN
ajst-32571	121	24	)	)	PUNCT
ajst-32571	121	25	,	,	PUNCT
ajst-32571	121	26	type	type	NOUN
ajst-32571	121	27	1	1	NUM
ajst-32571	121	28	diabetes	diabetes	NOUN
ajst-32571	121	29	,	,	PUNCT
ajst-32571	121	30	rheumatoid	rheumatoid	NOUN
ajst-32571	121	31	arthritis	arthritis	NOUN
ajst-32571	121	32	,	,	PUNCT
ajst-32571	121	33	ulcerative	ulcerative	ADJ
ajst-32571	121	34	colitis	colitis	NOUN
ajst-32571	121	35	,	,	PUNCT
ajst-32571	121	36	and	and	CCONJ
ajst-32571	121	37	cancer	cancer	NOUN
ajst-32571	122	1	[	[	X
ajst-32571	122	2	60	60	NUM
ajst-32571	122	3	]	]	PUNCT
ajst-32571	122	4	.	.	PUNCT
ajst-32571	123	1	the	the	DET
ajst-32571	123	2	cxcr1/2	cxcr1/2	ADJ
ajst-32571	123	3	inhibitor	inhibitor	NOUN
ajst-32571	123	4	reparixin	reparixin	PROPN
ajst-32571	123	5	was	be	AUX
ajst-32571	123	6	found	find	VERB
ajst-32571	123	7	to	to	PART
ajst-32571	123	8	be	be	AUX
ajst-32571	123	9	safe	safe	ADJ
ajst-32571	123	10	and	and	CCONJ
ajst-32571	123	11	well	well	ADV
ajst-32571	123	12	-	-	PUNCT
ajst-32571	123	13	tolerated	tolerate	VERB
ajst-32571	123	14	in	in	ADP
ajst-32571	123	15	clinical	clinical	ADJ
ajst-32571	123	16	trials	trial	NOUN
ajst-32571	123	17	for	for	ADP
ajst-32571	123	18	her-2	her-2	ADV
ajst-32571	123	19	-	-	PUNCT
ajst-32571	123	20	negative	negative	ADJ
ajst-32571	123	21	breast	breast	NOUN
ajst-32571	123	22	cancer	cancer	NOUN
ajst-32571	123	23	,	,	PUNCT
ajst-32571	123	24	resulting	result	VERB
ajst-32571	123	25	in	in	ADP
ajst-32571	123	26	a	a	DET
ajst-32571	123	27	successful	successful	ADJ
ajst-32571	123	28	reduction	reduction	NOUN
ajst-32571	123	29	in	in	ADP
ajst-32571	123	30	cancer	cancer	NOUN
ajst-32571	123	31	stem	stem	NOUN
ajst-32571	123	32	cells	cell	NOUN
ajst-32571	123	33	within	within	ADP
ajst-32571	123	34	patient	patient	ADJ
ajst-32571	123	35	tumors	tumor	NOUN
ajst-32571	123	36	[	[	X
ajst-32571	123	37	61	61	NUM
ajst-32571	123	38	]	]	PUNCT
ajst-32571	123	39	.	.	PUNCT
ajst-32571	124	1	in	in	ADP
ajst-32571	124	2	mouse	mouse	NOUN
ajst-32571	124	3	models	model	NOUN
ajst-32571	124	4	of	of	ADP
ajst-32571	124	5	head	head	NOUN
ajst-32571	124	6	and	and	CCONJ
ajst-32571	124	7	neck	neck	NOUN
ajst-32571	124	8	cancer	cancer	NOUN
ajst-32571	124	9	,	,	PUNCT
ajst-32571	124	10	treatment	treatment	NOUN
ajst-32571	124	11	with	with	ADP
ajst-32571	124	12	the	the	DET
ajst-32571	124	13	cxcr1/2	cxcr1/2	ADJ
ajst-32571	124	14	inhibitor	inhibitor	NOUN
ajst-32571	124	15	sx-682	sx-682	NOUN
ajst-32571	124	16	prevented	prevent	VERB
ajst-32571	124	17	the	the	DET
ajst-32571	124	18	migration	migration	NOUN
ajst-32571	124	19	of	of	ADP
ajst-32571	124	20	mdscs	mdsc	NOUN
ajst-32571	124	21	into	into	ADP
ajst-32571	124	22	tumors	tumor	NOUN
ajst-32571	124	23	and	and	CCONJ
ajst-32571	124	24	enhanced	enhance	VERB
ajst-32571	124	25	the	the	DET
ajst-32571	124	26	effectiveness	effectiveness	NOUN
ajst-32571	124	27	of	of	ADP
ajst-32571	124	28	natural	natural	ADJ
ajst-32571	124	29	killer	killer	NOUN
ajst-32571	124	30	cell	cell	NOUN
ajst-32571	124	31	therapy	therapy	NOUN
ajst-32571	124	32	[	[	X
ajst-32571	124	33	62	62	NUM
ajst-32571	124	34	]	]	PUNCT
ajst-32571	124	35	.	.	PUNCT
ajst-32571	125	1	the	the	DET
ajst-32571	125	2	same	same	ADJ
ajst-32571	125	3	compound	compound	NOUN
ajst-32571	125	4	was	be	AUX
ajst-32571	125	5	also	also	ADV
ajst-32571	125	6	later	later	ADV
ajst-32571	125	7	tested	test	VERB
ajst-32571	125	8	in	in	ADP
ajst-32571	125	9	non	non	ADJ
ajst-32571	125	10	-	-	ADJ
ajst-32571	125	11	small	small	ADJ
ajst-32571	125	12	-	-	PUNCT
ajst-32571	125	13	cell	cell	NOUN
ajst-32571	125	14	lung	lung	NOUN
ajst-32571	125	15	cancer	cancer	NOUN
ajst-32571	125	16	models	model	NOUN
ajst-32571	125	17	,	,	PUNCT
ajst-32571	125	18	where	where	SCONJ
ajst-32571	125	19	dual	dual	ADJ
ajst-32571	125	20	inhibition	inhibition	NOUN
ajst-32571	125	21	of	of	ADP
ajst-32571	125	22	shp2	shp2	NOUN
ajst-32571	125	23	and	and	CCONJ
ajst-32571	125	24	cxcr1/2	cxcr1/2	NOUN
ajst-32571	125	25	successfully	successfully	ADV
ajst-32571	125	26	reshaped	reshape	VERB
ajst-32571	125	27	the	the	DET
ajst-32571	125	28	tumour	tumour	NOUN
ajst-32571	125	29	microenvironment	microenvironment	NOUN
ajst-32571	125	30	,	,	PUNCT
ajst-32571	125	31	increased	increase	VERB
ajst-32571	125	32	cd8	cd8	PROPN
ajst-32571	125	33	+	+	PROPN
ajst-32571	125	34	t	t	PROPN
ajst-32571	125	35	cell	cell	NOUN
ajst-32571	125	36	activity	activity	NOUN
ajst-32571	125	37	,	,	PUNCT
ajst-32571	125	38	and	and	CCONJ
ajst-32571	125	39	led	lead	VERB
ajst-32571	125	40	to	to	ADP
ajst-32571	125	41	slower	slow	ADJ
ajst-32571	125	42	tumour	tumour	ADJ
ajst-32571	125	43	growth	growth	NOUN
ajst-32571	125	44	and	and	CCONJ
ajst-32571	125	45	longer	long	ADJ
ajst-32571	125	46	survival	survival	NOUN
ajst-32571	125	47	[	[	X
ajst-32571	125	48	63	63	NUM
ajst-32571	125	49	]	]	PUNCT
ajst-32571	125	50	.	.	PUNCT
ajst-32571	126	1	evidence	evidence	NOUN
ajst-32571	126	2	from	from	ADP
ajst-32571	126	3	liver	liver	NOUN
ajst-32571	126	4	cancer	cancer	NOUN
ajst-32571	126	5	models	model	NOUN
ajst-32571	126	6	linked	link	VERB
ajst-32571	126	7	to	to	ADP
ajst-32571	126	8	non	non	ADJ
ajst-32571	126	9	-	-	ADJ
ajst-32571	126	10	alcoholic	alcoholic	ADJ
ajst-32571	126	11	steatohepatitis	steatohepatitis	NOUN
ajst-32571	126	12	further	far	ADV
ajst-32571	126	13	supports	support	VERB
ajst-32571	126	14	this	this	DET
ajst-32571	126	15	approach	approach	NOUN
ajst-32571	126	16	.	.	PUNCT
ajst-32571	127	1	in	in	ADP
ajst-32571	127	2	these	these	DET
ajst-32571	127	3	studies	study	NOUN
ajst-32571	127	4	,	,	PUNCT
ajst-32571	127	5	cxcr2	cxcr2	NOUN
ajst-32571	127	6	inhibition	inhibition	NOUN
ajst-32571	127	7	reduced	reduce	VERB
ajst-32571	127	8	the	the	DET
ajst-32571	127	9	number	number	NOUN
ajst-32571	127	10	of	of	ADP
ajst-32571	127	11	pro	pro	ADJ
ajst-32571	127	12	-	-	ADJ
ajst-32571	127	13	tumour	tumour	ADJ
ajst-32571	127	14	neutrophils	neutrophil	NOUN
ajst-32571	127	15	and	and	CCONJ
ajst-32571	127	16	enhanced	enhance	VERB
ajst-32571	127	17	the	the	DET
ajst-32571	127	18	response	response	NOUN
ajst-32571	127	19	to	to	ADP
ajst-32571	127	20	anti	anti	ADJ
ajst-32571	127	21	-	-	ADJ
ajst-32571	127	22	pd1	pd1	VERB
ajst-32571	127	23	therapy	therapy	NOUN
ajst-32571	127	24	,	,	PUNCT
ajst-32571	127	25	producing	produce	VERB
ajst-32571	127	26	tumour	tumour	ADJ
ajst-32571	127	27	regression	regression	NOUN
ajst-32571	127	28	and	and	CCONJ
ajst-32571	127	29	improved	improve	VERB
ajst-32571	127	30	outcomes	outcome	NOUN
ajst-32571	127	31	in	in	ADP
ajst-32571	127	32	mice	mouse	NOUN
ajst-32571	127	33	[	[	X
ajst-32571	127	34	64	64	NUM
ajst-32571	127	35	]	]	PUNCT
ajst-32571	127	36	.	.	PUNCT
ajst-32571	128	1	broader	broad	ADJ
ajst-32571	128	2	reviews	review	NOUN
ajst-32571	128	3	have	have	AUX
ajst-32571	128	4	described	describe	VERB
ajst-32571	128	5	cxcr2	cxcr2	NOUN
ajst-32571	128	6	as	as	ADP
ajst-32571	128	7	a	a	DET
ajst-32571	128	8	central	central	ADJ
ajst-32571	128	9	regulator	regulator	NOUN
ajst-32571	128	10	of	of	ADP
ajst-32571	128	11	neutrophil	neutrophil	ADJ
ajst-32571	128	12	recruitment	recruitment	NOUN
ajst-32571	128	13	and	and	CCONJ
ajst-32571	128	14	immunosuppression	immunosuppression	NOUN
ajst-32571	128	15	,	,	PUNCT
ajst-32571	128	16	summarizing	summarize	VERB
ajst-32571	128	17	growing	grow	VERB
ajst-32571	128	18	clinical	clinical	ADJ
ajst-32571	128	19	and	and	CCONJ
ajst-32571	128	20	preclinical	preclinical	ADJ
ajst-32571	128	21	data	datum	NOUN
ajst-32571	128	22	that	that	PRON
ajst-32571	128	23	support	support	VERB
ajst-32571	128	24	cxcr2	cxcr2	NOUN
ajst-32571	128	25	inhibitors	inhibitor	NOUN
ajst-32571	128	26	,	,	PUNCT
ajst-32571	128	27	such	such	ADJ
ajst-32571	128	28	as	as	ADP
ajst-32571	128	29	sx-682	sx-682	NOUN
ajst-32571	128	30	and	and	CCONJ
ajst-32571	128	31	navarixin	navarixin	NOUN
ajst-32571	128	32	,	,	PUNCT
ajst-32571	128	33	in	in	ADP
ajst-32571	128	34	solid	solid	ADJ
ajst-32571	128	35	tumors	tumor	NOUN
ajst-32571	128	36	[	[	X
ajst-32571	128	37	65	65	NUM
ajst-32571	128	38	]	]	PUNCT
ajst-32571	128	39	.	.	PUNCT
ajst-32571	129	1	however	however	ADV
ajst-32571	129	2	,	,	PUNCT
ajst-32571	129	3	more	more	ADV
ajst-32571	129	4	recent	recent	ADJ
ajst-32571	129	5	animal	animal	NOUN
ajst-32571	129	6	studies	study	NOUN
ajst-32571	129	7	have	have	AUX
ajst-32571	129	8	shown	show	VERB
ajst-32571	129	9	that	that	SCONJ
ajst-32571	129	10	blocking	block	VERB
ajst-32571	129	11	cxcr2	cxcr2	NOUN
ajst-32571	129	12	does	do	AUX
ajst-32571	129	13	not	not	PART
ajst-32571	129	14	completely	completely	ADV
ajst-32571	129	15	prevent	prevent	VERB
ajst-32571	129	16	neutrophil	neutrophil	ADJ
ajst-32571	129	17	entry	entry	NOUN
ajst-32571	129	18	into	into	ADP
ajst-32571	129	19	circulation	circulation	NOUN
ajst-32571	129	20	,	,	PUNCT
ajst-32571	129	21	suggesting	suggest	VERB
ajst-32571	129	22	that	that	SCONJ
ajst-32571	129	23	single	single	ADJ
ajst-32571	129	24	-	-	PUNCT
ajst-32571	129	25	agent	agent	NOUN
ajst-32571	129	26	inhibition	inhibition	NOUN
ajst-32571	129	27	may	may	AUX
ajst-32571	129	28	need	need	VERB
ajst-32571	129	29	to	to	PART
ajst-32571	129	30	be	be	AUX
ajst-32571	129	31	combined	combine	VERB
ajst-32571	129	32	with	with	ADP
ajst-32571	129	33	other	other	ADJ
ajst-32571	129	34	treatments	treatment	NOUN
ajst-32571	129	35	to	to	PART
ajst-32571	129	36	achieve	achieve	VERB
ajst-32571	129	37	lasting	lasting	ADJ
ajst-32571	129	38	immune	immune	ADJ
ajst-32571	129	39	control	control	NOUN
ajst-32571	130	1	[	[	X
ajst-32571	130	2	66	66	NUM
ajst-32571	130	3	]	]	PUNCT
ajst-32571	130	4	.	.	PUNCT
ajst-32571	131	1	although	although	SCONJ
ajst-32571	131	2	no	no	DET
ajst-32571	131	3	such	such	ADJ
ajst-32571	131	4	drugs	drug	NOUN
ajst-32571	131	5	have	have	AUX
ajst-32571	131	6	yet	yet	ADV
ajst-32571	131	7	been	be	AUX
ajst-32571	131	8	approved	approve	VERB
ajst-32571	131	9	for	for	ADP
ajst-32571	131	10	treatment	treatment	NOUN
ajst-32571	131	11	,	,	PUNCT
ajst-32571	131	12	targeting	target	VERB
ajst-32571	131	13	cxcr2	cxcr2	NOUN
ajst-32571	131	14	to	to	PART
ajst-32571	131	15	inhibit	inhibit	VERB
ajst-32571	131	16	mdsc	mdsc	ADJ
ajst-32571	131	17	recruitment	recruitment	NOUN
ajst-32571	131	18	and	and	CCONJ
ajst-32571	131	19	counteract	counteract	VERB
ajst-32571	131	20	the	the	DET
ajst-32571	131	21	immunosuppressive	immunosuppressive	ADJ
ajst-32571	131	22	tme	tme	NOUN
ajst-32571	131	23	in	in	ADP
ajst-32571	131	24	line	line	NOUN
ajst-32571	131	25	with	with	ADP
ajst-32571	131	26	cldn6	cldn6	NOUN
ajst-32571	131	27	-	-	PUNCT
ajst-32571	131	28	car	car	NOUN
ajst-32571	131	29	-	-	PUNCT
ajst-32571	131	30	t	t	NOUN
ajst-32571	131	31	cell	cell	NOUN
ajst-32571	131	32	therapy	therapy	NOUN
ajst-32571	131	33	provides	provide	VERB
ajst-32571	131	34	a	a	DET
ajst-32571	131	35	potentially	potentially	ADV
ajst-32571	131	36	feasible	feasible	ADJ
ajst-32571	131	37	therapeutic	therapeutic	ADJ
ajst-32571	131	38	approach	approach	NOUN
ajst-32571	131	39	to	to	ADP
ajst-32571	131	40	ovarian	ovarian	ADJ
ajst-32571	131	41	cancer	cancer	NOUN
ajst-32571	131	42	.	.	PUNCT
ajst-32571	132	1	additionally	additionally	ADV
ajst-32571	132	2	,	,	PUNCT
ajst-32571	132	3	bionic	bionic	ADJ
ajst-32571	132	4	physical	physical	ADJ
ajst-32571	132	5	barriers	barrier	NOUN
ajst-32571	132	6	also	also	ADV
ajst-32571	132	7	offer	offer	VERB
ajst-32571	132	8	another	another	DET
ajst-32571	132	9	unique	unique	ADJ
ajst-32571	132	10	direction	direction	NOUN
ajst-32571	132	11	for	for	ADP
ajst-32571	132	12	combating	combat	VERB
ajst-32571	132	13	immunosuppression	immunosuppression	NOUN
ajst-32571	132	14	.	.	PUNCT
ajst-32571	133	1	a	a	DET
ajst-32571	133	2	research	research	NOUN
ajst-32571	133	3	team	team	NOUN
ajst-32571	133	4	has	have	AUX
ajst-32571	133	5	designed	design	VERB
ajst-32571	133	6	a	a	DET
ajst-32571	133	7	bionic	bionic	ADJ
ajst-32571	133	8	physical	physical	ADJ
ajst-32571	133	9	barrier	barrier	NOUN
ajst-32571	133	10	centred	centre	VERB
ajst-32571	133	11	on	on	ADP
ajst-32571	133	12	a	a	DET
ajst-32571	133	13	thermosensitive	thermosensitive	ADJ
ajst-32571	133	14	hydrogel	hydrogel	NOUN
ajst-32571	133	15	that	that	PRON
ajst-32571	133	16	can	can	AUX
ajst-32571	133	17	temporarily	temporarily	ADV
ajst-32571	133	18	block	block	VERB
ajst-32571	133	19	the	the	DET
ajst-32571	133	20	interaction	interaction	NOUN
ajst-32571	133	21	between	between	ADP
ajst-32571	133	22	t	t	NOUN
ajst-32571	133	23	cells	cell	NOUN
ajst-32571	133	24	and	and	CCONJ
ajst-32571	133	25	tumour	tumour	NOUN
ajst-32571	133	26	tissues	tissue	NOUN
ajst-32571	133	27	.	.	PUNCT
ajst-32571	134	1	once	once	ADV
ajst-32571	134	2	t	t	PROPN
ajst-32571	134	3	cells	cell	NOUN
ajst-32571	134	4	accumulate	accumulate	VERB
ajst-32571	134	5	to	to	ADP
ajst-32571	134	6	an	an	DET
ajst-32571	134	7	optimal	optimal	ADJ
ajst-32571	134	8	level	level	NOUN
ajst-32571	134	9	in	in	ADP
ajst-32571	134	10	the	the	DET
ajst-32571	134	11	tumour	tumour	NOUN
ajst-32571	134	12	tissues	tissue	NOUN
ajst-32571	134	13	,	,	PUNCT
ajst-32571	134	14	the	the	DET
ajst-32571	134	15	barrier	barrier	NOUN
ajst-32571	134	16	can	can	AUX
ajst-32571	134	17	be	be	AUX
ajst-32571	134	18	removed	remove	VERB
ajst-32571	134	19	by	by	ADP
ajst-32571	134	20	accepting	accept	VERB
ajst-32571	134	21	near	near	ADV
ajst-32571	134	22	-	-	PUNCT
ajst-32571	134	23	infrared	infrared	ADJ
ajst-32571	134	24	light	light	NOUN
ajst-32571	134	25	,	,	PUNCT
ajst-32571	134	26	allowing	allow	VERB
ajst-32571	134	27	t	t	NOUN
ajst-32571	134	28	cells	cell	NOUN
ajst-32571	134	29	to	to	PART
ajst-32571	134	30	attack	attack	VERB
ajst-32571	134	31	tumour	tumour	NOUN
ajst-32571	134	32	cells	cell	NOUN
ajst-32571	134	33	in	in	ADP
ajst-32571	134	34	a	a	DET
ajst-32571	134	35	more	more	ADV
ajst-32571	134	36	effective	effective	ADJ
ajst-32571	134	37	state	state	NOUN
ajst-32571	134	38	[	[	X
ajst-32571	134	39	67	67	NUM
ajst-32571	134	40	]	]	PUNCT
ajst-32571	134	41	.	.	PUNCT
ajst-32571	135	1	this	this	DET
ajst-32571	135	2	therapy	therapy	NOUN
ajst-32571	135	3	reduces	reduce	VERB
ajst-32571	135	4	the	the	DET
ajst-32571	135	5	exhaustion	exhaustion	NOUN
ajst-32571	135	6	of	of	ADP
ajst-32571	135	7	t	t	NOUN
ajst-32571	135	8	cells	cell	NOUN
ajst-32571	135	9	under	under	ADP
ajst-32571	135	10	immunosuppression	immunosuppression	NOUN
ajst-32571	135	11	and	and	CCONJ
ajst-32571	135	12	represents	represent	VERB
ajst-32571	135	13	an	an	DET
ajst-32571	135	14	innovative	innovative	ADJ
ajst-32571	135	15	approach	approach	NOUN
ajst-32571	135	16	for	for	ADP
ajst-32571	135	17	tumour	tumour	NOUN
ajst-32571	135	18	immunotherapy	immunotherapy	NOUN
ajst-32571	135	19	that	that	PRON
ajst-32571	135	20	can	can	AUX
ajst-32571	135	21	be	be	AUX
ajst-32571	135	22	applied	apply	VERB
ajst-32571	135	23	to	to	ADP
ajst-32571	135	24	cdln6	cdln6	NOUN
ajst-32571	135	25	-	-	PUNCT
ajst-32571	135	26	car	car	NOUN
ajst-32571	135	27	-	-	PUNCT
ajst-32571	135	28	t.	t.	NOUN
ajst-32571	135	29	4.3	4.3	NUM
ajst-32571	135	30	use	use	NOUN
ajst-32571	135	31	of	of	ADP
ajst-32571	135	32	hpse	hpse	NOUN
ajst-32571	135	33	to	to	PART
ajst-32571	135	34	break	break	VERB
ajst-32571	135	35	down	down	ADP
ajst-32571	135	36	the	the	DET
ajst-32571	135	37	ecm	ecm	NOUN
ajst-32571	135	38	heparan	heparan	ADJ
ajst-32571	135	39	sulphate	sulphate	NOUN
ajst-32571	135	40	(	(	PUNCT
ajst-32571	135	41	hs	hs	X
ajst-32571	135	42	)	)	PUNCT
ajst-32571	135	43	is	be	AUX
ajst-32571	135	44	an	an	DET
ajst-32571	135	45	important	important	ADJ
ajst-32571	135	46	component	component	NOUN
ajst-32571	135	47	of	of	ADP
ajst-32571	135	48	the	the	DET
ajst-32571	135	49	ecm	ecm	NOUN
ajst-32571	135	50	.	.	PUNCT
ajst-32571	136	1	the	the	DET
ajst-32571	136	2	enzyme	enzyme	NOUN
ajst-32571	136	3	heparanase	heparanase	NOUN
ajst-32571	136	4	(	(	PUNCT
ajst-32571	136	5	hpse	hpse	NOUN
ajst-32571	136	6	)	)	PUNCT
ajst-32571	136	7	can	can	AUX
ajst-32571	136	8	degrade	degrade	VERB
ajst-32571	136	9	hs	hs	PRON
ajst-32571	136	10	,	,	PUNCT
ajst-32571	136	11	thereby	thereby	ADV
ajst-32571	136	12	breaking	break	VERB
ajst-32571	136	13	the	the	DET
ajst-32571	136	14	physical	physical	ADJ
ajst-32571	136	15	obstacle	obstacle	NOUN
ajst-32571	136	16	that	that	PRON
ajst-32571	136	17	hinders	hinder	VERB
ajst-32571	136	18	car	car	NOUN
ajst-32571	136	19	-	-	PUNCT
ajst-32571	136	20	t	t	NOUN
ajst-32571	136	21	action	action	NOUN
ajst-32571	136	22	.	.	PUNCT
ajst-32571	137	1	designed	design	VERB
ajst-32571	137	2	hpseexpressing	hpseexpresse	VERB
ajst-32571	137	3	car	car	NOUN
ajst-32571	137	4	-	-	PUNCT
ajst-32571	137	5	t	t	NOUN
ajst-32571	137	6	cells	cell	NOUN
ajst-32571	137	7	(	(	PUNCT
ajst-32571	137	8	by	by	ADP
ajst-32571	137	9	gene	gene	NOUN
ajst-32571	137	10	modification	modification	NOUN
ajst-32571	137	11	)	)	PUNCT
ajst-32571	137	12	showed	show	VERB
ajst-32571	137	13	enhanced	enhanced	ADJ
ajst-32571	137	14	infiltration	infiltration	NOUN
ajst-32571	137	15	and	and	CCONJ
ajst-32571	137	16	tumour	tumour	NOUN
ajst-32571	137	17	suppression	suppression	NOUN
ajst-32571	137	18	in	in	ADP
ajst-32571	137	19	xenograft	xenograft	NOUN
ajst-32571	137	20	tumour	tumour	NOUN
ajst-32571	137	21	models	model	NOUN
ajst-32571	137	22	from	from	ADP
ajst-32571	137	23	an	an	DET
ajst-32571	137	24	experiment	experiment	NOUN
ajst-32571	137	25	by	by	ADP
ajst-32571	137	26	caruana	caruana	PROPN
ajst-32571	137	27	et	et	PROPN
ajst-32571	137	28	al	al	PROPN
ajst-32571	137	29	.	.	PUNCT
ajst-32571	138	1	[	[	X
ajst-32571	138	2	68	68	NUM
ajst-32571	138	3	]	]	PUNCT
ajst-32571	138	4	.	.	PUNCT
ajst-32571	139	1	this	this	DET
ajst-32571	139	2	work	work	NOUN
ajst-32571	139	3	first	first	ADV
ajst-32571	139	4	demonstrated	demonstrate	VERB
ajst-32571	139	5	that	that	SCONJ
ajst-32571	139	6	using	use	VERB
ajst-32571	139	7	hpse	hpse	NOUN
ajst-32571	139	8	to	to	PART
ajst-32571	139	9	enhance	enhance	VERB
ajst-32571	139	10	the	the	DET
ajst-32571	139	11	ability	ability	NOUN
ajst-32571	139	12	of	of	ADP
ajst-32571	139	13	immune	immune	ADJ
ajst-32571	139	14	cells	cell	NOUN
ajst-32571	139	15	could	could	AUX
ajst-32571	139	16	help	help	VERB
ajst-32571	139	17	overcome	overcome	VERB
ajst-32571	139	18	the	the	DET
ajst-32571	139	19	physical	physical	ADJ
ajst-32571	139	20	obstacles	obstacle	NOUN
ajst-32571	139	21	to	to	ADP
ajst-32571	139	22	cell	cell	NOUN
ajst-32571	139	23	-	-	PUNCT
ajst-32571	139	24	based	base	VERB
ajst-32571	139	25	immunotherapy	immunotherapy	NOUN
ajst-32571	139	26	in	in	ADP
ajst-32571	139	27	solid	solid	ADJ
ajst-32571	139	28	cancers	cancer	NOUN
ajst-32571	139	29	.	.	PUNCT
ajst-32571	140	1	in	in	ADP
ajst-32571	140	2	subsequent	subsequent	ADJ
ajst-32571	140	3	research	research	NOUN
ajst-32571	140	4	on	on	ADP
ajst-32571	140	5	other	other	ADJ
ajst-32571	140	6	immune	immune	ADJ
ajst-32571	140	7	cells	cell	NOUN
ajst-32571	140	8	,	,	PUNCT
ajst-32571	140	9	a	a	DET
ajst-32571	140	10	membrane	membrane	NOUN
ajst-32571	140	11	-	-	PUNCT
ajst-32571	140	12	bound	bind	VERB
ajst-32571	140	13	,	,	PUNCT
ajst-32571	140	14	constitutively	constitutively	ADV
ajst-32571	140	15	active	active	ADJ
ajst-32571	140	16	form	form	NOUN
ajst-32571	140	17	of	of	ADP
ajst-32571	140	18	hpse	hpse	NOUN
ajst-32571	140	19	was	be	AUX
ajst-32571	140	20	constructed	construct	VERB
ajst-32571	140	21	in	in	ADP
ajst-32571	140	22	natural	natural	ADJ
ajst-32571	140	23	killer	killer	NOUN
ajst-32571	140	24	cells	cell	NOUN
ajst-32571	140	25	.	.	PUNCT
ajst-32571	141	1	the	the	DET
ajst-32571	141	2	modified	modify	VERB
ajst-32571	141	3	cells	cell	NOUN
ajst-32571	141	4	maintained	maintain	VERB
ajst-32571	141	5	continuous	continuous	ADJ
ajst-32571	141	6	enzymatic	enzymatic	ADJ
ajst-32571	141	7	activity	activity	NOUN
ajst-32571	141	8	on	on	ADP
ajst-32571	141	9	their	their	PRON
ajst-32571	141	10	surfaces	surface	NOUN
ajst-32571	141	11	and	and	CCONJ
ajst-32571	141	12	demonstrated	demonstrate	VERB
ajst-32571	141	13	improved	improved	ADJ
ajst-32571	141	14	tumor	tumor	NOUN
ajst-32571	141	15	infiltration	infiltration	NOUN
ajst-32571	141	16	and	and	CCONJ
ajst-32571	141	17	growth	growth	NOUN
ajst-32571	141	18	control	control	NOUN
ajst-32571	141	19	in	in	ADP
ajst-32571	141	20	animal	animal	NOUN
ajst-32571	141	21	models	model	NOUN
ajst-32571	141	22	[	[	X
ajst-32571	141	23	69	69	NUM
ajst-32571	141	24	]	]	PUNCT
ajst-32571	141	25	.	.	PUNCT
ajst-32571	142	1	evidence	evidence	NOUN
ajst-32571	142	2	from	from	ADP
ajst-32571	142	3	immune	immune	ADJ
ajst-32571	142	4	regulation	regulation	NOUN
ajst-32571	142	5	studies	study	NOUN
ajst-32571	142	6	has	have	AUX
ajst-32571	142	7	further	far	ADV
ajst-32571	142	8	supported	support	VERB
ajst-32571	142	9	this	this	DET
ajst-32571	142	10	approach	approach	NOUN
ajst-32571	142	11	,	,	PUNCT
ajst-32571	142	12	where	where	SCONJ
ajst-32571	142	13	tregs	treg	NOUN
ajst-32571	142	14	were	be	AUX
ajst-32571	142	15	found	find	VERB
ajst-32571	142	16	to	to	PART
ajst-32571	142	17	use	use	VERB
ajst-32571	142	18	hpse	hpse	NOUN
ajst-32571	142	19	to	to	PART
ajst-32571	142	20	obtain	obtain	VERB
ajst-32571	142	21	il-2	il-2	NUM
ajst-32571	142	22	bound	bind	VERB
ajst-32571	142	23	to	to	ADP
ajst-32571	142	24	the	the	DET
ajst-32571	142	25	ecm	ecm	NOUN
ajst-32571	142	26	,	,	PUNCT
ajst-32571	142	27	enabling	enable	VERB
ajst-32571	142	28	them	they	PRON
ajst-32571	142	29	to	to	PART
ajst-32571	142	30	survive	survive	VERB
ajst-32571	142	31	and	and	CCONJ
ajst-32571	142	32	function	function	VERB
ajst-32571	142	33	within	within	ADP
ajst-32571	142	34	inflamed	inflamed	ADJ
ajst-32571	142	35	tissues	tissue	NOUN
ajst-32571	142	36	[	[	X
ajst-32571	142	37	70	70	NUM
ajst-32571	142	38	]	]	PUNCT
ajst-32571	142	39	.	.	PUNCT
ajst-32571	143	1	together	together	ADV
ajst-32571	143	2	,	,	PUNCT
ajst-32571	143	3	these	these	DET
ajst-32571	143	4	findings	finding	NOUN
ajst-32571	143	5	support	support	VERB
ajst-32571	143	6	that	that	SCONJ
ajst-32571	143	7	controlled	control	VERB
ajst-32571	143	8	use	use	NOUN
ajst-32571	143	9	of	of	ADP
ajst-32571	143	10	hpse	hpse	NOUN
ajst-32571	143	11	can	can	AUX
ajst-32571	143	12	enhance	enhance	VERB
ajst-32571	143	13	tissue	tissue	NOUN
ajst-32571	143	14	penetration	penetration	NOUN
ajst-32571	143	15	and	and	CCONJ
ajst-32571	143	16	support	support	NOUN
ajst-32571	143	17	immune	immune	ADJ
ajst-32571	143	18	cell	cell	NOUN
ajst-32571	143	19	function	function	NOUN
ajst-32571	143	20	without	without	ADP
ajst-32571	143	21	the	the	DET
ajst-32571	143	22	need	need	NOUN
ajst-32571	143	23	for	for	ADP
ajst-32571	143	24	broad	broad	ADJ
ajst-32571	143	25	systemic	systemic	ADJ
ajst-32571	143	26	matrix	matrix	NOUN
ajst-32571	143	27	degradation	degradation	NOUN
ajst-32571	143	28	,	,	PUNCT
ajst-32571	143	29	suggesting	suggest	VERB
ajst-32571	143	30	a	a	DET
ajst-32571	143	31	promising	promising	ADJ
ajst-32571	143	32	route	route	NOUN
ajst-32571	143	33	to	to	PART
ajst-32571	143	34	improve	improve	VERB
ajst-32571	143	35	the	the	DET
ajst-32571	143	36	efficiency	efficiency	NOUN
ajst-32571	143	37	of	of	ADP
ajst-32571	143	38	cldn6	cldn6	NOUN
ajst-32571	143	39	-	-	PUNCT
ajst-32571	143	40	car	car	NOUN
ajst-32571	143	41	-	-	PUNCT
ajst-32571	143	42	t	t	NOUN
ajst-32571	143	43	in	in	ADP
ajst-32571	143	44	ovarian	ovarian	ADJ
ajst-32571	143	45	cancer	cancer	NOUN
ajst-32571	143	46	treatment	treatment	NOUN
ajst-32571	143	47	.	.	PUNCT
ajst-32571	144	1	5	5	X
ajst-32571	144	2	.	.	X
ajst-32571	144	3	conclusion	conclusion	NOUN
ajst-32571	144	4	cldn6	cldn6	NOUN
ajst-32571	144	5	-	-	PUNCT
ajst-32571	144	6	car	car	NOUN
ajst-32571	144	7	-	-	PUNCT
ajst-32571	144	8	t	t	NOUN
ajst-32571	144	9	cell	cell	NOUN
ajst-32571	144	10	therapy	therapy	NOUN
ajst-32571	144	11	,	,	PUNCT
ajst-32571	144	12	as	as	SCONJ
ajst-32571	144	13	demonstrated	demonstrate	VERB
ajst-32571	144	14	in	in	ADP
ajst-32571	144	15	preclinical	preclinical	ADJ
ajst-32571	144	16	studies	study	NOUN
ajst-32571	144	17	,	,	PUNCT
ajst-32571	144	18	has	have	AUX
ajst-32571	144	19	shown	show	VERB
ajst-32571	144	20	significant	significant	ADJ
ajst-32571	144	21	improvement	improvement	NOUN
ajst-32571	144	22	in	in	ADP
ajst-32571	144	23	ovarian	ovarian	ADJ
ajst-32571	144	24	cancer	cancer	NOUN
ajst-32571	144	25	treatment	treatment	NOUN
ajst-32571	144	26	compared	compare	VERB
ajst-32571	144	27	to	to	ADP
ajst-32571	144	28	traditional	traditional	ADJ
ajst-32571	144	29	surgery	surgery	NOUN
ajst-32571	144	30	and	and	CCONJ
ajst-32571	144	31	chemotherapy	chemotherapy	NOUN
ajst-32571	144	32	,	,	PUNCT
ajst-32571	144	33	utilizing	utilize	VERB
ajst-32571	144	34	a	a	DET
ajst-32571	144	35	targetable	targetable	ADJ
ajst-32571	144	36	trait	trait	NOUN
ajst-32571	144	37	and	and	CCONJ
ajst-32571	144	38	presenting	present	VERB
ajst-32571	144	39	wide	wide	ADJ
ajst-32571	144	40	application	application	NOUN
ajst-32571	144	41	prospects	prospect	NOUN
ajst-32571	144	42	.	.	PUNCT
ajst-32571	145	1	however	however	ADV
ajst-32571	145	2	,	,	PUNCT
ajst-32571	145	3	due	due	ADP
ajst-32571	145	4	to	to	ADP
ajst-32571	145	5	the	the	DET
ajst-32571	145	6	inherent	inherent	ADJ
ajst-32571	145	7	characteristics	characteristic	NOUN
ajst-32571	145	8	of	of	ADP
ajst-32571	145	9	tumour	tumour	NOUN
ajst-32571	145	10	heterogeneity	heterogeneity	NOUN
ajst-32571	145	11	,	,	PUNCT
ajst-32571	145	12	tumour	tumour	NOUN
ajst-32571	145	13	-	-	PUNCT
ajst-32571	145	14	induced	induce	VERB
ajst-32571	145	15	immunosuppression	immunosuppression	NOUN
ajst-32571	145	16	,	,	PUNCT
ajst-32571	145	17	and	and	CCONJ
ajst-32571	145	18	physical	physical	ADJ
ajst-32571	145	19	184	184	NUM
ajst-32571	145	20	obstruction	obstruction	NOUN
ajst-32571	145	21	of	of	ADP
ajst-32571	145	22	cells	cell	NOUN
ajst-32571	145	23	in	in	ADP
ajst-32571	145	24	the	the	DET
ajst-32571	145	25	ecm	ecm	NOUN
ajst-32571	145	26	,	,	PUNCT
ajst-32571	145	27	a	a	DET
ajst-32571	145	28	gap	gap	NOUN
ajst-32571	145	29	still	still	ADV
ajst-32571	145	30	exists	exist	VERB
ajst-32571	145	31	between	between	ADP
ajst-32571	145	32	the	the	DET
ajst-32571	145	33	successful	successful	ADJ
ajst-32571	145	34	treatments	treatment	NOUN
ajst-32571	145	35	of	of	ADP
ajst-32571	145	36	haematologic	haematologic	ADJ
ajst-32571	145	37	malignancies	malignancy	NOUN
ajst-32571	145	38	and	and	CCONJ
ajst-32571	145	39	solid	solid	ADJ
ajst-32571	145	40	tumours	tumour	NOUN
ajst-32571	145	41	.	.	PUNCT
ajst-32571	146	1	therefore	therefore	ADV
ajst-32571	146	2	,	,	PUNCT
ajst-32571	146	3	it	it	PRON
ajst-32571	146	4	is	be	AUX
ajst-32571	146	5	necessary	necessary	ADJ
ajst-32571	146	6	to	to	PART
ajst-32571	146	7	continue	continue	VERB
ajst-32571	146	8	improving	improve	VERB
ajst-32571	146	9	anti	anti	ADJ
ajst-32571	146	10	-	-	ADJ
ajst-32571	146	11	tumoural	tumoural	ADJ
ajst-32571	146	12	mechanisms	mechanism	NOUN
ajst-32571	146	13	to	to	PART
ajst-32571	146	14	create	create	VERB
ajst-32571	146	15	breakthroughs	breakthrough	NOUN
ajst-32571	146	16	in	in	ADP
ajst-32571	146	17	treatment	treatment	NOUN
ajst-32571	146	18	.	.	PUNCT
ajst-32571	147	1	the	the	DET
ajst-32571	147	2	production	production	NOUN
ajst-32571	147	3	of	of	ADP
ajst-32571	147	4	t	t	PROPN
ajst-32571	147	5	cell	cell	NOUN
ajst-32571	147	6	-	-	PUNCT
ajst-32571	147	7	resistant	resistant	ADJ
ajst-32571	147	8	cells	cell	NOUN
ajst-32571	147	9	under	under	ADP
ajst-32571	147	10	the	the	DET
ajst-32571	147	11	influence	influence	NOUN
ajst-32571	147	12	of	of	ADP
ajst-32571	147	13	natural	natural	ADJ
ajst-32571	147	14	heterogeneous	heterogeneous	ADJ
ajst-32571	147	15	cldn6	cldn6	NOUN
ajst-32571	147	16	expression	expression	NOUN
ajst-32571	147	17	and	and	CCONJ
ajst-32571	147	18	cellular	cellular	ADJ
ajst-32571	147	19	evolution	evolution	NOUN
ajst-32571	147	20	,	,	PUNCT
ajst-32571	147	21	the	the	DET
ajst-32571	147	22	release	release	NOUN
ajst-32571	147	23	of	of	ADP
ajst-32571	147	24	tumorassisting	tumorassisting	NOUN
ajst-32571	147	25	,	,	PUNCT
ajst-32571	147	26	car	car	NOUN
ajst-32571	147	27	-	-	PUNCT
ajst-32571	147	28	t	t	NOUN
ajst-32571	147	29	-	-	PUNCT
ajst-32571	147	30	obstructing	obstruct	VERB
ajst-32571	147	31	cytokines	cytokine	NOUN
ajst-32571	147	32	,	,	PUNCT
ajst-32571	147	33	and	and	CCONJ
ajst-32571	147	34	the	the	DET
ajst-32571	147	35	presence	presence	NOUN
ajst-32571	147	36	of	of	ADP
ajst-32571	147	37	an	an	DET
ajst-32571	147	38	additional	additional	ADJ
ajst-32571	147	39	ecm	ecm	NOUN
ajst-32571	147	40	barrier	barrier	NOUN
ajst-32571	147	41	assisted	assist	VERB
ajst-32571	147	42	by	by	ADP
ajst-32571	147	43	cafs	cafs	NOUN
ajst-32571	147	44	all	all	PRON
ajst-32571	147	45	contribute	contribute	VERB
ajst-32571	147	46	to	to	ADP
ajst-32571	147	47	limiting	limit	VERB
ajst-32571	147	48	the	the	DET
ajst-32571	147	49	efficacy	efficacy	NOUN
ajst-32571	147	50	of	of	ADP
ajst-32571	147	51	cldn6	cldn6	PROPN
ajst-32571	147	52	-	-	PUNCT
ajst-32571	147	53	specific	specific	ADJ
ajst-32571	147	54	car	car	NOUN
ajst-32571	147	55	-	-	PUNCT
ajst-32571	147	56	t	t	NOUN
ajst-32571	147	57	cell	cell	NOUN
ajst-32571	147	58	function	function	NOUN
ajst-32571	147	59	.	.	PUNCT
ajst-32571	148	1	to	to	PART
ajst-32571	148	2	confront	confront	VERB
ajst-32571	148	3	these	these	DET
ajst-32571	148	4	limitations	limitation	NOUN
ajst-32571	148	5	,	,	PUNCT
ajst-32571	148	6	after	after	ADP
ajst-32571	148	7	passing	pass	VERB
ajst-32571	148	8	through	through	ADP
ajst-32571	148	9	long	long	ADJ
ajst-32571	148	10	preclinical	preclinical	ADJ
ajst-32571	148	11	evaluations	evaluation	NOUN
ajst-32571	148	12	,	,	PUNCT
ajst-32571	148	13	new	new	ADJ
ajst-32571	148	14	therapies	therapy	NOUN
ajst-32571	148	15	like	like	ADP
ajst-32571	148	16	dual	dual	ADV
ajst-32571	148	17	-	-	PUNCT
ajst-32571	148	18	targeting	target	VERB
ajst-32571	148	19	(	(	PUNCT
ajst-32571	148	20	cldn6	cldn6	NOUN
ajst-32571	148	21	/	/	SYM
ajst-32571	148	22	msln	msln	NOUN
ajst-32571	148	23	,	,	PUNCT
ajst-32571	148	24	cldn6	cldn6	NOUN
ajst-32571	148	25	/	/	SYM
ajst-32571	148	26	prame	prame	NOUN
ajst-32571	148	27	,	,	PUNCT
ajst-32571	148	28	cldn6	cldn6	PROPN
ajst-32571	148	29	/	/	SYM
ajst-32571	148	30	ctcfl	ctcfl	PROPN
ajst-32571	148	31	)	)	PUNCT
ajst-32571	148	32	or	or	CCONJ
ajst-32571	148	33	multi	multi	ADJ
ajst-32571	148	34	-	-	ADJ
ajst-32571	148	35	targeting	target	VERB
ajst-32571	148	36	car	car	NOUN
ajst-32571	148	37	-	-	PUNCT
ajst-32571	148	38	t	t	NOUN
ajst-32571	148	39	may	may	AUX
ajst-32571	148	40	be	be	AUX
ajst-32571	148	41	used	use	VERB
ajst-32571	148	42	for	for	ADP
ajst-32571	148	43	patients	patient	NOUN
ajst-32571	148	44	encountering	encounter	VERB
ajst-32571	148	45	partial	partial	ADJ
ajst-32571	148	46	,	,	PUNCT
ajst-32571	148	47	varying	vary	VERB
ajst-32571	148	48	lack	lack	NOUN
ajst-32571	148	49	of	of	ADP
ajst-32571	148	50	antigen	antigen	ADJ
ajst-32571	148	51	proteins	protein	NOUN
ajst-32571	148	52	on	on	ADP
ajst-32571	148	53	tumour	tumour	ADJ
ajst-32571	148	54	tissues	tissue	NOUN
ajst-32571	148	55	;	;	PUNCT
ajst-32571	148	56	other	other	ADJ
ajst-32571	148	57	novel	novel	ADJ
ajst-32571	148	58	strategies	strategy	NOUN
ajst-32571	148	59	,	,	PUNCT
ajst-32571	148	60	such	such	ADJ
ajst-32571	148	61	as	as	ADP
ajst-32571	148	62	cxcr2	cxcr2	NOUN
ajst-32571	148	63	-	-	PUNCT
ajst-32571	148	64	targeting	target	VERB
ajst-32571	148	65	to	to	PART
ajst-32571	148	66	inhibit	inhibit	VERB
ajst-32571	148	67	mdsc	mdsc	ADJ
ajst-32571	148	68	recruitment	recruitment	NOUN
ajst-32571	148	69	,	,	PUNCT
ajst-32571	148	70	thermosensitive	thermosensitive	ADJ
ajst-32571	148	71	hydrogel	hydrogel	NOUN
ajst-32571	148	72	barriers	barrier	NOUN
ajst-32571	148	73	preventing	prevent	VERB
ajst-32571	148	74	t	t	NOUN
ajst-32571	148	75	cell	cell	NOUN
ajst-32571	148	76	-	-	PUNCT
ajst-32571	148	77	exhaustion	exhaustion	NOUN
ajst-32571	148	78	,	,	PUNCT
ajst-32571	148	79	and	and	CCONJ
ajst-32571	148	80	using	use	VERB
ajst-32571	148	81	enzymes	enzyme	NOUN
ajst-32571	148	82	such	such	ADJ
ajst-32571	148	83	as	as	ADP
ajst-32571	148	84	heparanase	heparanase	NOUN
ajst-32571	148	85	on	on	ADP
ajst-32571	148	86	the	the	DET
ajst-32571	148	87	ecm	ecm	NOUN
ajst-32571	148	88	,	,	PUNCT
ajst-32571	148	89	are	be	AUX
ajst-32571	148	90	also	also	ADV
ajst-32571	148	91	worthy	worthy	ADJ
ajst-32571	148	92	of	of	ADP
ajst-32571	148	93	expansion	expansion	NOUN
ajst-32571	148	94	.	.	PUNCT
ajst-32571	149	1	these	these	PRON
ajst-32571	149	2	may	may	AUX
ajst-32571	149	3	be	be	AUX
ajst-32571	149	4	implemented	implement	VERB
ajst-32571	149	5	into	into	ADP
ajst-32571	149	6	future	future	ADJ
ajst-32571	149	7	cldn6	cldn6	NOUN
ajst-32571	149	8	-	-	PUNCT
ajst-32571	149	9	car	car	NOUN
ajst-32571	149	10	-	-	PUNCT
ajst-32571	149	11	t	t	NOUN
ajst-32571	149	12	regulation	regulation	NOUN
ajst-32571	149	13	of	of	ADP
ajst-32571	149	14	antitumor	antitumor	PROPN
ajst-32571	149	15	activity	activity	NOUN
ajst-32571	149	16	,	,	PUNCT
ajst-32571	149	17	with	with	ADP
ajst-32571	149	18	or	or	CCONJ
ajst-32571	149	19	without	without	ADP
ajst-32571	149	20	combined	combined	ADJ
ajst-32571	149	21	use	use	NOUN
ajst-32571	149	22	with	with	ADP
ajst-32571	149	23	other	other	ADJ
ajst-32571	149	24	drugs	drug	NOUN
ajst-32571	149	25	or	or	CCONJ
ajst-32571	149	26	therapies	therapy	NOUN
ajst-32571	149	27	.	.	PUNCT
ajst-32571	150	1	altogether	altogether	ADV
ajst-32571	150	2	,	,	PUNCT
ajst-32571	150	3	further	further	ADJ
ajst-32571	150	4	development	development	NOUN
ajst-32571	150	5	of	of	ADP
ajst-32571	150	6	cldn6	cldn6	PROPN
ajst-32571	150	7	-	-	PUNCT
ajst-32571	150	8	car	car	NOUN
ajst-32571	150	9	-	-	PUNCT
ajst-32571	150	10	t	t	NOUN
ajst-32571	150	11	may	may	AUX
ajst-32571	150	12	provide	provide	VERB
ajst-32571	150	13	potential	potential	ADJ
ajst-32571	150	14	tools	tool	NOUN
ajst-32571	150	15	not	not	PART
ajst-32571	150	16	only	only	ADV
ajst-32571	150	17	for	for	ADP
ajst-32571	150	18	combating	combat	VERB
ajst-32571	150	19	ovarian	ovarian	ADJ
ajst-32571	150	20	cancer	cancer	NOUN
ajst-32571	150	21	,	,	PUNCT
ajst-32571	150	22	but	but	CCONJ
ajst-32571	150	23	also	also	ADV
ajst-32571	150	24	for	for	ADP
ajst-32571	150	25	other	other	ADJ
ajst-32571	150	26	solid	solid	ADJ
ajst-32571	150	27	tumors	tumor	NOUN
ajst-32571	150	28	and	and	CCONJ
ajst-32571	150	29	tumor	tumor	NOUN
ajst-32571	150	30	cancers	cancer	NOUN
ajst-32571	150	31	.	.	PUNCT
ajst-32571	151	1	references	reference	NOUN
ajst-32571	151	2	[	[	X
ajst-32571	151	3	1	1	NUM
ajst-32571	151	4	]	]	PUNCT
ajst-32571	151	5	a.	a.	NOUN
ajst-32571	151	6	c.	c.	PROPN
ajst-32571	151	7	veneziani	veneziani	PROPN
ajst-32571	151	8	et	et	PROPN
ajst-32571	151	9	al	al	PROPN
ajst-32571	151	10	.	.	PROPN
ajst-32571	151	11	,	,	PUNCT
ajst-32571	151	12	“	"	PUNCT
ajst-32571	151	13	heterogeneity	heterogeneity	NOUN
ajst-32571	151	14	and	and	CCONJ
ajst-32571	151	15	treatment	treatment	NOUN
ajst-32571	151	16	landscape	landscape	NOUN
ajst-32571	151	17	of	of	ADP
ajst-32571	151	18	ovarian	ovarian	ADJ
ajst-32571	151	19	carcinoma	carcinoma	NOUN
ajst-32571	151	20	,	,	PUNCT
ajst-32571	151	21	”	"	PUNCT
ajst-32571	151	22	nature	nature	NOUN
ajst-32571	151	23	reviews	review	VERB
ajst-32571	151	24	clinical	clinical	ADJ
ajst-32571	151	25	oncology	oncology	NOUN
ajst-32571	151	26	,	,	PUNCT
ajst-32571	151	27	vol	vol	NOUN
ajst-32571	151	28	.	.	PROPN
ajst-32571	151	29	20	20	NUM
ajst-32571	151	30	,	,	PUNCT
ajst-32571	151	31	no	no	INTJ
ajst-32571	151	32	.	.	NOUN
ajst-32571	151	33	12	12	NUM
ajst-32571	151	34	,	,	PUNCT
ajst-32571	151	35	pp	pp	ADJ
ajst-32571	151	36	.	.	PUNCT
ajst-32571	152	1	820–842	820–842	NUM
ajst-32571	152	2	,	,	PUNCT
ajst-32571	152	3	dec	dec	PROPN
ajst-32571	152	4	.	.	PROPN
ajst-32571	152	5	2023	2023	NUM
ajst-32571	152	6	,	,	PUNCT
ajst-32571	152	7	doi	doi	NOUN
ajst-32571	152	8	:	:	PUNCT
ajst-32571	152	9	https://doi.org/10.1038/s41571-02300819-1	https://doi.org/10.1038/s41571-02300819-1	ADV
ajst-32571	152	10	.	.	PUNCT
ajst-32571	153	1	[	[	X
ajst-32571	153	2	2	2	X
ajst-32571	153	3	]	]	PUNCT
ajst-32571	153	4	ovarian	ovarian	ADJ
ajst-32571	153	5	cancer	cancer	NOUN
ajst-32571	153	6	action	action	NOUN
ajst-32571	153	7	,	,	PUNCT
ajst-32571	153	8	“	"	PUNCT
ajst-32571	153	9	types	type	NOUN
ajst-32571	153	10	of	of	ADP
ajst-32571	153	11	ovarian	ovarian	ADJ
ajst-32571	153	12	cancer	cancer	NOUN
ajst-32571	153	13	|	|	ADP
ajst-32571	153	14	ovarian	ovarian	ADJ
ajst-32571	153	15	cancer	cancer	NOUN
ajst-32571	153	16	information	information	NOUN
ajst-32571	153	17	,	,	PUNCT
ajst-32571	153	18	”	"	PUNCT
ajst-32571	153	19	ovarian	ovarian	ADJ
ajst-32571	153	20	cancer	cancer	NOUN
ajst-32571	153	21	action	action	NOUN
ajst-32571	153	22	,	,	PUNCT
ajst-32571	153	23	jun	jun	PROPN
ajst-32571	153	24	.	.	PROPN
ajst-32571	153	25	03	03	NUM
ajst-32571	153	26	,	,	PUNCT
ajst-32571	153	27	2024	2024	NUM
ajst-32571	153	28	.	.	PUNCT
ajst-32571	153	29	https://ovarian.org.uk/ovarian-cancer/types-of-ovarian-cancer/	https://ovarian.org.uk/ovarian-cancer/types-of-ovarian-cancer/	PART
ajst-32571	154	1	[	[	X
ajst-32571	154	2	3	3	X
ajst-32571	154	3	]	]	X
ajst-32571	154	4	r.	r.	PROPN
ajst-32571	154	5	c.	c.	PROPN
ajst-32571	154	6	sterner	sterner	PROPN
ajst-32571	154	7	and	and	CCONJ
ajst-32571	154	8	r.	r.	PROPN
ajst-32571	154	9	m.	m.	PROPN
ajst-32571	154	10	sterner	sterner	ADV
ajst-32571	154	11	,	,	PUNCT
ajst-32571	154	12	“	"	PUNCT
ajst-32571	154	13	car	car	NOUN
ajst-32571	154	14	-	-	PUNCT
ajst-32571	154	15	t	t	NOUN
ajst-32571	154	16	cell	cell	NOUN
ajst-32571	154	17	therapy	therapy	NOUN
ajst-32571	154	18	:	:	PUNCT
ajst-32571	154	19	current	current	ADJ
ajst-32571	154	20	limitations	limitation	NOUN
ajst-32571	154	21	and	and	CCONJ
ajst-32571	154	22	potential	potential	ADJ
ajst-32571	154	23	strategies	strategy	NOUN
ajst-32571	154	24	,	,	PUNCT
ajst-32571	154	25	”	"	PUNCT
ajst-32571	154	26	blood	blood	NOUN
ajst-32571	154	27	cancer	cancer	NOUN
ajst-32571	154	28	journal	journal	NOUN
ajst-32571	154	29	,	,	PUNCT
ajst-32571	154	30	vol	vol	NOUN
ajst-32571	154	31	.	.	PROPN
ajst-32571	154	32	11	11	NUM
ajst-32571	154	33	,	,	PUNCT
ajst-32571	154	34	no	no	INTJ
ajst-32571	154	35	.	.	NOUN
ajst-32571	154	36	4	4	NUM
ajst-32571	154	37	,	,	PUNCT
ajst-32571	154	38	apr	apr	NOUN
ajst-32571	154	39	.	.	NOUN
ajst-32571	154	40	2021	2021	NUM
ajst-32571	154	41	,	,	PUNCT
ajst-32571	154	42	doi	doi	NOUN
ajst-32571	154	43	:	:	PUNCT
ajst-32571	154	44	https://doi.org/10.1038/s41408-021-00459-7	https://doi.org/10.1038/s41408-021-00459-7	NUM
ajst-32571	154	45	.	.	PUNCT
ajst-32571	155	1	[	[	X
ajst-32571	155	2	4	4	NUM
ajst-32571	155	3	]	]	X
ajst-32571	155	4	r.	r.	PROPN
ajst-32571	155	5	c.	c.	PROPN
ajst-32571	155	6	larson	larson	PROPN
ajst-32571	155	7	and	and	CCONJ
ajst-32571	155	8	m.	m.	PROPN
ajst-32571	155	9	v.	v.	PROPN
ajst-32571	155	10	maus	maus	PROPN
ajst-32571	155	11	,	,	PUNCT
ajst-32571	155	12	“	"	PUNCT
ajst-32571	155	13	recent	recent	ADJ
ajst-32571	155	14	advances	advance	NOUN
ajst-32571	155	15	and	and	CCONJ
ajst-32571	155	16	discoveries	discovery	NOUN
ajst-32571	155	17	in	in	ADP
ajst-32571	155	18	the	the	DET
ajst-32571	155	19	mechanisms	mechanism	NOUN
ajst-32571	155	20	and	and	CCONJ
ajst-32571	155	21	functions	function	NOUN
ajst-32571	155	22	of	of	ADP
ajst-32571	155	23	car	car	NOUN
ajst-32571	155	24	t	t	NOUN
ajst-32571	155	25	cells	cell	NOUN
ajst-32571	155	26	,	,	PUNCT
ajst-32571	155	27	”	"	PUNCT
ajst-32571	155	28	nature	nature	NOUN
ajst-32571	155	29	reviews	review	NOUN
ajst-32571	155	30	cancer	cancer	NOUN
ajst-32571	155	31	,	,	PUNCT
ajst-32571	155	32	vol	vol	NOUN
ajst-32571	155	33	.	.	PROPN
ajst-32571	155	34	21	21	NUM
ajst-32571	155	35	,	,	PUNCT
ajst-32571	155	36	no	no	INTJ
ajst-32571	155	37	.	.	NOUN
ajst-32571	155	38	3	3	NUM
ajst-32571	155	39	,	,	PUNCT
ajst-32571	155	40	pp	pp	ADJ
ajst-32571	155	41	.	.	PUNCT
ajst-32571	156	1	145–161	145–161	NUM
ajst-32571	156	2	,	,	PUNCT
ajst-32571	156	3	jan	jan	PROPN
ajst-32571	156	4	.	.	PROPN
ajst-32571	156	5	2021	2021	NUM
ajst-32571	156	6	,	,	PUNCT
ajst-32571	156	7	doi	doi	NOUN
ajst-32571	156	8	:	:	PUNCT
ajst-32571	156	9	https://	https://	PROPN
ajst-32571	156	10	doi	doi	PROPN
ajst-32571	156	11	.	.	PUNCT
ajst-32571	157	1	org/	org/	NOUN
ajst-32571	157	2	10.1038	10.1038	NUM
ajst-32571	157	3	/	/	SYM
ajst-32571	157	4	s41568	s41568	NOUN
ajst-32571	157	5	-	-	PUNCT
ajst-32571	157	6	020	020	NUM
ajst-32571	157	7	-	-	PUNCT
ajst-32571	157	8	00323	00323	NUM
ajst-32571	157	9	-	-	PUNCT
ajst-32571	157	10	z.	z.	PROPN
ajst-32571	158	1	[	[	X
ajst-32571	158	2	5	5	X
ajst-32571	158	3	]	]	PUNCT
ajst-32571	158	4	j.	j.	PROPN
ajst-32571	158	5	li	li	PROPN
ajst-32571	158	6	et	et	PROPN
ajst-32571	158	7	al	al	PROPN
ajst-32571	158	8	.	.	PROPN
ajst-32571	158	9	,	,	PUNCT
ajst-32571	158	10	“	"	PUNCT
ajst-32571	158	11	nk-92mi	nk-92mi	ADJ
ajst-32571	158	12	cells	cell	NOUN
ajst-32571	158	13	engineered	engineer	VERB
ajst-32571	158	14	with	with	ADP
ajst-32571	158	15	anti	anti	ADJ
ajst-32571	158	16	-	-	ADJ
ajst-32571	158	17	claudin-6	claudin-6	NUM
ajst-32571	158	18	chimeric	chimeric	ADJ
ajst-32571	158	19	antigen	antigen	ADJ
ajst-32571	158	20	receptors	receptor	NOUN
ajst-32571	158	21	in	in	ADP
ajst-32571	158	22	immunotherapy	immunotherapy	NOUN
ajst-32571	158	23	for	for	ADP
ajst-32571	158	24	ovarian	ovarian	ADJ
ajst-32571	158	25	cancer	cancer	NOUN
ajst-32571	158	26	,	,	PUNCT
ajst-32571	158	27	”	"	PUNCT
ajst-32571	158	28	international	international	ADJ
ajst-32571	158	29	journal	journal	NOUN
ajst-32571	158	30	of	of	ADP
ajst-32571	158	31	biological	biological	ADJ
ajst-32571	158	32	sciences	science	NOUN
ajst-32571	158	33	,	,	PUNCT
ajst-32571	158	34	vol	vol	NOUN
ajst-32571	158	35	.	.	PROPN
ajst-32571	158	36	20	20	NUM
ajst-32571	158	37	,	,	PUNCT
ajst-32571	158	38	no	no	INTJ
ajst-32571	158	39	.	.	NOUN
ajst-32571	158	40	5	5	NUM
ajst-32571	158	41	,	,	PUNCT
ajst-32571	158	42	pp	pp	ADJ
ajst-32571	158	43	.	.	PUNCT
ajst-32571	158	44	1578–1601	1578–1601	NUM
ajst-32571	158	45	,	,	PUNCT
ajst-32571	158	46	feb	feb	PROPN
ajst-32571	158	47	.	.	PROPN
ajst-32571	158	48	2024	2024	NUM
ajst-32571	158	49	,	,	PUNCT
ajst-32571	158	50	doi	doi	NOUN
ajst-32571	158	51	:	:	PUNCT
ajst-32571	158	52	https://doi.org/10.7150/ijbs.88539	https://doi.org/10.7150/ijbs.88539	NOUN
ajst-32571	158	53	.	.	PUNCT
ajst-32571	159	1	[	[	X
ajst-32571	159	2	6	6	NUM
ajst-32571	159	3	]	]	X
ajst-32571	159	4	national	national	PROPN
ajst-32571	159	5	cancer	cancer	PROPN
ajst-32571	159	6	institute	institute	PROPN
ajst-32571	159	7	,	,	PUNCT
ajst-32571	159	8	“	"	PUNCT
ajst-32571	159	9	car	car	NOUN
ajst-32571	159	10	t	t	NOUN
ajst-32571	159	11	cells	cell	NOUN
ajst-32571	159	12	:	:	PUNCT
ajst-32571	159	13	engineering	engineer	VERB
ajst-32571	159	14	immune	immune	ADJ
ajst-32571	159	15	cells	cell	NOUN
ajst-32571	159	16	to	to	PART
ajst-32571	159	17	treat	treat	VERB
ajst-32571	159	18	cancer	cancer	NOUN
ajst-32571	159	19	,	,	PUNCT
ajst-32571	159	20	”	"	PUNCT
ajst-32571	159	21	cancer.gov	cancer.gov	NUM
ajst-32571	159	22	,	,	PUNCT
ajst-32571	159	23	feb	feb	PROPN
ajst-32571	159	24	.	.	PROPN
ajst-32571	159	25	26	26	NUM
ajst-32571	159	26	,	,	PUNCT
ajst-32571	159	27	2025	2025	NUM
ajst-32571	159	28	.	.	PUNCT
ajst-32571	160	1	https://www.cancer.gov/about-cancer/treatment/research/car-t-cells#closing-in-on-car-t-celltherapy-for-solid-tumors	https://www.cancer.gov/about-cancer/treatment/research/car-t-cells#closing-in-on-car-t-celltherapy-for-solid-tumor	NOUN
ajst-32571	161	1	[	[	X
ajst-32571	161	2	7	7	X
ajst-32571	161	3	]	]	PUNCT
ajst-32571	161	4	s.	s.	PROPN
ajst-32571	161	5	p.	p.	PROPN
ajst-32571	161	6	blagden	blagden	PROPN
ajst-32571	161	7	,	,	PUNCT
ajst-32571	161	8	“	"	PUNCT
ajst-32571	161	9	harnessing	harness	VERB
ajst-32571	161	10	pandemonium	pandemonium	NOUN
ajst-32571	161	11	:	:	PUNCT
ajst-32571	161	12	the	the	DET
ajst-32571	161	13	clinical	clinical	ADJ
ajst-32571	161	14	implications	implication	NOUN
ajst-32571	161	15	of	of	ADP
ajst-32571	161	16	tumor	tumor	NOUN
ajst-32571	161	17	heterogeneity	heterogeneity	NOUN
ajst-32571	161	18	in	in	ADP
ajst-32571	161	19	ovarian	ovarian	ADJ
ajst-32571	161	20	cancer	cancer	NOUN
ajst-32571	161	21	,	,	PUNCT
ajst-32571	161	22	”	"	PUNCT
ajst-32571	161	23	frontiers	frontier	NOUN
ajst-32571	161	24	in	in	ADP
ajst-32571	161	25	oncology	oncology	NOUN
ajst-32571	161	26	,	,	PUNCT
ajst-32571	161	27	vol	vol	NOUN
ajst-32571	161	28	.	.	PROPN
ajst-32571	161	29	5	5	NUM
ajst-32571	161	30	,	,	PUNCT
ajst-32571	161	31	jun	jun	PROPN
ajst-32571	161	32	.	.	PROPN
ajst-32571	161	33	2015	2015	NUM
ajst-32571	161	34	,	,	PUNCT
ajst-32571	161	35	doi	doi	NOUN
ajst-32571	161	36	:	:	PUNCT
ajst-32571	161	37	https://doi.org/10.3389/fonc.2015.00149	https://doi.org/10.3389/fonc.2015.00149	PROPN
ajst-32571	161	38	.	.	PUNCT
ajst-32571	162	1	[	[	X
ajst-32571	162	2	8	8	NUM
ajst-32571	162	3	]	]	X
ajst-32571	162	4	national	national	PROPN
ajst-32571	162	5	cancer	cancer	PROPN
ajst-32571	162	6	institute	institute	PROPN
ajst-32571	162	7	,	,	PUNCT
ajst-32571	162	8	“	"	PUNCT
ajst-32571	162	9	surgery	surgery	NOUN
ajst-32571	162	10	,	,	PUNCT
ajst-32571	162	11	”	"	PUNCT
ajst-32571	162	12	cancer.gov	cancer.gov	NUM
ajst-32571	162	13	,	,	PUNCT
ajst-32571	162	14	apr	apr	NOUN
ajst-32571	162	15	.	.	PROPN
ajst-32571	162	16	29	29	NUM
ajst-32571	162	17	,	,	PUNCT
ajst-32571	162	18	2015	2015	NUM
ajst-32571	162	19	.	.	PUNCT
ajst-32571	163	1	https://www.cancer.gov/about-cancer/	https://www.cancer.gov/about-cancer/	PROPN
ajst-32571	163	2	treatment/	treatment/	NUM
ajst-32571	163	3	types	type	NOUN
ajst-32571	163	4	/	/	SYM
ajst-32571	163	5	surgery	surgery	NOUN
ajst-32571	164	1	[	[	X
ajst-32571	164	2	9	9	NUM
ajst-32571	164	3	]	]	PUNCT
ajst-32571	164	4	a.	a.	NOUN
ajst-32571	164	5	zafar	zafar	PROPN
ajst-32571	164	6	,	,	PUNCT
ajst-32571	164	7	s.	s.	PROPN
ajst-32571	164	8	khatoon	khatoon	PROPN
ajst-32571	164	9	,	,	PUNCT
ajst-32571	164	10	m.	m.	PROPN
ajst-32571	164	11	j.	j.	PROPN
ajst-32571	164	12	khan	khan	PROPN
ajst-32571	164	13	,	,	PUNCT
ajst-32571	164	14	j.	j.	PROPN
ajst-32571	164	15	abu	abu	PROPN
ajst-32571	164	16	,	,	PUNCT
ajst-32571	164	17	and	and	CCONJ
ajst-32571	164	18	a.	a.	NOUN
ajst-32571	164	19	naeem	naeem	PROPN
ajst-32571	164	20	,	,	PUNCT
ajst-32571	164	21	“	"	PUNCT
ajst-32571	164	22	advancements	advancement	NOUN
ajst-32571	164	23	and	and	CCONJ
ajst-32571	164	24	limitations	limitation	NOUN
ajst-32571	164	25	in	in	ADP
ajst-32571	164	26	traditional	traditional	ADJ
ajst-32571	164	27	anti	anti	ADJ
ajst-32571	164	28	-	-	ADJ
ajst-32571	164	29	cancer	cancer	ADJ
ajst-32571	164	30	therapies	therapy	NOUN
ajst-32571	164	31	:	:	PUNCT
ajst-32571	164	32	a	a	DET
ajst-32571	164	33	comprehensive	comprehensive	ADJ
ajst-32571	164	34	review	review	NOUN
ajst-32571	164	35	of	of	ADP
ajst-32571	164	36	surgery	surgery	NOUN
ajst-32571	164	37	,	,	PUNCT
ajst-32571	164	38	chemotherapy	chemotherapy	NOUN
ajst-32571	164	39	,	,	PUNCT
ajst-32571	164	40	radiation	radiation	NOUN
ajst-32571	164	41	therapy	therapy	NOUN
ajst-32571	164	42	,	,	PUNCT
ajst-32571	164	43	and	and	CCONJ
ajst-32571	164	44	hormonal	hormonal	ADJ
ajst-32571	164	45	therapy	therapy	NOUN
ajst-32571	164	46	,	,	PUNCT
ajst-32571	164	47	”	"	PUNCT
ajst-32571	164	48	discover	discover	VERB
ajst-32571	164	49	oncology	oncology	NOUN
ajst-32571	164	50	,	,	PUNCT
ajst-32571	164	51	vol	vol	NOUN
ajst-32571	164	52	.	.	PROPN
ajst-32571	165	1	16	16	NUM
ajst-32571	165	2	,	,	PUNCT
ajst-32571	165	3	no	no	INTJ
ajst-32571	165	4	.	.	NOUN
ajst-32571	165	5	1	1	NUM
ajst-32571	165	6	,	,	PUNCT
ajst-32571	165	7	apr	apr	NOUN
ajst-32571	165	8	.	.	NOUN
ajst-32571	166	1	2025	2025	NUM
ajst-32571	166	2	,	,	PUNCT
ajst-32571	166	3	doi	doi	NOUN
ajst-32571	166	4	:	:	PUNCT
ajst-32571	166	5	https://doi.org/10.1007/s12672-025-021988	https://doi.org/10.1007/s12672-025-021988	PROPN
ajst-32571	166	6	.	.	PUNCT
ajst-32571	167	1	[	[	X
ajst-32571	167	2	10	10	NUM
ajst-32571	167	3	]	]	PUNCT
ajst-32571	167	4	m.	m.	NOUN
ajst-32571	167	5	chidambaram	chidambaram	PROPN
ajst-32571	167	6	,	,	PUNCT
ajst-32571	167	7	r.	r.	PROPN
ajst-32571	167	8	manavalan	manavalan	PROPN
ajst-32571	167	9	,	,	PUNCT
ajst-32571	167	10	and	and	CCONJ
ajst-32571	167	11	k.	k.	PROPN
ajst-32571	167	12	kathiresan	kathiresan	PROPN
ajst-32571	167	13	,	,	PUNCT
ajst-32571	167	14	“	"	PUNCT
ajst-32571	167	15	nanotherapeutics	nanotherapeutic	NOUN
ajst-32571	167	16	to	to	PART
ajst-32571	167	17	overcome	overcome	VERB
ajst-32571	167	18	conventional	conventional	ADJ
ajst-32571	167	19	cancer	cancer	NOUN
ajst-32571	167	20	chemotherapy	chemotherapy	NOUN
ajst-32571	167	21	limitations	limitation	NOUN
ajst-32571	167	22	,	,	PUNCT
ajst-32571	167	23	”	"	PUNCT
ajst-32571	167	24	journal	journal	NOUN
ajst-32571	167	25	of	of	ADP
ajst-32571	167	26	pharmacy	pharmacy	PROPN
ajst-32571	167	27	&	&	CCONJ
ajst-32571	167	28	pharmaceutical	pharmaceutical	NOUN
ajst-32571	167	29	sciences	sciences	PROPN
ajst-32571	167	30	,	,	PUNCT
ajst-32571	167	31	vol	vol	NOUN
ajst-32571	167	32	.	.	PROPN
ajst-32571	168	1	14	14	NUM
ajst-32571	168	2	,	,	PUNCT
ajst-32571	168	3	no	no	INTJ
ajst-32571	168	4	.	.	NOUN
ajst-32571	168	5	1	1	NUM
ajst-32571	168	6	,	,	PUNCT
ajst-32571	168	7	pp	pp	ADJ
ajst-32571	168	8	.	.	PUNCT
ajst-32571	169	1	67–77	67–77	NUM
ajst-32571	169	2	,	,	PUNCT
ajst-32571	169	3	feb	feb	PROPN
ajst-32571	169	4	.	.	PROPN
ajst-32571	169	5	2011	2011	NUM
ajst-32571	169	6	,	,	PUNCT
ajst-32571	169	7	doi	doi	NOUN
ajst-32571	169	8	:	:	PUNCT
ajst-32571	169	9	https://doi.org/10.18433/j30c7d	https://doi.org/10.18433/j30c7d	PROPN
ajst-32571	169	10	.	.	PUNCT
ajst-32571	170	1	[	[	X
ajst-32571	170	2	11	11	NUM
ajst-32571	170	3	]	]	X
ajst-32571	170	4	h.	h.	PROPN
ajst-32571	170	5	e.	e.	PROPN
ajst-32571	170	6	hughes	hughes	PROPN
ajst-32571	170	7	-	-	PUNCT
ajst-32571	170	8	parry	parry	PROPN
ajst-32571	170	9	,	,	PUNCT
ajst-32571	170	10	r.	r.	PROPN
ajst-32571	170	11	s.	s.	PROPN
ajst-32571	170	12	cross	cross	PROPN
ajst-32571	170	13	,	,	PUNCT
ajst-32571	170	14	and	and	CCONJ
ajst-32571	170	15	m.	m.	PROPN
ajst-32571	170	16	r.	r.	PROPN
ajst-32571	170	17	jenkins	jenkins	PROPN
ajst-32571	170	18	,	,	PUNCT
ajst-32571	170	19	“	"	PUNCT
ajst-32571	170	20	the	the	DET
ajst-32571	170	21	evolving	evolve	VERB
ajst-32571	170	22	protein	protein	NOUN
ajst-32571	170	23	engineering	engineering	NOUN
ajst-32571	170	24	in	in	ADP
ajst-32571	170	25	the	the	DET
ajst-32571	170	26	design	design	NOUN
ajst-32571	170	27	of	of	ADP
ajst-32571	170	28	chimeric	chimeric	ADJ
ajst-32571	170	29	antigen	antigen	ADJ
ajst-32571	170	30	receptor	receptor	NOUN
ajst-32571	170	31	t	t	NOUN
ajst-32571	170	32	cells	cell	NOUN
ajst-32571	170	33	,	,	PUNCT
ajst-32571	170	34	”	"	PUNCT
ajst-32571	170	35	international	international	ADJ
ajst-32571	170	36	journal	journal	NOUN
ajst-32571	170	37	of	of	ADP
ajst-32571	170	38	molecular	molecular	ADJ
ajst-32571	170	39	sciences	science	NOUN
ajst-32571	170	40	,	,	PUNCT
ajst-32571	170	41	vol	vol	NOUN
ajst-32571	170	42	.	.	PROPN
ajst-32571	170	43	21	21	NUM
ajst-32571	170	44	,	,	PUNCT
ajst-32571	170	45	no	no	INTJ
ajst-32571	170	46	.	.	NOUN
ajst-32571	170	47	1	1	NUM
ajst-32571	170	48	,	,	PUNCT
ajst-32571	170	49	p.	p.	NOUN
ajst-32571	170	50	204	204	NUM
ajst-32571	170	51	,	,	PUNCT
ajst-32571	170	52	dec	dec	PROPN
ajst-32571	170	53	.	.	PROPN
ajst-32571	170	54	2019	2019	NUM
ajst-32571	170	55	,	,	PUNCT
ajst-32571	170	56	doi	doi	NOUN
ajst-32571	170	57	:	:	PUNCT
ajst-32571	170	58	https://doi.org/10.3390/ijms21010204	https://doi.org/10.3390/ijms21010204	NOUN
ajst-32571	170	59	.	.	PUNCT
ajst-32571	171	1	[	[	X
ajst-32571	171	2	12	12	NUM
ajst-32571	171	3	]	]	PUNCT
ajst-32571	171	4	a.	a.	NOUN
ajst-32571	171	5	alnefaie	alnefaie	PROPN
ajst-32571	171	6	et	et	PROPN
ajst-32571	171	7	al	al	PROPN
ajst-32571	171	8	.	.	PROPN
ajst-32571	171	9	,	,	PUNCT
ajst-32571	171	10	“	"	PUNCT
ajst-32571	171	11	chimeric	chimeric	ADJ
ajst-32571	171	12	antigen	antigen	ADJ
ajst-32571	171	13	receptor	receptor	NOUN
ajst-32571	171	14	t	t	NOUN
ajst-32571	171	15	-	-	PUNCT
ajst-32571	171	16	cells	cell	NOUN
ajst-32571	171	17	:	:	PUNCT
ajst-32571	171	18	an	an	DET
ajst-32571	171	19	overview	overview	NOUN
ajst-32571	171	20	of	of	ADP
ajst-32571	171	21	concepts	concept	NOUN
ajst-32571	171	22	,	,	PUNCT
ajst-32571	171	23	applications	application	NOUN
ajst-32571	171	24	,	,	PUNCT
ajst-32571	171	25	limitations	limitation	NOUN
ajst-32571	171	26	,	,	PUNCT
ajst-32571	171	27	and	and	CCONJ
ajst-32571	171	28	proposed	propose	VERB
ajst-32571	171	29	solutions	solution	NOUN
ajst-32571	171	30	,	,	PUNCT
ajst-32571	171	31	”	"	PUNCT
ajst-32571	171	32	frontiers	frontier	NOUN
ajst-32571	171	33	in	in	ADP
ajst-32571	171	34	bioengineering	bioengineering	NOUN
ajst-32571	171	35	and	and	CCONJ
ajst-32571	171	36	biotechnology	biotechnology	NOUN
ajst-32571	171	37	,	,	PUNCT
ajst-32571	171	38	vol	vol	NOUN
ajst-32571	171	39	.	.	PROPN
ajst-32571	171	40	10	10	NUM
ajst-32571	171	41	,	,	PUNCT
ajst-32571	171	42	p.	p.	NOUN
ajst-32571	171	43	797440	797440	NUM
ajst-32571	171	44	,	,	PUNCT
ajst-32571	171	45	jun	jun	PROPN
ajst-32571	171	46	.	.	PROPN
ajst-32571	171	47	2022	2022	NUM
ajst-32571	171	48	,	,	PUNCT
ajst-32571	171	49	doi	doi	NOUN
ajst-32571	171	50	:	:	PUNCT
ajst-32571	171	51	https://doi.org/10.3389/fbioe.2022.797440	https://doi.org/10.3389/fbioe.2022.797440	PROPN
ajst-32571	171	52	.	.	PROPN
ajst-32571	171	53	185	185	NUM
ajst-32571	171	54	[	[	SYM
ajst-32571	171	55	13	13	NUM
ajst-32571	171	56	]	]	PUNCT
ajst-32571	171	57	h.	h.	NOUN
ajst-32571	171	58	balke	balke	NOUN
ajst-32571	171	59	-	-	PUNCT
ajst-32571	171	60	want	want	VERB
ajst-32571	171	61	et	et	PROPN
ajst-32571	171	62	al	al	PROPN
ajst-32571	171	63	.	.	PROPN
ajst-32571	171	64	,	,	PUNCT
ajst-32571	171	65	“	"	PUNCT
ajst-32571	171	66	non	non	ADJ
ajst-32571	171	67	-	-	ADJ
ajst-32571	171	68	viral	viral	ADJ
ajst-32571	171	69	chimeric	chimeric	ADJ
ajst-32571	171	70	antigen	antigen	ADJ
ajst-32571	171	71	receptor	receptor	NOUN
ajst-32571	171	72	(	(	PUNCT
ajst-32571	171	73	car	car	NOUN
ajst-32571	171	74	)	)	PUNCT
ajst-32571	171	75	t	t	PROPN
ajst-32571	171	76	cells	cell	NOUN
ajst-32571	171	77	going	go	VERB
ajst-32571	171	78	viral	viral	ADJ
ajst-32571	171	79	,	,	PUNCT
ajst-32571	171	80	”	"	PUNCT
ajst-32571	171	81	immuno	immuno	ADJ
ajst-32571	171	82	-	-	PUNCT
ajst-32571	171	83	oncology	oncology	NOUN
ajst-32571	171	84	and	and	CCONJ
ajst-32571	171	85	technology	technology	NOUN
ajst-32571	171	86	,	,	PUNCT
ajst-32571	171	87	vol	vol	NOUN
ajst-32571	171	88	.	.	PROPN
ajst-32571	171	89	18	18	NUM
ajst-32571	171	90	,	,	PUNCT
ajst-32571	171	91	p.	p.	NOUN
ajst-32571	171	92	100375	100375	NUM
ajst-32571	171	93	,	,	PUNCT
ajst-32571	171	94	jun	jun	PROPN
ajst-32571	171	95	.	.	PROPN
ajst-32571	171	96	2023	2023	NUM
ajst-32571	171	97	,	,	PUNCT
ajst-32571	171	98	doi	doi	NOUN
ajst-32571	171	99	:	:	PUNCT
ajst-32571	171	100	https://doi.org/10.1016/j.iotech.2023.100375	https://doi.org/10.1016/j.iotech.2023.100375	PROPN
ajst-32571	171	101	.	.	PUNCT
ajst-32571	172	1	[	[	X
ajst-32571	172	2	14	14	NUM
ajst-32571	172	3	]	]	PUNCT
ajst-32571	172	4	t.	t.	PROPN
ajst-32571	172	5	a.	a.	NOUN
ajst-32571	172	6	bui	bui	PROPN
ajst-32571	172	7	,	,	PUNCT
ajst-32571	172	8	h.	h.	PROPN
ajst-32571	172	9	mei	mei	PROPN
ajst-32571	172	10	,	,	PUNCT
ajst-32571	172	11	r.	r.	PROPN
ajst-32571	172	12	sang	sang	PROPN
ajst-32571	172	13	,	,	PUNCT
ajst-32571	172	14	d.	d.	PROPN
ajst-32571	172	15	g.	g.	PROPN
ajst-32571	172	16	ortega	ortega	PROPN
ajst-32571	172	17	,	,	PUNCT
ajst-32571	172	18	and	and	CCONJ
ajst-32571	172	19	w.	w.	PROPN
ajst-32571	172	20	deng	deng	PROPN
ajst-32571	172	21	,	,	PUNCT
ajst-32571	172	22	“	"	PUNCT
ajst-32571	172	23	advancements	advancement	NOUN
ajst-32571	172	24	and	and	CCONJ
ajst-32571	172	25	challenges	challenge	NOUN
ajst-32571	172	26	in	in	ADP
ajst-32571	172	27	developing	develop	VERB
ajst-32571	172	28	in	in	ADP
ajst-32571	172	29	vivo	vivo	ADJ
ajst-32571	172	30	car	car	NOUN
ajst-32571	172	31	t	t	NOUN
ajst-32571	172	32	cell	cell	NOUN
ajst-32571	172	33	therapies	therapy	NOUN
ajst-32571	172	34	for	for	ADP
ajst-32571	172	35	cancer	cancer	NOUN
ajst-32571	172	36	treatment	treatment	NOUN
ajst-32571	172	37	,	,	PUNCT
ajst-32571	172	38	”	"	PUNCT
ajst-32571	172	39	ebiomedicine	ebiomedicine	ADJ
ajst-32571	172	40	,	,	PUNCT
ajst-32571	172	41	vol	vol	NOUN
ajst-32571	172	42	.	.	PROPN
ajst-32571	172	43	106	106	NUM
ajst-32571	172	44	,	,	PUNCT
ajst-32571	172	45	p.	p.	NOUN
ajst-32571	172	46	105266	105266	NUM
ajst-32571	172	47	,	,	PUNCT
ajst-32571	172	48	aug	aug	PROPN
ajst-32571	172	49	.	.	PROPN
ajst-32571	172	50	2024	2024	NUM
ajst-32571	172	51	,	,	PUNCT
ajst-32571	172	52	doi	doi	NOUN
ajst-32571	172	53	:	:	PUNCT
ajst-32571	172	54	https://doi.org/10.1016/j.ebiom.2024.105266	https://doi.org/10.1016/j.ebiom.2024.105266	NOUN
ajst-32571	172	55	.	.	PUNCT
ajst-32571	173	1	[	[	X
ajst-32571	173	2	15	15	NUM
ajst-32571	173	3	]	]	X
ajst-32571	173	4	u.	u.	PROPN
ajst-32571	173	5	ahmad	ahmad	PROPN
ajst-32571	173	6	et	et	PROPN
ajst-32571	173	7	al	al	PROPN
ajst-32571	173	8	.	.	PROPN
ajst-32571	173	9	,	,	PUNCT
ajst-32571	173	10	“	"	PUNCT
ajst-32571	173	11	chimeric	chimeric	ADJ
ajst-32571	173	12	antigen	antigen	ADJ
ajst-32571	173	13	receptor	receptor	NOUN
ajst-32571	173	14	t	t	NOUN
ajst-32571	173	15	cell	cell	NOUN
ajst-32571	173	16	structure	structure	NOUN
ajst-32571	173	17	,	,	PUNCT
ajst-32571	173	18	its	its	PRON
ajst-32571	173	19	manufacturing	manufacturing	NOUN
ajst-32571	173	20	,	,	PUNCT
ajst-32571	173	21	and	and	CCONJ
ajst-32571	173	22	related	related	ADJ
ajst-32571	173	23	toxicities	toxicity	NOUN
ajst-32571	173	24	;	;	PUNCT
ajst-32571	173	25	a	a	DET
ajst-32571	173	26	comprehensive	comprehensive	ADJ
ajst-32571	173	27	review	review	NOUN
ajst-32571	173	28	,	,	PUNCT
ajst-32571	173	29	”	"	PUNCT
ajst-32571	173	30	advances	advance	NOUN
ajst-32571	173	31	in	in	ADP
ajst-32571	173	32	cancer	cancer	NOUN
ajst-32571	173	33	biology	biology	NOUN
ajst-32571	173	34	metastasis	metastasis	NOUN
ajst-32571	173	35	,	,	PUNCT
ajst-32571	173	36	vol	vol	NOUN
ajst-32571	173	37	.	.	PROPN
ajst-32571	173	38	4	4	NUM
ajst-32571	173	39	,	,	PUNCT
ajst-32571	173	40	p.	p.	NOUN
ajst-32571	173	41	100035	100035	NUM
ajst-32571	173	42	,	,	PUNCT
ajst-32571	173	43	jul	jul	PROPN
ajst-32571	173	44	.	.	PROPN
ajst-32571	173	45	2022	2022	NUM
ajst-32571	173	46	,	,	PUNCT
ajst-32571	173	47	doi	doi	NOUN
ajst-32571	173	48	:	:	PUNCT
ajst-32571	173	49	https://doi.org/10.1016/j.adcanc.2022.100035	https://doi.org/10.1016/j.adcanc.2022.100035	PROPN
ajst-32571	173	50	.	.	PUNCT
ajst-32571	174	1	[	[	X
ajst-32571	174	2	16	16	NUM
ajst-32571	174	3	]	]	PUNCT
ajst-32571	174	4	z.	z.	PROPN
ajst-32571	174	5	zhao	zhao	PROPN
ajst-32571	174	6	,	,	PUNCT
ajst-32571	174	7	y.	y.	PROPN
ajst-32571	174	8	chen	chen	PROPN
ajst-32571	174	9	,	,	PUNCT
ajst-32571	174	10	n.	n.	PROPN
ajst-32571	174	11	m.	m.	PROPN
ajst-32571	174	12	francisco	francisco	PROPN
ajst-32571	174	13	,	,	PUNCT
ajst-32571	174	14	y.	y.	PROPN
ajst-32571	174	15	zhang	zhang	PROPN
ajst-32571	174	16	,	,	PUNCT
ajst-32571	174	17	and	and	CCONJ
ajst-32571	174	18	m.	m.	PROPN
ajst-32571	174	19	wu	wu	PROPN
ajst-32571	174	20	,	,	PUNCT
ajst-32571	174	21	“	"	PUNCT
ajst-32571	174	22	the	the	DET
ajst-32571	174	23	application	application	NOUN
ajst-32571	174	24	of	of	ADP
ajst-32571	174	25	car	car	NOUN
ajst-32571	174	26	-	-	PUNCT
ajst-32571	174	27	t	t	NOUN
ajst-32571	174	28	cell	cell	NOUN
ajst-32571	174	29	therapy	therapy	NOUN
ajst-32571	174	30	in	in	ADP
ajst-32571	174	31	hematological	hematological	ADJ
ajst-32571	174	32	malignancies	malignancy	NOUN
ajst-32571	174	33	:	:	PUNCT
ajst-32571	174	34	advantages	advantage	NOUN
ajst-32571	174	35	and	and	CCONJ
ajst-32571	174	36	challenges	challenge	NOUN
ajst-32571	174	37	,	,	PUNCT
ajst-32571	174	38	”	"	PUNCT
ajst-32571	174	39	acta	acta	PROPN
ajst-32571	174	40	pharmaceutica	pharmaceutica	PROPN
ajst-32571	174	41	sinica	sinica	PROPN
ajst-32571	174	42	b	b	PROPN
ajst-32571	174	43	,	,	PUNCT
ajst-32571	174	44	vol	vol	NOUN
ajst-32571	174	45	.	.	NOUN
ajst-32571	174	46	8	8	NUM
ajst-32571	174	47	,	,	PUNCT
ajst-32571	174	48	no	no	INTJ
ajst-32571	174	49	.	.	NOUN
ajst-32571	174	50	4	4	NUM
ajst-32571	174	51	,	,	PUNCT
ajst-32571	174	52	pp	pp	ADJ
ajst-32571	174	53	.	.	PUNCT
ajst-32571	175	1	539–551	539–551	NUM
ajst-32571	175	2	,	,	PUNCT
ajst-32571	175	3	jul	jul	PROPN
ajst-32571	175	4	.	.	PROPN
ajst-32571	175	5	2018	2018	NUM
ajst-32571	175	6	,	,	PUNCT
ajst-32571	175	7	doi	doi	NOUN
ajst-32571	175	8	:	:	PUNCT
ajst-32571	175	9	https://doi.org/10.1016/j.apsb.2018.03.001	https://doi.org/10.1016/j.apsb.2018.03.001	NOUN
ajst-32571	175	10	.	.	PUNCT
ajst-32571	176	1	[	[	X
ajst-32571	176	2	17	17	NUM
ajst-32571	176	3	]	]	X
ajst-32571	176	4	myeloma	myeloma	PROPN
ajst-32571	176	5	uk	uk	PROPN
ajst-32571	176	6	,	,	PUNCT
ajst-32571	176	7	“	"	PUNCT
ajst-32571	176	8	ask	ask	VERB
ajst-32571	176	9	the	the	DET
ajst-32571	176	10	nurse	nurse	NOUN
ajst-32571	176	11	:	:	PUNCT
ajst-32571	176	12	car	car	NOUN
ajst-32571	176	13	-	-	PUNCT
ajst-32571	176	14	t	t	NOUN
ajst-32571	176	15	cell	cell	NOUN
ajst-32571	176	16	treatments	treatment	NOUN
ajst-32571	176	17	,	,	PUNCT
ajst-32571	176	18	”	"	PUNCT
ajst-32571	176	19	myeloma	myeloma	PROPN
ajst-32571	176	20	uk	uk	PROPN
ajst-32571	176	21	,	,	PUNCT
ajst-32571	176	22	feb	feb	PROPN
ajst-32571	176	23	.	.	PROPN
ajst-32571	176	24	2022	2022	NUM
ajst-32571	176	25	.	.	PUNCT
ajst-32571	177	1	https://www	https://www	PROPN
ajst-32571	177	2	.	.	PUNCT
ajst-32571	178	1	myeloma	myeloma	PROPN
ajst-32571	178	2	.	.	PUNCT
ajst-32571	179	1	org.uk/library/ask-the-nurse-car-t-cells/	org.uk/library/ask-the-nurse-car-t-cells/	NOUN
ajst-32571	180	1	[	[	X
ajst-32571	180	2	18	18	NUM
ajst-32571	180	3	]	]	X
ajst-32571	180	4	r.	r.	PROPN
ajst-32571	180	5	c.	c.	PROPN
ajst-32571	180	6	de	de	PROPN
ajst-32571	180	7	marco	marco	PROPN
ajst-32571	180	8	,	,	PUNCT
ajst-32571	180	9	h.	h.	PROPN
ajst-32571	180	10	j.	j.	PROPN
ajst-32571	180	11	monzo	monzo	PROPN
ajst-32571	180	12	,	,	PUNCT
ajst-32571	180	13	and	and	CCONJ
ajst-32571	180	14	p.	p.	NOUN
ajst-32571	180	15	m.	m.	NOUN
ajst-32571	180	16	ojala	ojala	PROPN
ajst-32571	180	17	,	,	PUNCT
ajst-32571	180	18	“	"	PUNCT
ajst-32571	180	19	car	car	NOUN
ajst-32571	180	20	t	t	NOUN
ajst-32571	180	21	cell	cell	NOUN
ajst-32571	180	22	therapy	therapy	NOUN
ajst-32571	180	23	:	:	PUNCT
ajst-32571	180	24	a	a	DET
ajst-32571	180	25	versatile	versatile	ADJ
ajst-32571	180	26	living	living	NOUN
ajst-32571	180	27	drug	drug	NOUN
ajst-32571	180	28	,	,	PUNCT
ajst-32571	180	29	”	"	PUNCT
ajst-32571	180	30	international	international	ADJ
ajst-32571	180	31	journal	journal	NOUN
ajst-32571	180	32	of	of	ADP
ajst-32571	180	33	molecular	molecular	ADJ
ajst-32571	180	34	sciences	science	NOUN
ajst-32571	180	35	,	,	PUNCT
ajst-32571	180	36	vol	vol	NOUN
ajst-32571	180	37	.	.	PROPN
ajst-32571	180	38	24	24	NUM
ajst-32571	180	39	,	,	PUNCT
ajst-32571	180	40	no	no	INTJ
ajst-32571	180	41	.	.	NOUN
ajst-32571	180	42	7	7	NUM
ajst-32571	180	43	,	,	PUNCT
ajst-32571	180	44	mar	mar	PROPN
ajst-32571	180	45	.	.	PROPN
ajst-32571	180	46	2023	2023	NUM
ajst-32571	180	47	,	,	PUNCT
ajst-32571	180	48	doi	doi	NOUN
ajst-32571	180	49	:	:	PUNCT
ajst-32571	180	50	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajst-32571	180	51	ijms	ijm	VERB
ajst-32571	180	52	24076300	24076300	NUM
ajst-32571	180	53	.	.	PUNCT
ajst-32571	181	1	[	[	X
ajst-32571	181	2	19	19	NUM
ajst-32571	181	3	]	]	X
ajst-32571	181	4	d.	d.	NOUN
ajst-32571	181	5	günzel	günzel	NOUN
ajst-32571	181	6	and	and	CCONJ
ajst-32571	181	7	a.	a.	PROPN
ajst-32571	181	8	s.	s.	PROPN
ajst-32571	181	9	l.	l.	PROPN
ajst-32571	181	10	yu	yu	PROPN
ajst-32571	181	11	,	,	PUNCT
ajst-32571	181	12	“	"	PUNCT
ajst-32571	181	13	claudins	claudin	NOUN
ajst-32571	181	14	and	and	CCONJ
ajst-32571	181	15	the	the	DET
ajst-32571	181	16	modulation	modulation	NOUN
ajst-32571	181	17	of	of	ADP
ajst-32571	181	18	tight	tight	ADJ
ajst-32571	181	19	junction	junction	NOUN
ajst-32571	181	20	permeability	permeability	NOUN
ajst-32571	181	21	,	,	PUNCT
ajst-32571	181	22	”	"	PUNCT
ajst-32571	181	23	physiological	physiological	ADJ
ajst-32571	181	24	reviews	review	NOUN
ajst-32571	181	25	,	,	PUNCT
ajst-32571	181	26	vol	vol	NOUN
ajst-32571	181	27	.	.	PROPN
ajst-32571	181	28	93	93	NUM
ajst-32571	181	29	,	,	PUNCT
ajst-32571	181	30	no	no	INTJ
ajst-32571	181	31	.	.	NOUN
ajst-32571	181	32	2	2	NUM
ajst-32571	181	33	,	,	PUNCT
ajst-32571	181	34	pp	pp	ADJ
ajst-32571	181	35	.	.	PUNCT
ajst-32571	182	1	525–569	525–569	NUM
ajst-32571	182	2	,	,	PUNCT
ajst-32571	182	3	2013	2013	NUM
ajst-32571	182	4	,	,	PUNCT
ajst-32571	182	5	doi	doi	NOUN
ajst-32571	182	6	:	:	PUNCT
ajst-32571	182	7	https://doi.org/10.1152/physrev.00019.2012	https://doi.org/10.1152/physrev.00019.2012	PROPN
ajst-32571	182	8	.	.	PUNCT
ajst-32571	183	1	[	[	X
ajst-32571	183	2	20	20	NUM
ajst-32571	183	3	]	]	PUNCT
ajst-32571	183	4	g.	g.	PROPN
ajst-32571	183	5	krause	krause	PROPN
ajst-32571	183	6	,	,	PUNCT
ajst-32571	183	7	l.	l.	PROPN
ajst-32571	183	8	winkler	winkler	PROPN
ajst-32571	183	9	,	,	PUNCT
ajst-32571	183	10	s.	s.	PROPN
ajst-32571	183	11	l.	l.	PROPN
ajst-32571	183	12	mueller	mueller	PROPN
ajst-32571	183	13	,	,	PUNCT
ajst-32571	183	14	r.	r.	PROPN
ajst-32571	183	15	f.	f.	PROPN
ajst-32571	183	16	haseloff	haseloff	PROPN
ajst-32571	183	17	,	,	PUNCT
ajst-32571	183	18	j.	j.	PROPN
ajst-32571	183	19	piontek	piontek	PROPN
ajst-32571	183	20	,	,	PUNCT
ajst-32571	183	21	and	and	CCONJ
ajst-32571	183	22	i.	i.	PROPN
ajst-32571	183	23	e.	e.	PROPN
ajst-32571	183	24	blasig	blasig	PROPN
ajst-32571	183	25	,	,	PUNCT
ajst-32571	183	26	“	"	PUNCT
ajst-32571	183	27	structure	structure	NOUN
ajst-32571	183	28	and	and	CCONJ
ajst-32571	183	29	function	function	NOUN
ajst-32571	183	30	of	of	ADP
ajst-32571	183	31	claudins	claudin	NOUN
ajst-32571	183	32	,	,	PUNCT
ajst-32571	183	33	”	"	PUNCT
ajst-32571	183	34	biochimica	biochimica	PROPN
ajst-32571	183	35	et	et	PROPN
ajst-32571	183	36	biophysica	biophysica	PROPN
ajst-32571	183	37	acta	acta	PROPN
ajst-32571	183	38	,	,	PUNCT
ajst-32571	183	39	vol	vol	NOUN
ajst-32571	183	40	.	.	PROPN
ajst-32571	183	41	1778	1778	NUM
ajst-32571	183	42	,	,	PUNCT
ajst-32571	183	43	no	no	INTJ
ajst-32571	183	44	.	.	NOUN
ajst-32571	183	45	3	3	NUM
ajst-32571	183	46	,	,	PUNCT
ajst-32571	183	47	pp	pp	ADJ
ajst-32571	183	48	.	.	PUNCT
ajst-32571	184	1	631–645	631–645	NUM
ajst-32571	184	2	,	,	PUNCT
ajst-32571	184	3	2007	2007	NUM
ajst-32571	184	4	,	,	PUNCT
ajst-32571	184	5	doi	doi	NOUN
ajst-32571	184	6	:	:	PUNCT
ajst-32571	184	7	https://doi.org/	https://doi.org/	NOUN
ajst-32571	184	8	10	10	NUM
ajst-32571	184	9	.	.	PUNCT
ajst-32571	185	1	1016/	1016/	NUM
ajst-32571	185	2	j.bbamem.2007.10.018	j.bbamem.2007.10.018	ADP
ajst-32571	185	3	.	.	PUNCT
ajst-32571	186	1	[	[	X
ajst-32571	186	2	21	21	NUM
ajst-32571	186	3	]	]	PUNCT
ajst-32571	186	4	a.	a.	NOUN
ajst-32571	186	5	berselli	berselli	PROPN
ajst-32571	186	6	,	,	PUNCT
ajst-32571	186	7	f.	f.	PROPN
ajst-32571	186	8	benfenati	benfenati	PROPN
ajst-32571	186	9	,	,	PUNCT
ajst-32571	186	10	l.	l.	PROPN
ajst-32571	186	11	maragliano	maragliano	PROPN
ajst-32571	186	12	,	,	PUNCT
ajst-32571	186	13	and	and	CCONJ
ajst-32571	186	14	g.	g.	PROPN
ajst-32571	186	15	alberini	alberini	PROPN
ajst-32571	186	16	,	,	PUNCT
ajst-32571	186	17	“	"	PUNCT
ajst-32571	186	18	multiscale	multiscale	ADJ
ajst-32571	186	19	modelling	modelling	NOUN
ajst-32571	186	20	of	of	ADP
ajst-32571	186	21	claudin	claudin	VERB
ajst-32571	186	22	-	-	PUNCT
ajst-32571	186	23	based	base	VERB
ajst-32571	186	24	assemblies	assembly	NOUN
ajst-32571	186	25	:	:	PUNCT
ajst-32571	186	26	a	a	DET
ajst-32571	186	27	magnifying	magnify	VERB
ajst-32571	186	28	glass	glass	NOUN
ajst-32571	186	29	for	for	ADP
ajst-32571	186	30	novel	novel	ADJ
ajst-32571	186	31	structures	structure	NOUN
ajst-32571	186	32	of	of	ADP
ajst-32571	186	33	biological	biological	ADJ
ajst-32571	186	34	interfaces	interface	NOUN
ajst-32571	186	35	,	,	PUNCT
ajst-32571	186	36	”	"	PUNCT
ajst-32571	186	37	computational	computational	ADJ
ajst-32571	186	38	and	and	CCONJ
ajst-32571	186	39	structural	structural	ADJ
ajst-32571	186	40	biotechnology	biotechnology	NOUN
ajst-32571	186	41	journal	journal	NOUN
ajst-32571	186	42	,	,	PUNCT
ajst-32571	186	43	vol	vol	NOUN
ajst-32571	186	44	.	.	PROPN
ajst-32571	186	45	20	20	NUM
ajst-32571	186	46	,	,	PUNCT
ajst-32571	186	47	pp	pp	ADJ
ajst-32571	186	48	.	.	PUNCT
ajst-32571	187	1	5984–6010	5984–6010	NUM
ajst-32571	187	2	,	,	PUNCT
ajst-32571	187	3	oct	oct	PROPN
ajst-32571	187	4	.	.	PROPN
ajst-32571	187	5	2022	2022	NUM
ajst-32571	187	6	,	,	PUNCT
ajst-32571	187	7	doi	doi	NOUN
ajst-32571	187	8	:	:	PUNCT
ajst-32571	187	9	https://doi.org/	https://doi.org/	NOUN
ajst-32571	187	10	10.1016	10.1016	NUM
ajst-32571	187	11	/	/	SYM
ajst-32571	187	12	j.	j.	PROPN
ajst-32571	187	13	csbj	csbj	PROPN
ajst-32571	187	14	.	.	PUNCT
ajst-32571	188	1	2022.10.038	2022.10.038	NOUN
ajst-32571	188	2	.	.	PUNCT
ajst-32571	189	1	[	[	X
ajst-32571	189	2	22	22	NUM
ajst-32571	189	3	]	]	PUNCT
ajst-32571	189	4	m.	m.	NOUN
ajst-32571	189	5	s.	s.	PROPN
ajst-32571	189	6	j.	j.	PROPN
ajst-32571	189	7	mcdermott	mcdermott	PROPN
ajst-32571	189	8	et	et	PROPN
ajst-32571	189	9	al	al	PROPN
ajst-32571	189	10	.	.	PROPN
ajst-32571	189	11	,	,	PUNCT
ajst-32571	189	12	“	"	PUNCT
ajst-32571	189	13	preclinical	preclinical	ADJ
ajst-32571	189	14	efficacy	efficacy	NOUN
ajst-32571	189	15	of	of	ADP
ajst-32571	189	16	the	the	DET
ajst-32571	189	17	antibody	antibody	NOUN
ajst-32571	189	18	–	–	PUNCT
ajst-32571	189	19	drug	drug	NOUN
ajst-32571	189	20	conjugate	conjugate	ADJ
ajst-32571	189	21	cldn6–23	cldn6–23	NOUN
ajst-32571	189	22	-	-	PUNCT
ajst-32571	189	23	adc	adc	NOUN
ajst-32571	189	24	for	for	ADP
ajst-32571	189	25	the	the	DET
ajst-32571	189	26	treatment	treatment	NOUN
ajst-32571	189	27	of	of	ADP
ajst-32571	189	28	cldn6	cldn6	NOUN
ajst-32571	189	29	-	-	PUNCT
ajst-32571	189	30	positive	positive	ADJ
ajst-32571	189	31	solid	solid	ADJ
ajst-32571	189	32	tumors	tumor	NOUN
ajst-32571	189	33	,	,	PUNCT
ajst-32571	189	34	”	"	PUNCT
ajst-32571	189	35	clinical	clinical	ADJ
ajst-32571	189	36	cancer	cancer	NOUN
ajst-32571	189	37	research	research	NOUN
ajst-32571	189	38	,	,	PUNCT
ajst-32571	189	39	vol	vol	NOUN
ajst-32571	189	40	.	.	PROPN
ajst-32571	189	41	29	29	NUM
ajst-32571	189	42	,	,	PUNCT
ajst-32571	189	43	no	no	INTJ
ajst-32571	189	44	.	.	NOUN
ajst-32571	189	45	11	11	NUM
ajst-32571	189	46	,	,	PUNCT
ajst-32571	189	47	pp	pp	ADJ
ajst-32571	189	48	.	.	PUNCT
ajst-32571	189	49	2131	2131	NUM
ajst-32571	189	50	–	–	PUNCT
ajst-32571	189	51	2143	2143	NUM
ajst-32571	189	52	,	,	PUNCT
ajst-32571	189	53	2023	2023	NUM
ajst-32571	189	54	,	,	PUNCT
ajst-32571	189	55	doi	doi	NOUN
ajst-32571	189	56	:	:	PUNCT
ajst-32571	189	57	https://doi.org/10.1158/1078-0432.ccr-22-2981	https://doi.org/10.1158/1078-0432.ccr-22-2981	X
ajst-32571	189	58	.	.	PUNCT
ajst-32571	190	1	[	[	X
ajst-32571	190	2	23	23	NUM
ajst-32571	190	3	]	]	X
ajst-32571	190	4	h.	h.	PROPN
ajst-32571	190	5	qu	qu	PROPN
ajst-32571	190	6	,	,	PUNCT
ajst-32571	190	7	j.	j.	PROPN
ajst-32571	190	8	qiu	qiu	PROPN
ajst-32571	190	9	,	,	PUNCT
ajst-32571	190	10	and	and	CCONJ
ajst-32571	190	11	c.	c.	PROPN
ajst-32571	190	12	quan	quan	PROPN
ajst-32571	190	13	,	,	PUNCT
ajst-32571	190	14	“	"	PUNCT
ajst-32571	190	15	cldn6	cldn6	PROPN
ajst-32571	190	16	:	:	PUNCT
ajst-32571	190	17	from	from	ADP
ajst-32571	190	18	traditional	traditional	ADJ
ajst-32571	190	19	barrier	barrier	NOUN
ajst-32571	190	20	function	function	NOUN
ajst-32571	190	21	to	to	ADP
ajst-32571	190	22	emerging	emerge	VERB
ajst-32571	190	23	roles	role	NOUN
ajst-32571	190	24	in	in	ADP
ajst-32571	190	25	cancers	cancer	NOUN
ajst-32571	190	26	,	,	PUNCT
ajst-32571	190	27	”	"	PUNCT
ajst-32571	190	28	international	international	ADJ
ajst-32571	190	29	journal	journal	NOUN
ajst-32571	190	30	of	of	ADP
ajst-32571	190	31	molecular	molecular	ADJ
ajst-32571	190	32	sciences	science	NOUN
ajst-32571	190	33	,	,	PUNCT
ajst-32571	190	34	vol	vol	NOUN
ajst-32571	190	35	.	.	PROPN
ajst-32571	190	36	22	22	NUM
ajst-32571	190	37	,	,	PUNCT
ajst-32571	190	38	no	no	INTJ
ajst-32571	190	39	.	.	NOUN
ajst-32571	190	40	24	24	NUM
ajst-32571	190	41	,	,	PUNCT
ajst-32571	190	42	dec	dec	PROPN
ajst-32571	190	43	.	.	PROPN
ajst-32571	190	44	2021	2021	NUM
ajst-32571	190	45	,	,	PUNCT
ajst-32571	190	46	doi	doi	NOUN
ajst-32571	190	47	:	:	PUNCT
ajst-32571	190	48	https://doi.org/10	https://doi.org/10	PROPN
ajst-32571	190	49	.	.	PUNCT
ajst-32571	190	50	3390	3390	NUM
ajst-32571	190	51	/	/	SYM
ajst-32571	190	52	ijms	ijm	VERB
ajst-32571	190	53	222413416	222413416	NUM
ajst-32571	190	54	.	.	PUNCT
ajst-32571	191	1	[	[	X
ajst-32571	191	2	24	24	NUM
ajst-32571	191	3	]	]	PUNCT
ajst-32571	191	4	l.	l.	PROPN
ajst-32571	191	5	wang	wang	PROPN
ajst-32571	191	6	et	et	PROPN
ajst-32571	191	7	al	al	PROPN
ajst-32571	191	8	.	.	PROPN
ajst-32571	191	9	,	,	PUNCT
ajst-32571	191	10	“	"	PUNCT
ajst-32571	191	11	clinicopathologic	clinicopathologic	ADJ
ajst-32571	191	12	significance	significance	NOUN
ajst-32571	191	13	of	of	ADP
ajst-32571	191	14	claudin-6	claudin-6	NUM
ajst-32571	191	15	,	,	PUNCT
ajst-32571	191	16	occludin	occludin	NOUN
ajst-32571	191	17	,	,	PUNCT
ajst-32571	191	18	and	and	CCONJ
ajst-32571	191	19	matrix	matrix	VERB
ajst-32571	191	20	metalloproteinases-2	metalloproteinases-2	PROPN
ajst-32571	191	21	expression	expression	NOUN
ajst-32571	191	22	in	in	ADP
ajst-32571	191	23	ovarian	ovarian	ADJ
ajst-32571	191	24	carcinoma	carcinoma	NOUN
ajst-32571	191	25	,	,	PUNCT
ajst-32571	191	26	”	"	PUNCT
ajst-32571	191	27	diagnostic	diagnostic	ADJ
ajst-32571	191	28	pathology	pathology	NOUN
ajst-32571	191	29	,	,	PUNCT
ajst-32571	191	30	vol	vol	NOUN
ajst-32571	191	31	.	.	PROPN
ajst-32571	191	32	8	8	NUM
ajst-32571	191	33	,	,	PUNCT
ajst-32571	191	34	no	no	INTJ
ajst-32571	191	35	.	.	NOUN
ajst-32571	191	36	1	1	NUM
ajst-32571	191	37	,	,	PUNCT
ajst-32571	191	38	nov	nov	PROPN
ajst-32571	191	39	.	.	PROPN
ajst-32571	191	40	2013	2013	NUM
ajst-32571	191	41	,	,	PUNCT
ajst-32571	191	42	doi	doi	NOUN
ajst-32571	191	43	:	:	PUNCT
ajst-32571	191	44	https://doi.org/	https://doi.org/	NOUN
ajst-32571	191	45	10.1186/	10.1186/	PROPN
ajst-32571	191	46	1746	1746	NUM
ajst-32571	191	47	-	-	SYM
ajst-32571	191	48	1596	1596	NUM
ajst-32571	191	49	-	-	SYM
ajst-32571	191	50	8	8	NUM
ajst-32571	191	51	-	-	NUM
ajst-32571	191	52	190	190	NUM
ajst-32571	191	53	.	.	PUNCT
ajst-32571	192	1	[	[	X
ajst-32571	192	2	25	25	NUM
ajst-32571	192	3	]	]	X
ajst-32571	192	4	h.	h.	PROPN
ajst-32571	192	5	du	du	PROPN
ajst-32571	192	6	,	,	PUNCT
ajst-32571	192	7	x.	x.	PROPN
ajst-32571	192	8	yang	yang	PROPN
ajst-32571	192	9	,	,	PUNCT
ajst-32571	192	10	j.	j.	PROPN
ajst-32571	192	11	fan	fan	PROPN
ajst-32571	192	12	,	,	PUNCT
ajst-32571	192	13	and	and	CCONJ
ajst-32571	192	14	x.	x.	NOUN
ajst-32571	192	15	du	du	PROPN
ajst-32571	192	16	,	,	PUNCT
ajst-32571	192	17	“	"	PUNCT
ajst-32571	192	18	claudin	claudin	VERB
ajst-32571	192	19	6	6	NUM
ajst-32571	192	20	:	:	PUNCT
ajst-32571	192	21	therapeutic	therapeutic	ADJ
ajst-32571	192	22	prospects	prospect	NOUN
ajst-32571	192	23	for	for	ADP
ajst-32571	192	24	tumours	tumour	NOUN
ajst-32571	192	25	,	,	PUNCT
ajst-32571	192	26	and	and	CCONJ
ajst-32571	192	27	mechanisms	mechanism	NOUN
ajst-32571	192	28	of	of	ADP
ajst-32571	192	29	expression	expression	NOUN
ajst-32571	192	30	and	and	CCONJ
ajst-32571	192	31	regulation	regulation	NOUN
ajst-32571	192	32	(	(	PUNCT
ajst-32571	192	33	review	review	NOUN
ajst-32571	192	34	)	)	PUNCT
ajst-32571	192	35	,	,	PUNCT
ajst-32571	192	36	”	"	PUNCT
ajst-32571	192	37	molecular	molecular	ADJ
ajst-32571	192	38	medicine	medicine	NOUN
ajst-32571	192	39	reports	report	NOUN
ajst-32571	192	40	,	,	PUNCT
ajst-32571	192	41	vol	vol	NOUN
ajst-32571	192	42	.	.	PROPN
ajst-32571	192	43	24	24	NUM
ajst-32571	192	44	,	,	PUNCT
ajst-32571	192	45	no	no	INTJ
ajst-32571	192	46	.	.	NOUN
ajst-32571	192	47	3	3	NUM
ajst-32571	192	48	,	,	PUNCT
ajst-32571	192	49	jul	jul	PROPN
ajst-32571	192	50	.	.	PROPN
ajst-32571	192	51	2021	2021	NUM
ajst-32571	192	52	,	,	PUNCT
ajst-32571	192	53	doi	doi	NOUN
ajst-32571	192	54	:	:	PUNCT
ajst-32571	192	55	https://doi.org/10.3892/mmr.2021.12316	https://doi.org/10.3892/mmr.2021.12316	ADJ
ajst-32571	192	56	.	.	PUNCT
ajst-32571	193	1	[	[	X
ajst-32571	193	2	26	26	NUM
ajst-32571	193	3	]	]	X
ajst-32571	193	4	l.	l.	PROPN
ajst-32571	193	5	seidmann	seidmann	PROPN
ajst-32571	193	6	et	et	PROPN
ajst-32571	193	7	al	al	PROPN
ajst-32571	193	8	.	.	PROPN
ajst-32571	193	9	,	,	PUNCT
ajst-32571	193	10	“	"	PUNCT
ajst-32571	193	11	the	the	DET
ajst-32571	193	12	chimeric	chimeric	ADJ
ajst-32571	193	13	antigen	antigen	ADJ
ajst-32571	193	14	receptor	receptor	NOUN
ajst-32571	193	15	t	t	NOUN
ajst-32571	193	16	cell	cell	NOUN
ajst-32571	193	17	target	target	NOUN
ajst-32571	193	18	claudin	claudin	VERB
ajst-32571	193	19	6	6	NUM
ajst-32571	193	20	is	be	AUX
ajst-32571	193	21	a	a	DET
ajst-32571	193	22	marker	marker	NOUN
ajst-32571	193	23	for	for	ADP
ajst-32571	193	24	early	early	ADJ
ajst-32571	193	25	organspecific	organspecific	ADJ
ajst-32571	193	26	epithelial	epithelial	ADJ
ajst-32571	193	27	progenitors	progenitor	NOUN
ajst-32571	193	28	and	and	CCONJ
ajst-32571	193	29	is	be	AUX
ajst-32571	193	30	expressed	express	VERB
ajst-32571	193	31	in	in	ADP
ajst-32571	193	32	some	some	DET
ajst-32571	193	33	pediatric	pediatric	ADJ
ajst-32571	193	34	solid	solid	ADJ
ajst-32571	193	35	tumor	tumor	NOUN
ajst-32571	193	36	entities	entity	NOUN
ajst-32571	193	37	,	,	PUNCT
ajst-32571	193	38	”	"	PUNCT
ajst-32571	193	39	cancers	cancer	NOUN
ajst-32571	193	40	,	,	PUNCT
ajst-32571	193	41	vol	vol	NOUN
ajst-32571	193	42	.	.	PROPN
ajst-32571	193	43	17	17	NUM
ajst-32571	193	44	,	,	PUNCT
ajst-32571	193	45	no	no	INTJ
ajst-32571	193	46	.	.	NOUN
ajst-32571	193	47	6	6	NUM
ajst-32571	193	48	,	,	PUNCT
ajst-32571	193	49	p.	p.	NOUN
ajst-32571	193	50	920	920	NUM
ajst-32571	193	51	,	,	PUNCT
ajst-32571	193	52	mar	mar	PROPN
ajst-32571	193	53	.	.	PROPN
ajst-32571	193	54	2025	2025	NUM
ajst-32571	193	55	,	,	PUNCT
ajst-32571	193	56	doi	doi	NOUN
ajst-32571	193	57	:	:	PUNCT
ajst-32571	193	58	https://doi.org/10.3390/cancers17060920	https://doi.org/10.3390/cancers17060920	PROPN
ajst-32571	193	59	.	.	PUNCT
ajst-32571	194	1	[	[	X
ajst-32571	194	2	27	27	NUM
ajst-32571	194	3	]	]	PUNCT
ajst-32571	194	4	a.	a.	NOUN
ajst-32571	194	5	mackensen	mackensen	NOUN
ajst-32571	194	6	et	et	PROPN
ajst-32571	194	7	al	al	PROPN
ajst-32571	194	8	.	.	PROPN
ajst-32571	194	9	,	,	PUNCT
ajst-32571	194	10	“	"	PUNCT
ajst-32571	194	11	cldn6	cldn6	NOUN
ajst-32571	194	12	-	-	PUNCT
ajst-32571	194	13	specific	specific	ADJ
ajst-32571	194	14	car	car	NOUN
ajst-32571	194	15	-	-	PUNCT
ajst-32571	194	16	t	t	NOUN
ajst-32571	194	17	cells	cell	NOUN
ajst-32571	194	18	plus	plus	CCONJ
ajst-32571	194	19	amplifying	amplifying	ADJ
ajst-32571	194	20	rna	rna	NOUN
ajst-32571	194	21	vaccine	vaccine	NOUN
ajst-32571	194	22	in	in	ADP
ajst-32571	194	23	relapsed	relapse	VERB
ajst-32571	194	24	or	or	CCONJ
ajst-32571	194	25	refractory	refractory	NOUN
ajst-32571	194	26	solid	solid	ADJ
ajst-32571	194	27	tumors	tumor	NOUN
ajst-32571	194	28	:	:	PUNCT
ajst-32571	194	29	the	the	DET
ajst-32571	194	30	phase	phase	NOUN
ajst-32571	194	31	1	1	NUM
ajst-32571	194	32	bnt211	bnt211	PROPN
ajst-32571	194	33	-	-	PUNCT
ajst-32571	194	34	01	01	NUM
ajst-32571	194	35	trial	trial	NOUN
ajst-32571	194	36	,	,	PUNCT
ajst-32571	194	37	”	"	PUNCT
ajst-32571	194	38	nature	nature	NOUN
ajst-32571	194	39	medicine	medicine	NOUN
ajst-32571	194	40	,	,	PUNCT
ajst-32571	194	41	vol	vol	NOUN
ajst-32571	194	42	.	.	PROPN
ajst-32571	194	43	29	29	NUM
ajst-32571	194	44	,	,	PUNCT
ajst-32571	194	45	no	no	INTJ
ajst-32571	194	46	.	.	NOUN
ajst-32571	194	47	11	11	NUM
ajst-32571	194	48	,	,	PUNCT
ajst-32571	194	49	pp	pp	ADJ
ajst-32571	194	50	.	.	PUNCT
ajst-32571	195	1	2844–2853	2844–2853	NUM
ajst-32571	195	2	,	,	PUNCT
ajst-32571	195	3	oct	oct	PROPN
ajst-32571	195	4	.	.	PROPN
ajst-32571	195	5	2023	2023	NUM
ajst-32571	195	6	,	,	PUNCT
ajst-32571	195	7	doi	doi	NOUN
ajst-32571	195	8	:	:	PUNCT
ajst-32571	195	9	https://doi.org/10.1038/s41591-023-02612-0	https://doi.org/10.1038/s41591-023-02612-0	NUM
ajst-32571	195	10	.	.	PUNCT
ajst-32571	196	1	[	[	X
ajst-32571	196	2	28	28	NUM
ajst-32571	196	3	]	]	X
ajst-32571	196	4	f.	f.	PROPN
ajst-32571	196	5	rieux	rieux	PROPN
ajst-32571	196	6	-	-	PUNCT
ajst-32571	196	7	laucat	laucat	NOUN
ajst-32571	196	8	et	et	PROPN
ajst-32571	196	9	al	al	PROPN
ajst-32571	196	10	.	.	PROPN
ajst-32571	196	11	,	,	PUNCT
ajst-32571	196	12	“	"	PUNCT
ajst-32571	196	13	inherited	inherit	VERB
ajst-32571	196	14	and	and	CCONJ
ajst-32571	196	15	somatic	somatic	ADJ
ajst-32571	196	16	cd3ζ	cd3ζ	NOUN
ajst-32571	196	17	mutations	mutation	NOUN
ajst-32571	196	18	in	in	ADP
ajst-32571	196	19	a	a	DET
ajst-32571	196	20	patient	patient	NOUN
ajst-32571	196	21	with	with	ADP
ajst-32571	196	22	t	t	NOUN
ajst-32571	196	23	-	-	PUNCT
ajst-32571	196	24	cell	cell	NOUN
ajst-32571	196	25	deficiency	deficiency	NOUN
ajst-32571	196	26	,	,	PUNCT
ajst-32571	196	27	”	"	PUNCT
ajst-32571	196	28	the	the	DET
ajst-32571	196	29	new	new	PROPN
ajst-32571	196	30	england	england	PROPN
ajst-32571	196	31	journal	journal	PROPN
ajst-32571	196	32	of	of	ADP
ajst-32571	196	33	medicine	medicine	NOUN
ajst-32571	196	34	,	,	PUNCT
ajst-32571	196	35	vol	vol	NOUN
ajst-32571	196	36	.	.	PROPN
ajst-32571	196	37	354	354	NUM
ajst-32571	196	38	,	,	PUNCT
ajst-32571	196	39	no	no	INTJ
ajst-32571	196	40	.	.	NOUN
ajst-32571	196	41	18	18	NUM
ajst-32571	196	42	,	,	PUNCT
ajst-32571	196	43	pp	pp	ADJ
ajst-32571	196	44	.	.	PUNCT
ajst-32571	197	1	1913–1921	1913–1921	NUM
ajst-32571	197	2	,	,	PUNCT
ajst-32571	197	3	may	may	PROPN
ajst-32571	197	4	2006	2006	NUM
ajst-32571	197	5	,	,	PUNCT
ajst-32571	197	6	doi	doi	NOUN
ajst-32571	197	7	:	:	PUNCT
ajst-32571	197	8	https://doi.org/	https://doi.org/	NOUN
ajst-32571	197	9	10	10	NUM
ajst-32571	197	10	.	.	PUNCT
ajst-32571	198	1	1056	1056	NUM
ajst-32571	198	2	/	/	SYM
ajst-32571	198	3	nejmoa053750	nejmoa053750	PROPN
ajst-32571	198	4	.	.	PUNCT
ajst-32571	199	1	[	[	X
ajst-32571	199	2	29	29	NUM
ajst-32571	199	3	]	]	X
ajst-32571	199	4	r.	r.	PROPN
ajst-32571	199	5	singh	singh	PROPN
ajst-32571	199	6	,	,	PUNCT
ajst-32571	199	7	y.-h	y.-h	PROPN
ajst-32571	199	8	.	.	PUNCT
ajst-32571	200	1	kim	kim	PROPN
ajst-32571	200	2	,	,	PUNCT
ajst-32571	200	3	s.-j	s.-j	PROPN
ajst-32571	200	4	.	.	PUNCT
ajst-32571	201	1	lee	lee	PROPN
ajst-32571	201	2	,	,	PUNCT
ajst-32571	201	3	h.-s	h.-s	PROPN
ajst-32571	201	4	.	.	PUNCT
ajst-32571	202	1	eom	eom	PROPN
ajst-32571	202	2	,	,	PUNCT
ajst-32571	202	3	and	and	CCONJ
ajst-32571	202	4	b.	b.	PROPN
ajst-32571	202	5	k.	k.	PROPN
ajst-32571	202	6	choi	choi	PROPN
ajst-32571	202	7	,	,	PUNCT
ajst-32571	202	8	“	"	PUNCT
ajst-32571	202	9	4	4	NUM
ajst-32571	202	10	-	-	PUNCT
ajst-32571	202	11	1bb	1bb	NUM
ajst-32571	202	12	immunotherapy	immunotherapy	NOUN
ajst-32571	202	13	:	:	PUNCT
ajst-32571	202	14	advances	advance	NOUN
ajst-32571	202	15	and	and	CCONJ
ajst-32571	202	16	hurdles	hurdle	NOUN
ajst-32571	202	17	,	,	PUNCT
ajst-32571	202	18	”	"	PUNCT
ajst-32571	202	19	experimental	experimental	ADJ
ajst-32571	202	20	&	&	CCONJ
ajst-32571	202	21	molecular	molecular	ADJ
ajst-32571	202	22	medicine	medicine	NOUN
ajst-32571	202	23	,	,	PUNCT
ajst-32571	202	24	vol	vol	NOUN
ajst-32571	202	25	.	.	PROPN
ajst-32571	202	26	56	56	NUM
ajst-32571	202	27	,	,	PUNCT
ajst-32571	202	28	no	no	INTJ
ajst-32571	202	29	.	.	NOUN
ajst-32571	202	30	1	1	NUM
ajst-32571	202	31	,	,	PUNCT
ajst-32571	202	32	pp	pp	ADJ
ajst-32571	202	33	.	.	PUNCT
ajst-32571	203	1	32–39	32–39	NUM
ajst-32571	203	2	,	,	PUNCT
ajst-32571	203	3	jan	jan	PROPN
ajst-32571	203	4	.	.	PROPN
ajst-32571	203	5	2024	2024	NUM
ajst-32571	203	6	,	,	PUNCT
ajst-32571	203	7	doi	doi	NOUN
ajst-32571	203	8	:	:	PUNCT
ajst-32571	203	9	https://doi.org/	https://doi.org/	NOUN
ajst-32571	203	10	10.1038	10.1038	NUM
ajst-32571	203	11	/	/	SYM
ajst-32571	203	12	s12276	s12276	NOUN
ajst-32571	203	13	-	-	PUNCT
ajst-32571	203	14	023	023	NUM
ajst-32571	203	15	-	-	PUNCT
ajst-32571	203	16	01136	01136	NUM
ajst-32571	203	17	-	-	PUNCT
ajst-32571	203	18	4	4	NUM
ajst-32571	203	19	.	.	PUNCT
ajst-32571	204	1	[	[	X
ajst-32571	204	2	30	30	NUM
ajst-32571	204	3	]	]	X
ajst-32571	204	4	c.	c.	PROPN
ajst-32571	204	5	cutri	cutri	PROPN
ajst-32571	204	6	-	-	PUNCT
ajst-32571	204	7	french	french	PROPN
ajst-32571	204	8	,	,	PUNCT
ajst-32571	204	9	d.	d.	PROPN
ajst-32571	204	10	nasioudis	nasioudis	PROPN
ajst-32571	204	11	,	,	PUNCT
ajst-32571	204	12	e.	e.	PROPN
ajst-32571	204	13	george	george	PROPN
ajst-32571	204	14	,	,	PUNCT
ajst-32571	204	15	and	and	CCONJ
ajst-32571	204	16	j.	j.	PROPN
ajst-32571	204	17	l.	l.	PROPN
ajst-32571	204	18	tanyi	tanyi	PROPN
ajst-32571	204	19	,	,	PUNCT
ajst-32571	204	20	“	"	PUNCT
ajst-32571	204	21	car	car	NOUN
ajst-32571	204	22	-	-	PUNCT
ajst-32571	204	23	t	t	NOUN
ajst-32571	204	24	cell	cell	NOUN
ajst-32571	204	25	therapy	therapy	NOUN
ajst-32571	204	26	in	in	ADP
ajst-32571	204	27	ovarian	ovarian	ADJ
ajst-32571	204	28	cancer	cancer	NOUN
ajst-32571	204	29	:	:	PUNCT
ajst-32571	204	30	where	where	SCONJ
ajst-32571	204	31	are	be	AUX
ajst-32571	204	32	we	we	PRON
ajst-32571	204	33	now	now	ADV
ajst-32571	204	34	?	?	PUNCT
ajst-32571	204	35	,	,	PUNCT
ajst-32571	204	36	”	"	PUNCT
ajst-32571	204	37	diagnostics	diagnostic	NOUN
ajst-32571	204	38	,	,	PUNCT
ajst-32571	204	39	vol	vol	NOUN
ajst-32571	204	40	.	.	PROPN
ajst-32571	204	41	14	14	NUM
ajst-32571	204	42	,	,	PUNCT
ajst-32571	204	43	no	no	INTJ
ajst-32571	204	44	.	.	NOUN
ajst-32571	204	45	8	8	NUM
ajst-32571	204	46	,	,	PUNCT
ajst-32571	204	47	p.	p.	NOUN
ajst-32571	204	48	819	819	NUM
ajst-32571	204	49	,	,	PUNCT
ajst-32571	204	50	apr	apr	NOUN
ajst-32571	204	51	.	.	NOUN
ajst-32571	204	52	2024	2024	NUM
ajst-32571	204	53	,	,	PUNCT
ajst-32571	204	54	doi	doi	NOUN
ajst-32571	204	55	:	:	PUNCT
ajst-32571	204	56	https://doi.org/10.3390/	https://doi.org/10.3390/	PROPN
ajst-32571	204	57	diagnostics14080819	diagnostics14080819	PROPN
ajst-32571	204	58	.	.	PUNCT
ajst-32571	205	1	186	186	NUM
ajst-32571	206	1	[	[	X
ajst-32571	206	2	31	31	NUM
ajst-32571	206	3	]	]	PUNCT
ajst-32571	206	4	b.	b.	PROPN
ajst-32571	206	5	screnci	screnci	PROPN
ajst-32571	206	6	et	et	PROPN
ajst-32571	206	7	al	al	PROPN
ajst-32571	206	8	.	.	PROPN
ajst-32571	206	9	,	,	PUNCT
ajst-32571	206	10	“	"	PUNCT
ajst-32571	206	11	antibody	antibody	NOUN
ajst-32571	206	12	specificity	specificity	NOUN
ajst-32571	206	13	against	against	ADP
ajst-32571	206	14	highly	highly	ADV
ajst-32571	206	15	conserved	conserved	ADJ
ajst-32571	206	16	membrane	membrane	NOUN
ajst-32571	206	17	protein	protein	NOUN
ajst-32571	206	18	claudin	claudin	VERB
ajst-32571	206	19	6	6	NUM
ajst-32571	206	20	driven	drive	VERB
ajst-32571	206	21	by	by	ADP
ajst-32571	206	22	single	single	ADJ
ajst-32571	206	23	atomic	atomic	ADJ
ajst-32571	206	24	contact	contact	NOUN
ajst-32571	206	25	point	point	NOUN
ajst-32571	206	26	,	,	PUNCT
ajst-32571	206	27	”	"	PUNCT
ajst-32571	206	28	iscience	iscience	NOUN
ajst-32571	206	29	,	,	PUNCT
ajst-32571	206	30	vol	vol	NOUN
ajst-32571	206	31	.	.	PROPN
ajst-32571	206	32	25	25	NUM
ajst-32571	206	33	,	,	PUNCT
ajst-32571	206	34	no	no	INTJ
ajst-32571	206	35	.	.	NOUN
ajst-32571	206	36	12	12	NUM
ajst-32571	206	37	,	,	PUNCT
ajst-32571	206	38	pp	pp	ADJ
ajst-32571	206	39	.	.	PUNCT
ajst-32571	207	1	105665–105665	105665–105665	NUM
ajst-32571	207	2	,	,	PUNCT
ajst-32571	207	3	nov	nov	PROPN
ajst-32571	207	4	.	.	PROPN
ajst-32571	207	5	2022	2022	NUM
ajst-32571	207	6	,	,	PUNCT
ajst-32571	207	7	doi	doi	NOUN
ajst-32571	207	8	:	:	PUNCT
ajst-32571	207	9	https://doi	https://doi	PROPN
ajst-32571	207	10	.	.	PUNCT
ajst-32571	208	1	org/	org/	PRON
ajst-32571	208	2	10.1016	10.1016	NUM
ajst-32571	208	3	/	/	SYM
ajst-32571	208	4	j.isci.2022.105665	j.isci.2022.105665	NOUN
ajst-32571	208	5	.	.	PUNCT
ajst-32571	209	1	[	[	X
ajst-32571	209	2	32	32	NUM
ajst-32571	209	3	]	]	PUNCT
ajst-32571	209	4	d.	d.	PROPN
ajst-32571	209	5	d.	d.	PROPN
ajst-32571	209	6	bowtell	bowtell	PROPN
ajst-32571	209	7	et	et	PROPN
ajst-32571	209	8	al	al	PROPN
ajst-32571	209	9	.	.	PROPN
ajst-32571	209	10	,	,	PUNCT
ajst-32571	209	11	“	"	PUNCT
ajst-32571	209	12	rethinking	rethink	VERB
ajst-32571	209	13	ovarian	ovarian	ADJ
ajst-32571	209	14	cancer	cancer	NOUN
ajst-32571	209	15	ii	ii	PROPN
ajst-32571	209	16	:	:	PUNCT
ajst-32571	209	17	reducing	reduce	VERB
ajst-32571	209	18	mortality	mortality	NOUN
ajst-32571	209	19	from	from	ADP
ajst-32571	209	20	high	high	ADJ
ajst-32571	209	21	-	-	PUNCT
ajst-32571	209	22	grade	grade	NOUN
ajst-32571	209	23	serous	serous	ADJ
ajst-32571	209	24	ovarian	ovarian	ADJ
ajst-32571	209	25	cancer	cancer	NOUN
ajst-32571	209	26	,	,	PUNCT
ajst-32571	209	27	”	"	PUNCT
ajst-32571	209	28	nature	nature	NOUN
ajst-32571	209	29	reviews	review	NOUN
ajst-32571	209	30	cancer	cancer	NOUN
ajst-32571	209	31	,	,	PUNCT
ajst-32571	209	32	vol	vol	NOUN
ajst-32571	209	33	.	.	PROPN
ajst-32571	209	34	15	15	NUM
ajst-32571	209	35	,	,	PUNCT
ajst-32571	209	36	no	no	INTJ
ajst-32571	209	37	.	.	NOUN
ajst-32571	209	38	11	11	NUM
ajst-32571	209	39	,	,	PUNCT
ajst-32571	209	40	pp	pp	ADJ
ajst-32571	209	41	.	.	PUNCT
ajst-32571	210	1	668–679	668–679	NUM
ajst-32571	210	2	,	,	PUNCT
ajst-32571	210	3	oct	oct	PROPN
ajst-32571	210	4	.	.	PROPN
ajst-32571	210	5	2015	2015	NUM
ajst-32571	210	6	,	,	PUNCT
ajst-32571	210	7	doi	doi	NOUN
ajst-32571	210	8	:	:	PUNCT
ajst-32571	210	9	https://doi.org/10.1038/	https://doi.org/10.1038/	NOUN
ajst-32571	210	10	nrc4019	nrc4019	VERB
ajst-32571	210	11	.	.	PUNCT
ajst-32571	211	1	[	[	X
ajst-32571	211	2	33	33	NUM
ajst-32571	211	3	]	]	PUNCT
ajst-32571	211	4	c.	c.	PROPN
ajst-32571	211	5	e.	e.	PROPN
ajst-32571	211	6	meacham	meacham	PROPN
ajst-32571	211	7	and	and	CCONJ
ajst-32571	211	8	s.	s.	PROPN
ajst-32571	211	9	j.	j.	PROPN
ajst-32571	211	10	morrison	morrison	PROPN
ajst-32571	211	11	,	,	PUNCT
ajst-32571	211	12	“	"	PUNCT
ajst-32571	211	13	tumour	tumour	ADJ
ajst-32571	211	14	heterogeneity	heterogeneity	NOUN
ajst-32571	211	15	and	and	CCONJ
ajst-32571	211	16	cancer	cancer	NOUN
ajst-32571	211	17	cell	cell	NOUN
ajst-32571	211	18	plasticity	plasticity	NOUN
ajst-32571	211	19	,	,	PUNCT
ajst-32571	211	20	”	"	PUNCT
ajst-32571	211	21	nature	nature	NOUN
ajst-32571	211	22	,	,	PUNCT
ajst-32571	211	23	vol	vol	NOUN
ajst-32571	211	24	.	.	PROPN
ajst-32571	211	25	501	501	NUM
ajst-32571	211	26	,	,	PUNCT
ajst-32571	211	27	no	no	INTJ
ajst-32571	211	28	.	.	NOUN
ajst-32571	211	29	7467	7467	NUM
ajst-32571	211	30	,	,	PUNCT
ajst-32571	211	31	pp	pp	ADJ
ajst-32571	211	32	.	.	PUNCT
ajst-32571	212	1	328–337	328–337	NUM
ajst-32571	212	2	,	,	PUNCT
ajst-32571	212	3	sep	sep	PROPN
ajst-32571	212	4	.	.	PROPN
ajst-32571	213	1	2013	2013	NUM
ajst-32571	213	2	,	,	PUNCT
ajst-32571	213	3	doi	doi	NOUN
ajst-32571	213	4	:	:	PUNCT
ajst-32571	213	5	https://doi.org/10.1038/nature12624	https://doi.org/10.1038/nature12624	NOUN
ajst-32571	213	6	.	.	PUNCT
ajst-32571	214	1	[	[	X
ajst-32571	214	2	34	34	NUM
ajst-32571	214	3	]	]	PUNCT
ajst-32571	214	4	m.	m.	NOUN
ajst-32571	214	5	gerlinger	gerlinger	NOUN
ajst-32571	214	6	et	et	PROPN
ajst-32571	214	7	al	al	PROPN
ajst-32571	214	8	.	.	PROPN
ajst-32571	214	9	,	,	PUNCT
ajst-32571	214	10	“	"	PUNCT
ajst-32571	214	11	intratumor	intratumor	VERB
ajst-32571	214	12	heterogeneity	heterogeneity	NOUN
ajst-32571	214	13	and	and	CCONJ
ajst-32571	214	14	branched	branched	ADJ
ajst-32571	214	15	evolution	evolution	NOUN
ajst-32571	214	16	revealed	reveal	VERB
ajst-32571	214	17	by	by	ADP
ajst-32571	214	18	multiregion	multiregion	NOUN
ajst-32571	214	19	sequencing	sequence	VERB
ajst-32571	214	20	,	,	PUNCT
ajst-32571	214	21	”	"	PUNCT
ajst-32571	214	22	new	new	PROPN
ajst-32571	214	23	england	england	PROPN
ajst-32571	214	24	journal	journal	PROPN
ajst-32571	214	25	of	of	ADP
ajst-32571	214	26	medicine	medicine	NOUN
ajst-32571	214	27	,	,	PUNCT
ajst-32571	214	28	vol	vol	NOUN
ajst-32571	214	29	.	.	PROPN
ajst-32571	214	30	366	366	NUM
ajst-32571	214	31	,	,	PUNCT
ajst-32571	214	32	no	no	INTJ
ajst-32571	214	33	.	.	NOUN
ajst-32571	214	34	10	10	NUM
ajst-32571	214	35	,	,	PUNCT
ajst-32571	214	36	pp	pp	ADJ
ajst-32571	214	37	.	.	PUNCT
ajst-32571	215	1	883–892	883–892	NUM
ajst-32571	215	2	,	,	PUNCT
ajst-32571	215	3	mar	mar	PROPN
ajst-32571	215	4	.	.	PROPN
ajst-32571	215	5	2012	2012	NUM
ajst-32571	215	6	,	,	PUNCT
ajst-32571	215	7	doi	doi	NOUN
ajst-32571	215	8	:	:	PUNCT
ajst-32571	215	9	https://doi.org/10.1056/nejmoa1113205	https://doi.org/10.1056/nejmoa1113205	PROPN
ajst-32571	215	10	.	.	PUNCT
ajst-32571	216	1	[	[	X
ajst-32571	216	2	35	35	NUM
ajst-32571	216	3	]	]	PUNCT
ajst-32571	216	4	m.	m.	NOUN
ajst-32571	216	5	greaves	greave	NOUN
ajst-32571	216	6	and	and	CCONJ
ajst-32571	216	7	c.	c.	PROPN
ajst-32571	216	8	c.	c.	PROPN
ajst-32571	216	9	maley	maley	PROPN
ajst-32571	216	10	,	,	PUNCT
ajst-32571	216	11	“	"	PUNCT
ajst-32571	216	12	clonal	clonal	ADJ
ajst-32571	216	13	evolution	evolution	NOUN
ajst-32571	216	14	in	in	ADP
ajst-32571	216	15	cancer	cancer	NOUN
ajst-32571	216	16	,	,	PUNCT
ajst-32571	216	17	”	"	PUNCT
ajst-32571	216	18	nature	nature	NOUN
ajst-32571	216	19	,	,	PUNCT
ajst-32571	216	20	vol	vol	NOUN
ajst-32571	216	21	.	.	PUNCT
ajst-32571	217	1	481	481	NUM
ajst-32571	217	2	,	,	PUNCT
ajst-32571	217	3	no	no	INTJ
ajst-32571	217	4	.	.	NOUN
ajst-32571	217	5	7381	7381	NUM
ajst-32571	217	6	,	,	PUNCT
ajst-32571	217	7	pp	pp	ADJ
ajst-32571	217	8	.	.	PUNCT
ajst-32571	218	1	306–313	306–313	NUM
ajst-32571	218	2	,	,	PUNCT
ajst-32571	218	3	jan	jan	PROPN
ajst-32571	218	4	.	.	PROPN
ajst-32571	218	5	2012	2012	NUM
ajst-32571	218	6	,	,	PUNCT
ajst-32571	218	7	doi	doi	NOUN
ajst-32571	218	8	:	:	PUNCT
ajst-32571	218	9	https://doi.org/10.1038/nature10762	https://doi.org/10.1038/nature10762	NOUN
ajst-32571	218	10	.	.	PUNCT
ajst-32571	219	1	[	[	X
ajst-32571	219	2	36	36	NUM
ajst-32571	219	3	]	]	X
ajst-32571	219	4	d.	d.	PROPN
ajst-32571	219	5	gumber	gumber	PROPN
ajst-32571	219	6	and	and	CCONJ
ajst-32571	219	7	l.	l.	PROPN
ajst-32571	219	8	d.	d.	PROPN
ajst-32571	219	9	wang	wang	PROPN
ajst-32571	219	10	,	,	PUNCT
ajst-32571	219	11	“	"	PUNCT
ajst-32571	219	12	improving	improve	VERB
ajst-32571	219	13	car	car	NOUN
ajst-32571	219	14	-	-	PUNCT
ajst-32571	219	15	t	t	NOUN
ajst-32571	219	16	immunotherapy	immunotherapy	NOUN
ajst-32571	219	17	:	:	PUNCT
ajst-32571	219	18	overcoming	overcome	VERB
ajst-32571	219	19	the	the	DET
ajst-32571	219	20	challenges	challenge	NOUN
ajst-32571	219	21	of	of	ADP
ajst-32571	219	22	t	t	NOUN
ajst-32571	219	23	cell	cell	NOUN
ajst-32571	219	24	exhaustion	exhaustion	NOUN
ajst-32571	219	25	,	,	PUNCT
ajst-32571	219	26	”	"	PUNCT
ajst-32571	219	27	ebiomedicine	ebiomedicine	ADJ
ajst-32571	219	28	,	,	PUNCT
ajst-32571	219	29	vol	vol	NOUN
ajst-32571	219	30	.	.	PROPN
ajst-32571	219	31	77	77	NUM
ajst-32571	219	32	,	,	PUNCT
ajst-32571	219	33	p.	p.	NOUN
ajst-32571	219	34	103941	103941	NUM
ajst-32571	219	35	,	,	PUNCT
ajst-32571	219	36	mar	mar	PROPN
ajst-32571	219	37	.	.	PROPN
ajst-32571	219	38	2022	2022	NUM
ajst-32571	219	39	,	,	PUNCT
ajst-32571	219	40	doi	doi	NOUN
ajst-32571	219	41	:	:	PUNCT
ajst-32571	219	42	https://doi.org/10	https://doi.org/10	PROPN
ajst-32571	219	43	.	.	PUNCT
ajst-32571	220	1	1016	1016	NUM
ajst-32571	220	2	/	/	SYM
ajst-32571	220	3	j.ebiom	j.ebiom	NOUN
ajst-32571	220	4	.	.	PUNCT
ajst-32571	221	1	2022	2022	NUM
ajst-32571	221	2	.	.	PUNCT
ajst-32571	222	1	103941	103941	NUM
ajst-32571	222	2	.	.	PUNCT
ajst-32571	223	1	[	[	X
ajst-32571	223	2	37	37	NUM
ajst-32571	223	3	]	]	X
ajst-32571	223	4	m.	m.	NOUN
ajst-32571	223	5	ijaz	ijaz	PROPN
ajst-32571	223	6	et	et	PROPN
ajst-32571	223	7	al	al	PROPN
ajst-32571	223	8	.	.	PROPN
ajst-32571	223	9	,	,	PUNCT
ajst-32571	223	10	“	"	PUNCT
ajst-32571	223	11	overcoming	overcome	VERB
ajst-32571	223	12	barriers	barrier	NOUN
ajst-32571	223	13	in	in	ADP
ajst-32571	223	14	glioblastoma	glioblastoma	NOUN
ajst-32571	223	15	:	:	PUNCT
ajst-32571	223	16	the	the	DET
ajst-32571	223	17	potential	potential	NOUN
ajst-32571	223	18	of	of	ADP
ajst-32571	223	19	car	car	NOUN
ajst-32571	223	20	t	t	NOUN
ajst-32571	223	21	cell	cell	NOUN
ajst-32571	223	22	immunotherapy	immunotherapy	NOUN
ajst-32571	223	23	,	,	PUNCT
ajst-32571	223	24	”	"	PUNCT
ajst-32571	223	25	theranostics	theranostic	NOUN
ajst-32571	223	26	,	,	PUNCT
ajst-32571	223	27	vol	vol	NOUN
ajst-32571	223	28	.	.	PROPN
ajst-32571	223	29	15	15	NUM
ajst-32571	223	30	,	,	PUNCT
ajst-32571	223	31	no	no	INTJ
ajst-32571	223	32	.	.	NOUN
ajst-32571	223	33	14	14	NUM
ajst-32571	223	34	,	,	PUNCT
ajst-32571	223	35	pp	pp	ADJ
ajst-32571	223	36	.	.	PUNCT
ajst-32571	224	1	7090–7126	7090–7126	NOUN
ajst-32571	224	2	,	,	PUNCT
ajst-32571	224	3	jun	jun	PROPN
ajst-32571	224	4	.	.	PROPN
ajst-32571	224	5	2025	2025	NUM
ajst-32571	224	6	,	,	PUNCT
ajst-32571	224	7	doi	doi	NOUN
ajst-32571	224	8	:	:	PUNCT
ajst-32571	224	9	https://doi.org/10.7150/thno.114257	https://doi.org/10.7150/thno.114257	NOUN
ajst-32571	224	10	.	.	PUNCT
ajst-32571	225	1	[	[	X
ajst-32571	225	2	38	38	NUM
ajst-32571	225	3	]	]	PUNCT
ajst-32571	225	4	k.	k.	PROPN
ajst-32571	226	1	p.	p.	PROPN
ajst-32571	226	2	lim	lim	PROPN
ajst-32571	226	3	et	et	PROPN
ajst-32571	226	4	al	al	PROPN
ajst-32571	226	5	.	.	PROPN
ajst-32571	226	6	,	,	PUNCT
ajst-32571	226	7	“	"	PUNCT
ajst-32571	226	8	cd4+cd25hicd127low	cd4+cd25hicd127low	PROPN
ajst-32571	226	9	regulatory	regulatory	PROPN
ajst-32571	226	10	t	t	PROPN
ajst-32571	226	11	cells	cell	NOUN
ajst-32571	226	12	are	be	AUX
ajst-32571	226	13	increased	increase	VERB
ajst-32571	226	14	in	in	ADP
ajst-32571	226	15	oral	oral	ADJ
ajst-32571	226	16	squamous	squamous	ADJ
ajst-32571	226	17	cell	cell	NOUN
ajst-32571	226	18	carcinoma	carcinoma	NOUN
ajst-32571	226	19	patients	patient	NOUN
ajst-32571	226	20	,	,	PUNCT
ajst-32571	226	21	”	"	PUNCT
ajst-32571	226	22	plos	plos	PROPN
ajst-32571	226	23	one	one	NUM
ajst-32571	226	24	,	,	PUNCT
ajst-32571	226	25	vol	vol	NOUN
ajst-32571	226	26	.	.	NOUN
ajst-32571	227	1	9	9	NUM
ajst-32571	227	2	,	,	PUNCT
ajst-32571	227	3	no	no	INTJ
ajst-32571	227	4	.	.	NOUN
ajst-32571	227	5	8	8	NUM
ajst-32571	227	6	,	,	PUNCT
ajst-32571	227	7	p.	p.	NOUN
ajst-32571	227	8	e103975	e103975	PROPN
ajst-32571	227	9	,	,	PUNCT
ajst-32571	227	10	aug	aug	PROPN
ajst-32571	227	11	.	.	PROPN
ajst-32571	227	12	2014	2014	NUM
ajst-32571	227	13	,	,	PUNCT
ajst-32571	227	14	doi	doi	NOUN
ajst-32571	227	15	:	:	PUNCT
ajst-32571	227	16	https://doi.org/10.1371/	https://doi.org/10.1371/	PROPN
ajst-32571	227	17	journal	journal	NOUN
ajst-32571	227	18	.	.	PUNCT
ajst-32571	228	1	pone.0103975	pone.0103975	NOUN
ajst-32571	228	2	.	.	PUNCT
ajst-32571	229	1	[	[	X
ajst-32571	229	2	39	39	NUM
ajst-32571	229	3	]	]	X
ajst-32571	229	4	y.	y.	PROPN
ajst-32571	229	5	qi	qi	PROPN
ajst-32571	229	6	,	,	PUNCT
ajst-32571	229	7	l.	l.	PROPN
ajst-32571	229	8	zhang	zhang	PROPN
ajst-32571	229	9	,	,	PUNCT
ajst-32571	229	10	y.	y.	PROPN
ajst-32571	229	11	liu	liu	PROPN
ajst-32571	229	12	,	,	PUNCT
ajst-32571	229	13	y.	y.	PROPN
ajst-32571	229	14	li	li	PROPN
ajst-32571	229	15	,	,	PUNCT
ajst-32571	229	16	y.	y.	PROPN
ajst-32571	229	17	liu	liu	PROPN
ajst-32571	229	18	,	,	PUNCT
ajst-32571	229	19	and	and	CCONJ
ajst-32571	229	20	z.	z.	PROPN
ajst-32571	229	21	zhang	zhang	PROPN
ajst-32571	229	22	,	,	PUNCT
ajst-32571	229	23	“	"	PUNCT
ajst-32571	229	24	targeted	target	VERB
ajst-32571	229	25	modulation	modulation	NOUN
ajst-32571	229	26	of	of	ADP
ajst-32571	229	27	myeloid	myeloid	NOUN
ajst-32571	229	28	-	-	PUNCT
ajst-32571	229	29	derived	derive	VERB
ajst-32571	229	30	suppressor	suppressor	NOUN
ajst-32571	229	31	cells	cell	NOUN
ajst-32571	229	32	in	in	ADP
ajst-32571	229	33	the	the	DET
ajst-32571	229	34	tumor	tumor	NOUN
ajst-32571	229	35	microenvironment	microenvironment	NOUN
ajst-32571	229	36	:	:	PUNCT
ajst-32571	229	37	implications	implication	NOUN
ajst-32571	229	38	for	for	ADP
ajst-32571	229	39	cancer	cancer	NOUN
ajst-32571	229	40	therapy	therapy	NOUN
ajst-32571	229	41	,	,	PUNCT
ajst-32571	229	42	”	"	PUNCT
ajst-32571	229	43	biomedicine	biomedicine	NOUN
ajst-32571	229	44	&	&	CCONJ
ajst-32571	229	45	pharmacotherapy	pharmacotherapy	NOUN
ajst-32571	229	46	,	,	PUNCT
ajst-32571	229	47	vol	vol	NOUN
ajst-32571	229	48	.	.	NOUN
ajst-32571	229	49	180	180	NUM
ajst-32571	229	50	,	,	PUNCT
ajst-32571	229	51	p.	p.	NOUN
ajst-32571	229	52	117590	117590	NUM
ajst-32571	229	53	,	,	PUNCT
ajst-32571	229	54	2024	2024	NUM
ajst-32571	229	55	,	,	PUNCT
ajst-32571	229	56	doi	doi	NOUN
ajst-32571	229	57	:	:	PUNCT
ajst-32571	229	58	https://doi.org/10.1016/j.biopha.2024.117590	https://doi.org/10.1016/j.biopha.2024.117590	NOUN
ajst-32571	229	59	.	.	PUNCT
ajst-32571	230	1	[	[	X
ajst-32571	230	2	40	40	NUM
ajst-32571	230	3	]	]	PUNCT
ajst-32571	230	4	m.	m.	NOUN
ajst-32571	230	5	motallebnezhad	motallebnezhad	PROPN
ajst-32571	230	6	,	,	PUNCT
ajst-32571	230	7	f.	f.	PROPN
ajst-32571	230	8	jadidi	jadidi	PROPN
ajst-32571	230	9	-	-	PUNCT
ajst-32571	230	10	niaragh	niaragh	PROPN
ajst-32571	230	11	,	,	PUNCT
ajst-32571	230	12	e.	e.	PROPN
ajst-32571	230	13	s.	s.	PROPN
ajst-32571	230	14	qamsari	qamsari	PROPN
ajst-32571	230	15	,	,	PUNCT
ajst-32571	230	16	s.	s.	PROPN
ajst-32571	230	17	bagheri	bagheri	PROPN
ajst-32571	230	18	,	,	PUNCT
ajst-32571	230	19	t.	t.	NOUN
ajst-32571	230	20	gharibi	gharibi	NOUN
ajst-32571	230	21	,	,	PUNCT
ajst-32571	230	22	and	and	CCONJ
ajst-32571	230	23	m.	m.	NOUN
ajst-32571	230	24	yousefi	yousefi	PROPN
ajst-32571	230	25	,	,	PUNCT
ajst-32571	230	26	“	"	PUNCT
ajst-32571	230	27	the	the	DET
ajst-32571	230	28	immunobiology	immunobiology	NOUN
ajst-32571	230	29	of	of	ADP
ajst-32571	230	30	myeloid	myeloid	NOUN
ajst-32571	230	31	-	-	PUNCT
ajst-32571	230	32	derived	derive	VERB
ajst-32571	230	33	suppressor	suppressor	NOUN
ajst-32571	230	34	cells	cell	NOUN
ajst-32571	230	35	in	in	ADP
ajst-32571	230	36	cancer	cancer	NOUN
ajst-32571	230	37	,	,	PUNCT
ajst-32571	230	38	”	"	PUNCT
ajst-32571	230	39	tumor	tumor	NOUN
ajst-32571	230	40	biology	biology	NOUN
ajst-32571	230	41	,	,	PUNCT
ajst-32571	230	42	vol	vol	NOUN
ajst-32571	230	43	.	.	PROPN
ajst-32571	230	44	37	37	NUM
ajst-32571	230	45	,	,	PUNCT
ajst-32571	230	46	no	no	INTJ
ajst-32571	230	47	.	.	NOUN
ajst-32571	230	48	2	2	NUM
ajst-32571	230	49	,	,	PUNCT
ajst-32571	230	50	pp	pp	ADJ
ajst-32571	230	51	.	.	PUNCT
ajst-32571	230	52	1387	1387	NUM
ajst-32571	230	53	–	–	PUNCT
ajst-32571	230	54	1406	1406	NUM
ajst-32571	230	55	,	,	PUNCT
ajst-32571	230	56	nov	nov	PROPN
ajst-32571	230	57	.	.	PROPN
ajst-32571	230	58	2015	2015	NUM
ajst-32571	230	59	,	,	PUNCT
ajst-32571	230	60	doi	doi	NOUN
ajst-32571	230	61	:	:	PUNCT
ajst-32571	230	62	https://doi.org/10.1007/s13277-015-4477-9	https://doi.org/10.1007/s13277-015-4477-9	NOUN
ajst-32571	230	63	.	.	PUNCT
ajst-32571	231	1	[	[	X
ajst-32571	231	2	41	41	NUM
ajst-32571	231	3	]	]	PUNCT
ajst-32571	231	4	k.	k.	PROPN
ajst-32571	231	5	newick	newick	PROPN
ajst-32571	231	6	,	,	PUNCT
ajst-32571	231	7	s.	s.	PROPN
ajst-32571	231	8	o’brien	o’brien	PROPN
ajst-32571	231	9	,	,	PUNCT
ajst-32571	231	10	e.	e.	PROPN
ajst-32571	231	11	moon	moon	PROPN
ajst-32571	231	12	,	,	PUNCT
ajst-32571	231	13	and	and	CCONJ
ajst-32571	231	14	s.	s.	PROPN
ajst-32571	231	15	m.	m.	PROPN
ajst-32571	231	16	albelda	albelda	PROPN
ajst-32571	231	17	,	,	PUNCT
ajst-32571	231	18	“	"	PUNCT
ajst-32571	231	19	car	car	NOUN
ajst-32571	231	20	t	t	NOUN
ajst-32571	231	21	cell	cell	NOUN
ajst-32571	231	22	therapy	therapy	NOUN
ajst-32571	231	23	for	for	ADP
ajst-32571	231	24	solid	solid	ADJ
ajst-32571	231	25	tumors	tumor	NOUN
ajst-32571	231	26	,	,	PUNCT
ajst-32571	231	27	”	"	PUNCT
ajst-32571	231	28	annual	annual	ADJ
ajst-32571	231	29	review	review	NOUN
ajst-32571	231	30	of	of	ADP
ajst-32571	231	31	medicine	medicine	NOUN
ajst-32571	231	32	,	,	PUNCT
ajst-32571	231	33	vol	vol	NOUN
ajst-32571	231	34	.	.	PROPN
ajst-32571	232	1	68	68	NUM
ajst-32571	232	2	,	,	PUNCT
ajst-32571	232	3	no	no	INTJ
ajst-32571	232	4	.	.	NOUN
ajst-32571	232	5	1	1	NUM
ajst-32571	232	6	,	,	PUNCT
ajst-32571	232	7	pp	pp	ADJ
ajst-32571	232	8	.	.	PUNCT
ajst-32571	233	1	139–152	139–152	NUM
ajst-32571	233	2	,	,	PUNCT
ajst-32571	233	3	jan	jan	PROPN
ajst-32571	233	4	.	.	PROPN
ajst-32571	233	5	2017	2017	NUM
ajst-32571	233	6	,	,	PUNCT
ajst-32571	233	7	doi	doi	NOUN
ajst-32571	233	8	:	:	PUNCT
ajst-32571	233	9	https://doi.org/10.1146/annurev-med062315-120245	https://doi.org/10.1146/annurev-med062315-120245	X
ajst-32571	233	10	.	.	PUNCT
ajst-32571	234	1	[	[	X
ajst-32571	234	2	42	42	NUM
ajst-32571	234	3	]	]	PUNCT
ajst-32571	234	4	m.	m.	NOUN
ajst-32571	234	5	schwab	schwab	PROPN
ajst-32571	234	6	,	,	PUNCT
ajst-32571	234	7	encyclopedia	encyclopedia	NOUN
ajst-32571	234	8	of	of	ADP
ajst-32571	234	9	cancer	cancer	NOUN
ajst-32571	234	10	,	,	PUNCT
ajst-32571	234	11	4th	4th	ADJ
ajst-32571	234	12	ed	ed	NOUN
ajst-32571	234	13	.	.	PUNCT
ajst-32571	234	14	springer	springer	PROPN
ajst-32571	234	15	berlin	berlin	PROPN
ajst-32571	234	16	,	,	PUNCT
ajst-32571	234	17	heidelberg	heidelberg	PROPN
ajst-32571	234	18	,	,	PUNCT
ajst-32571	234	19	2017	2017	NUM
ajst-32571	234	20	.	.	PUNCT
ajst-32571	235	1	doi	doi	NOUN
ajst-32571	235	2	:	:	PUNCT
ajst-32571	235	3	https://doi.org/	https://doi.org/	NOUN
ajst-32571	235	4	10.1007/	10.1007/	NUM
ajst-32571	235	5	978	978	NUM
ajst-32571	235	6	-	-	SYM
ajst-32571	235	7	3	3	NUM
ajst-32571	235	8	-	-	PUNCT
ajst-32571	235	9	662	662	NUM
ajst-32571	235	10	-	-	PUNCT
ajst-32571	235	11	46875	46875	NUM
ajst-32571	235	12	-	-	SYM
ajst-32571	235	13	3	3	NUM
ajst-32571	235	14	.	.	PUNCT
ajst-32571	236	1	[	[	X
ajst-32571	236	2	43	43	NUM
ajst-32571	236	3	]	]	X
ajst-32571	236	4	j.	j.	PROPN
ajst-32571	236	5	m.	m.	PROPN
ajst-32571	236	6	pitt	pitt	PROPN
ajst-32571	236	7	,	,	PUNCT
ajst-32571	236	8	a.	a.	NOUN
ajst-32571	236	9	marabelle	marabelle	PROPN
ajst-32571	236	10	,	,	PUNCT
ajst-32571	236	11	a.	a.	NOUN
ajst-32571	236	12	eggermont	eggermont	NOUN
ajst-32571	236	13	,	,	PUNCT
ajst-32571	236	14	j.-c	j.-c	PROPN
ajst-32571	236	15	.	.	PUNCT
ajst-32571	236	16	.	.	PUNCT
ajst-32571	237	1	soria	soria	PROPN
ajst-32571	237	2	,	,	PUNCT
ajst-32571	237	3	g.	g.	PROPN
ajst-32571	237	4	kroemer	kroemer	PROPN
ajst-32571	237	5	,	,	PUNCT
ajst-32571	237	6	and	and	CCONJ
ajst-32571	237	7	l.	l.	PROPN
ajst-32571	237	8	zitvogel	zitvogel	PROPN
ajst-32571	237	9	,	,	PUNCT
ajst-32571	237	10	“	"	PUNCT
ajst-32571	237	11	targeting	target	VERB
ajst-32571	237	12	the	the	DET
ajst-32571	237	13	tumor	tumor	NOUN
ajst-32571	237	14	microenvironment	microenvironment	NOUN
ajst-32571	237	15	:	:	PUNCT
ajst-32571	237	16	removing	remove	VERB
ajst-32571	237	17	obstruction	obstruction	NOUN
ajst-32571	237	18	to	to	PART
ajst-32571	237	19	anticancer	anticancer	VERB
ajst-32571	237	20	immune	immune	ADJ
ajst-32571	237	21	responses	response	NOUN
ajst-32571	237	22	and	and	CCONJ
ajst-32571	237	23	immunotherapy	immunotherapy	NOUN
ajst-32571	237	24	,	,	PUNCT
ajst-32571	237	25	”	"	PUNCT
ajst-32571	237	26	annals	annals	NOUN
ajst-32571	237	27	of	of	ADP
ajst-32571	237	28	oncology	oncology	NOUN
ajst-32571	237	29	,	,	PUNCT
ajst-32571	237	30	vol	vol	NOUN
ajst-32571	237	31	.	.	PROPN
ajst-32571	237	32	27	27	NUM
ajst-32571	237	33	,	,	PUNCT
ajst-32571	237	34	no	no	INTJ
ajst-32571	237	35	.	.	NOUN
ajst-32571	237	36	8	8	NUM
ajst-32571	237	37	,	,	PUNCT
ajst-32571	237	38	pp	pp	ADJ
ajst-32571	237	39	.	.	PUNCT
ajst-32571	237	40	1482–1492	1482–1492	NUM
ajst-32571	237	41	,	,	PUNCT
ajst-32571	237	42	2016	2016	NUM
ajst-32571	237	43	,	,	PUNCT
ajst-32571	237	44	doi	doi	NOUN
ajst-32571	237	45	:	:	PUNCT
ajst-32571	237	46	https://doi.org/10.1093/annonc/mdw168	https://doi.org/10.1093/annonc/mdw168	NOUN
ajst-32571	237	47	.	.	PUNCT
ajst-32571	238	1	[	[	X
ajst-32571	238	2	44	44	NUM
ajst-32571	238	3	]	]	PUNCT
ajst-32571	238	4	r.	r.	PROPN
ajst-32571	238	5	a.	a.	PROPN
ajst-32571	238	6	van	van	PROPN
ajst-32571	238	7	amerongen	amerongen	PROPN
ajst-32571	238	8	et	et	PROPN
ajst-32571	238	9	al	al	PROPN
ajst-32571	238	10	.	.	PROPN
ajst-32571	238	11	,	,	PUNCT
ajst-32571	238	12	“	"	PUNCT
ajst-32571	238	13	prame	prame	NOUN
ajst-32571	238	14	and	and	CCONJ
ajst-32571	238	15	ctcfl	ctcfl	NOUN
ajst-32571	238	16	-	-	PUNCT
ajst-32571	238	17	reactive	reactive	ADJ
ajst-32571	238	18	tcrs	tcrs	NOUN
ajst-32571	238	19	for	for	ADP
ajst-32571	238	20	the	the	DET
ajst-32571	238	21	treatment	treatment	NOUN
ajst-32571	238	22	of	of	ADP
ajst-32571	238	23	ovarian	ovarian	ADJ
ajst-32571	238	24	cancer	cancer	NOUN
ajst-32571	238	25	,	,	PUNCT
ajst-32571	238	26	”	"	PUNCT
ajst-32571	238	27	frontiers	frontier	NOUN
ajst-32571	238	28	in	in	ADP
ajst-32571	238	29	immunology	immunology	NOUN
ajst-32571	238	30	,	,	PUNCT
ajst-32571	238	31	vol	vol	NOUN
ajst-32571	238	32	.	.	PROPN
ajst-32571	238	33	14	14	NUM
ajst-32571	238	34	,	,	PUNCT
ajst-32571	238	35	mar	mar	PROPN
ajst-32571	238	36	.	.	PROPN
ajst-32571	238	37	2023	2023	NUM
ajst-32571	238	38	,	,	PUNCT
ajst-32571	238	39	doi	doi	NOUN
ajst-32571	238	40	:	:	PUNCT
ajst-32571	238	41	https://doi.org/10.3389/fimmu.2023.1121973	https://doi.org/10.3389/fimmu.2023.1121973	X
ajst-32571	238	42	.	.	PUNCT
ajst-32571	239	1	[	[	X
ajst-32571	239	2	45	45	NUM
ajst-32571	239	3	]	]	PUNCT
ajst-32571	239	4	t.	t.	PROPN
ajst-32571	239	5	k.	k.	PROPN
ajst-32571	239	6	bera	bera	PROPN
ajst-32571	239	7	and	and	CCONJ
ajst-32571	239	8	i.	i.	PROPN
ajst-32571	239	9	pastan	pastan	PROPN
ajst-32571	239	10	,	,	PUNCT
ajst-32571	239	11	“	"	PUNCT
ajst-32571	239	12	mesothelin	mesothelin	NOUN
ajst-32571	239	13	is	be	AUX
ajst-32571	239	14	not	not	PART
ajst-32571	239	15	required	require	VERB
ajst-32571	239	16	for	for	ADP
ajst-32571	239	17	normal	normal	ADJ
ajst-32571	239	18	mouse	mouse	NOUN
ajst-32571	239	19	development	development	NOUN
ajst-32571	239	20	or	or	CCONJ
ajst-32571	239	21	reproduction	reproduction	NOUN
ajst-32571	239	22	,	,	PUNCT
ajst-32571	239	23	”	"	PUNCT
ajst-32571	239	24	molecular	molecular	ADJ
ajst-32571	239	25	and	and	CCONJ
ajst-32571	239	26	cellular	cellular	ADJ
ajst-32571	239	27	biology	biology	NOUN
ajst-32571	239	28	,	,	PUNCT
ajst-32571	239	29	vol	vol	NOUN
ajst-32571	239	30	.	.	PROPN
ajst-32571	239	31	20	20	NUM
ajst-32571	239	32	,	,	PUNCT
ajst-32571	239	33	no	no	INTJ
ajst-32571	239	34	.	.	NOUN
ajst-32571	239	35	8	8	NUM
ajst-32571	239	36	,	,	PUNCT
ajst-32571	239	37	pp	pp	ADJ
ajst-32571	239	38	.	.	PUNCT
ajst-32571	240	1	2902–2906	2902–2906	NUM
ajst-32571	240	2	,	,	PUNCT
ajst-32571	240	3	apr	apr	NOUN
ajst-32571	240	4	.	.	PROPN
ajst-32571	240	5	2000	2000	NUM
ajst-32571	240	6	,	,	PUNCT
ajst-32571	240	7	doi	doi	NOUN
ajst-32571	240	8	:	:	PUNCT
ajst-32571	240	9	https://doi.org/	https://doi.org/	NOUN
ajst-32571	240	10	10.1128/	10.1128/	NUM
ajst-32571	240	11	mcb.20.8.2902	mcb.20.8.2902	PROPN
ajst-32571	240	12	-	-	PUNCT
ajst-32571	240	13	2906.2000	2906.2000	NUM
ajst-32571	240	14	.	.	PUNCT
ajst-32571	241	1	[	[	X
ajst-32571	241	2	46	46	NUM
ajst-32571	241	3	]	]	X
ajst-32571	241	4	m.	m.	NOUN
ajst-32571	241	5	schwab	schwab	PROPN
ajst-32571	241	6	,	,	PUNCT
ajst-32571	241	7	encyclopedia	encyclopedia	NOUN
ajst-32571	241	8	of	of	ADP
ajst-32571	241	9	cancer	cancer	NOUN
ajst-32571	241	10	,	,	PUNCT
ajst-32571	241	11	3rd	3rd	ADJ
ajst-32571	241	12	ed	ed	NOUN
ajst-32571	241	13	.	.	PUNCT
ajst-32571	241	14	springer	springer	PROPN
ajst-32571	241	15	berlin	berlin	PROPN
ajst-32571	241	16	,	,	PUNCT
ajst-32571	241	17	heidelberg	heidelberg	PROPN
ajst-32571	241	18	,	,	PUNCT
ajst-32571	241	19	2011	2011	NUM
ajst-32571	241	20	.	.	PUNCT
ajst-32571	242	1	doi	doi	NOUN
ajst-32571	242	2	:	:	PUNCT
ajst-32571	243	1	https://doi	https://doi	PROPN
ajst-32571	243	2	.	.	PUNCT
ajst-32571	243	3	org/10	org/10	PROPN
ajst-32571	243	4	.	.	PUNCT
ajst-32571	244	1	1007/978	1007/978	NUM
ajst-32571	244	2	-	-	SYM
ajst-32571	244	3	3	3	NUM
ajst-32571	244	4	-	-	PUNCT
ajst-32571	244	5	642	642	NUM
ajst-32571	244	6	-	-	PUNCT
ajst-32571	244	7	16483	16483	NUM
ajst-32571	244	8	-	-	SYM
ajst-32571	244	9	5	5	NUM
ajst-32571	244	10	.	.	PUNCT
ajst-32571	245	1	[	[	X
ajst-32571	245	2	47	47	NUM
ajst-32571	245	3	]	]	PUNCT
ajst-32571	245	4	a.	a.	NOUN
ajst-32571	245	5	morello	morello	PROPN
ajst-32571	245	6	,	,	PUNCT
ajst-32571	245	7	m.	m.	NOUN
ajst-32571	245	8	sadelain	sadelain	PROPN
ajst-32571	245	9	,	,	PUNCT
ajst-32571	245	10	and	and	CCONJ
ajst-32571	245	11	p.	p.	PROPN
ajst-32571	245	12	s.	s.	PROPN
ajst-32571	245	13	adusumilli	adusumilli	PROPN
ajst-32571	245	14	,	,	PUNCT
ajst-32571	245	15	“	"	PUNCT
ajst-32571	245	16	mesothelin	mesothelin	NOUN
ajst-32571	245	17	-	-	PUNCT
ajst-32571	245	18	targeted	target	VERB
ajst-32571	245	19	cars	car	NOUN
ajst-32571	245	20	:	:	PUNCT
ajst-32571	245	21	driving	drive	VERB
ajst-32571	245	22	t	t	NOUN
ajst-32571	245	23	cells	cell	NOUN
ajst-32571	245	24	to	to	ADP
ajst-32571	245	25	solid	solid	ADJ
ajst-32571	245	26	tumors	tumor	NOUN
ajst-32571	245	27	,	,	PUNCT
ajst-32571	245	28	”	"	PUNCT
ajst-32571	245	29	cancer	cancer	NOUN
ajst-32571	245	30	discovery	discovery	NOUN
ajst-32571	245	31	,	,	PUNCT
ajst-32571	245	32	vol	vol	NOUN
ajst-32571	245	33	.	.	PROPN
ajst-32571	245	34	6	6	NUM
ajst-32571	245	35	,	,	PUNCT
ajst-32571	245	36	no	no	INTJ
ajst-32571	245	37	.	.	NOUN
ajst-32571	245	38	2	2	NUM
ajst-32571	245	39	,	,	PUNCT
ajst-32571	245	40	pp	pp	ADJ
ajst-32571	245	41	.	.	PUNCT
ajst-32571	246	1	133–146	133–146	NUM
ajst-32571	246	2	,	,	PUNCT
ajst-32571	246	3	oct	oct	PROPN
ajst-32571	246	4	.	.	PROPN
ajst-32571	246	5	2015	2015	NUM
ajst-32571	246	6	,	,	PUNCT
ajst-32571	246	7	doi	doi	NOUN
ajst-32571	246	8	:	:	PUNCT
ajst-32571	246	9	https://doi.org/10.1158/2159-8290	https://doi.org/10.1158/2159-8290	PROPN
ajst-32571	246	10	.	.	PUNCT
ajst-32571	246	11	cd-15	cd-15	NOUN
ajst-32571	246	12	-	-	PUNCT
ajst-32571	246	13	0583	0583	NUM
ajst-32571	246	14	.	.	PUNCT
ajst-32571	247	1	[	[	X
ajst-32571	247	2	48	48	NUM
ajst-32571	247	3	]	]	PUNCT
ajst-32571	247	4	k.	k.	PROPN
ajst-32571	247	5	reinhard	reinhard	PROPN
ajst-32571	247	6	et	et	PROPN
ajst-32571	247	7	al	al	PROPN
ajst-32571	247	8	.	.	PROPN
ajst-32571	247	9	,	,	PUNCT
ajst-32571	247	10	“	"	PUNCT
ajst-32571	247	11	an	an	DET
ajst-32571	247	12	rna	rna	NOUN
ajst-32571	247	13	vaccine	vaccine	NOUN
ajst-32571	247	14	drives	drive	VERB
ajst-32571	247	15	expansion	expansion	NOUN
ajst-32571	247	16	and	and	CCONJ
ajst-32571	247	17	efficacy	efficacy	NOUN
ajst-32571	247	18	of	of	ADP
ajst-32571	247	19	claudin	claudin	VERB
ajst-32571	247	20	-	-	PUNCT
ajst-32571	247	21	car	car	NOUN
ajst-32571	247	22	-	-	PUNCT
ajst-32571	247	23	t	t	NOUN
ajst-32571	247	24	cells	cell	NOUN
ajst-32571	247	25	against	against	ADP
ajst-32571	247	26	solid	solid	ADJ
ajst-32571	247	27	tumors	tumor	NOUN
ajst-32571	247	28	,	,	PUNCT
ajst-32571	247	29	”	"	PUNCT
ajst-32571	247	30	science	science	NOUN
ajst-32571	247	31	,	,	PUNCT
ajst-32571	247	32	vol	vol	NOUN
ajst-32571	247	33	.	.	PROPN
ajst-32571	247	34	367	367	NUM
ajst-32571	247	35	,	,	PUNCT
ajst-32571	247	36	no	no	INTJ
ajst-32571	247	37	.	.	NOUN
ajst-32571	247	38	6476	6476	NUM
ajst-32571	247	39	,	,	PUNCT
ajst-32571	247	40	pp	pp	ADV
ajst-32571	247	41	.	.	PUNCT
ajst-32571	248	1	446–453	446–453	NUM
ajst-32571	248	2	,	,	PUNCT
ajst-32571	248	3	jan	jan	PROPN
ajst-32571	248	4	.	.	PROPN
ajst-32571	248	5	2020	2020	NUM
ajst-32571	248	6	,	,	PUNCT
ajst-32571	248	7	doi	doi	NOUN
ajst-32571	248	8	:	:	PUNCT
ajst-32571	248	9	https://doi.org/10.1126/	https://doi.org/10.1126/	PROPN
ajst-32571	248	10	science.aay	science.aay	X
ajst-32571	248	11	5967	5967	NUM
ajst-32571	248	12	.	.	PUNCT
ajst-32571	249	1	[	[	X
ajst-32571	249	2	49	49	NUM
ajst-32571	249	3	]	]	X
ajst-32571	249	4	c.	c.	PROPN
ajst-32571	249	5	r.	r.	PROPN
ajst-32571	249	6	stadler	stadler	PROPN
ajst-32571	249	7	et	et	PROPN
ajst-32571	250	1	al	al	PROPN
ajst-32571	250	2	.	.	PROPN
ajst-32571	250	3	,	,	PUNCT
ajst-32571	250	4	“	"	PUNCT
ajst-32571	250	5	preclinical	preclinical	ADJ
ajst-32571	250	6	efficacy	efficacy	NOUN
ajst-32571	250	7	and	and	CCONJ
ajst-32571	250	8	pharmacokinetics	pharmacokinetic	NOUN
ajst-32571	250	9	of	of	ADP
ajst-32571	250	10	an	an	DET
ajst-32571	250	11	rna	rna	NOUN
ajst-32571	250	12	-	-	PUNCT
ajst-32571	250	13	encoded	encode	VERB
ajst-32571	250	14	t	t	NOUN
ajst-32571	250	15	cell	cell	NOUN
ajst-32571	250	16	–	–	PUNCT
ajst-32571	250	17	engaging	engage	VERB
ajst-32571	250	18	bispecific	bispecific	NOUN
ajst-32571	250	19	antibody	antibody	NOUN
ajst-32571	250	20	targeting	target	VERB
ajst-32571	250	21	human	human	NOUN
ajst-32571	250	22	claudin	claudin	VERB
ajst-32571	250	23	6	6	NUM
ajst-32571	250	24	,	,	PUNCT
ajst-32571	250	25	”	"	PUNCT
ajst-32571	250	26	science	science	NOUN
ajst-32571	250	27	translational	translational	ADJ
ajst-32571	250	28	medicine	medicine	NOUN
ajst-32571	250	29	,	,	PUNCT
ajst-32571	250	30	vol	vol	NOUN
ajst-32571	250	31	.	.	PROPN
ajst-32571	251	1	16	16	NUM
ajst-32571	251	2	,	,	PUNCT
ajst-32571	251	3	no	no	INTJ
ajst-32571	251	4	.	.	NOUN
ajst-32571	251	5	748	748	NUM
ajst-32571	251	6	,	,	PUNCT
ajst-32571	251	7	may	may	AUX
ajst-32571	251	8	2024	2024	NUM
ajst-32571	251	9	,	,	PUNCT
ajst-32571	251	10	doi	doi	NOUN
ajst-32571	251	11	:	:	PUNCT
ajst-32571	251	12	https://doi.org/10.1126/scitranslmed.adl2720	https://doi.org/10.1126/scitranslmed.adl2720	NOUN
ajst-32571	251	13	.	.	PUNCT
ajst-32571	252	1	187	187	NUM
ajst-32571	253	1	[	[	SYM
ajst-32571	253	2	50	50	NUM
ajst-32571	253	3	]	]	PUNCT
ajst-32571	253	4	j.-i	j.-i	PROPN
ajst-32571	253	5	.	.	PUNCT
ajst-32571	254	1	youn	youn	PROPN
ajst-32571	254	2	and	and	CCONJ
ajst-32571	254	3	d.	d.	PROPN
ajst-32571	254	4	i.	i.	PROPN
ajst-32571	254	5	gabrilovich	gabrilovich	PROPN
ajst-32571	254	6	,	,	PUNCT
ajst-32571	254	7	“	"	PUNCT
ajst-32571	254	8	the	the	DET
ajst-32571	254	9	biology	biology	NOUN
ajst-32571	254	10	of	of	ADP
ajst-32571	254	11	myeloid	myeloid	NOUN
ajst-32571	254	12	-	-	PUNCT
ajst-32571	254	13	derived	derive	VERB
ajst-32571	254	14	suppressor	suppressor	NOUN
ajst-32571	254	15	cells	cell	NOUN
ajst-32571	254	16	:	:	PUNCT
ajst-32571	254	17	the	the	DET
ajst-32571	254	18	blessing	blessing	NOUN
ajst-32571	254	19	and	and	CCONJ
ajst-32571	254	20	the	the	DET
ajst-32571	254	21	curse	curse	NOUN
ajst-32571	254	22	of	of	ADP
ajst-32571	254	23	morphological	morphological	ADJ
ajst-32571	254	24	and	and	CCONJ
ajst-32571	254	25	functional	functional	ADJ
ajst-32571	254	26	heterogeneity	heterogeneity	NOUN
ajst-32571	254	27	,	,	PUNCT
ajst-32571	254	28	”	"	PUNCT
ajst-32571	254	29	european	european	ADJ
ajst-32571	254	30	journal	journal	PROPN
ajst-32571	254	31	of	of	ADP
ajst-32571	254	32	immunology	immunology	NOUN
ajst-32571	254	33	,	,	PUNCT
ajst-32571	254	34	vol	vol	NOUN
ajst-32571	254	35	.	.	PROPN
ajst-32571	254	36	40	40	NUM
ajst-32571	254	37	,	,	PUNCT
ajst-32571	254	38	no	no	INTJ
ajst-32571	254	39	.	.	NOUN
ajst-32571	254	40	11	11	NUM
ajst-32571	254	41	,	,	PUNCT
ajst-32571	254	42	pp	pp	ADJ
ajst-32571	254	43	.	.	PUNCT
ajst-32571	254	44	2969–2975	2969–2975	NUM
ajst-32571	254	45	,	,	PUNCT
ajst-32571	254	46	2010	2010	NUM
ajst-32571	254	47	,	,	PUNCT
ajst-32571	254	48	doi	doi	NOUN
ajst-32571	254	49	:	:	PUNCT
ajst-32571	254	50	https://doi.org/10.1002/eji.201040895	https://doi.org/10.1002/eji.201040895	X
ajst-32571	254	51	.	.	PUNCT
ajst-32571	255	1	[	[	X
ajst-32571	255	2	51	51	NUM
ajst-32571	255	3	]	]	X
ajst-32571	255	4	o.	o.	PROPN
ajst-32571	255	5	s.	s.	PROPN
ajst-32571	255	6	blomberg	blomberg	PROPN
ajst-32571	255	7	,	,	PUNCT
ajst-32571	255	8	l.	l.	PROPN
ajst-32571	255	9	spagnuolo	spagnuolo	PROPN
ajst-32571	255	10	,	,	PUNCT
ajst-32571	255	11	and	and	CCONJ
ajst-32571	255	12	k.	k.	PROPN
ajst-32571	255	13	e.	e.	PROPN
ajst-32571	255	14	de	de	PROPN
ajst-32571	255	15	visser	visser	PROPN
ajst-32571	255	16	,	,	PUNCT
ajst-32571	255	17	“	"	PUNCT
ajst-32571	255	18	immune	immune	ADJ
ajst-32571	255	19	regulation	regulation	NOUN
ajst-32571	255	20	of	of	ADP
ajst-32571	255	21	metastasis	metastasis	NOUN
ajst-32571	255	22	:	:	PUNCT
ajst-32571	255	23	mechanistic	mechanistic	ADJ
ajst-32571	255	24	insights	insight	NOUN
ajst-32571	255	25	and	and	CCONJ
ajst-32571	255	26	therapeutic	therapeutic	ADJ
ajst-32571	255	27	opportunities	opportunity	NOUN
ajst-32571	255	28	,	,	PUNCT
ajst-32571	255	29	”	"	PUNCT
ajst-32571	255	30	disease	disease	NOUN
ajst-32571	255	31	models	model	NOUN
ajst-32571	255	32	&	&	CCONJ
ajst-32571	255	33	mechanisms	mechanism	NOUN
ajst-32571	255	34	,	,	PUNCT
ajst-32571	255	35	vol	vol	NOUN
ajst-32571	255	36	.	.	PROPN
ajst-32571	255	37	11	11	NUM
ajst-32571	255	38	,	,	PUNCT
ajst-32571	255	39	no	no	INTJ
ajst-32571	255	40	.	.	NOUN
ajst-32571	255	41	10	10	NUM
ajst-32571	255	42	,	,	PUNCT
ajst-32571	255	43	2018	2018	NUM
ajst-32571	255	44	,	,	PUNCT
ajst-32571	255	45	doi	doi	NOUN
ajst-32571	255	46	:	:	PUNCT
ajst-32571	255	47	https://doi.org/10.1242/dmm.036236	https://doi.org/10.1242/dmm.036236	ADJ
ajst-32571	255	48	.	.	PUNCT
ajst-32571	256	1	[	[	X
ajst-32571	256	2	52	52	NUM
ajst-32571	256	3	]	]	PUNCT
ajst-32571	256	4	k.	k.	PROPN
ajst-32571	256	5	okła	okła	VERB
ajst-32571	256	6	et	et	PROPN
ajst-32571	256	7	al	al	PROPN
ajst-32571	256	8	.	.	PROPN
ajst-32571	256	9	,	,	PUNCT
ajst-32571	256	10	“	"	PUNCT
ajst-32571	256	11	clinical	clinical	ADJ
ajst-32571	256	12	relevance	relevance	NOUN
ajst-32571	256	13	and	and	CCONJ
ajst-32571	256	14	immunosuppressive	immunosuppressive	ADJ
ajst-32571	256	15	pattern	pattern	NOUN
ajst-32571	256	16	of	of	ADP
ajst-32571	256	17	circulating	circulate	VERB
ajst-32571	256	18	and	and	CCONJ
ajst-32571	256	19	infiltrating	infiltrating	ADJ
ajst-32571	256	20	subsets	subset	NOUN
ajst-32571	256	21	of	of	ADP
ajst-32571	256	22	myeloid	myeloid	NOUN
ajst-32571	256	23	-	-	PUNCT
ajst-32571	256	24	derived	derive	VERB
ajst-32571	256	25	suppressor	suppressor	NOUN
ajst-32571	256	26	cells	cell	NOUN
ajst-32571	256	27	(	(	PUNCT
ajst-32571	256	28	mdscs	mdsc	NOUN
ajst-32571	256	29	)	)	PUNCT
ajst-32571	256	30	in	in	ADP
ajst-32571	256	31	epithelial	epithelial	ADJ
ajst-32571	256	32	ovarian	ovarian	ADJ
ajst-32571	256	33	cancer	cancer	NOUN
ajst-32571	256	34	,	,	PUNCT
ajst-32571	256	35	”	"	PUNCT
ajst-32571	256	36	frontiers	frontier	NOUN
ajst-32571	256	37	in	in	ADP
ajst-32571	256	38	immunology	immunology	NOUN
ajst-32571	256	39	,	,	PUNCT
ajst-32571	256	40	vol	vol	NOUN
ajst-32571	256	41	.	.	PROPN
ajst-32571	256	42	10	10	NUM
ajst-32571	256	43	,	,	PUNCT
ajst-32571	256	44	apr	apr	NOUN
ajst-32571	256	45	.	.	PROPN
ajst-32571	256	46	2019	2019	NUM
ajst-32571	256	47	,	,	PUNCT
ajst-32571	256	48	doi	doi	NOUN
ajst-32571	256	49	:	:	PUNCT
ajst-32571	256	50	https://doi.org/10.3389/fimmu.2019.00691	https://doi.org/10.3389/fimmu.2019.00691	PROPN
ajst-32571	256	51	.	.	PUNCT
ajst-32571	257	1	[	[	X
ajst-32571	257	2	53	53	NUM
ajst-32571	257	3	]	]	PUNCT
ajst-32571	257	4	d.	d.	PROPN
ajst-32571	257	5	i.	i.	PROPN
ajst-32571	257	6	gabrilovich	gabrilovich	PROPN
ajst-32571	257	7	,	,	PUNCT
ajst-32571	257	8	“	"	PUNCT
ajst-32571	257	9	myeloid	myeloid	ADJ
ajst-32571	257	10	-	-	PUNCT
ajst-32571	257	11	derived	derive	VERB
ajst-32571	257	12	suppressor	suppressor	NOUN
ajst-32571	257	13	cells	cell	NOUN
ajst-32571	257	14	,	,	PUNCT
ajst-32571	257	15	”	"	PUNCT
ajst-32571	257	16	cancer	cancer	NOUN
ajst-32571	257	17	immunology	immunology	NOUN
ajst-32571	257	18	research	research	NOUN
ajst-32571	257	19	,	,	PUNCT
ajst-32571	257	20	vol	vol	NOUN
ajst-32571	257	21	.	.	PROPN
ajst-32571	257	22	5	5	NUM
ajst-32571	257	23	,	,	PUNCT
ajst-32571	257	24	no	no	INTJ
ajst-32571	257	25	.	.	NOUN
ajst-32571	257	26	1	1	NUM
ajst-32571	257	27	,	,	PUNCT
ajst-32571	257	28	pp	pp	ADJ
ajst-32571	257	29	.	.	PUNCT
ajst-32571	258	1	3–8	3–8	NUM
ajst-32571	258	2	,	,	PUNCT
ajst-32571	258	3	2017	2017	NUM
ajst-32571	258	4	,	,	PUNCT
ajst-32571	258	5	doi	doi	NOUN
ajst-32571	258	6	:	:	PUNCT
ajst-32571	258	7	https://doi.org/10.1158/2326-6066.cir-16-0297	https://doi.org/10.1158/2326-6066.cir-16-0297	NUM
ajst-32571	258	8	.	.	PUNCT
ajst-32571	259	1	[	[	X
ajst-32571	259	2	54	54	NUM
ajst-32571	259	3	]	]	PUNCT
ajst-32571	259	4	s.	s.	PROPN
ajst-32571	259	5	ruixin	ruixin	PROPN
ajst-32571	259	6	et	et	PROPN
ajst-32571	259	7	al	al	PROPN
ajst-32571	259	8	.	.	PROPN
ajst-32571	259	9	,	,	PUNCT
ajst-32571	259	10	“	"	PUNCT
ajst-32571	259	11	cxcr4	cxcr4	NOUN
ajst-32571	259	12	-	-	PUNCT
ajst-32571	259	13	modified	modify	VERB
ajst-32571	259	14	car	car	NOUN
ajst-32571	259	15	-	-	PUNCT
ajst-32571	259	16	t	t	NOUN
ajst-32571	259	17	cells	cell	NOUN
ajst-32571	259	18	suppresses	suppress	VERB
ajst-32571	259	19	mdscs	mdsc	NOUN
ajst-32571	259	20	recruitment	recruitment	NOUN
ajst-32571	259	21	via	via	ADP
ajst-32571	259	22	stat3	stat3	PROPN
ajst-32571	259	23	/	/	SYM
ajst-32571	259	24	nf	nf	PROPN
ajst-32571	259	25	-	-	PUNCT
ajst-32571	259	26	κb	κb	ADJ
ajst-32571	259	27	/	/	SYM
ajst-32571	259	28	sdf1α	sdf1α	PROPN
ajst-32571	259	29	axis	axis	NOUN
ajst-32571	259	30	to	to	PART
ajst-32571	259	31	enhance	enhance	VERB
ajst-32571	259	32	efficacy	efficacy	NOUN
ajst-32571	259	33	against	against	ADP
ajst-32571	259	34	pancreatic	pancreatic	ADJ
ajst-32571	259	35	cancer	cancer	NOUN
ajst-32571	259	36	,	,	PUNCT
ajst-32571	259	37	”	"	PUNCT
ajst-32571	259	38	molecular	molecular	ADJ
ajst-32571	259	39	therapy	therapy	NOUN
ajst-32571	259	40	,	,	PUNCT
ajst-32571	259	41	vol	vol	NOUN
ajst-32571	259	42	.	.	PROPN
ajst-32571	259	43	31	31	NUM
ajst-32571	259	44	,	,	PUNCT
ajst-32571	259	45	no	no	INTJ
ajst-32571	259	46	.	.	NOUN
ajst-32571	259	47	11	11	NUM
ajst-32571	259	48	,	,	PUNCT
ajst-32571	259	49	pp	pp	ADJ
ajst-32571	259	50	.	.	PUNCT
ajst-32571	259	51	3193	3193	NUM
ajst-32571	259	52	–	–	PUNCT
ajst-32571	259	53	3209	3209	NUM
ajst-32571	259	54	,	,	PUNCT
ajst-32571	259	55	nov	nov	PROPN
ajst-32571	259	56	.	.	PROPN
ajst-32571	259	57	2023	2023	NUM
ajst-32571	259	58	,	,	PUNCT
ajst-32571	259	59	doi	doi	NOUN
ajst-32571	259	60	:	:	PUNCT
ajst-32571	259	61	https://doi.org/10.1016/j.ymthe.2023.09.010	https://doi.org/10.1016/j.ymthe.2023.09.010	PROPN
ajst-32571	259	62	.	.	PUNCT
ajst-32571	260	1	[	[	X
ajst-32571	260	2	55	55	NUM
ajst-32571	260	3	]	]	X
ajst-32571	260	4	d.	d.	PROPN
ajst-32571	260	5	raman	raman	PROPN
ajst-32571	260	6	,	,	PUNCT
ajst-32571	260	7	p.	p.	PROPN
ajst-32571	260	8	j.	j.	PROPN
ajst-32571	260	9	baugher	baugher	PROPN
ajst-32571	260	10	,	,	PUNCT
ajst-32571	260	11	y.	y.	PROPN
ajst-32571	260	12	m.	m.	PROPN
ajst-32571	260	13	thu	thu	PROPN
ajst-32571	260	14	,	,	PUNCT
ajst-32571	260	15	and	and	CCONJ
ajst-32571	260	16	a.	a.	PROPN
ajst-32571	260	17	richmond	richmond	PROPN
ajst-32571	260	18	,	,	PUNCT
ajst-32571	260	19	“	"	PUNCT
ajst-32571	260	20	role	role	NOUN
ajst-32571	260	21	of	of	ADP
ajst-32571	260	22	chemokines	chemokine	NOUN
ajst-32571	260	23	in	in	ADP
ajst-32571	260	24	tumor	tumor	NOUN
ajst-32571	260	25	growth	growth	NOUN
ajst-32571	260	26	,	,	PUNCT
ajst-32571	260	27	”	"	PUNCT
ajst-32571	260	28	cancer	cancer	NOUN
ajst-32571	260	29	letters	letter	NOUN
ajst-32571	260	30	,	,	PUNCT
ajst-32571	260	31	vol	vol	NOUN
ajst-32571	260	32	.	.	PROPN
ajst-32571	261	1	256	256	NUM
ajst-32571	261	2	,	,	PUNCT
ajst-32571	261	3	no	no	INTJ
ajst-32571	261	4	.	.	NOUN
ajst-32571	261	5	2	2	NUM
ajst-32571	261	6	,	,	PUNCT
ajst-32571	261	7	pp	pp	ADJ
ajst-32571	261	8	.	.	PUNCT
ajst-32571	262	1	137–165	137–165	NUM
ajst-32571	262	2	,	,	PUNCT
ajst-32571	262	3	2007	2007	NUM
ajst-32571	262	4	,	,	PUNCT
ajst-32571	262	5	doi	doi	NOUN
ajst-32571	262	6	:	:	PUNCT
ajst-32571	262	7	https://doi.org/10.1016/j.canlet.2007.05.013	https://doi.org/10.1016/j.canlet.2007.05.013	PROPN
ajst-32571	262	8	.	.	PUNCT
ajst-32571	263	1	[	[	X
ajst-32571	263	2	56	56	NUM
ajst-32571	263	3	]	]	PUNCT
ajst-32571	263	4	k.	k.	PROPN
ajst-32571	263	5	bullock	bullock	PROPN
ajst-32571	263	6	and	and	CCONJ
ajst-32571	263	7	a.	a.	PROPN
ajst-32571	263	8	richmond	richmond	PROPN
ajst-32571	263	9	,	,	PUNCT
ajst-32571	263	10	“	"	PUNCT
ajst-32571	263	11	suppressing	suppress	VERB
ajst-32571	263	12	mdsc	mdsc	ADJ
ajst-32571	263	13	recruitment	recruitment	NOUN
ajst-32571	263	14	to	to	ADP
ajst-32571	263	15	the	the	DET
ajst-32571	263	16	tumor	tumor	NOUN
ajst-32571	263	17	microenvironment	microenvironment	NOUN
ajst-32571	263	18	by	by	ADP
ajst-32571	263	19	antagonizing	antagonize	VERB
ajst-32571	263	20	cxcr2	cxcr2	NOUN
ajst-32571	263	21	to	to	PART
ajst-32571	263	22	enhance	enhance	VERB
ajst-32571	263	23	the	the	DET
ajst-32571	263	24	efficacy	efficacy	NOUN
ajst-32571	263	25	of	of	ADP
ajst-32571	263	26	immunotherapy	immunotherapy	NOUN
ajst-32571	263	27	,	,	PUNCT
ajst-32571	263	28	”	"	PUNCT
ajst-32571	263	29	cancers	cancer	NOUN
ajst-32571	263	30	,	,	PUNCT
ajst-32571	263	31	vol	vol	NOUN
ajst-32571	263	32	.	.	PROPN
ajst-32571	263	33	13	13	NUM
ajst-32571	263	34	,	,	PUNCT
ajst-32571	263	35	no	no	INTJ
ajst-32571	263	36	.	.	NOUN
ajst-32571	263	37	24	24	NUM
ajst-32571	263	38	,	,	PUNCT
ajst-32571	263	39	p.	p.	NOUN
ajst-32571	263	40	6293	6293	NUM
ajst-32571	263	41	,	,	PUNCT
ajst-32571	263	42	dec	dec	PROPN
ajst-32571	263	43	.	.	PROPN
ajst-32571	263	44	2021	2021	NUM
ajst-32571	263	45	,	,	PUNCT
ajst-32571	263	46	doi	doi	NOUN
ajst-32571	263	47	:	:	PUNCT
ajst-32571	263	48	https://doi.org/10.3390/cancers13246293	https://doi.org/10.3390/cancers13246293	X
ajst-32571	263	49	.	.	PUNCT
ajst-32571	264	1	[	[	X
ajst-32571	264	2	57	57	NUM
ajst-32571	264	3	]	]	PUNCT
ajst-32571	264	4	l.	l.	PROPN
ajst-32571	264	5	jin	jin	PROPN
ajst-32571	264	6	et	et	PROPN
ajst-32571	264	7	al	al	PROPN
ajst-32571	264	8	.	.	PROPN
ajst-32571	264	9	,	,	PUNCT
ajst-32571	264	10	“	"	PUNCT
ajst-32571	264	11	cxcr1or	cxcr1or	PROPN
ajst-32571	264	12	cxcr2	cxcr2	NOUN
ajst-32571	264	13	-	-	PUNCT
ajst-32571	264	14	modified	modify	VERB
ajst-32571	264	15	car	car	NOUN
ajst-32571	264	16	t	t	NOUN
ajst-32571	264	17	cells	cell	NOUN
ajst-32571	264	18	co	co	VERB
ajst-32571	264	19	-	-	VERB
ajst-32571	264	20	opt	opt	ADJ
ajst-32571	264	21	il-8	il-8	NOUN
ajst-32571	264	22	for	for	ADP
ajst-32571	264	23	maximal	maximal	ADJ
ajst-32571	264	24	antitumor	antitumor	PROPN
ajst-32571	264	25	efficacy	efficacy	NOUN
ajst-32571	264	26	in	in	ADP
ajst-32571	264	27	solid	solid	ADJ
ajst-32571	264	28	tumors	tumor	NOUN
ajst-32571	264	29	,	,	PUNCT
ajst-32571	264	30	”	"	PUNCT
ajst-32571	264	31	nature	nature	NOUN
ajst-32571	264	32	communications	communication	NOUN
ajst-32571	264	33	,	,	PUNCT
ajst-32571	264	34	vol	vol	NOUN
ajst-32571	264	35	.	.	PROPN
ajst-32571	264	36	10	10	NUM
ajst-32571	264	37	,	,	PUNCT
ajst-32571	264	38	no	no	INTJ
ajst-32571	264	39	.	.	NOUN
ajst-32571	264	40	1	1	NUM
ajst-32571	264	41	,	,	PUNCT
ajst-32571	264	42	sep	sep	PROPN
ajst-32571	264	43	.	.	PROPN
ajst-32571	264	44	2019	2019	NUM
ajst-32571	264	45	,	,	PUNCT
ajst-32571	264	46	doi	doi	NOUN
ajst-32571	264	47	:	:	PUNCT
ajst-32571	264	48	https://doi.org/10.1038/s41467019-11869-4	https://doi.org/10.1038/s41467019-11869-4	NOUN
ajst-32571	264	49	.	.	PUNCT
ajst-32571	265	1	[	[	X
ajst-32571	265	2	58	58	NUM
ajst-32571	265	3	]	]	PUNCT
ajst-32571	265	4	l.	l.	PROPN
ajst-32571	265	5	m.	m.	PROPN
ajst-32571	265	6	whilding	whilde	VERB
ajst-32571	265	7	et	et	PROPN
ajst-32571	265	8	al	al	PROPN
ajst-32571	265	9	.	.	PROPN
ajst-32571	265	10	,	,	PUNCT
ajst-32571	265	11	“	"	PUNCT
ajst-32571	265	12	car	car	NOUN
ajst-32571	265	13	t	t	NOUN
ajst-32571	265	14	-	-	PUNCT
ajst-32571	265	15	cells	cell	NOUN
ajst-32571	265	16	targeting	target	VERB
ajst-32571	265	17	the	the	DET
ajst-32571	265	18	integrin	integrin	NOUN
ajst-32571	265	19	αvβ6	αvβ6	NOUN
ajst-32571	265	20	and	and	CCONJ
ajst-32571	265	21	co	co	VERB
ajst-32571	265	22	-	-	VERB
ajst-32571	265	23	expressing	express	VERB
ajst-32571	265	24	the	the	DET
ajst-32571	265	25	chemokine	chemokine	ADJ
ajst-32571	265	26	receptor	receptor	NOUN
ajst-32571	265	27	cxcr2	cxcr2	NOUN
ajst-32571	265	28	demonstrate	demonstrate	VERB
ajst-32571	265	29	enhanced	enhanced	ADJ
ajst-32571	265	30	homing	homing	NOUN
ajst-32571	265	31	and	and	CCONJ
ajst-32571	265	32	efficacy	efficacy	NOUN
ajst-32571	265	33	against	against	ADP
ajst-32571	265	34	several	several	ADJ
ajst-32571	265	35	solid	solid	ADJ
ajst-32571	265	36	malignancies	malignancy	NOUN
ajst-32571	265	37	,	,	PUNCT
ajst-32571	265	38	”	"	PUNCT
ajst-32571	265	39	cancers	cancer	NOUN
ajst-32571	265	40	,	,	PUNCT
ajst-32571	265	41	vol	vol	NOUN
ajst-32571	265	42	.	.	PROPN
ajst-32571	265	43	11	11	NUM
ajst-32571	265	44	,	,	PUNCT
ajst-32571	265	45	no	no	INTJ
ajst-32571	265	46	.	.	NOUN
ajst-32571	265	47	5	5	NUM
ajst-32571	265	48	,	,	PUNCT
ajst-32571	265	49	p.	p.	NOUN
ajst-32571	265	50	674	674	NUM
ajst-32571	265	51	,	,	PUNCT
ajst-32571	265	52	may	may	PROPN
ajst-32571	265	53	2019	2019	NUM
ajst-32571	265	54	,	,	PUNCT
ajst-32571	265	55	doi	doi	NOUN
ajst-32571	265	56	:	:	PUNCT
ajst-32571	265	57	https://doi.org/10.3390/cancers11050674	https://doi.org/10.3390/cancers11050674	NOUN
ajst-32571	265	58	.	.	PUNCT
ajst-32571	266	1	[	[	X
ajst-32571	266	2	59	59	NUM
ajst-32571	266	3	]	]	PUNCT
ajst-32571	266	4	g.	g.	PROPN
ajst-32571	266	5	liu	liu	PROPN
ajst-32571	266	6	et	et	PROPN
ajst-32571	266	7	al	al	PROPN
ajst-32571	266	8	.	.	PROPN
ajst-32571	266	9	,	,	PUNCT
ajst-32571	266	10	“	"	PUNCT
ajst-32571	266	11	cxcr2	cxcr2	NOUN
ajst-32571	266	12	-	-	PUNCT
ajst-32571	266	13	modified	modify	VERB
ajst-32571	266	14	car	car	NOUN
ajst-32571	266	15	-	-	PUNCT
ajst-32571	266	16	t	t	NOUN
ajst-32571	266	17	cells	cell	NOUN
ajst-32571	266	18	have	have	AUX
ajst-32571	266	19	enhanced	enhance	VERB
ajst-32571	266	20	trafficking	trafficking	NOUN
ajst-32571	266	21	ability	ability	NOUN
ajst-32571	266	22	that	that	PRON
ajst-32571	266	23	improves	improve	VERB
ajst-32571	266	24	treatment	treatment	NOUN
ajst-32571	266	25	of	of	ADP
ajst-32571	266	26	hepatocellular	hepatocellular	ADJ
ajst-32571	266	27	carcinoma	carcinoma	NOUN
ajst-32571	266	28	,	,	PUNCT
ajst-32571	266	29	”	"	PUNCT
ajst-32571	266	30	european	european	ADJ
ajst-32571	266	31	journal	journal	PROPN
ajst-32571	266	32	of	of	ADP
ajst-32571	266	33	immunology	immunology	NOUN
ajst-32571	266	34	,	,	PUNCT
ajst-32571	266	35	vol	vol	NOUN
ajst-32571	266	36	.	.	PROPN
ajst-32571	267	1	50	50	NUM
ajst-32571	267	2	,	,	PUNCT
ajst-32571	267	3	no	no	INTJ
ajst-32571	267	4	.	.	NOUN
ajst-32571	267	5	5	5	NUM
ajst-32571	267	6	,	,	PUNCT
ajst-32571	267	7	pp	pp	ADJ
ajst-32571	267	8	.	.	PUNCT
ajst-32571	268	1	712–724	712–724	NUM
ajst-32571	268	2	,	,	PUNCT
ajst-32571	268	3	may	may	AUX
ajst-32571	268	4	2020	2020	NUM
ajst-32571	268	5	,	,	PUNCT
ajst-32571	268	6	doi	doi	NOUN
ajst-32571	268	7	:	:	PUNCT
ajst-32571	268	8	https://doi.org/10.1002/eji.201948457	https://doi.org/10.1002/eji.201948457	PROPN
ajst-32571	268	9	.	.	PUNCT
ajst-32571	269	1	[	[	X
ajst-32571	269	2	60	60	NUM
ajst-32571	269	3	]	]	PUNCT
ajst-32571	269	4	x.	x.	PROPN
ajst-32571	269	5	zhang	zhang	PROPN
ajst-32571	269	6	,	,	PUNCT
ajst-32571	269	7	r.	r.	PROPN
ajst-32571	269	8	guo	guo	PROPN
ajst-32571	269	9	,	,	PUNCT
ajst-32571	269	10	h.	h.	PROPN
ajst-32571	269	11	kambara	kambara	PROPN
ajst-32571	269	12	,	,	PUNCT
ajst-32571	269	13	f.	f.	PROPN
ajst-32571	269	14	ma	ma	PROPN
ajst-32571	269	15	,	,	PUNCT
ajst-32571	269	16	and	and	CCONJ
ajst-32571	269	17	h.	h.	PROPN
ajst-32571	269	18	luo	luo	PROPN
ajst-32571	269	19	,	,	PUNCT
ajst-32571	269	20	“	"	PUNCT
ajst-32571	269	21	the	the	DET
ajst-32571	269	22	role	role	NOUN
ajst-32571	269	23	of	of	ADP
ajst-32571	269	24	cxcr2	cxcr2	NOUN
ajst-32571	269	25	in	in	ADP
ajst-32571	269	26	acute	acute	ADJ
ajst-32571	269	27	inflammatory	inflammatory	ADJ
ajst-32571	269	28	responses	response	NOUN
ajst-32571	269	29	and	and	CCONJ
ajst-32571	269	30	its	its	PRON
ajst-32571	269	31	antagonists	antagonist	NOUN
ajst-32571	269	32	as	as	ADP
ajst-32571	269	33	anti	anti	ADJ
ajst-32571	269	34	-	-	ADJ
ajst-32571	269	35	inflammatory	inflammatory	ADJ
ajst-32571	269	36	therapeutics	therapeutic	NOUN
ajst-32571	269	37	,	,	PUNCT
ajst-32571	269	38	”	"	PUNCT
ajst-32571	269	39	current	current	ADJ
ajst-32571	269	40	opinion	opinion	NOUN
ajst-32571	269	41	in	in	ADP
ajst-32571	269	42	hematology	hematology	NOUN
ajst-32571	269	43	,	,	PUNCT
ajst-32571	269	44	vol	vol	NOUN
ajst-32571	269	45	.	.	PROPN
ajst-32571	269	46	26	26	NUM
ajst-32571	269	47	,	,	PUNCT
ajst-32571	269	48	no	no	INTJ
ajst-32571	269	49	.	.	NOUN
ajst-32571	269	50	1	1	NUM
ajst-32571	269	51	,	,	PUNCT
ajst-32571	269	52	pp	pp	ADJ
ajst-32571	269	53	.	.	PUNCT
ajst-32571	270	1	28–33	28–33	NUM
ajst-32571	270	2	,	,	PUNCT
ajst-32571	270	3	2019	2019	NUM
ajst-32571	270	4	,	,	PUNCT
ajst-32571	270	5	doi	doi	NOUN
ajst-32571	270	6	:	:	PUNCT
ajst-32571	270	7	https://doi.org/10.1097/moh.0000000000000476	https://doi.org/10.1097/moh.0000000000000476	ADJ
ajst-32571	270	8	.	.	PUNCT
ajst-32571	271	1	[	[	X
ajst-32571	271	2	61	61	NUM
ajst-32571	271	3	]	]	PUNCT
ajst-32571	271	4	l.	l.	PROPN
ajst-32571	271	5	j.	j.	PROPN
ajst-32571	271	6	goldstein	goldstein	PROPN
ajst-32571	271	7	et	et	PROPN
ajst-32571	271	8	al	al	PROPN
ajst-32571	271	9	.	.	PROPN
ajst-32571	271	10	,	,	PUNCT
ajst-32571	271	11	“	"	PUNCT
ajst-32571	271	12	a	a	DET
ajst-32571	271	13	window	window	NOUN
ajst-32571	271	14	-	-	PUNCT
ajst-32571	271	15	of	of	ADP
ajst-32571	271	16	-	-	PUNCT
ajst-32571	271	17	opportunity	opportunity	NOUN
ajst-32571	271	18	trial	trial	NOUN
ajst-32571	271	19	of	of	ADP
ajst-32571	271	20	the	the	DET
ajst-32571	271	21	cxcr1/2	cxcr1/2	ADJ
ajst-32571	271	22	inhibitor	inhibitor	NOUN
ajst-32571	271	23	reparixin	reparixin	NOUN
ajst-32571	271	24	in	in	ADP
ajst-32571	271	25	operable	operable	ADJ
ajst-32571	271	26	her-2	her-2	NOUN
ajst-32571	271	27	-	-	PUNCT
ajst-32571	271	28	negative	negative	ADJ
ajst-32571	271	29	breast	breast	NOUN
ajst-32571	271	30	cancer	cancer	NOUN
ajst-32571	271	31	,	,	PUNCT
ajst-32571	271	32	”	"	PUNCT
ajst-32571	271	33	breast	breast	NOUN
ajst-32571	271	34	cancer	cancer	NOUN
ajst-32571	271	35	research	research	NOUN
ajst-32571	271	36	:	:	PUNCT
ajst-32571	271	37	bcr	bcr	ADJ
ajst-32571	271	38	,	,	PUNCT
ajst-32571	271	39	vol	vol	NOUN
ajst-32571	271	40	.	.	PROPN
ajst-32571	271	41	22	22	NUM
ajst-32571	271	42	,	,	PUNCT
ajst-32571	271	43	no	no	INTJ
ajst-32571	271	44	.	.	NOUN
ajst-32571	271	45	1	1	NUM
ajst-32571	271	46	,	,	PUNCT
ajst-32571	271	47	p.	p.	NOUN
ajst-32571	271	48	4	4	NUM
ajst-32571	271	49	,	,	PUNCT
ajst-32571	271	50	jan	jan	PROPN
ajst-32571	271	51	.	.	PROPN
ajst-32571	271	52	2020	2020	NUM
ajst-32571	271	53	,	,	PUNCT
ajst-32571	271	54	doi	doi	NOUN
ajst-32571	271	55	:	:	PUNCT
ajst-32571	271	56	https://doi.org/10.1186/s13058-019-1243-8	https://doi.org/10.1186/s13058-019-1243-8	NUM
ajst-32571	271	57	.	.	PUNCT
ajst-32571	272	1	[	[	X
ajst-32571	272	2	62	62	NUM
ajst-32571	272	3	]	]	PUNCT
ajst-32571	272	4	s.	s.	PROPN
ajst-32571	272	5	greene	greene	PROPN
ajst-32571	272	6	et	et	PROPN
ajst-32571	272	7	al	al	PROPN
ajst-32571	272	8	.	.	PROPN
ajst-32571	272	9	,	,	PUNCT
ajst-32571	272	10	“	"	PUNCT
ajst-32571	272	11	inhibition	inhibition	NOUN
ajst-32571	272	12	of	of	ADP
ajst-32571	272	13	mdsc	mdsc	ADJ
ajst-32571	272	14	trafficking	trafficking	NOUN
ajst-32571	272	15	with	with	ADP
ajst-32571	272	16	sx-682	sx-682	PROPN
ajst-32571	272	17	,	,	PUNCT
ajst-32571	272	18	a	a	DET
ajst-32571	272	19	cxcr1/2	cxcr1/2	ADJ
ajst-32571	272	20	inhibitor	inhibitor	NOUN
ajst-32571	272	21	,	,	PUNCT
ajst-32571	272	22	enhances	enhance	VERB
ajst-32571	272	23	nk	nk	NOUN
ajst-32571	272	24	-	-	PUNCT
ajst-32571	272	25	cell	cell	NOUN
ajst-32571	272	26	immunotherapy	immunotherapy	NOUN
ajst-32571	272	27	in	in	ADP
ajst-32571	272	28	head	head	NOUN
ajst-32571	272	29	and	and	CCONJ
ajst-32571	272	30	neck	neck	NOUN
ajst-32571	272	31	cancer	cancer	NOUN
ajst-32571	272	32	models	model	NOUN
ajst-32571	272	33	,	,	PUNCT
ajst-32571	272	34	”	"	PUNCT
ajst-32571	272	35	clinical	clinical	ADJ
ajst-32571	272	36	cancer	cancer	NOUN
ajst-32571	272	37	research	research	NOUN
ajst-32571	272	38	:	:	PUNCT
ajst-32571	272	39	an	an	DET
ajst-32571	272	40	official	official	ADJ
ajst-32571	272	41	journal	journal	NOUN
ajst-32571	272	42	of	of	ADP
ajst-32571	272	43	the	the	DET
ajst-32571	272	44	american	american	PROPN
ajst-32571	272	45	association	association	PROPN
ajst-32571	272	46	for	for	ADP
ajst-32571	272	47	cancer	cancer	NOUN
ajst-32571	272	48	research	research	NOUN
ajst-32571	272	49	,	,	PUNCT
ajst-32571	272	50	vol	vol	NOUN
ajst-32571	272	51	.	.	PROPN
ajst-32571	272	52	26	26	NUM
ajst-32571	272	53	,	,	PUNCT
ajst-32571	272	54	no	no	INTJ
ajst-32571	272	55	.	.	NOUN
ajst-32571	272	56	6	6	NUM
ajst-32571	272	57	,	,	PUNCT
ajst-32571	272	58	pp	pp	ADJ
ajst-32571	272	59	.	.	PUNCT
ajst-32571	273	1	1420–1431	1420–1431	NUM
ajst-32571	273	2	,	,	PUNCT
ajst-32571	273	3	mar	mar	PROPN
ajst-32571	273	4	.	.	PROPN
ajst-32571	273	5	2020	2020	NUM
ajst-32571	273	6	,	,	PUNCT
ajst-32571	273	7	doi	doi	NOUN
ajst-32571	273	8	:	:	PUNCT
ajst-32571	273	9	https://doi.org/10.1158/1078-0432.ccr-19-2625	https://doi.org/10.1158/1078-0432.ccr-19-2625	X
ajst-32571	273	10	.	.	PUNCT
ajst-32571	274	1	[	[	X
ajst-32571	274	2	63	63	NUM
ajst-32571	274	3	]	]	PUNCT
ajst-32571	274	4	k.	k.	PROPN
ajst-32571	274	5	h.	h.	PROPN
ajst-32571	274	6	tang	tang	PROPN
ajst-32571	274	7	et	et	PROPN
ajst-32571	274	8	al	al	PROPN
ajst-32571	274	9	.	.	PROPN
ajst-32571	274	10	,	,	PUNCT
ajst-32571	274	11	“	"	PUNCT
ajst-32571	274	12	combined	combine	VERB
ajst-32571	274	13	inhibition	inhibition	NOUN
ajst-32571	274	14	of	of	ADP
ajst-32571	274	15	shp2	shp2	NOUN
ajst-32571	274	16	and	and	CCONJ
ajst-32571	274	17	cxcr1/2	cxcr1/2	PROPN
ajst-32571	274	18	promotes	promote	VERB
ajst-32571	274	19	antitumor	antitumor	PROPN
ajst-32571	274	20	t	t	PROPN
ajst-32571	274	21	-	-	PUNCT
ajst-32571	274	22	cell	cell	NOUN
ajst-32571	274	23	response	response	NOUN
ajst-32571	274	24	in	in	ADP
ajst-32571	274	25	nsclc	nsclc	NOUN
ajst-32571	274	26	,	,	PUNCT
ajst-32571	274	27	”	"	PUNCT
ajst-32571	274	28	cancer	cancer	NOUN
ajst-32571	274	29	discovery	discovery	NOUN
ajst-32571	274	30	,	,	PUNCT
ajst-32571	274	31	vol	vol	NOUN
ajst-32571	274	32	.	.	PROPN
ajst-32571	274	33	12	12	NUM
ajst-32571	274	34	,	,	PUNCT
ajst-32571	274	35	no	no	INTJ
ajst-32571	274	36	.	.	NOUN
ajst-32571	274	37	1	1	NUM
ajst-32571	274	38	,	,	PUNCT
ajst-32571	274	39	pp	pp	ADJ
ajst-32571	274	40	.	.	PUNCT
ajst-32571	275	1	47–61	47–61	NUM
ajst-32571	275	2	,	,	PUNCT
ajst-32571	275	3	aug	aug	PROPN
ajst-32571	275	4	.	.	PROPN
ajst-32571	275	5	2021	2021	NUM
ajst-32571	275	6	,	,	PUNCT
ajst-32571	275	7	doi	doi	NOUN
ajst-32571	275	8	:	:	PUNCT
ajst-32571	275	9	https://doi.org/10.1158/2159-8290	https://doi.org/10.1158/2159-8290	PROPN
ajst-32571	275	10	.	.	PUNCT
ajst-32571	276	1	cd-21	cd-21	NOUN
ajst-32571	276	2	-	-	SYM
ajst-32571	276	3	0369	0369	NUM
ajst-32571	276	4	.	.	PUNCT
ajst-32571	277	1	[	[	X
ajst-32571	277	2	64	64	NUM
ajst-32571	277	3	]	]	PUNCT
ajst-32571	277	4	j.	j.	PROPN
ajst-32571	277	5	leslie	leslie	PROPN
ajst-32571	277	6	et	et	PROPN
ajst-32571	277	7	al	al	PROPN
ajst-32571	277	8	.	.	PROPN
ajst-32571	277	9	,	,	PUNCT
ajst-32571	277	10	“	"	PUNCT
ajst-32571	277	11	cxcr2	cxcr2	NOUN
ajst-32571	277	12	inhibition	inhibition	NOUN
ajst-32571	277	13	enables	enable	VERB
ajst-32571	277	14	nash	nash	NOUN
ajst-32571	277	15	-	-	PUNCT
ajst-32571	277	16	hcc	hcc	PROPN
ajst-32571	277	17	immunotherapy	immunotherapy	NOUN
ajst-32571	277	18	,	,	PUNCT
ajst-32571	277	19	”	"	PUNCT
ajst-32571	277	20	gut	gut	NOUN
ajst-32571	277	21	,	,	PUNCT
ajst-32571	277	22	vol	vol	NOUN
ajst-32571	277	23	.	.	PROPN
ajst-32571	278	1	71	71	NUM
ajst-32571	278	2	,	,	PUNCT
ajst-32571	278	3	no	no	INTJ
ajst-32571	278	4	.	.	NOUN
ajst-32571	278	5	10	10	NUM
ajst-32571	278	6	,	,	PUNCT
ajst-32571	278	7	pp	pp	ADJ
ajst-32571	278	8	.	.	PUNCT
ajst-32571	279	1	2093	2093	NUM
ajst-32571	279	2	–	–	PUNCT
ajst-32571	279	3	2106	2106	NUM
ajst-32571	279	4	,	,	PUNCT
ajst-32571	279	5	apr	apr	PROPN
ajst-32571	279	6	.	.	PROPN
ajst-32571	279	7	2022	2022	NUM
ajst-32571	279	8	,	,	PUNCT
ajst-32571	279	9	doi	doi	NOUN
ajst-32571	279	10	:	:	PUNCT
ajst-32571	279	11	https://doi.org/10.1136/gutjnl-2021-326259	https://doi.org/10.1136/gutjnl-2021-326259	NOUN
ajst-32571	279	12	.	.	PUNCT
ajst-32571	280	1	[	[	X
ajst-32571	280	2	65	65	NUM
ajst-32571	280	3	]	]	X
ajst-32571	280	4	g.	g.	PROPN
ajst-32571	280	5	lazennec	lazennec	PROPN
ajst-32571	280	6	,	,	PUNCT
ajst-32571	280	7	k.	k.	PROPN
ajst-32571	280	8	rajarathnam	rajarathnam	PROPN
ajst-32571	280	9	,	,	PUNCT
ajst-32571	280	10	and	and	CCONJ
ajst-32571	280	11	a.	a.	PROPN
ajst-32571	280	12	richmond	richmond	PROPN
ajst-32571	280	13	,	,	PUNCT
ajst-32571	280	14	“	"	PUNCT
ajst-32571	280	15	cxcr2	cxcr2	X
ajst-32571	280	16	chemokine	chemokine	ADJ
ajst-32571	280	17	receptor	receptor	NOUN
ajst-32571	280	18	a	a	DET
ajst-32571	280	19	master	master	NOUN
ajst-32571	280	20	regulator	regulator	NOUN
ajst-32571	280	21	in	in	ADP
ajst-32571	280	22	cancer	cancer	NOUN
ajst-32571	280	23	and	and	CCONJ
ajst-32571	280	24	physiology	physiology	NOUN
ajst-32571	280	25	,	,	PUNCT
ajst-32571	280	26	”	"	PUNCT
ajst-32571	280	27	trends	trend	NOUN
ajst-32571	280	28	in	in	ADP
ajst-32571	280	29	molecular	molecular	ADJ
ajst-32571	280	30	medicine	medicine	NOUN
ajst-32571	280	31	,	,	PUNCT
ajst-32571	280	32	vol	vol	NOUN
ajst-32571	280	33	.	.	PROPN
ajst-32571	280	34	30	30	NUM
ajst-32571	280	35	,	,	PUNCT
ajst-32571	280	36	no	no	INTJ
ajst-32571	280	37	.	.	NOUN
ajst-32571	280	38	1	1	NUM
ajst-32571	280	39	,	,	PUNCT
ajst-32571	280	40	pp	pp	ADJ
ajst-32571	280	41	.	.	PUNCT
ajst-32571	281	1	37–55	37–55	NUM
ajst-32571	281	2	,	,	PUNCT
ajst-32571	281	3	2024	2024	NUM
ajst-32571	281	4	,	,	PUNCT
ajst-32571	281	5	doi	doi	NOUN
ajst-32571	281	6	:	:	PUNCT
ajst-32571	281	7	https://doi	https://doi	PROPN
ajst-32571	281	8	.	.	PUNCT
ajst-32571	282	1	org/	org/	PRON
ajst-32571	282	2	10.1016	10.1016	NUM
ajst-32571	282	3	/	/	SYM
ajst-32571	282	4	j.molmed.2023.09.003	j.molmed.2023.09.003	PROPN
ajst-32571	282	5	.	.	PUNCT
ajst-32571	283	1	[	[	X
ajst-32571	283	2	66	66	NUM
ajst-32571	283	3	]	]	PUNCT
ajst-32571	283	4	j.	j.	PROPN
ajst-32571	283	5	w.	w.	PROPN
ajst-32571	283	6	kwak	kwak	PROPN
ajst-32571	283	7	et	et	PROPN
ajst-32571	283	8	al	al	PROPN
ajst-32571	283	9	.	.	PROPN
ajst-32571	283	10	,	,	PUNCT
ajst-32571	283	11	“	"	PUNCT
ajst-32571	283	12	cxcr1/2	cxcr1/2	ADJ
ajst-32571	283	13	antagonism	antagonism	NOUN
ajst-32571	283	14	inhibits	inhibit	VERB
ajst-32571	283	15	neutrophil	neutrophil	ADJ
ajst-32571	283	16	function	function	NOUN
ajst-32571	283	17	and	and	CCONJ
ajst-32571	283	18	not	not	PART
ajst-32571	283	19	recruitment	recruitment	NOUN
ajst-32571	283	20	in	in	ADP
ajst-32571	283	21	cancer	cancer	NOUN
ajst-32571	283	22	,	,	PUNCT
ajst-32571	283	23	”	"	PUNCT
ajst-32571	283	24	oncoimmunology	oncoimmunology	NOUN
ajst-32571	283	25	,	,	PUNCT
ajst-32571	283	26	vol	vol	NOUN
ajst-32571	283	27	.	.	PROPN
ajst-32571	283	28	13	13	NUM
ajst-32571	283	29	,	,	PUNCT
ajst-32571	283	30	no	no	INTJ
ajst-32571	283	31	.	.	NOUN
ajst-32571	283	32	1	1	NUM
ajst-32571	283	33	,	,	PUNCT
ajst-32571	283	34	jul	jul	PROPN
ajst-32571	283	35	.	.	PROPN
ajst-32571	283	36	2024	2024	NUM
ajst-32571	283	37	,	,	PUNCT
ajst-32571	283	38	doi	doi	NOUN
ajst-32571	283	39	:	:	PUNCT
ajst-32571	283	40	https://doi.org/10.1080/2162402x.2024.2384674	https://doi.org/10.1080/2162402x.2024.2384674	X
ajst-32571	283	41	.	.	PUNCT
ajst-32571	284	1	[	[	X
ajst-32571	284	2	67	67	X
ajst-32571	284	3	]	]	X
ajst-32571	284	4	y.	y.	PROPN
ajst-32571	284	5	zhang	zhang	PROPN
ajst-32571	284	6	et	et	PROPN
ajst-32571	284	7	al	al	PROPN
ajst-32571	284	8	.	.	PROPN
ajst-32571	284	9	,	,	PUNCT
ajst-32571	284	10	“	"	PUNCT
ajst-32571	284	11	controlling	control	VERB
ajst-32571	284	12	t	t	NOUN
ajst-32571	284	13	cell	cell	NOUN
ajst-32571	284	14	-	-	PUNCT
ajst-32571	284	15	tumor	tumor	NOUN
ajst-32571	284	16	cell	cell	NOUN
ajst-32571	284	17	interaction	interaction	NOUN
ajst-32571	284	18	with	with	ADP
ajst-32571	284	19	a	a	DET
ajst-32571	284	20	biomimetic	biomimetic	ADJ
ajst-32571	284	21	physical	physical	ADJ
ajst-32571	284	22	barrier	barrier	NOUN
ajst-32571	284	23	for	for	ADP
ajst-32571	284	24	cancer	cancer	NOUN
ajst-32571	284	25	immunotherapy	immunotherapy	NOUN
ajst-32571	284	26	.	.	PUNCT
ajst-32571	284	27	,	,	PUNCT
ajst-32571	284	28	”	"	PUNCT
ajst-32571	284	29	pubmed	pubmed	PROPN
ajst-32571	284	30	,	,	PUNCT
ajst-32571	284	31	vol	vol	NOUN
ajst-32571	284	32	.	.	PROPN
ajst-32571	284	33	122	122	NUM
ajst-32571	284	34	,	,	PUNCT
ajst-32571	284	35	no	no	INTJ
ajst-32571	284	36	.	.	NOUN
ajst-32571	284	37	28	28	NUM
ajst-32571	284	38	,	,	PUNCT
ajst-32571	284	39	jul	jul	PROPN
ajst-32571	284	40	.	.	PROPN
ajst-32571	284	41	2025	2025	NUM
ajst-32571	284	42	,	,	PUNCT
ajst-32571	284	43	doi	doi	NOUN
ajst-32571	284	44	:	:	PUNCT
ajst-32571	284	45	https://doi.org/10.1073/pnas.2500589122	https://doi.org/10.1073/pnas.2500589122	NOUN
ajst-32571	284	46	.	.	PUNCT
ajst-32571	285	1	188	188	NUM
ajst-32571	285	2	[	[	SYM
ajst-32571	285	3	68	68	NUM
ajst-32571	285	4	]	]	X
ajst-32571	285	5	caruana	caruana	PROPN
ajst-32571	285	6	et	et	PROPN
ajst-32571	285	7	al	al	PROPN
ajst-32571	285	8	.	.	PROPN
ajst-32571	285	9	,	,	PUNCT
ajst-32571	285	10	“	"	PUNCT
ajst-32571	285	11	heparanase	heparanase	NOUN
ajst-32571	285	12	promotes	promote	VERB
ajst-32571	285	13	tumor	tumor	NOUN
ajst-32571	285	14	infiltration	infiltration	NOUN
ajst-32571	285	15	and	and	CCONJ
ajst-32571	285	16	antitumor	antitumor	PROPN
ajst-32571	285	17	activity	activity	NOUN
ajst-32571	285	18	of	of	ADP
ajst-32571	285	19	car	car	NOUN
ajst-32571	285	20	-	-	PUNCT
ajst-32571	285	21	redirected	redirect	VERB
ajst-32571	285	22	t	t	NOUN
ajst-32571	285	23	lymphocytes	lymphocyte	NOUN
ajst-32571	285	24	,	,	PUNCT
ajst-32571	285	25	”	"	PUNCT
ajst-32571	285	26	nature	nature	NOUN
ajst-32571	285	27	medicine	medicine	NOUN
ajst-32571	285	28	,	,	PUNCT
ajst-32571	285	29	vol	vol	NOUN
ajst-32571	285	30	.	.	PROPN
ajst-32571	286	1	21	21	NUM
ajst-32571	286	2	,	,	PUNCT
ajst-32571	286	3	no	no	INTJ
ajst-32571	286	4	.	.	NOUN
ajst-32571	286	5	5	5	NUM
ajst-32571	286	6	,	,	PUNCT
ajst-32571	286	7	pp	pp	ADJ
ajst-32571	286	8	.	.	PUNCT
ajst-32571	287	1	524–529	524–529	NUM
ajst-32571	287	2	,	,	PUNCT
ajst-32571	287	3	may	may	PROPN
ajst-32571	287	4	2015	2015	NUM
ajst-32571	287	5	,	,	PUNCT
ajst-32571	287	6	doi	doi	NOUN
ajst-32571	287	7	:	:	PUNCT
ajst-32571	287	8	https://doi.org/10	https://doi.org/10	PROPN
ajst-32571	287	9	.	.	PUNCT
ajst-32571	287	10	1038	1038	NUM
ajst-32571	287	11	/	/	SYM
ajst-32571	287	12	nm	nm	NOUN
ajst-32571	287	13	.	.	PUNCT
ajst-32571	287	14	3833	3833	NUM
ajst-32571	287	15	.	.	PUNCT
ajst-32571	288	1	[	[	X
ajst-32571	288	2	69	69	NUM
ajst-32571	288	3	]	]	PUNCT
ajst-32571	288	4	l.-r	l.-r	NOUN
ajst-32571	288	5	.	.	PUNCT
ajst-32571	289	1	sofia	sofia	PROPN
ajst-32571	289	2	et	et	PROPN
ajst-32571	289	3	al	al	PROPN
ajst-32571	289	4	.	.	PROPN
ajst-32571	289	5	,	,	PUNCT
ajst-32571	289	6	“	"	PUNCT
ajst-32571	289	7	an	an	DET
ajst-32571	289	8	integral	integral	ADJ
ajst-32571	289	9	membrane	membrane	NOUN
ajst-32571	289	10	constitutively	constitutively	ADV
ajst-32571	289	11	active	active	ADJ
ajst-32571	289	12	heparanase	heparanase	NOUN
ajst-32571	289	13	enhances	enhance	VERB
ajst-32571	289	14	the	the	DET
ajst-32571	289	15	tumor	tumor	NOUN
ajst-32571	289	16	infiltration	infiltration	NOUN
ajst-32571	289	17	capability	capability	NOUN
ajst-32571	289	18	of	of	ADP
ajst-32571	289	19	nk	nk	PROPN
ajst-32571	289	20	cells	cell	NOUN
ajst-32571	289	21	,	,	PUNCT
ajst-32571	289	22	”	"	PUNCT
ajst-32571	289	23	oncoimmunology	oncoimmunology	NOUN
ajst-32571	289	24	,	,	PUNCT
ajst-32571	289	25	vol	vol	NOUN
ajst-32571	289	26	.	.	PROPN
ajst-32571	290	1	14	14	NUM
ajst-32571	290	2	,	,	PUNCT
ajst-32571	290	3	no	no	INTJ
ajst-32571	290	4	.	.	NOUN
ajst-32571	290	5	1	1	NUM
ajst-32571	290	6	,	,	PUNCT
ajst-32571	290	7	dec	dec	PROPN
ajst-32571	290	8	.	.	PROPN
ajst-32571	290	9	2024	2024	NUM
ajst-32571	290	10	,	,	PUNCT
ajst-32571	290	11	doi	doi	NOUN
ajst-32571	290	12	:	:	PUNCT
ajst-32571	290	13	https://doi.org/	https://doi.org/	NOUN
ajst-32571	290	14	10.1080/	10.1080/	NUM
ajst-32571	290	15	2162402x.2024.2437917	2162402x.2024.2437917	NUM
ajst-32571	290	16	.	.	PUNCT
ajst-32571	291	1	[	[	X
ajst-32571	291	2	70	70	X
ajst-32571	291	3	]	]	X
ajst-32571	291	4	h.	h.	PROPN
ajst-32571	291	5	a.	a.	PROPN
ajst-32571	291	6	martinez	martinez	PROPN
ajst-32571	291	7	et	et	PROPN
ajst-32571	291	8	al	al	PROPN
ajst-32571	291	9	.	.	PROPN
ajst-32571	291	10	,	,	PUNCT
ajst-32571	291	11	“	"	PUNCT
ajst-32571	291	12	regulatory	regulatory	ADJ
ajst-32571	291	13	t	t	NOUN
ajst-32571	291	14	cells	cell	NOUN
ajst-32571	291	15	use	use	VERB
ajst-32571	291	16	heparanase	heparanase	NOUN
ajst-32571	291	17	to	to	PART
ajst-32571	291	18	access	access	VERB
ajst-32571	291	19	il-2	il-2	PROPN
ajst-32571	291	20	bound	bind	VERB
ajst-32571	291	21	to	to	ADP
ajst-32571	291	22	extracellular	extracellular	ADJ
ajst-32571	291	23	matrix	matrix	NOUN
ajst-32571	291	24	in	in	ADP
ajst-32571	291	25	inflamed	inflamed	ADJ
ajst-32571	291	26	tissue	tissue	NOUN
ajst-32571	291	27	,	,	PUNCT
ajst-32571	291	28	”	"	PUNCT
ajst-32571	291	29	nature	nature	NOUN
ajst-32571	291	30	communications	communication	NOUN
ajst-32571	291	31	,	,	PUNCT
ajst-32571	291	32	vol	vol	NOUN
ajst-32571	291	33	.	.	PROPN
ajst-32571	291	34	15	15	NUM
ajst-32571	291	35	,	,	PUNCT
ajst-32571	291	36	no	no	INTJ
ajst-32571	291	37	.	.	NOUN
ajst-32571	291	38	1	1	NUM
ajst-32571	291	39	,	,	PUNCT
ajst-32571	291	40	feb	feb	PROPN
ajst-32571	291	41	.	.	PROPN
ajst-32571	291	42	2024	2024	NUM
ajst-32571	291	43	,	,	PUNCT
ajst-32571	291	44	doi	doi	NOUN
ajst-32571	291	45	:	:	PUNCT
ajst-32571	291	46	https://doi.org/10.1038/s41467024-45012-9	https://doi.org/10.1038/s41467024-45012-9	NOUN
ajst-32571	291	47	.	.	PUNCT